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SUMMARY OF THE THESIS “NEW MULTITARGET THERANOSTIC 
COMPOUNDS AGAINST PROTEINOPATHIES AND INFECTIOUS DISEASE” 
Introduction 
Drug innovation is a long and high-cost process with no guarantee for success. 
Paradoxically, despite the great investment and innovations applied in the drug 
discovery field during the past decades, fewer successful drugs against etiologically 
complex maladies, such as neurodegenerative and cardiovascular diseases or cancer 
have been reported. Thus, new approaches in the drug discovery process need to be 
considered. In multifactorial pathologies, where several receptors or signalling 
pathways are involved, the inhibition of a single target often does not lead to successful 
drugs. In this context, the use of multitarget drugs inhibiting several checkpoints of the 
same disease appears as an attractive alternative. On the other hand, the failure of 
several drug candidates has been associated to their administration when the pathology 
is too advanced. In this scenario, theranostic compounds able to combine the modalities 
of therapy and diagnostic imaging under the same dose appear as a good option to 
optimize the efficacy and safety of the therapy. Moreover, combining both strategies in 
a single molecule appears as a promising approach for the treatment of these 
pathologies. 
Objectives 
- Design, synthesis and characterization of a family of small-molecule theranostic 
agents based on the 2-stryrylquinoline scaffold bearing a push-pull system in order 
to improve their spectroscopic properties. 
- Design, synthesis and characterization of a family of 2-styrylquinolines decorated 
with polyamine chains in position 4 of the quinoline scaffold, increasing this way 
their basicity and consequently preferential mitochondrion accumulation. 
- Development of a new one-pot mechanochemical methodology for the obtention of 
bis-indolylquinones, an interesting scaffold to develop MSOT probes. 
- Design, synthesis and characterization of a family of multitarget directed ligands 
based on pyrrole isoniazid hybrids, able to inhibit MmpL3 and InhA, two different 




Results and discussion  
A family of theranostic styrylquinolines bearing a push-pull architecture has been 
designed and synthesized via a good-yielding four-step procedure. Their 
pharmacological profiles were studied by Drs. Paloma Bermejo and Sagrario Martín-
Aragón, showing their ability to inhibit tau aggregation and neuroprotective effects in 
okadaic acid models. Their full spectroscopic characterization has been carried out with 
the collaboration of Drs. María Antonia Martín and Ana Isabel Olives, showing that the 
compounds have native fluorescence in the NIR region.  
 
Further their ability to act as amyloid sensors has been verified with different 
amyloidogenic proteins. First, they were used for ex-vivo imaging, showing the capacity 
to selectively detect -amyloid plaques in the somatosensory cortex of APP/PS1 
transgenic mice and in the temporal cortex of human Alzheimer’s disease samples. Due 
to the ability to interact with amyloidogenic proteins, styrylquinolines were also used to 
detect amylin, a pancreatic protein overexpressed in type II Diabetes mellitus that may 
be involved in the development of Alzheimer’s disease. These studies were done in 





The leishmanicidal activity of a family of 4-amino-2-styrylquinolines was tested thanks 




Further mechanistical studies were carried out, pointing out their ability to cause 
mitochondrial disruption. 
 
In order to achieve our goal of developing novel push-pull multi-spectral optoacoustic 
tomography (MSOT) probes, a new one-pot mechanochemical methodology to obtain 
dihalo-bis-indolylquinones as starting scaffolds has been developed.  
 
Finally, a novel family of pyrrole-isoniazid hybrid compounds have been synthesised. 
Their antitubercular activities have been studied, showing interesting activities against 
Mycobacterium tuberculosis, including multidrug-resistant tuberculosis. Further, their 
ability to inhibit MmpL3 and InhA was verified, proving that they act through a 
metabolism-activated multitargeting (MAMUT) mechanism. 
 
Conclusions 
The work performed in this thesis shows that the theranostic and multitarget strategies 
are promising approaches towards the discovery of molecules that can be used as hits 




RESUMEN DE LA TESIS “NUEVOS COMPUESTOS TERANÓSTICOS 
MULTIDIANA CONTRA PROTEINOPATÍAS Y ENFERMEDADES 
INFECCIOSAS” 
Introducción 
El proceso de descubrimiento de nuevos fármacos es un camino largo y costoso en el 
que el éxito no siempre está garantizado. Las grandes inversiones y nuevas tecnologías 
aplicadas en este proceso durante las últimas décadas, no se han visto reflejadas en el 
número de fármacos comercializados, especialmente en el caso de enfermedades de 
etiología compleja, como las neurodegenerativas las cardiovasculares o el cáncer. Por 
estos motivos, es necesario empezar a aplicar nuevas estrategias en el diseño de 
fármacos. En el caso de las enfermedades multifactoriales, que involucran diversos 
receptores y vías de señalización, la inhibición de una sola diana no conlleva un 
significativo efecto terapéutico. De esta manera, una estrategia prometedora sería el 
empleo de compuestos multidiana capaces de inhibir diferentes vías de señalización de 
manera simultánea. Por otro lado, la ineficacia de muchos fármacos en fases clínicas se 
achaca a su administración tardía, cuando las enfermedades están demasiado 
desarrolladas. En este contexto, el empleo de compuestos teranósticos capaces de 
detectar y tratar la enfermedad de manera simultánea parece una herramienta 
prometedora. La suma de ambas estrategias en una sola entidad química parece una 
metodología prometedora para el desarrollo de nuevos fármacos contra enfermedades 
neurodegenerativas. 
Objetivos 
En la presente tesis se han planteado los objetivos de desarrollar diferentes familias de 
compuestos basados en algunas de las estrategias anteriormente comentadas, frente a 
proteinopatías, entre las que se incluyen las enfermedades de Alzheimer y la diabetes 
mellitus tipo 2, o enfermedades infecciosas como la tuberculosis o leishmaniasis. 
- En primer lugar, se planteó el diseño, síntesis y caracterización de una familia de 
agentes teranósticos basados en un núcleo de estirilquinolina. Para mejorar sus 




-  En segundo lugar, se planteó el diseño, síntesis y caracterización de una familia de 
estirilquinolinas que posean cadenas poliamínicas en la position 4 del núcleo de 
quinolina, con el fin de incrementar así su basicidad y favorecer su acumulación 
mitocondrial, lo que resulta especialmente toxico para este tipo de parásitos. 
- En tercer lugar, nos planteamos el desarrollo de una nueva metodología one-pot en 
condiciones mecano-químicas para el desarrollo de bis-indolilquinonas, compuestos 
interesantes para el posible desarrollo de sondas MSOT. 
- Finalmente, nos planteamos el diseño, síntesis y caracterización de una quimioteca 
de compuestos multidiana con actividad antituberculosa, basados en estructuras 
hibridas pirrol-isoniazida, capaces de inhibir simultáneamente MmpL3 e InhA, 
ambas proteínas esenciales para la supervivencia de Mycobacterium tuberculosis. 
Resultados y discusión  
La familia de estirilquinolinas teranósticas ha sido sintetizada gracias a una ruta en 
cuatro pasos que nos permite obtener los compuestos deseados con buenos 
rendimientos. En primer lugar, sus propiedades farmacológicas han sido estudiadas 
gracias a la colaboración de las Drs. Paloma Bermejo y Sagrario Martín Aragón, que han 
confirmado sus propiedades neuro protectoras en un modelo de toxicidad celular por 
ácido okadaico, así como su capacidad de inhibir la agregación de la proteína tau. En 
segundo lugar, su complete caracterización espectroscópica, así como su capacidad para 
detectar agregados de distintas proteínas amiloidogénicas, ha sido realizada por las 
Dras. María Antonia Martín y Ana Isabel Olives. 
 
Finalmente, su capacidad de actuar como sensores de distintos tipos de agregados ha 
sido verificada. En primer lugar, gracias al Dr. Gonzalo León se evaluó su capacidad para 
detectar agregados de -amiloide en muestras de corteza somatosensorial en un 




sensores ex-vivo de -amiloide fue evaluada en muestras humanas de corteza temporal 
de pacientes con la enfermedad de Alzheimer. 
Debido a su capacidad de interactuar con agregados amiloides, las estiririlquinolinas 
fueron empleadas para detectar agregados de amilina, proteína sobreexpresada en 
diabetes mellitus tipo II que podría estar relacionada con el desarrollo de la enfermedad 
de Alzheimer en este tipo de pacientes. Este estudio se llevó a cabo en colaboración con 
el grupo dirigido por el Dr. Manuel Benito. 
 
 
La actividad leishmanicida de la quimioteca de 4-amino-2 estirilquinolinas, fue evaluada 
gracias al grupo del Dr. Luis Rivas, presentando actividades e índices de selectividad 
prometedores. Debido a estos resultados, se realizaron diversos estudios mecanísticos 
que permitieron verificar la habilidad de estos compuestos para alterar la polarización 











Con el fin de desarrollar compuestos con estructuras tipo push-pull que sirvan como 
sondas MSOT, hemos desarrollado una nueva metodología one-pot en condiciones 
mecanoquímicas que nos permite la obtención de los núcleos de bis-indolilquinonas en 
un solo paso. 
 
Finalmente, la quimitoteca de compuestos híbridos pirrol-isoniazida fue sintetizada y 
debidamente caracterizada. Su actividad antituberculosa fue evaluada mostrando 
resultados prometedores contra Mycobacterium tuberculosis. Posteriores estudios 
mecanísticos corroboraron su habilidad para inhibir tanto MmpL3 como InhA, probando 
así que su acción tiene lugar a través de un mecanismo multidiana activado por el 
metabolismo (metabolism-activated multitargeting, MAMUT).  
 
Conclusiones 
El trabajo desarrollado en la presente tesis doctoral verifica que el empleo de 
compuestos teranósticos y multidiana, resulta una estrategia prometedora para el 
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1.1. What is a theranostic agent? 
The “theranostic” concept was firstly proposed in 2002 by Funkhouser 1 to describe a 
material that combines the modalities of therapy and diagnostic imaging, providing 
therapeutic effects and diagnostic imaging simultaneously under the same dose. 2 
(Figure 1.1)  
 
Figure 1.1. Theranostic concept. 
 
In many different pathologies such as infections, cardiovascular diseases, 
neurodegenerative and inflammation-related disorders or cancer,3 before starting any 
kind of treatment it is fundamental to carry out imaging diagnostic tests to evaluate the 
stage of advancement of the disease. The current approach of using different agents for 
diagnosis and therapy usually provides several drawbacks in terms of selectivity and 
biodistribution.  
Against this backdrop, the idea of combining these two different objectives in one 
chemical entity brings the opportunity of overcoming these undesirable side effects. 
Over the last decades the concept of individualized medicine is gaining more relevance 
as an approach that can afford more effective and personalize treatments.4 
Simultaneously, as the data show (Figure 1.2), the theranostic field is also becoming a 
topic of broad interest as one of its main goals is to provide real time information of the 
diseased tissues and drug efficacy and kinetics.  This technology not only allows to save 
time and decrease costs, but also enables physicians to make well informed decisions 
 
1 Funkhouser, J. Curr. Drug Discovery 2002, 2, 17. 
2 Kelkar, S. S.; Reineke, T. M. Bioconjug. Chem. 2011, 22, 1879. 
3 Shetty, Y.; Prabhu, P.; Prabhakar, B. Int. J. Pharm. 2019, 558, 29. 
4 Warenius, H. M. Expert Opin. Med. Diagn. 2009, 3, 381. 
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regarding dose adjustment, variations of delivery routes or discontinuation of 
treatments, obtaining better patient outcomes.5,6,7,8 
 
Figure 1.2. Number of publications per year in the corresponding fields. Data obtained from SciFinder. 
Progress in molecular biology, material science and imaging techniques are essential to 
propel the development of theranostics. 
1.2. Non-invasive diagnosis techniques 
Since the theranostic approach needs non- invasive molecular imaging technologies to 
facilitate the visualization of different in vivo phenomena, current imaging techniques, 
such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasound 
imaging (US), single photon emission computed tomography (SPECT), positron emission 
tomography (PET), optical imaging (OI) and fluorescence imaging (FI) are under study.9 
One important aspect in the choice of technique is the need for a contrast agent, which 
requires a pre-scan in order to detect the amount of signal preceding the contrast agent 
administration, thus no background signal is detected and consequently anatomical 
information is not provided. 
 
5 Shetty, Y.; Prabhu, P.; Prabhakar, B. Int. J. Pharm. 2019, 558, 29. 
6 Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Mol. Pharm. 2010, 7, 1899.  
7 Duncan, R. Nat. Rev. Drug Discov. 2003, 2, 347. 
8 Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nat. Nanotechnol. 2007, 2, 751. 
9 Kunjachan, S.; Ehling, J.; Storm, G.; Kiessling, F.; Lammers, T. Chem. Rev. 2015, 115, 10907. 
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Among the technologies mentioned above, CT, US and MRI do not need to be used with 
a contrast agent, while SPECT, PET, OI and FI need the presence of a contrast agent to 
achieve suitable detection, For this reason, hybrid techniques such as PET-CT, SPECT-CT 
or PETC-MRI have been developed. These technologies afford the possibility of locating 
the contrast agents in the correct organs or tissues.9  It is important to consider that each 
of these imaging techniques is used for different purposes, depending on its capabilities. 
Since each of them has different advantages and disadvantages is better to have a 
deeper understood. (Figure 1.3) 
 
Figure 1.3. Reproduced with permission from reference. 9 
 
1.2.1.  Computed tomography (CT)  
Computed tomography is an X-ray-based imaging technique that allows the visualization 
of cross-section images from the organs and tissues of interest. High-resolution images 
are obtained in the presence of highly radiopaque contrast agents, such as iodine or 
barium.  
CT is mainly used for visualizing high electron density tissues, such as bones, 
consequently, is mainly used for orthopaedic applications. Its main drawback is 
associated with the low sensitivity of the contrast agents, requiring high doses and the 
consequent toxicity-associated problems.9 
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1.2.2. Magnetic resonance imaging (MRI) 
Magnetic resonance imaging and nuclear magnetic resonance (NMR) are based on the 
same principle, in which the spin states of certain atomic nuclei are detected.  
 As MRI can be done in the presence or absence of contrast agents, it is widely used for 
diagnosis, therapy monitoring, biodistribution or pharmacokinetic assays. Thus, MRI is a 
versatile tool for (pre)clinical diagnosis and therapy monitoring.9  
The contrast generation depends on freely diffusing water molecules, meaning that the 
signals of a tracer would be different inside or outside a nanocarrier. Thus, MRI is a 
perfect technique to monitor drug release and efficacy. 10 
On the other hand, MRI has several disadvantages usually associated with low contrast 
agent sensitivity and difficulties in quantification.  
 
1.2.3. Positron emission tomography (PET) 
During a positron emission tomography (PET) experiment, positron-emitting isotopes, 
such as 11C, 13N, 15O, 18F, 44Sc, 62Cu, 64Cu, 68Ga, 72As, 74As, 76Br, 82Rb, 86Y, 89Zr or 124I, are 
administered. These radionuclides emit positrons that annihilate with nearby electrons, 
generating two photons that shoot off in opposite directions and can be detected by the 
PET scanners. Thanks to the exceptional penetration depth of these photons and the 
high sensitivity of PET scanners, radionuclides can generate useful and quantitative 
information even when administered below picomolar concentrations. Due to these 
properties PET is widely used in clinic for diagnosis, disease staging, and therapy 
monitoring. Moreover, is an interesting technique to monitor drug pharmacokinetics, 
biodistribution, and accumulation at its target site. 
The radionuclide necessary for PET probes can be encapsulate via chelating groups such 
as 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA), 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or hydrazinonicotinic acid 
 
10 Terreno, E.; Castelli, D. D.; Viale, A.; Aime, S. Chem. Rev. 2012, 110, 3019. 
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(HYNIC). Drugs incorporating 11C or 18F can also be synthesized immediately before their 
administration. 
 The main disadvantages associated with PET are the low spatial resolution, the need for 
radioactive probes and the fact that no anatomical information is obtained. 9 
 
1.2.4. Single photon emission computed tomography (SPECT) 
The main difference between PET and SPECT is the type of radiotracers used, some of 
the radionuclides most commonly employed in SPECT are 99mTc, 111In, 123I, and 201Tl. Also, 
while the first technique measures coincident γ-rays, the second one is based on 
noncoincident γ-rays. For this reason, SPECT sensitivity is one order of magnitude lower 
than PET and consequently its quantification is more difficult. 
The main advantage of SPECT is that while in PET all emitted γ-photons have the same 
energy, energies used in SPECT are different. This energy-dependent imaging enables 
the use of different probes at the same time. As in the case of PET. SPECT provides high 
sensitivity, quantitative results and high penetration depth but it lacks anatomical 
information and spatial resolution. In both cases, the need for radioactive probes can be 
regarded a disadvantage. 9 
 
1.2.5. Optical imaging (OI) 
 Due to its simplicity compared to PET or SPECT, interest in the use of optical imaging 
(OI) techniques has increased during the past decades. 
Fluorescence reflectance imaging (FRI) is the most widely employed technique for drug 
delivery monitoring. It allows comparison between free vs. bound ligand, giving valuable 
semiquantitative information about the location of fluoresecence-labeled compounds 
in tissue. The accessibility, sensitivity, low-cost and the possibility of using multiple 
fluorophores at the same time are the main advantages of OI. 
Fluorescence molecular tomography (FMT) enables deeper and more quantitative 
information of the probe biodistribution by using optical measurements through 
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different illumination and detection paths around the tissue of interest and 
mathematically combines this information to reconstruct three-dimensional 
images.11,12,13 Despite the improvements made by FMT, its fundamental limitation is 
that fluorescence signals cannot be precisely localized. For this reason, hybrid 
approaches such as OI-MRI 14  or OI-CT 15 , 16  have been developed that offer highly 
versatile tools with clinical applications. 
The main drawbacks of optical imaging are associated with autofluorescence and poor 
penetration depth, but it is important to remark that these problems can be improved 
by using the appropriate probes. These probes should emit fluorescence in the first 
near-infrared (NIR-I) or second near-infrared (NIR-II) regions (600-1700 nm),17 which 
afford deeper penetration, higher spatial resolution, non-invasive operation, lower 
optical absorption and scattering from biological substrates with minimal tissue 
autofluorescence.18 (Figure 1.4) 
 




11 Ntziachristos, V.; Weissleder, R. Opt. Lett. 2001, 26, 893. 
12 Kunjachan, S.; Pola, R.; Gremse, F.; Theek, B.; Ehling, J.; Moeckel, D.; Hermanns-Sachweh, B.; Pechar, 
M.; Ulbrich, K.; Hennink, W. E.; Storm, G.; Lederle, W.; Kiessling, F.; Lammers, T. Nano Lett. 2014, 14, 972. 
13 Ntziachristos, V.; Bremer, C.; Weissleder, R. Eur. J. Radiol. 2003, 13, 195. 
14 Davis, S. C.; Pogue, B. W.; Springett, R.; Leussler, C.; Mazurkewitz, P.; Tuttle, S. B.; Gibbs-Strauss, S. L.; 
Jiang, S. S.; Dehghani, H.; Paulsen, K. D. Rev. Sci. Instrum. 2008, 79, 10. 
15  Hyde, D.; de Kleine, R.; MacLaurin, S. A.; Miller, E.; Brooks, D. H.; Krucker, T.; Ntziachristos, V. 
Neuroimage 2009, 44, 1304. 
16 Schulz, R. B.; Ale, A.; Sarantopoulos, A.; Freyer, M.; Soehngen, E.; Zientkowska, M.; Ntziachristos, V. IEEE 
Trans. Med. Imaging 2010, 29, 465. 
17 Kenry, D. Y.; Liu, B.  Adv. Mater. 2018, 30, 1. 
18 Staderini, M.; Martín, M. A.; Bolognesi, M. L.; Menéndez, J. C. Chem. Soc Rev.  2015, 44, 1807. 
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1.2.6. Ultrasound imaging (sonography) 
Ultrasound imaging (USI) is based on the principle of back-scattering, which is the 
reflection of waves, particles or signals back to the direction from where they came. US 
can provide real-time and highly spatially resolved images of the area of interest and can 
be carried out with or without contrast agents, usually formed by 1−5 μm sized bubbles 
filled with gas or air. 
Even though US is an inexpensive, fast, versatile and well-established technique, its main 
drawbacks rely on the low versatility of the contrast agent, the impossibility to perform 
whole body images and the high dependency of the quality of the study from the 
operator performing the scan.9  
 
1.2.7. Photo Acoustic Imaging (PAI) 
Photo acoustic imaging is a hybrid technique based on the detection of acoustic waves 
produced as consequence of the absorption of light pulses of ultrashort duration. In 
1880 Alexander Graham Bell described for first time the optoacoustic phenomenon,19 
but its applications were not considered until more recently.20,21,22 
In the past decades, the availability of pulsed laser technology and the sensitive of 
acoustic detectors, created the possibility of developing optoacoustic technologies, 
which enable the visualization of subsurface blood vessels with high resolution.23  
As PAI detection measures the acoustic waves generated by the imaged targets after 
light excitation, it is capable to overcome the problems associated with optical diffusion 
and depth penetration. This way PAI has emerged as one of the most promising imaging 
techniques.17 The main limitation of this type of detection is the light scattering created 
by biological tissues. Several endogenous species, such as haemoglobin and 
deoxyhaemoglobin, are PAI-active because they absorb light significantly in the desired 
 
19 Bell, A. G. Am. J. Sci. 1881, 20, 305. 
20 Rosencwaig, A. Science 1973, 181, 657. 
21 Bowen, T.; Nasoni, L.; Pifer, A. E.; Sembroski, G. H. Proc. IEEE Ultrasonics Symp. 1981, 2, 823. 
22 Oraevsky, A. A.; Jacques, S. L.; Esenaliev, R. O.; Tittel, F. K. Proc. SPIE 1994, 2134A, 122. 
23 Wang, X.; Pang, Y.; Ku, G.; Xie, X.; Stoica, G.; Wang, L. Nat. Biotechnol. 2003, 21, 803. 
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wavelength range, but unfortunately, they do not produce a sufficiently strong PA 
signal.24 
PA imaging is usually performed in the NIR-I region (700-900 nm), so that deeper 
penetration can be achieved, and unwanted background signals can be avoided. For this 
purpose, the best option is the use of exogenous PA probes. The detection of these 
probes usually requires its differentiation from background absorption, and this has led 
to the development of multispectral optoacoustic tomography (MSOT), which measures 
chromophores over background tissue absorption. In this technique pulses of different 
wavelengths, selected to excite the PA agent, are used simultaneously. In response to 
absorption the PA agent undergoes a thermoelastic expansion that emits ultrasound 
waves, which can then be detected by acoustic detectors. Afterwards, using appropriate 
mathematical methods, images of the tissues are obtained. 25  One of the main 
advantages of this technique is that by scanning at different bands, multiple 
chromophores can be detected in the same imaging session. To summarize, PA emerges 
as a new, fast, versatile technique that needs to be explored more deeply.  On the other 
hand, its main drawbacks are once again the limitations of the existing contrast agents 
and on the operator performing the scan. (Figure 1.5) 
 
Figure 1.5. Reproduced with permission from reference. 26  
 
24 Kenry, D. Y.; Liu, B. Adv. Mater. 2018, 30, 1. 
25 Ntziachristos, V.; Razansky, D. Chem. Rev. 2010, 110, 2783. 
26 Gujrati, V.; Mishra, A.; Ntziachristos, V. Chem. Commun. 2017, 53, 4653. 
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1.3. Design of imaging probes  
As previously mentioned, one of the limiting factors in both OI and PAI is the selection 
of the appropriate probes. Thus, when it comes to the design of imaging probes several 
considerations should be taken into account. In the next section the essential 
characteristics that they should exhibit will be discussed. 
 
1.3.1. Design of fluorescence probes 
When a determined amount of energy is given to a molecule, electrons promote from 
an occupied, low-energy molecular orbital to an empty, higher-energy one, and that 
transition corresponds to an absorption band in the spectrum.  In many cases this energy 
is dissipated by collision with the solvent, but in the case of fluorescent compounds the 
excited electrons return to the ground state by emission of photons. This phenomenon 
is known as fluorescence. 
 The difference in energy between the highest occupied molecular orbital (HOMO) and 
the lowest unoccupied molecular orbital (LUMO) is the smallest difference of energy 
that can be found between a full and an empty orbital. This is the so-called HOMO-LUMO 
gap, which is correlated with the emission and absorption wavelengths.  
As previously mentioned, in vivo fluorescence probes should ideally possess certain 
spectral properties, such as: emission in the NIR-I or NIR-II regions, high fluorescence 
quantum yields and a large Stokes shift. Smaller HOMO-LUMO gaps are associated with 
longer absorption and emission wavelengths, and for this reason, NIR probes must be 
designed with the aim of reducing the HOMO–LUMO gap. (Figure 1.6) 






Apart from suitable spectral properties, fluorescence probes should present: high 
specificity, sensitivity and affinity, the ability to change their fluorescence properties 
upon target binding, minimum interference with human serum albumin (HSA) allowing 
in vivo applications, suitable lipophilicity to cross membranes and low toxicity. 
For this purpose, there are two potential approaches: the use of fluorescence 
nanoparticles (quantum dots) or small organic molecules. The main advantages of 
nanoparticles are their spectral properties, since they present narrower emission 
spectra and higher Stokes shifts. However, these inorganic nanoparticles usually present 
a high number of health risks, low biocompatibility, low clearance and long-term 
toxicological problems.17,18, 27  For these reasons, organic molecules appear as an 
attractive alternative for developing NIR-I and NIR-II probes.  
 
27  Hardman, R. Environ. Health Perspect. 2006, 114, 165. 
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Focusing our attention on small organic molecules, NIR emission can be achieved by 
following several strategies: 
• Introduction of extended conjugation systems: changes in the conjugation length 
are an effective approach for reducing the HOMO-LUMO energy gap. For this 
reason, the use of extended -systems is a good option for probe construction.18  
• Introduction of push-pull systems: Another approach to reduce the HOMO-
LUMO gap is the introduction of electron donors (D) and electron acceptor 
groups (A) as terminal moieties of the conjugated system, leading to the so-
called push-pull systems. In the past years, several authors have also introduced 
D-A-D systems in order to obtained longer absorption and emission wavelengths. 
Moreover, to achieve NIR-II probes, dialkyl fluorenes were introduced in these 
structures as shielding (S) groups, obtaining S-D-A-D-S sturctures.24 
The reason why these push-pull systems works is that D-A molecules can be 
described by two resonance forms: one neutral and one zwitterionic, the latter 
of which mimics the excited state better. Thus, due to the presence of this kind 
of D-A systems the whole molecule is more polarized and consequently the 
ground state is closer to the excited state, meaning that less energy is needed 
for excitation.18 
On one hand, the electron donor group has to bear a lone pair of electrons in a 
-orbital that can be shared with the -molecular orbital of the conjugated 
system. On the other hand, the electron-acceptor group must have antibonding 
free -orbitals. This way, the energy of the HOMO is increased and the LUMO is 
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• Bond length alternation (BLA):  BLA is the difference in length between 
consecutive single and double bonds. Its value quantifies the delocalization of 
electrons across a molecule.  
A standard single bond measures 154 pm and a double bond 134 pm. In a 
conjugated system a C-C single bond has slightly shorter length and consequently 
a partial double character. For this reason, these bonds are harder to rotate and 
molecular structures tend to adopt planar conformations. BLA values close to 
zero means that the overlap is great, the system is highly conjugated, and the 
electrons are very delocalized. Push-pull systems also increase the double bond 
character and consequently reduce the BLA value.18  
• Planarity:  In planar molecules -orbitals overlap and combine better. As 
previously mentioned, this allows strong  conjugation and better electron 
delocalization. This explains why fluorescence emission of solid compounds 
takes place at longer wavelengths. Planarity is a common structural character 
but is not essential.18  
 
1.3.2. Design of MSOT probes 
As with fluorescence probes, to design MSOT probes for in vivo imaging, they must have 
some general characteristics such as: low toxicity, bio-compatibility, high specificity, 
sensitivity and affinity, suitable lipophilicity to cross membranes and good clearance 
values. 
Several inorganic nanoparticles have been described as MSOT probes, but even though 
they commonly present better spectroscopic profiles, their toxicity and low clearance 
make them inappropriate candidates for in vivo imaging. In this context, small organic 
molecules appear again as a better alternative.26 
When it comes to the spectral properties, although many fluorophores present 
absorption spectra suitable for MSOT, they do not have the proper characteristics for 
Chapter 1. Introduction 
15 
 
optoacoustic detection. This kind of probes should ideally present the following 
properties:26,28 
• Absorbance maximum (λ abs) should be between 680 and 950 nm in order to 
achieve minimal interference from tissues.  
• High absorption, meaning a high molar extinction coefficient (>104 M−1 cm−1) to 
maximize the amount of light absorbed. 
• Low fluorescence quantum yield in order to minimize the emission of light 
energy and maximize the production of acoustic waves. Apart from quantum 
yield, other parameter such as solubility, triplet state contributions, excited state 
absorption, relaxation kinetics can affect the photoacoustic signal strength. 
• Efficient conversion of heat energy to produce acoustic waves. 
• Narrow spectral profiles, leading to more accurate and sensitive measurements 
and avoid overlapping spectral responses. 
• Resistant to photodynamic damage of bleaching following excitation.  
• Contrast agent efficiency: to accurately measure the probe efficiency it should 
be concentration-normalized (cm-1/(mg/mL)). This value shows the optical 
absorption coefficient (in cm-1) that can be created in the target volume by using 
a 1 mg/mL concentration of the contrast agent. For example, some inorganic 
compounds, such as gold nanoparticles, present high molar extinction values but 
compared to other chromophores they are quite large and heavy. Thus, after 
normalizing by molecular weight, organic dyes may have higher absorptivity.11 
Depending on their specificity, MSOT probes can be divided in two main groups:26 
• Non-specific imaging probes, which provide contrast wherever they are 
delivered. Thus, successful imaging depends on compound biodistribution. 
• Specific imaging probes target tissue sites or moieties. In this case the imaging 
not only depends on biodistribution, but also on target binding. They can be 
divided in two main categories: 
- Probes binding to specific receptors or preferentially encapsulated by specific 
uptake mechanism. 
 
28 Knox, H. J. Acc. Chem. Res. 2018, 51, 2897. 
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- Activatable probes, which change their spectral properties (shift in the 
absorption peak wavelength) upon changes in molecular or biochemical 
parameters (enzymes, pH, ROS, analytes…). This kind of probes minimize the 
influence of the background signal from endogenous chromophores, 
appearing as the most attractive alternative due to their higher specificity and 
sensitivity. 
 
From a chemical point of view, the structure of these probes can be tuned in order to 
optimize their properties.  The main problems of organic MSOT probes are associated 
with low molar extinction coefficients, tendency to aggregate, low solubility and 
photobleach. To avoid these issues an ideal MSOT dye must possess:26,29 
 
• Conjugated double bonds or aromatic systems in order to present higher molar 
extinction coefficient in the NIR region. 
• D-A or D-A-D push-pull structures, to produce sharp absorption bands in the NIR 
region. 
• Hydrophilic groups to present better solubility and avoid aggregation issues. 
• Introduction of triplet state quenchers to inhibit fluorescence.30,31 




29 Weber, J.; Beard, P. C.; Bohndiek, S. E. Nat. Publ. Gr. 2016, 13, 639. 
30 Onoe, S.; Temma, T.; Kanazaki, K.; Ono, M.; Saji, H. J. Biomed. Opt. 2015, 20, 096006. 
31 Gong, W.; Das, P.; Samanta, S.; Xiong, J.; Pan, W.; Gu, Z.; Zhang, J.; Qu, J.; Yang, Z. Chem. Commun. 2019, 
55, 8695. 
32 Reynolds, G. A.; Drexhage, K. H. J. Org. Chem. 1977, 42, 885. 
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1.4. Protein misfolding diseases (PMDs) 
Proteins are one of the most versatile macromolecules. Mammalian proteomes include 
between 10.000 and 20.000 proteins, and to maintain its integrity there must be a 
balance between protein synthesis, folding and degradation. 
The number of conformations that a small polypeptide (about 100 amino acids) can 
adopt is about 1030.33  However, the biologically active conformation is usually only 
stable under physiological conditions. Thus, is not surprising that errors frequently take 
place during the folding process, giving misfolded states and aggregates. 34  These 
aggregates cause the loss of function or toxicity of the proteins leading to the so-called 
proteinopathies. 
In 1854, Rudolph Virchow introduced the term amyloid, from the Latin amylum and 
meaning “starch-like”, to describe a macroscopic tissue abnormality that, like starch, 
could be stained with iodine. It was in 1859 when Friedreich and Kekulé identified 
proteins as the real molecular main component of the amyloid deposits. 35  The 
abnormalities that Virchow described are the main hallmark of proteinopathies. 
Depending on the aggregated protein and the tissue of accumulation, this misfolding 
can lead to several diseases. Moreover, these kinds of diseases can be separated into 
two main groups:36 
1. Loss-of-function: characterized by protein dysfunction resulting from mutations 
that produce metastable proteins prone to degradation. Examples of these 
diseases are: cystic fibrosis, Gaucher’s disease, hypogonadotropic 
hypogonadism, nephrogenic diabetes insipidus or retinitis pigmentosa. 
2. Toxic gain-of-function: characterized by the formation of metastable proteins 
that lead to toxic oligomers or aggregates that affect cell functions. Examples of 
such diseases are: Alzheimer’s disease, Type II diabetes, Parkinson’s disease, 
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease), Huntington’s disease, 
 
33 Dobson, C.M.; Sali, A.; Karplus, M. Angew. Chem. 1998, 37, 868. 
34 Hartl, F. U. Annu. Rev. Biochem. 2017, 86, 21. 
35 Bayer, T. A. P Eur. Neuropsychopharmacol. 2015, 25, 713. 
36 Denny, R. A.; Gavrin, L. K.; Saiah, E. Bioorg. Med. Chem. Lett. 2013, 23, 1935. 
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Creutzfeldt-Jakob disease (mad cow’s disease) or Familial amyloid 
polyneuropathy  
This list is by far not complete, but they reflect the heterogeneity of different 
proteinopathies. Some of them are characterized by a single type of aggregate, while 
others can present two or more aggregated proteins. (Figure 1.8) 
 
Figure 1.8. 
Under physiological conditions, aggregation-prone proteins are usually soluble and lack 
pathogenic properties, but their conformational change and its consequent change in 
its aggregation properties is the key step to trigger pathogenic aggregation. There are 
several factors that can alter the conformational stability and initiate the aggregation 
processes:35,37,38 
• Genetic mutations on structural regions of the protein can change their 
physicochemical properties and make them more prone to aggregation 
processes. 
• Mutations in regulatory regions can activate their transcription increasing their 
concentration and shifting the equilibrium toward the aggregation products. 
 
37 Shelkovnikova, T.A.; Kulikova, A.A.; Tsvetkov, Ph.O.; Peters, O.; Bachurin, S.O.; Buchman, V.L.; Ninkina, 
N.N. Mol. Biol. 2012, 46, 362. 
38 Melki, R. The multitude of therapeutic targets in neurodegenerative proteinopathies. Disease-Modifying 
Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies, Elsevier Inc. 
2017. doi:10.1016/B978-0-12-805120-7.00001-4. 
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• Truncation and/or post-translational modifications of the protein, which change 
their physicochemical properties.  
• Interaction with another aberrant protein that acts as a template and triggers 
conformation change. This can also be consider a propagation pathway, and a 
wide range of recent experimental evidence suggest that protein aggregates can 
spread in such a prion like manner. 
•  Several environmental changes as: oxidative stress, metal ions, neurotoxins or 
virus infections can also alter protein conformation.  
 
Once the aggregation-prone protein changes its conformation, the first aggregation step 
is oligomerization, and next these oligomers form soluble protofibrils. Both processes 
take place in a functionally active space of the cell and are cytotoxic. Most frequently 
this kind of structures produce membrane damage, as they have exposed sticky surfaces 
(hydrophobic amino acid residues), which have the ability to disturb phospholipid 
bilayers. The most frequently damaged organelle is the mitochondrion, whose 
membrane permeability is changed, leading to alterations in electron transport and 
overproduction of reactive oxygen species. Usually these soluble oligomers and 
protofibrils contribute considerably to cell degeneration, and therefore the subsequent 
steps of the aggregation pathway are considered as elements of protective mechanisms. 
Protofibrils are transformed into insoluble fibrils and later into larger packed fibrillar 
structures. These denser packs act as a trap for other proteins or even organelles. This 
last product of protein aggregation does not have a direct toxic effect and it may form 
deposits if cells fail to eliminate it in previous steps.  
The integrated cellular machinery that regulates the synthesis, proper folding, 
degradation and clearance of proteins is known as proteostasis. The proteostatic system 
is regulated by two main components, the chaperones that refold proteins into a stable 
conformation and two proteolytic pathways, namely the ubiquitinproteasome and the 
lysosome-autophagy system. (Figures 1.9 and Figure 1.10)        




Figure 1.9. Stages in protein aggregation. 
 
Figure 1.10. The proteostatic system. Reproduced with permission from reference. 39 
 
1.4.1. Alzheimer’s disease (AD) 
In 1906 Auguste Deter died at the age of 51, she had been internalized in a mental 
asylum after experimenting progressive changes in her personality, loss of memory and 
hallucinations. Auguste ended up completely apathetic and losing the ability to speak. 
 
39 Kaushik, S.; Cuervo, A. M. Nat. Med. 2015, 21, 1406. 
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After her death, Dr. Alois Alzheimer examined her brain, finding pathological hallmarks 
and introducing the term Alzheimer´s disease (AD).40 
During the last decades the population above 65 has increased exponentially, thus 
leading to an associated surge in age-related diseases, such as dementia. Nowadays, AD 
is the most common form of dementia, forming between 60 to 70 % of the cases.41 In 
2018, the number of people diagnosed with dementias was estimated to be about 50 
million, in 2030 it is projected to be 65 million, and 115 million by 2050. These data show 
the important socio-economic impact of these diseases.42 
AD is described as a chronic and progressive neurodegenerative disease, with a still 
unclear etiopathology, that is known to appear several years before the clinical 
symptoms.  The severity of these symptoms is a reflection of the neuronal damage that 
the disease produces. Depending on the onset of the disease it can be classified into 
different stages:43 
1. Predementia: no symptomatology. 
2. Mild cognitive impairments: recent memory loss. 
3. Early-moderate dementia: difficulty in daily tasks, communication, changes in 
personality, reasoning difficulties and poor judgment. 
4. Late stage dementia: social isolation, disorientation and complete dependency. 
Nowadays, diagnosis is mainly base on cognitive, physical and neurobiological tests.42 
Even though significant advances in different fields as molecular biology or genetics have 
been made, the specific causes of AD remain unclear. Currently, the main hypothesis is 
that Alzheimer’s has a multi-factorial etiology, in which several biochemical pathways 
are involved including: beta-amyloid aggregation, forming amyloid plaques, intracellular 
neurofibrillary tangles, containing hyperphosphorylated tau protein, calcium 
homeostasis deregulation, mitochondrial dysfunction, oxidative stress, 
 
40 Cipriani, G.; Dolciotti, C.; Picchi, L.; Bonuccelli, U. Neurological Sciences, 2011, 32, 275. 
41 Association, A. Alzheimer´s & Dementia: The Journal of the Alzheimer´s Association, 2018, 14, 367. 
42 Dementia: a public health priority. World Health Organization. World Health Organization 2012. 
43  Early signs and symptoms of Alzheimer´s. hhttps:// alz.org/alzheimers-dementia/10_sign?lang=en-
US2019 checked on the 22/01/2020. 
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neuroinflammation and deterioration of synaptic transmission, particularly at 
cholinergic neurons. (Figure 1.11) 
 
Figure 1.11.  
 
1.4.2. Type II Diabetes mellitus (T2DM) 
Diabetes mellitus (DM) is probably one of the oldest diseases known to man, as it was 
first reported in Egyptian manuscript about 3000 years ago. 44  Is a chronic disease 
characterized by hyperglycaemia, insulin resistance, and relative insulin deficiency. 
T2DM is much more common (more than 90% of all cases) than either type 1 diabetes 
mellitus (T1DM) or gestational diabetes.  Even if the exact aetiology of T2DM remains 
unclear, it is known that it results from an interaction between genetic, environmental 
and behavioural risk factors. Further, T2DM patients are more vulnerable to various 
microvascular complications, such as retinopathy, nephropathy and neuropathy or 
 
44 Ahmed, A. M. Saudi Med. J. 2002, 23, 373. 
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macrovascular complications, as a heart attack and stroke, which often lead to their 
premature death.45 
Usually, T2DM starts with insulin resistance in skeletal muscle, liver and adipose tissue, 
follow by a progressive impairment of insulin secretion by pancreatic β‑cells. The 
prediabetic stage is characterized by fasting plasma glucose levels that are higher than 
normal but do not meet the criteria for the diagnosis of diabetes. The clinical 
presentation of patients with diabetes can vary considerably among individuals, making 
the classification of T2DM difficult. Moreover, at the diagnosis time, many patients are 
asymptomatic, while others present severe hyperglycaemia or even diabetic 
ketoacidosis. For this reason, screening risk individuals is important, as is common than 
around of 30% of T2DM patients are undiagnosed.46 
In the past decades, T2DM has become a major global public health concern. In 2013 
the International Diabetes Federation estimated that there were 382 million T2DM 
patients worldwide, and this number is expected to increase to 592 million by 2035. 
Surprisingly, particularly affected areas are China and India, where the prevalence of it 
has dramatically increased despite the relatively low obesity prevalence, this is due to 
the fact that, with the same body mass index, Asians tend to have a higher percentage 
of body fat mass, greater abdominal obesity and less muscle mass.46  
During recent years, epidemiological studies have improved our understanding of T2DM 
risk factors. Increasing adiposity is the most important one. In addition, good dietary 
habits, enough physical activity, sleeping habits and no cigarette smoking are also 
associated with a reduced risk of T2DM. Although genetics plays a key role in T2DM 
development, the ongoing diabetes epidemic cannot be explained by just by genetic 
mutations.46  
From a molecular point of view, after a meal insulin secretion is stimulated and glucagon 
secretion is inhibited. Together, the changes in glucagon, glucose and insulin levels 
 
45 Olokoba, A. B.; Obateru, O. A.; Olokoba, L. B. Oman Med. J. 2012, 27, 269. 
46 DeFronzo, R. A.; Ferrannini, E.; Groop, L.; Henry, R.R.; Herman, W. H.; Holst, J. J.; Hu, F.B.; Kahn, C. R.; 
Raz, I.; Shulman, G.I.; Simonson, D. C.; Testa, M. A.; Weiss, R. 
Nat. Rev. Dis. Prim. 2015, 1, 1. 
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suppress hepatic glucose production, stimulate muscle glucose uptake and inhibit 
lipolysis. In type 2 diabetes all these processes are altered. Insulin secretion is impaired, 
plasma glucagon levels are increased, failing to suppress normally after a meal; analogy 
hepatic glucose production and plasma free fatty acid levels, also increase instead of 
being inhibited and finally muscle glucose uptake fails. (Figure 1.12) 
As shown, T2DM is a complex chronic disorder which should be viewed and treated as a 
multifactorial disease with multiple physio pathological abnormalities. This way, to find 
a ¨true cure¨’ for T2DM requires the elucidation of its molecular aetiology.46 
 
Figure 1.12. Reproduced with permission from reference.47 
 
47 Cornell, S. Ther. Clin. Risk Manag. 2015, 11, 621. 
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1.5. Neglected tropical diseases (NTDs) 
Neglected tropical diseases are a diverse group of infections, commonly from tropical or 
sub-tropical low-income regions of Asia, Africa or America. (Figure 1.13) NTDs can be 
considered to arise a result of poverty and they contribute to develop further poverty. 
Moreover, the prevalence of some of them has been proposed as an indicator of 
underdevelopment. It is estimated that more than 1 billion people is infected with one 
or more NTDs and another billion is at risk. This group of diseases share some 
characteristics, including:48 
• Slow development which becomes progressively worse. 
• Usually they are chronic and can cause irreversible damages. 
• Patients with NTDs are often stigmatised and excluded. 
• Usually affect people without access to sanitation, safe water or basic heath. 




NTDs are mainly caused by viruses, bacteria, protozoa and helminths. The main 
examples in each category are:48 
• Viruses: dengue and rabies. 
• Bacteria: leprosy, tuberculosis, trachoma and Buruli ulcer. 
• Protozoa: leishmaniasis and trypanosomiases. 
 
48 Molyneux, D.; Foster, A.; Sightsavers, K. H. Community Eye Health Journal, 2013, 26, 21.  
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• Helminths: lymphatic filariasis, onchocerciases, intestinal worms and 
schistosomiasis. 
Depending on the infectious agent the transmission is diverse, including:48 
• Vectors like flies or snails. 
• Faeco-oral route or food-related transmission. 
• Fomites or direct contact. 
 Currently available drugs for NTDs present several drawbacks as: low efficacy, high 
toxicity with important side effects, limited number of available treatments, long 
treatments needed and the appearance of resistant strains. For this reason, the research 
for new drugs for the treatment of these diseases is still an imperative. 
 
1.5.1. Leishmaniasis 
Leishmaniases are a group of protozoal diseases, caused by over 20 species of the 
gender Leishmania. These parasites are transmitted to the main host, humans or other 
mammals, by the bites of their infected vectors, female Phlebotomus or Lutzomyia sand-
flies.  There are between 12 and 15 million people infected worldwide, and 350 million 
are at risk of acquiring the disease.  It is estimated that around 1.5 to 2 million patients 
acquire leishmaniasis each year, and it causes 70.000 deaths per year. There are three 
main forms of leishmaniasis.49 (Figure 1.14) 
1. Cutaneous leishmaniasis is endemic in more than 70 countries around Central 
and South America, Middle East, Central Asia and Africa. 
2. Mucocutaneous leishmaniasis is observed mostly in Latin America and rarely in 
Africa. 
Their mains symptoms are: 
- Single or multiple lesions on skin, starting with an erythematous papule with 
the sand-fly bite, which enlarge to a nodule and extends in surface and depth, 
ending in ulcers. These ulcers are usually painless and can heal spontaneously 
leaving a scar. 
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- Lesions can also spread into mucosa, giving rise to the mucocutaneous form 
of the disease, which can cause severe disfigurements. 
 
3. Visceral leishmaniasis or Kala-Azar occurs in more than 60 countries around 
Africa, Asia, Central and South America and South Europe. Its symptoms 
leishmaniasis are more severe, ending in pancytopenia, immunosuppression 
and death if left untreated. The starting symptomatology involves irregular 
fever for around 2 weeks, splenomegaly, hepatomegaly, anaemia, diarrhoea, 
epistaxis, lymphadenopathy and weight loss. It is also common that patients 
develop co-infections like bacterial diarrhoea, pneumonia or tuberculosis.  
 
Figure 1.14:  Distribution of leishmaniasis: (A) show cutaneous leishmania distribution while (B) shows 
visceral leishmaniasis distribution. Both data were reported by WHO in 2013. 
 
It is also worth noting that many infected patients do not develop any symptoms 
throughout their lives, remaining as asymptomatic reservoirs of the disease.49 
As regards the biological cycle of Leishmania, the infectious agent is always a unicellular 
protozoon of the Trypanosomatidae family and Leishmania genus. There are two stages 
in its life cycle:50 (Figure 1.15) 
• Amastigotes are non-flagelated intracellular forms, measuring between 2.5-3.5 
μm, which are located in the phagocytic cells of the host. When the uninfected 
female of the phlebotomus bites an infected animal, it absorbs the amastigote 
forms from their blood. During their time in the insect’s gut (between 4-25 days) 
 
49 https://medicalguidelines.msf.org/viewport/CG/english/leishmaniases-16689769.html checked on the 
29/01/2020. 
50 Ocampo, V. D; Gladman, D. F1000Research 2019, 8, 1. 
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the parasite begins its transformation into procyclic amastigote, which finally 
evolves into metacyclic amastigotes. The latter have infectious capacity and after 
biting a healthy mammal, the vector infects it with the regurgitated 
promastigotes. 
• Promastigotes are the flagellated form that measures between 12-20 μm and is 
mainly found in the vectors. When the mammal host is infected, the 
promastigotes are phagocytized by epidermal Langerhans cells or macrophages. 
Even though the mechanism of amastigote uptake is poorly understood, it is 
known that they bind the Fc human receptor, and thus the macrophage infection 
is an immunoglobulin-mediated process. Once inside the phagolysosome, 
promastigotes evolve into amastigotes and proliferate by binary fission. 
The whole biological cycle lasts between 53 to 100 days. 
 
Figure 1.15. 
Regarding the treatments, usually cutaneous lesions heal spontaneously in 3 to 6 
months. If they persist more than 6 months, leading to ulceration, dissemination or 
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disfiguration, pharmacological treatment is needed. First the cutaneous lesions are 
treated with local pentavalent antimonials such as sodium stibogluconate or meglumine 
antimoniate, in more severe cases miltefosine is given orally or a pentavalent antimonial 
is administered intramuscularly or intravenously. 
In the case of visceral leishmaniasis, intramuscular or intravenous pentavalent 
antimonial + paromomycin or paromomycin are administered. In case of relapse or for 
specific vulnerable groups such as pregnant women, patients over 45 years or severe 
disease, liposomal amphotericin B is given by intravenous infusion. 
All the available treatments present serious drawbacks such as low safety, a high rate of 
resistance and cost. As mentioned, these drugs are used as monotherapy or under 
combinations, usually with low tolerability, with long treatment durations and difficult 
administration routes. 
 
1.5.2. Tuberculosis (TB) 
In 1882, Robert Koch identified Mycobacterium tuberculosis as the causative agent of 
tuberculosis. Nowadays, it is known that tuberculosis is caused by different members of 
this family, which includes: Mycobacterium tuberculosis (Mtb), the main etiologic agent 
of TB in humans; M. africanum, which causes TB in humans only in certain regions of 
Africa; M. bovis, M. caprae and M. pinnipedii, which cause TB in wild and domesticated 
mammals. 
Mtb is an obligated aerobe, a non-motile and non-spore forming bacillum, which is 
classified as weakly gram positive. Mycobacterium tuberculosis owes its high virulence 
to the fact that is an intracellular bacterium, with a high latent capacity, a slow 
generation time (15-20 h) and its major feature is the peculiar cell wall structure, which 
provides an exceptionally strong impermeable barrier to noxious compounds and drugs. 
Moreover, over the last decades the rate of appearance of multiresistant (MDR-TB) and 
extremely multiresistant (XDR-TB) strains has considerably increased, making TB one of 
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the top 10 causes of death worldwide and the leading cause of death from a single 
infectious agent, already above HIV.51,52 
About one quarter of the world’s population is infected with tuberculosis and hence at 
risk of developing the disease. In 2018, about 10 million people developed TB, and 1.2 
million HIV-negative and 251.000 HIV-positive patients died because of it. TB is mainly 
localized in South-East Asia, Africa and the Western Pacific region, even if some cases 
are developed in the Eastern Mediterranean, the Americas or Europe.53 
TB is mainly spread from person to person through the air. When a patient with lung TB 
coughs, sneezes or spits, the TB bacilli are propelled and only a low infectious dose is 
needed to be inhaled to become infected. When a bacillus reaches the alveoli of the 
lungs it is phagocyted by alveolar macrophages. Inside them, most of these bacteria are 
destroyed; but some of them may multiply and be released upon macrophage death. 
This initial stage of the disease is characterized by an innate immune response that 
involves the recruitment of inflammatory cells to the lungs. 
The remaining alive bacilli will spread through bloodstream or lymphatic channels, 
reaching other organs where the disease can be developed, such as: brain, larynx, lymph 
node, lung, spine, bone, or kidney. This dissemination process provokes an adaptative 
immune systemic response, and in 2 to 8 weeks the formed effector T cells and other 
leukocytes migrate to the infectious area, where they digest and surround Mtb forming 
a barrier called granuloma. Granulomas are organized structures where the bacilli are 
controlled that contain macrophages, lymphocytes and fibroblasts. In this stage, 
patients remain as asymptomatic reservoirs of the disease, but are not infectious. This 
stage can last during the whole life of some patients. If the immune system fails to 
control the bacilli, they begin to multiply rapidly, and patients will suffer tuberculosis. 
Among all infected persons without any treatment, about 5% of the infected will 
develop the disease in the first 2 years after infection, and another 5% will develop it at 
some point of their life. It is also well known that several factors can trigger tuberculosis 
development, the most common example is HIV coinfection, which affects CD4 T cells 
 
51 Singh, A.; Budhraj, A.; Shrivastava, A.; Satyavana, A.; Gupta, A.; Gupta, M.; Wadhwa, G.; Sharma, S. K.; 
Jain, C. J. Recent. Pat. Anti-infec. Drug Discov. 2014, 9, 25. 
52 Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. Nature 2011, 469, 483.  
53 Global tuberculosis report, WHO, 2019. 
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that play a pivotal role in controlling Mtb replication. Moreover, biological therapies 
with anti-TNF, corticosteroids, vitamin D deficiencies and any other conditions affecting 
T cell function may also increase the risk of developing the disease. (Figure 1.16) 54,55,56 
The most common type of tuberculosis is the pulmonary disease, which courses with 
cough up to blood or sputum, chest pain, weight loss, weakness, no appetite, fever and 
nigh sweating. 
More rarely extrapulmonary tuberculosis can be developed, usually affecting the larynx, 
lymph nodes, pleura, kidneys, bones or even brain, producing tuberculous meningitis. 
In the most severe cases tubercle bacilli can enter the bloodstream and disseminate to 
all parts of the body, where they grow and cause the disease in multiple sites causing 
miliary tuberculosis, which is fatal if untreated.56 
 
Figure 1.16. Reproduced with permission from reference. 55 
 
54 Delogu, G.; Sali, M.; Fadda, G. Mediterr. J. Hematol. Infect. Dis. 2013, 5, e2013070. 
55 Nunes-Alves, C.; Booty, M. G.; Carpenter, S. M.; Jayaraman, P.; Rothchild A. C.; Behar. S. M. Nat. Rev. 
Microbiol. 2014, 12, 289. 
56  Farhat, M. R.; Shapiro, B. J.; Kieser, K. J.;Sultana, R.; Jacobson, K. R.; Victor, T. C.; Warren, R. M.; 
Streicher, E. M.; Calver, A.; Sloutsky, A.; Kaur, D.; Posey, J. E.; Plikaytis, B.; Oggioni, M. R.; Gardy, J. L.; 
Johnston, J. C.; Rodrigues, M.;Tang, P. K.C.; Kato-Maeda, M.; Borowsky, M.L.; Muddukrishna, B.; 
Kreiswirth, B. N.; Kurepina, N.; Galagan, J.; Gagneux, S.; Birren, B.; Rubin, E.J.; Lander, E. S.; Sabeti, P. C.; 
Murray, M. Nat. Genet. 2013, 45, 1183. 
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Current antitubercular therapy depends on the type of strain causing the infection. In 
the case of drug-susceptible tuberculosis (DS-TB) the first line antitubercular agents can 
be used. This treatment involves isoniazid, rifamycin, pyrazinamide, streptomycin and 
ethambutol. Usually a combination of four of them is taken for 2 months, rapidly killing 
the actively dividing bacteria and resulting in the negativization of sputum. This is 
followed by a continuation phase in which isoniazid and rifamycin are administered for 
another 4 to 7 months, in order to kill any remaining or dormant bacilli and prevent 
recurrence. With this regimen about 95% of DS-TB are cured in about 6 to 9 months. 
The most popular second-line treatments for tuberculosis involve: fluoroquinolones as 
moxifloxacin, levofloxacin and gatifloxacin, aminoglycosides such as kanamycin and 
amikacin the polypeptide capreomycin, cycloserine and the thioamides ethionamide 
and prothionamide.  
MDR-TB are usually resistant to at least isoniazid and rifampicin, while XDR-TB are 
resistant to these two drugs and usually to fluoroquinolones. In these cases, second-line 
antitubercular drugs need to be used. It is worth nothing that some of them are 
injectable forms and usually the treatments last between 9 to 20 months, making then 
long and tedious. Moreover, the cure rates for MDR-TB are quite low, typically ranging 
from 50% to 70%; in the case of XDR-TB, the prognosis is even worse.56 
A further complication comes from the existence of several drug-drug interactions that 
restrain the coadministration of some anti TB agents with certain treatments, such as 
anti-HIV or antidiabetics. For these reasons, to control the diseases there is an urgent 
need to develop new antitubercular agents able to: 57 
- Target MDR and XMDR strains. 
- Lower dosing frequency and simplify day posology. 
- Shorten treatments. 
- Be co-administered with other drugs, such as HIV medications. 
  
 
57 Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. Nature 2011, 469, 483. 
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1.6. Multitarget drugs 
During the 20th century, the “one molecule, one target, one disease” was the main 
approach for drug discovery in pharmaceutical industry. 58  This paradigm helped to 
develop variety of successful selective drugs against certain diseases. However, this 
mindset started to change in 2005 after the publication of the perspective article 
entitled “Designed multiple ligands. An emerging drug discovery paradigm”.59  
In multifactorial pathologies, such as neurodegenerative, cancer, cardiovascular or 
infectious diseases, several receptors or signalling pathways are involved. Thus, the 
inhibition of a single target does not lead to successful drugs. In this context, inhibition 
of several checkpoints of the same disease appears as an attractive alternative. 
Moreover, the mentioned strategy would have the possibility of overcoming resistance 
to single-target agents in chemotherapy.60 
The polypharmacology approach can be achieved by three different strategies:60 
1. Mixture of monotherapies, or drug cocktails: several drugs, each with a single 
active ingredient. 
2. Drug combination: one formula with multiple active ingredients. 
3. Multitarget Directed Ligands (MTDL): one chemical entity with multiple 




58 Medina-Franco, J. L.; Giulianotti, M. A.; Welmaker, G. S.; Houghten, R. A. Drug Discovery Today 2013, 
18, 495. 
59  Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523. 
60  Bolognesi, M. L. Curr. Med. Chem. 2013, 20, 1639. 
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While a mixture of monotherapies can offer a better dose flexibility, sequential 
administration due to clinical experience and lower treatments cost. Multiple directed 
ligands offer easier development and regulatory procedures, reduced adverse effects, 
drug-drug interactions and wider therapeutic windows, higher efficacy due to synergic 
effects, easier pharmacokinetic and pharmacodynamic profiles, resistance development 
prevention and the avoidance of poor patient compliance issues compared to drug 
cocktails. 
On the other hand, developing balanced and multiselective ligands towards multiple 
targets is not an easy process.61 
From an economical point of view, even if the starting hit identification and optimization 
processes would be more expensive, MTDL are more efficient in cost terms. As 
previously mentioned, pharmacodynamic and pharmacokinetic profiles would be 
significantly simpler to study. Formulation and manufacturing would be easier and 
cheaper; and in terms of regulatory approval processes there would be advantages also, 
making them more cost-effective.60 
Depending on their design strategy, MTDL can be classified into three groups:61 (Figure 
1.18)  
1. Hybrid or linked: two or more pharmacophores separated by a linker. The 
position, length and composition of the linker must be rationally designed in 
order to maintain the activity of the pharmacophores. This linker can be 
metabolically stable or both fragments can be cleaved in vivo acting like mutual 
prodrugs. Usually linked pharmacophores are not the best choice due to their 
high molecular weight and consequently poor bioavailability. 
2. Fused: the pharmacophores are partially overlapped. 
3. Merged: with this strategy the highest level of pharmacophore overlapping is 
achieved. For this reason, even if is the most complicated one is the most 
attractive approach in terms of drug-likeness properties.  
 
61 Junting, Z.; Xueyang, J.; Siyu, H.; Hongli, J.; Feng, F.; Wenyuan, L.; Wei, Q.; Haopeng, S. J. Med. Chem. 
2019, 62, 8881. 





Figure 1.18: Different types of multitarget directed ligands. 
 
Finally, a different design strategy is the use of metabolism-activated multitarget ligands 
(MAMUT), based on the combination of synergistic effects of a parent drug and its active 
metabolite(s).62 
1.6.1. Multitarget drug discovery for Alzheimer´s and neglected tropical diseases 
As previously mentioned, the multitarget approach is particularly suitable for the 
treatment of multifactorial diseases.  In this kind of diseases is rare to find one single 
physiological pathway altered, instead the histopathological pathways are usually 
interconnected as networks. These networks have evolved to be very robust and 
reductant. Thus, it is very unlikely that the disease can be stopped by modulating one 
single check-point. This way is clear that a multimodal approach needs to be used to 
impact the disease pathogenesis. 
Apparently, drug discovery approaches for Alzheimer´s and neglected diseases may 
seem the opposite, however nowadays both are mayor worldwide health problems 
without available effective treatments.   
There are about 50 million Alzheimer patients worldwide, and every year 7.7 million new 
cases are diagnosed. It is estimated that this value will increase to 115.4 million in 2050. 
In parallel drug research has accelerated, but no effective drugs have been found. 
Neglected tropical diseases are another of the main health global problems. It is 
estimated that over one billion people are affected worldwide, mainly in low-income 
 
62 Mátyus, P.; Chai, C. L. L. ChemMedChem, 2016, 11, 1197. 
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countries. Nowadays, all the available drugs suffer from toxic side effects, resistance or 
poor efficacy. For these reasons new strategies are needed to beat these diseases. 
In this scenario, MTDL able to inhibit different targets of Alzheimer or neglected diseases 
appear as an attractive alternative, which could be more efficacious, simple and 
adequate.63 
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Objective 1  
The word “theranostic“ describes a compound or material that provides therapeutic 
effects and diagnostic imaging under the same dose. The first objective of this thesis is 
to develop small-molecule theranostic agents for optical detection based on the 2-
styrylquinoline framework. The ideal in vivo fluorescence probe should show emission 
in the near infrared region, high fluorescence quantum yields and a large Stokes shift. 
These features can be achieved by reducing the HOMO-LUMO energy gap by the 
presence of an extended conjugation system and the introduction of an electron donor 
and electron acceptor groups as terminal moieties of the conjugated system. Thus, the 
first objective becomes the preparation and spectral characterization of compounds 




Protein-misfolding diseases are due to errors that take place during the protein folding 
process, giving misfolded states and the so-called amyloid aggregates. They are 
increasingly important and include most of the neurodegenerative diseases (Alzheimer’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, 
Creutzfeldt-Jakob disease, etc.) and type II diabetes, among others. In this context, our 
second objective was to test the styrylquinoline derivatives as theranostic agents in the 
context of Alzheimer’s disease, by studying their neuroprotective properties in parallel 
with their use for the imaging of -amyloid protein. Furthermore, the use of these 
molecules as markers for amylin, an amyloidogenic protein involved in diabetes, was 
also examined.   
 




Quinolines have shown a high potential to develop effective and affordable oral 
treatments as leishmanicidal agents. Using as a starting point the activities of 8-
aminoquinoline-based polyamines, we reasoned that an increase in the positive charge 
of quinoline core would enable the molecules to have a preferential mitochondrial 
accumulation because mitochondria present a high electrochemical potential (m). In 
this context, we designed a library of 2-substituded styrylquinolines, which were 
decorated with polyamine chains in the C-4 position of the quinoline scaffold. The 
presence of the 2-styryl fragment, besides potentially increasing activity according to 
some literature precedent, was expected to confer fluorescence to the molecules and, 




Besides fluorescence-based optical imaging, multi-spectral optoacoustic tomography 
(MSOT) is appealing as an alternative imaging technique, but its main problem lies on 
the difficulty of developing adequate molecules acting as MSOT probes. These probes 
should exhibit absorbance maxima in the NIR range but a low fluorescence quantum 
yield. To achieve this goal, conjugated structures bearing aromatic systems with push-
pull architectures and fluorescence quenchers can be viewed as a good strategy. We 
envisioned the use of dihalo-bis-indolylquinones for this purpose. 
 





Finally, we undertook the preparation and study of antitubercular compounds acting by 
a mechanism designed to involve the synergistic effects of the compound itself and an 
active metabolite. This is an emerging type of multitarget strategy described as 
metabolism-activated multitargeting (MAMUT). More specifically, our compounds are 
meant to act at the MmpL3 mycobacterial membrane transport protein and the InhA 
enzyme, necessary for the biosynthesis of mycobacterial mycolic acids, following 
activation by the katG peroxidase. These compounds are based on a pyrrole framework, 
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3.1. A more detailed view of Alzheimer´s disease etiopathology 
As previously mentioned, Alzheimer´s disease has a complex and multifactorial 
ethology, in which several factor as: -amyloid aggregates, neurofibrillary tangles, 
calcium homeostasis deregulation, mitochondrial dysfunction, oxidative stress, chronic 
neuroinflammation and cholinergic disbalance, are involved. Some of these factors will 
be analysed below. 
 
3.1.1. -amyloid hypothesis 
As its name shows, the amyloid protein precursor (APP) is the protein that initiates the 
cascade of events ending in -sheet aggregation (A). Its physiological function is still 
unknown, although it is thought to be involved in synaptogenesis, neural maturation, 
differentiation and viability. APP is a transmembrane glycoprotein, which under 
physiological conditions is easily metabolized. During the normal process, -secretase 
metabolizes APP into sAPP, an extracellular soluble fragment, and a transmembrane 
C-terminal fragment (CTF), which is further split into P3 and APP intracellular domain 
(AICD) by -secretase; it is worth highlighting that none of these products is toxic. On 
the other hand, under pathological conditions, APP is metabolized by -secretase (-site 
amyloid cleaving enzyme 1, BACE1), leading to sAPP that is further excised by -
secretase, giving AICD and A, which is able to form oligomers, fibrils and finally 
plaques.64 (Figure 3.1)  
This hypothesis was postulated in 1992 by Hardy and Higgins and has been corroborated 
by the studies done in patients with familiar AD, in which mutations in APP, Psen1 or 
Psen2 (genes codifying secretases) were found.65 
Even though no correlation between A plaques and cognitive damage has been found 
yet, it is known that A accumulation precede in 15-20 years the clinical symptoms. 
 
64 Coronel, R.; Bernabeu-Zornoza, A.; Palmer, C.; Muñiz-Moreno, M.; Zambrano, A.; Cano, E.; Liste, I. Mol. 
Neurobiol. 2018, 55, 7107. 
65 Hardy, J. A.; Higgins, G. A. Science, 1992, 256, 184. 
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Nowadays, it is accepted that  aggregation contributes to disease development, even 
if is not its cause.66 
 
 
Figure 3.1: Physiological and amyloidogenic pathways of IAPP. 
3.1.2. Tau hypothesis 
Under physiological conditions, tau oversees the stability and assembly of microtubules, 
it also affects axonal transport and synapses and is involved in protein trafficking and 
signalling.67 
From a structural point of view, tau possess three domains:68 
1. N-terminal or projection domain. 
2. Proline-rich domain, which is the target of serine/proline and threonine/proline 
directed kinases (PDPKs) that regulate the binding to tubulin by 
phosphorylation/dephosphorylation equilibria. 
3. C-terminal or assembly domain, which interacts with microtubules and stabilizes 
them. 
 
66 Herrup, K. Nat. Neurosci. 2015, 18, 794. 
67 Iqbal, K. Alonso, A.; Chen, S.; Chohan, M. O.; El-Akkad, E.; Gong, C.; Khatoon, S.; Li, B.; Liu, F.; Rahman, 
A.; Tanimukai, H.; Grundke-Iqbal, I. Biochimica et Biophysica Acta 2005, 1739, 198. 
68 Rao, S.S.; Adlard, P. A.  Frontiers in molecular neuroscience 2018, 11, 276. 
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The enzyme in charge of modulating tau phosphorylation is glycogen synthase kinase 3 
(GSK3), protein kinase A (PKA), serine/threonine protein phosphatase 2A (PP2A) and 
cyclin-dependent-like kinase 5 (CDK5), which are therefore essential for microtubule 
regulation. In AD patients, the activity of some of these enzymes is compromised and as 
a result the levels of phosphorylated tau increase. Phospho-tau is considered an 
aggregation-prone protein, which generates helical filaments that finally lead to 
neurofibrillary tangles. Moreover, this phosphor-tau accumulation disrupts microtubule 
assembly, which leads to neuronal death.69 (Figure 3.2) 
 
Figure 3.2: Physiological and pathological pathways of tau. 
 
3.1.3. Oxidative stress hypothesis 
A radical is a chemical species that contains one or more unpaired electrons in an atomic 
or molecular orbital, usually coming (in biological settings) from the reduction of an 
oxygen molecule. Reactive oxygen species (ROS) comprise two oxygen radicals, namely 
superoxide anion (O2•-) and the hydroxyl radical (•OH), and hydrogen peroxide 
(H2O2).70  
 
69 Iqbal, K.; Liu, F., Gong, C. X. Nature Reviews. Neurology, 2016, 12, 15. 
70 D'Autréaux, B.; Toledano, M. B. Nat. Rev. Mol. Cell Biol. 2007, 8, 813. 
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While under moderate concentrations ROS play key roles in physiological signaling 
pathways, an increase in ROS activity induces oxidative stress, which in turn leads to 
senescence, which is correlated with pathological processes. Moreover, the main 
characteristics of neuronal tissues are their rich lipid content, high energy demand, weak 
antioxidant capacity and low regenerative ability. For these reasons, the 
hyperproduction of ROS specifically in these tissues causes neuronal death and brain 
damage.71,72  
ROS can be generated through different pathways. In the first place, molecular oxygen 
is transformed into O2•- by accepting one electron through mitochondrial oxidative 
phosphorylation or through the action of several enzymes such as cyclooxygenase (COX) 
and others. Once superoxide anion is formed it can be eliminated by different pathway 
such as superoxide dismutase enzymes (SOD) giving H2O2. This hydrogen peroxide can 
be transformed into O2 and H2O by different enzymes as peroxidase catalase (CAT). H2O2 
can also be a substrate of the Fenton reaction, giving •OH, a highly reactive radical with 
short half-life. The deregulation of these redox-equilibriums can lead to ROS 
overproduction; moreover, β-amyloid aggregates contain Cu2+ or Fe2+, which can 
catalyze the Fenton reaction and contribute to ROS formation.73,74   
Once these oxygen reactive species are formed, they can be toxic in through different 
pathways, such as lipid peroxidation, 75 , 76   DNA oxidative damage 77  or calcium 
overload,78,79 all of them leading into cytotoxicity and cell death. (Figure 3.3) 
  
 
71 Lotharius, J.; Brundin, P. Nat. Rev. Neurosci. 2002, 3, 932. 
72 Barnham, K. J.; Masters, C. L.; Bush, A. I. Nat. Rev. Drug Discov. 2004, 3, 205. 
73 Salim, S. J. Pharmacol. Exp. Ther. 2017, 360, 201. 
74 Prousek, J. Pure appl. Chem.y 2007, 79, 2325. 
75 Selley, M. L.; Close, D. R.; Stern, S. E. Neurobiol. Aging 2002, 23, 383. 
76 Dexter, D. T.; Carter, C. J.; Wells, F. R.; Javoy‐Agid, F.; Agid, Y.; Lees, A.; Marsden, C. D. J. Neurochem. 
1989, 52, 381. 
77 Alam, Z. I.; Jenner, A.; Daniel, S. E.; Lees, A. J.; Cairns, N.; Marsden, C. D.; Jenner, P.; Halliwell, B. J. 
Neurochem. 1997, 69, 1196. 
78 LaFerla, F. M. Nat. Rev. Neurosci. 2002, 3, 862. 
79 Gibson, G. E. Free Radic. Biol. Med. 2002, 32, 1061. 





Figure 3.3: ROS formation. 
3.1.4. Multifactorial hypothesis 
A model based on five of biomarkers has been proposed for tracking the temporal 
evolution of Alzheimer´s disease. In the first stage, 10-5 years before the dementia is 
diagnosed, a steep increase in Aβ42 can be detected, while level of phospho-tau in 
cerebrospinal fluid increases in a more progressive way.80,81 The increases of Aβ42 and 
tau levels are an early even that precedes hypometabolism and finally atrophy, 
neurodegeneration and clinical symptoms.82  (Figure 3.4)  
 
 
80 Jack Jr, C. R.; Knopman, D. S.; Jagust, W. J.; Petersen, R. C.; Weiner, M. W.; Aisen, P. S.; Shaw L. M.; 
Vemuri, P.; Wiste, H. J.; Weigand, S. D.; Lesnick, T. G.; Pankratz, V. S.; Donohue, M. C.; Trojanowski, J. Q. 
Lancet Neurol. 2013, 12, 207. 
81 Buchhave, P.; Minthon, L.; Zetterberg, H.; Wallin, Å. K.; Blennow, K.; Hansson, O. JAMA Psychiatry 2012, 
69, 98. 
82 Pawlowski, M.; Meuth, S. G.; Duning, T. Diagnostics, 2017, 7, 42. 




Figure 3.4. MCI: mild cognitive impairment, CSF A: -amyloid in cerebrospinal fluid, CSF: tau in 
cerebrospinal fluid, MRI: magnetic resonance imaging, FDG: fluorodeoxyglucose uptake, PET: positron-
emission tomography 
Even though it seems that some sequential order can be elucidated, is also known that 
all these hallmarks are interconnected, and it is not clear if they are causes or 
consequences. For instance, protein misfolding may cause oxidative stress, calcium 
overloads, neuroinflammation or mitochondrial dysfunction. However, this pathway is 
bidirectional cause oxidative stress may cause modifications in DNA, lipids and proteins, 
which may lead to the misfolding and aggregation of the latter. Several of these factors 
can also trigger the formation of oligomers.83, 84  
In this context, we can highlight that: 
✓ Trying to develop new methodologies that allow an early visualization of Aβ42 
deposits would be a good approach for an early diagnosis of the disease. 
✓ The development of new drugs that act selectively on one of the hallmarks seems 
an unsuccessful strategy, and thus the multitarget approach appears as a more 
efficient alternative. 
 
3.2 Theranostic agents for Alzheimer’s disease. 
In spite of the great therapeutic advances achieved for many diseases in the last 
decades, AD and other neurodegenerative diseases remain incurable and are extremely 
 
83 Angelova, P. R.; Abramov, A. Y. Biochem. Biophys. Res. Commun. 2017, 483, 1110.  
84 Höhn, A.; Weber, D.; Jung, T.; Ott, C.; Hugo, M.; Kochlik, B.; Kehm, R.; König, J.; Grune, T.; Castro, J. P. 
Redox Biol. 2016, 11, 482.  
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challenging for medicinal chemists. 85  Moreover, although the investment in drug 
discovery against these maladies has increased, this effort has paradoxically  led to 
fewer successful drugs, and there are still no treatments able to stop the course of the 
disease.86 
This situation has been associated with several difficulties related to neurodegenerative 
diseases in general: 
1. As mentioned above, the understanding of their aetiology remains poor, and the 
fact that many pathways are involved leads to the existence of no truly validated 
targets.86 
2. The poorly predictive animal models available for these diseases complicate the 
development of effective drugs.87 
3. Finally, the failure of many drug candidates has been associated to their 
administration when the pathology is too advanced.88 
In this scenario, the theranostic approach appears as a good option to optimize the 
efficacy and safety of the therapy, as well as to streamline the whole drug discovery 
process. 89, 90  
A deposits are the main pathological hallmark of Alzheimer’s disease and they are 
believed to precede clinical symptoms by several years. Therefore, the imaging of 
fibrillar aggregates is particularly suitable to diagnose the onset of the disease in its early 
stage and monitor its progression. 91  Thus, the use of theranostics agents targeting 
amyloid plaques appears as a particularly suitable approach.92,93 An ideal theranostic 
agent would have the ability to simultaneously allow real time evaluation of the amount 
 
85 Chen, B.; Thompson, M.; Louth, J.; Guo, K. Curr. Top. Med. Chem. 2013, 13, 2441. 
86 Pangalos, M. N.; Schechter, L. E.; Hurko, O. Nat. Rev. Drug Discov. 2007, 6, 521. 
87 Enna, S. J.; Williams, M. J. Pharmacol. Exp. Ther. 2009, 329, 404. 
88 Markou, A.; Chiamulera, C.; Geyer, M. A.; Tricklebank, M.; Steckler, Neuropsychopharmacology 2009, 
34, 74. 
89 Kelkar, S. S.; Reineke, T. M. Bioconjug. Chem. 2011, 22, 1879. 
90 Lammers, T.; Aime, S.; Hennink, W. E.; Storm, G.; Kiessling, F. Acc. Chem. Res. 2011, 44, 1029. 
91 Aulić, S.; Bolognesi, M. L.; Legname, G. Int. J. Cell Biol. 2013, 2013, 150952. 
92 Bongarzone, S.; Staderini, M.; Bolognesi, M. L. Future Med. Chem. 2014, 6, 1017.  
93 Schulz-Schaeffer, W. J.; Tschoke, S.; Kranefuss, N. et al. Am. J. Pathol. 2000, 156, 51. 
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of drug reaching the pathological area, while visualizing the molecular changes caused 
by its therapeutic effects.  
During the past years, several molecules able to stain A fibrils and inhibit their 
aggregation have been reported, as summarized in the following Section. 
 
3.3 NIR probes for the detection of amyloid plaques 
NIR fluorescent probes have been mainly used in the oncology field although, as 
mentioned above, they are extremely useful to visualize and monitor amyloid plaque 
formation and to evaluate the effectiveness of drug treatment in animal models, 
therefore they are considered a promising tool for AD early diagnosis.  
The clinical application of NIR imaging in AD is specially challenging, since amyloid 
deposits are formed inside the skull-shielded brain and optical imaging resolution 
decreases with increasing depth of penetration due to fluorescence scattering in the 
biological environment. Indeed, traditional fluorescence-based optical imaging of the 
brain of small animals relied on craniotomy or cranial windows techniques. However, 
the development of novel techniques such as fluorescent molecular tomography (FMT) 
or FMT-CT has enabled the in vivo visualization of A plaques in mice with an intact 
cranium.94 Although these techniques are still in need of technological improvements 
and it is most likely that the human brain cannot be entirely visualized by optical 
methods, it has nevertheless been proposed that it will be feasible to image the brain 
cortex at depths up to 3–5 cm.95, 96 Considering that most of the amyloid depositions are 
located on the neocortical surface, this should be enough to obtain information from AD 
patients. 
Another approach for in vivo AD NIR imaging could be based on the use of parts of the 
central nervous system that are not skull-shielded. Some examples are the retina or the 
olfactory ephytellium. The retina turns out to be equivalent to a physiological skull 
 
94 Jucker, M. Nature Medicine 2010, 16, 1210. 
95 Ntziachristos, V. Nature Methods 2010, 7, 603. 
96  Hyde, D.; de Kleine, R.; MacLaurin, S. A.; Miller, E.; Brooks, D. H.; Krucker, T.; Ntziachristos, V. 
Neuroimage. 2009, 44, 1304. 
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window, easily accessible for non-invasive direct imaging. Even though there are 
controversies in the results, some authors have demonstrated the presence of Aβ 
plaques in the retina of AD patients, while others were able to detect fibrillar tau 
aggregates in transgenic mice retina and hyperphosphorylated tau AD human retina.97,98 
On the other hand, it is also worth noting that neurofibrillary tangles have been detected 
in the olfactory epithelium.99 
Although several fluorescent probes with high affinity for amyloid plaques have been 
reported through the years, most of them cannot be translated into clinically useful 
agents due to their low sensitivity and specificity, toxicity or inability to cross the blood 
brain barrier.100 
To overcome these drawbacks, it has been proposed that an ideal NIR probe for amyloid 
deposits imaging should:18 
- Emit fluorescence in the NIR region. 
- Present specificity to amyloid plaques. 
- Be able to change fluorescence properties upon fibrils binding. 
- Present a high binding affinity. 
- Have a high fluorescence quantum yield and large Stokes shift. 
- Shown minimum binding with human serum albumin (HSA).  
- Be able to cross the BBB. 
- Show low toxicity. 
During the past years several families of NIRF probes have been reported. Depending on 
their structures they can be classified as follows:101 
Curcumin and derivatives:  Curcumin is a yellow pigment obtained from Curcuma longa 
rhizomes. Due to its highly delocalized -electron system and symmetric structure, 
curcumin itself has been considered as a potential NIRF probe for imaging A deposits 
 
97 Koronyo, Y.; Salumbides, B. C.; Black, K. L.; Koronyo-Hamaoui, M. Neurodegener. Dis. 2012, 10, 285. 
98 Schon, C.; Hoffmann, N. A.; Ochs, S. M.; Burgold, S.; Filser, S.; Steinbach, S.; Seeliger, M. W.; Arzberger, 
T.; Goedert, M.; Kretzschmar, H. A.; Schmidt, B.; Herms, J. Plos One 2012, 7, e53547. 
99 Gu, J.; Anumala, U. R.; Heyny-von Haußen, R.; Hölzer, J.; Goetschy-Meyer, V.; Mall, G.; Hilger, I.; Czech, 
C.; Schmidt, B. ChemMedChem 2013, 8, 891. 
100 Hong, Y.; Meng, L.; Chen, S.; Leung, C. W.; Da, L. T.; Faisal, M.; Silva, D. A.; Liu, J.; Lam, J.W.; Huang, 
X.; Tang, B. Z. J. Am. Chem. Soc. 2012, 134, 1680. 
101 Gyasi, Y. I.; Pang, Y.P.; Li, X. R.; Gu, J. X.; Cheng, X. J.; Liu, J.; Xu, T.; Liu, Y. Eur. J. Med. Chem. 2020, 187, 
111982. 
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and tau fibrils. However, its short emission wavelength and low quantum yield 
frustrated the use of curcumin as a NIR probe. In an effort to improve these properties, 
several authors reported curcumin derivatives, named CRANAD, presenting chemical 
modifications as the introduction of difluoroboronate and p-dimethylamino phenyl 
groups based on a donor-acceptor-donor design, which enhanced the emission 
wavelength and led to successful bio-imaging probes.101 (Figure 3.5) 
BODIPY and derivatives: Since Treibs and Kreuzer described for first time BODIPY (boron 
dipyrromethane or 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dye in 1968, it has 
gained much popularity among fluorescent probes.102 It is known that BODIPY dyes 
present high quantum yield and are biocompatible, although they possess low BBB 
permeability and emission wavelength. For this reason, several modifications on the 
BOPIPY core have been reported to overcome these issues, resulting in different 
functional NIR probes.101 (Figure 3.5) 
  
 Figure 3.5. 
NIAD dyes:  The design of NIAD probes is based on Thioflavin T (ThT) and Congo Red 
(CR), (Figure 3.6) which are based on planarized or easily planarized -systems. NIADs 
present several donor-acceptor structures to enhance longer excitation/emission 
wavelengths, while their central core is based on hydrophilic groups (thiophene) which 
avoid high lipophilicity. Moreover, hydroxyl groups are frequently introduced to balance 
the BBB permeability and amyloid fibrils affinity.101 (Figure 3.6)  
  
 
102 Treibs, A.; Kreuzer, F.H. Justus Liebigs. Ann. Chem. 1968, 718, 208. 






Oxazines:  Oxazines presents oxygen and nitrogen atoms in a doubly unsaturated six-
membered ring. Their design is based on p-benzoquinone imines or diimines and they 
are mainly characterized by their solvatochromism, which makes them sensitive to their 
environment and is an important feature of good probes.101 (Figure 3.7) 
DANIR (Donor-Acceptor Near-Infrared): In 2014, Cui et al. employed the Donor-
Acceptor approach and the extension of -conjugation to increase electron 
delocalization and consequently the emission wavelength, reporting this way three 
novel NIR fluorescence probes to detect A deposits, named DANIR. These dyes 
exhibited a high affinity for A plaques in AD patients and double transgenic mice. 
Moreover, they were able to penetrate the BBB while presenting fast kinetics of 
washout.103 (Figure 3.7) 
THK-265: was developed in 2011 by Okaruma and coworkers, the dye was able to label 
A deposits and it exhibited high quantum yields, molar absorption and binding affinity. 
Unfortunately, when it came to in vivo imaging THK-265 was unable to cross the BBB.104 
(Figure 3.7)  
  
 
103 Cui, M.; Ono, M.; Watanabe, H.; Kimura, H.; Liu, B.; Saji, H.; J. Am. Chem. Soc. 2014, 136, 3388. 
104 Okamura, N.; Mori, M.; Furumoto, S.; Yoshikawa, T.; Kudo, Y. J. Alzheimer’s Dis. 2010, 2337. 





Coumarin derivatives: Shin and co-workers reported iminocoumarin probe IRI-1, 105 
designed by combining IBC-2, a large two-photon coumarin-based dye, with ThT. This 
compound presents large signal-to-background ratios and near-infrared emission, 
resulting in a dye with excellent properties for in vivo and ex vivo imaging.101 (Figure 3.8) 
Cyanine derivatives: Yang and co-workers presented a few years ago a representative 
example of a family of theranostic agents against Alzheimer’s disease, based on a family 
of carbazole-based cyanidine derivatives. Among them, SLOH (Figure 3.8) was the most 
attractive candidate, showing selective binding towards A(1-40) peptides, aggregates 
and plaques, with strong fluorescence enhancement. Moreover, it was able to inhibit 
A aggregation and fibrinogenesis, while being non-toxic to neuronal cells. A 
neuroprotector effect of SLOH against A(1-40) induced toxicity was also demonstrated. 
Finally, in vivo experiments verified the ability of the compound to cross the BBB and 
target A plaques. 106 The related SLM, another carbazole-based quinolinium cyanine 
dye,106 has also been reported as an effective theranostic agents for in vivo imaging of 
A in AD mouse models.101  
Quinoline-malononitrile:  TM-1 and TM-2 were synthesized in order to improve NIR 
probes solubility, by introducing a sulfonate group and replacing a naphthalene with a 
phenyl moiety. These probes present the typical D-A architecture and exhibit maximum 
 
105 Shin, J.; Verwilst, P.; Choi, H.; Kang, S.; Han, J.; Kim, N.H.; Choi, J.G.; Oh, M.S.; Hwang, J.S.; Kim, D. 
Angew. Chem. 2019, 58, 5648. 
106 Yang, W.; Wong, Y.; Ng, O. T. W.; Bai, L.; Kwong, D. W. J.; Ke, Y.; Jiang, Z.; Li, H.; Yung, K. K. L.; Wong, 
M. S. Angew. Chem. Int. Ed. 2012, 51, 1804. 
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emission wavelengths at 680-650 nm. TM-1 and TM-2 were able to bound amyloid fibrils 
and exhibited significant fluorescence enhancement upon detection.101 (Figure 3.8) 
 
Figure 3.8. 
Although many efforts to design better in vivo amyloid imaging NIR probes have been 
done in recent years, most of these compounds still present several drawbacks, usually 
associated with their solubility, toxicity, inability to cross the BBB, poor sensitivity or 
sub-optimal spectroscopic properties. Thus, the goal of development ideal amyloid-NIR 
fluorescence probes is a field that still needs to be improved. For a review of this area, 
reference 101101 can be perused. 
 
3.4. Design of NIR styrylquinolines as theranostic agents 
Some years ago, our group disclosed styrylquinoline A, which exhibited excellent 
properties as a starting point for developing theranostic agents against protein 
misfolding diseases. This compound showed the ability cross the BBB in a parallel 
artificial membrane permeability assay (PAMPA). Then its ability to inhibit Aβ42 
aggregation was assessed by a ThT-based fluorometric assay, behaving as a moderate 
fibrillization inhibitor and amyloid binder. To investigate the binding mode of 
styrylquinoline A to Aβ, displacement studies in the presence of aggregated Aβ42 were 
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carried out using a fixed concentration of Aβ42 and ThT and an increasing concentration 
of A. As a conclusion from these experiments it was proposed that styrylquinoline A 
may have a primary high affinity binding site distinct from ThT and a secondary low-
affinity binding site in common with ThT. Moreover, compound A was able to detect 
Aβ42 while no interaction with human seric albumin (HSA) was observed. Afterwards, its 
antiprion activity was tested. In a first assay, compound A was able to delay prion fibril 
formation. Then, in cell-based models of prion disease (ScGT1 cells), compound A 
showed remarkable antiprion activity in nontoxic concentrations. Finally, PrPSc specific 
binding was confirmed by fluorescent staining with styrylquinoline A carried out using 
ScGT1 living cells.  
From a spectroscopic point of view, the native fluorescence of styrylquinoline A greatly 
depended on solvent polarity and its fluorescence emission in ethanol, whose polarity 
mimics the protein environment, was red-shifted compared to more polar solvents. 
Moreover, the emission spectra of styrylquinoline A showed a hypsochromic shift (from 
528 to 490 nm) and a hyperchromic effect upon binding to Aβ42. Finally, the solid state 
fluorescence spectrum of styrylquinoline A, as a hydrochloride salt, exhibited an 
emission maximum above 600 nm.107 
Xiao-Qin Wang and collaborators 108  also reported a family of 2-styrylquinoline 
derivatives as multitarget agents for the treatment of Alzheimer’s disease. These 
compounds were able to inhibit Aβ1-42 aggregation, they also acted as potential 
antioxidant and biometal chelators, moreover, some of them were able to inhibit 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). 
In this scenario, we viewed styrylquinoline A as a good starting point, which can be 
easily manipulated for developing theranostic agents for protein misfolding diseases. On 
one hand, it has been proved that the styrylquinoline core can inhibit several 
pathological pathways involved in Alzheimer’s disease, and thus they can be considered 
multitarget-directed ligands. On the other hand, from an imaging point of view the 
 
107 Staderini, M.; Aulić, S.; Bartolini, M.; Tran, H.N.; González-Ruiz, V.; Pérez, D. I.; Cabezas, N.; Martínez, 
A.; Martín, M. A.; Andrisano, V.; Legname, G.; Menéndez, J. C.; Bolognesi. M. L.  ACS Med. Chem. Lett. 
2012, 4, 225. 
108 Wang, X. Q.; Xia, C. L.; Chen, S. B.; Tan, J. H.; Ou, T. M.; Huang, S. L.; Li, D.; Gu, L. Q.; Huang, Z. S. Eur. J. 
Med. Chem. 2015, 89, 349.  
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absorbance and emission maxima could be easily modified by introducing a push-pull 
architecture, thus reinforcing the electron-donating/accepting ability of the molecule to 
enhance the spectral bathochromic shift. 
For this purpose, we designed a family of styrylquinoline derivatives, in which different 
amines bearing diverse substituents were use as electron-donor groups, while a 
dicyanomethylene groups was chosen as electron acceptor. We also started building a 
second family of derivatives, this time using the well-known BODIPY core as the electron 
acceptor part of the molecule. (Figure 3.9A and 3.9B)  
 





3.5. Synthesis of stryrilquinoline derivatives 
For the synthesis of the dicyanomethylene derivatives some difficulties needed to be 
faced, and the beginning different alternative pathways were explored. (Scheme 3.1) 
 
Scheme 3.1. 
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Finally, we were able to devise a simple four-step route (Scheme 3.2) that allowed us to 




Cpd. 6a 6b 6c 6d 
R 
    
Yield (%) 85 55 40 58 






Yield (%) 20 40 56 76 
Table 3.1. 
Unfortunately, this route did not allow us to obtain compounds 6i-m. (Table 3.2) 
Derivatives 6i-k resulted unstable, while all the attempts to obtain compounds 6l and 
6m from their analogues 6e and 6f respectively, resulted in compound decomposition.  
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Depending on the starting commercial quinoline, two different reduction methodologies 
were carried out. In the case of the ester derivative 1, a direct reduction to alcohol 3 with 
lithium aluminium hydride in THF was performed. For the carboxylic acid derivative 2, 
an initial activation step to form a mixed anhydride was needed. After this activation, 
the reduction was directly performed with NaBH4 yielding the desired alcohol 3 without 
the need for further purification. In a second step, this alcohol was directly oxidized in 
dichloromethane in the presence of manganesum oxide to give the aldehyde 4. All 
attempts to directly transform the ester 1 into 4 by treatment with DIBAL were 
unsuccessful.  
With the aldehyde 4 in our hands, we next carried out its Knoevenagel condensation 
with malononitrile, obtaining intermediate 5, which was finally reacted with different 
commercially available aldehydes through an aldol condensation promoted by acetic 
anhydride to give the desire derivatives. It is worth highlighting that this reaction had 
been previously carried out in our group on a simpler substrate.109,110 In most cases, the 
simple presence of acetic anhydride under microwave irradiation was enough to 
promote the condensation, but in the case of aromatic aldehydes bearing electron‐
donor groups this reaction did not take place, due to the low reactivity of the aldehyde.  
After trying several conditions, we established that the presence of zinc chloride as a 
Lewis acid catalyst for aldehyde activation allowed the aldol condensation. (Scheme 3.3) 
 
109 Staderini, M.; Cabezas, N.; Bolognesi, M. L.; Menéndez, J. C. Synlett. 2011, 2577. 
110 Doctoral tesis, Matteo Staderini, Universidad Complutense de Madrid, February, 2015. 




Scheme 3.3. Condensation mechanism. 
For the synthesis of the second family of derivatives we altered the order of steps of the 
sequence. (Scheme 3.4) First the condensation with the starting quinoline with the 
corresponding aldehydes was performed using the Ac2O-ZnCl2 protocol, yielding the 
desired styrylquinolines 7. The ester group was then treated with lithium aluminium 
hydride, and this reduction took place in much shorter time (1 h vs 24 h), probably due 
to the fact that the substrate has a push‐pull structure, which a lower HOMO‐LUMO gap, 
increasing this way the reactivity of the molecule. When it came to the oxidation step, 
several conditions had to be tried. (Scheme 3.5)  
Scheme 3.4. 
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In a first attempt, we tried the same oxidation conditions previously described, MnO2 in 
dichloromethane, but observed a complete decomposition of the starting material. We 
next decided to use the Dess Martin periodinane, and in this case we were able to isolate 
the desired product 9 in 32% yield. It is worth highlighting that the reaction time and 
temperature needed to be precisely controlled, since longer times or higher 
temperatures led to compound decomposition. Moreover, when we tried to scale up 
the reaction, the yields dropped to 15 %.  
In our next attempt, we used pyridinum chlorocromate supported on alumina. This time, 
no product was observed after several hours of reaction, and after 72 h the maximum 
amount of aldehyde found was an 18%, showing that PCC was not a better alternative. 
In a next attempt, a Swern oxidadation was also tried, yielding only traces of the desired 
product, and consequently being discarded as an alternative.  
Finally, an oxidation with the Ley-Griffith reagent or tetrapropylammonium 
perruthenate (TPAP) was also performed, yielding the desired aldehyde 9 in a 40% yield, 
which decreased to 33% at a higher scale. 
The yields obtained in each condition are summarized in Scheme 3.5 and Table 3.3. In 
order to improve these results, further studies are needed, although the low 
chromatographic stability of the aldehyde is also a factor to be considered 
 
Scheme 3.5. 
R Conditions Yield % 
Me MnO2, r.t.,6 h Decomposition 
Me Dess Martin periodinane, 0°C, 20 min 15-32 
Et PCC-alumina, r.t., 72 h 18 
Me 
1) Oxalyl bromide, DMSO,  
- 78 °C 
2) Et3N, CH2Cl2, r.t., 1 h 
Traces 
Et TPAP, NMO, CH3CN, r.t., 3.5 h 33-40 
Table 3.3. 
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The BODIPY core 10 was synthesized in parallel by treatment of benzaldehyde with two 
equivalents of 2,4-dimethylpyrrole in the presence of trifluoroacetic acid and DDQ. 
(Scheme 3.6) Using the small amounts of aldehyde 9 previously obtained, we used 
typical Knoevenagel condensation conditions under microwave irradiation to carry out 
the final coupling. This way we were able to isolate the desired compound, albeit in poor 




In order to be able to obtain and study more BOPIPY-quinoline derivatives two different 
alternative pathways were tried, unfortunately any of them led into the desire 
compounds Scheme 3.8 and Scheme 3.9. Thus, further efforts to optimize the synthetic 
route are needed.  






3.6. Styrylquinoline pharmacological evaluation 
The initial pharmacological evaluation of compounds 6a-h was carried out by Macarena 
Hernández and Drs. Paloma Bermejo and Sagrario Martín-Aragón, at the Departamento 
de Farmacología, Facultad de Farmacia, Universidad Complutense. Further 
characterization of the pharmacological profile of these compounds is in progress. 
(a) Cellular viability in the Hek-Tau cell line (MTT) 
Firstly, neurotoxicity for compounds 6a-h was determined by MTT assay in HEK293-
Tau3R cells, which are characterized by the overexpression of tau protein. Compounds 
6a-h were tested between 1-10 µM concentrations for 24 h and then cellular viability 
was determined. No toxicity was detected at concentrations lower than 5 µM. As it is 
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shown in Figure 3.9, at 5-10 µM concentrations compounds 6a-h start to produce some 
neurotoxic effect.  
 
Figure 3.9. Cell viability assay of compounds 6a-h; p < 0.05 indicates statistically significative differences 
with the control, using the Newman-Keuls test. 
(b) Free radical scavenging in the Hek-Tau cell line (DCFA-DA) 
Radical oxygen scavenging was tested in HEek293-Tau3R cells using a cellular 
antioxidant activity assay. The cells were exposed to hydrogen peroxide (200 µM) and 
treated with the non-fluorescent compound 2,7-dichlorofluorescin acetate (DFCA), a 
probe that is captured by cells and further hydrolysed by cellular esterase. The resulting 
2,7-dichlorofluorescin (DFCH) is still non-fluorescent, but upon oxidation by ROS 
becomes dichlorofluorescein (DCF) which is highly fluorescent. Thus, the fluorescence 
measured in the assay is inverse to the scavenging ability of the tested compounds. 
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With this essay, variations in the fluorescence signal after 50 min of treatment with 
compounds 6a-h were measured. Concentrations lower than 1 µM showed a moderate 
antioxidant activity of the compounds. (Figure 3.11) 
 
 
Figure 3.11. Representative example of the antioxidant capacity of compound 6a at 100 nM; *, meaning 
p < 0.05, indicates statistically significative differences with the control, using the Newman-Keuls test. 
 
(c) Tau aggregation inhibition 
For the tau aggregation in vitro test, the N-acetylated and C-amidated hexapeptide 
AcPHF6 (MeO2C-VQIVYK-NH2) was used. This peptide derives from the native tau-
hexapeptide sequence 306VQIVYK311, which is involved in fibril aggregation processes 
and can be used as suitable model to study tau aggregation inhibition.111  
The styrylquinolines 6a-h and methylene blue as a control were studied in a 0,5-20 µM 
range of concentrations.  All tested compounds were able to inhibit the aggregation of 
AcPHF6 peptide in a dose dependent manner. Moreover, compounds 6c, 6e and 6h were 
able to inhibit more than 50% of aggregation at 1 µM concentration, thus being the most 
active stryrylquinolines. (Figure 3.12)  
 
 
111  See, for instance: Mohamed, T.; Hoang, T.; Jelokhani-Niaraki, M.; Rao, P. P. N. ACS Chem. Neurosci. 
2013, 4, 1559-1570. 




Figure 3.12. AcPHF6 peptide aggregation inhibition. 
 
(d) Neuroprotective effect on an okadaic acid neurotoxic model. 
To evaluate the neuroprotective effect of compounds 6a-h, a neurotoxic model based 
on okadaic acid was set up. First the HEK293-Tau3R cells were treated with okadaic acid 
concentrations of from 10-50 nM during 24 h, and it was observed that above a 30 nM 
concentration the viability of the cells considerably decreased. To further evaluate if this 
decrease in viability was due to a necrosis process, the levels of dehydrogenase lactate 
(LDH) on the cells supernatant was evaluated. LDH is a cytoplasmatic enzyme involved 
in glycolysis and gluconeogenesis processes, and if it is found in the supernatant media 
it means that it was liberated due to a process of cellular lysis. As no significant changes 
on LDH levels were found, the decrease in cell viability is not cause by a necrosis process. 
Afterwards, to test if cell death was an apoptosis-mediated process, the levels of 
caspases 3, 8 and 9 were evaluated. To this end, cells were treated with okadaic acid in 
a range on 10-50 nM concentrations, up to a 25 nM concentration an increase in caspase 
3 activity was observed. This caspase is involved in both the intrinsic and extrinsic 
apoptosis pathways. (Figure 3.13) 
 




Figure 3.13. Caspase 3 activation by oxadaic acid in a HEK293-Tau3R cell line. 
In the light of these results, as the cell viability was decreasing up to a 30 nM 
concentration, while the caspase 3 activity was increasing from a 25 nM concrentration, 
it was decided to expose the HEK293-Tau3R to a 25 nM concentration of okadaic acid 
and evaluate the neuroprotection exerted by compounds 6a-h. 
First, it was evaluated that under normal conditions compounds 6a-h were not 
exhibiting any influence in the activities of caspases 3, 8 and 9. Then cells were exposed 
to 25 nM concentrations of okadaic acid and 10 or 100 nM concentrations of the 
compounds. It was observed that compounds 6b, 6d, 6e, 6g and 6h were able to 
considerably decrease the activity of caspase 3. (Figure 3.14)  
 
Figure 3.14.  Activity of caspase 3 after co-treatment with okadaic acid and compounds 6a-h. 
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To further evaluate the potential neuroprotective mechanisms of styrylquinolines 6a-h, 
the activities of SOD and CAT enzymes, both involved in controlling oxidative stress 
processes, were measured in the neurotoxic okadaic acid model.  On one hand, SOD is 
one of the first-line defence mechanisms against oxidative stress, as it is in charge of 
catalysing the transformation of the superoxide anion into hydrogen peroxide. On the 
other side CAT is involved in the transformation of hydrogen peroxide into water and 
oxygen. It has been proved that higher levels of SOD and CAT are associated with ROS 
control and consequently have a neuroprotective effect.112 (Figure 3.15) 
 
Figure 3.15.  
It was observed that only compound 6a and 6b were able to increase the SOD activity 
after treatment with okadaic acid. (Figure 3.15) In the case of CAT, a decrease in its 
activity was observed upon okadaic acid treatment, but none of the styrylquinolines was 
able to recover this activity. (Figure 3.16) 
 
 
Figure 3.15. SOD activity after co-treatment with okadaic acid and compounds 6a-h. 
 
112 Kim, H.; Oshikawa, J.; Urao, N.; Kaplan, N.; Razvi, N.; McKinney, R.; Poole, L.B.; Fukai, T.; Ushio-Fukai, 
M. Plos One 2010, 5, e10189. 
 
 




Figure 3.16. CAT activity after co-treatment with oxadaic acid and compounds 6a-h. 
 
3.7. Styrylquinoline imaging properties 
To further evaluate the imaging properties of compounds 6a-h, a complete 
characterization of their spectral porperties was carried out by Latoya Bote and 
Francisca Aguilar under the supervision of Drs. María Antonia Martín and Ana Isabel 
Olives in the Unidad Docente de Química Analítica, Facutad de Farmacia, Universidad 
Complutense. Further experiments of these compounds are in progress. In order to 
simplify the discussion, we chose compound 6b as a representative example, although 
all the experiments summarized below have been done for all the compounds of the 
family, which have shown a similar behaviour. The choice of 6b was guided by its good 
pharmacological profile; being able to act as ROS scavenger, inhibit tau in vitro 
aggregation and inhibit caspase 3 activity while enhancing SOD activity after treatment 
with okadaic acid. 
 
3.7.1. Spectrophotometric studies. 
First, a calibration curve of all compounds was carried out in ethanol and their molar 
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Compound  max/ nm  (M-1 cm-1) Formula R 
Xb 
485 5926.8 Y=5926.8 x + 0.0446 0.9949 
336 3746.3 Y=3746.3 x + 0.0397 0.9982 
263 3416 Y=3416 x + 0.056 0.9899 
Table 3.3.  Compound 6b calibration curve. 
(a) Solvatochromism studies. 
In order to evaluate how the polarity of the solvent affects to the absorption properties 
of the compounds their absorption spectra were measured in solvents with different 
properties. The chosen solvents were water, acetonitrile, dioxane, ethanol, methanol 
and hexane. In the case of water and hexane, due to solubility issues, 1:10 dilutions of 
ethanol: water or ethanol: hexane needed to be done. (Figure 3.17)  
 
Figure 3.17. UV-Vis in polar and non-polar environments. of compound 6b Inset: hexane: methanol 
titration compound 6a. 
From this study, we observed that in general in more apolar enviroments compounds 
tend to present a batochromic shift (towards higher wavelengths) and an increase in 
their absorbance, while in more polar environments the absorbance decreases with an 
hipsochromic shift (towards lower wavelegnths). To study this effect more directly, 
some compounds, such as 6a were titrated with hexane containing increasing amounts 
of methanol. (Inset Figure 3.17) 
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(b) Proton transfer reaction studies. 
In order to evaluate the influence of pH in the spectral behaviour of our compounds, 
titrations with HCl in all the different solvents were done. In Figure 3.18, the titration of 
Compound 6b in ethanol with different HCl concentrations is shown. 
 
Figure 3.18. UV-Vis.  HCl titration of compound 6b in ethanol. 
In all studied solvents, the addition of acid brings about the protonation of the molecule, 
disappearing the absorbance maximum around 450 nm, while a new maximum around 
550-600 nm appears. With further increases in the concentration of HCl, this maximum 
tends to disappear while the intensity of the one at 375 nm increases. This behaviour is 
associated with the protonation of the two basic nitrogens present in the molecule, each 
of them associated with one of the absorption bands. 
  










  +0,01M HCl
  +0,1M HCl 
  +1M HCl 
  + 5M HCl
 In ethanol
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3.7.2. Spectrofluorimetry studies 
(a) Solvatochromism  
All compounds 6 exhibited native fluorescence. To evaluate the influence of solvent 
polarity in the fluorescence properties of the compounds, a soltavochromism study was 
carried out, this time using ethanol, hexane, water and dioxane. As in the previous case, 
in the case of hexane and water dilutions of the solvents with hexane needed to be done. 
(Figure 3.19)  
 
Figure 3.19. Emission spectra of 6b in different solvents. ex=480. 
The excitation maxima selected to record the emission spectra were 330-350 nm and 
438-480 nm. As shown in Graphic 3.3, the fluorescence intensity considerably increases 
in non-polar environments. Moreover, the position of the maximum is clearly polarity-
dependent, being red-shifted in dioxane. This behaviour is promising in that it leads to 
expect very noticeable changes in compound fluorescence when it is transferred from 
the aqueous phase to the ordered, highly lipophilic environment found inside the fibrils.   
It is also worth noting that for the lower excitation wavelength two fluorescence bands 
can be detected, the first one associated with the main fluorophore while the second 
one is associated with an energy charge transfer phenomenon. 
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 (b) Proton transfer reaction studies. 
Again, to evaluate the influence of pH on our compounds, reflected this time in their 
fluorescence properties, titrations with HCl in different solvents were carried out. In 
Figure 3.20, the titration of Compound 6b in ethanol containing varying HCl 
concentrations is shown. 
For all compounds and solvents, increasing concentrations of acid caused a decrease in 
fluorescence intensity of the energy charge transfer band, and at the end of the titration 
process only the main fluorophore band can be observed. 
 
Figure 3.20. Fluorescence HCl titration of compound 6b in ethanol. 
3.7.3. Amyloidogenic protein interference studies 
(a) Detection of insulin fibrils 
Once the spectral properties of our compounds were determined, their ability to 
interact with amyloidogenic proteins was evaluated. To this end, an initial study was 
performed in the presence of native insulin and insulin fibrils, using thioflavin as a 
control. For all the studied compounds the behaviour was similar to the one described 
below for compound 6b.  
When native insulin was titrated with thioflavin or with our compounds, no significative 
changes in the emission spectra were observed. On the other hand, the titration of 
thioflavin and our compounds with insulin fibrils exhibited a clear increase in 
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fluorescence upon fibril addition, using several molar protein/sensor ratios. (Figure 3.21 
and 3.22) The detection of insulin fibrils causes an increase in the energy charge transfer 
band (longer wavelengths), which is the same phenomenon observed in non-polar 
solvents. Thus, we can conclude that the compounds are surrounded by a non-polar 
environment inside the protein fibrils. 






























ThT- 1x10-6M in phosphate buffer 50mM Insuline fibrills  (ex=440)
                     
Wavelength(nm)
 
Figure 3.21. Fluorescence titration of thioflavin with insulin fibrils λex = 440 nm. 





















Figure 3.22. Fluorescence titration of compound 6b with insulin fibrils λex = 447 nm. 
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(b) Detection of beta-amyloid fibrils. 
The same experiment was then carried out, this time with fibrils generated from the 
A42 peptide. First, a titration of thioflavin as a positive control with the putative A42 
fibrils showed a clear increase in fluorescence intensity and consequently the formation 
of fibrils was verified. (Figure 3.23)  
 
Figure 3.23. ThT - β amyloid fibrils λex = 440 nm. 
Afterwards, the titriation of compounds 6a-h with A42 fibrils was performed, showing 
the same behaviour as thioflavin, i.e. an increase in fluorescence intensity upon fibril 
addition in protein/sensor molar ratios studied varying from 1 to 2. (Figure 3.24)  
 
Figure 3.24. Compound 6b - β amyloid fibrils λex = 374 nm and λex = 470 nm 
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3.7.4. Styrylquinolines ex vivo imaging. 
Once the full spectroscopic characterization of the compounds was finished, we 
evaluated their ability to identify  amyloid plaques ex vivo. To this end, Dr Gonzalo 
León, from Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad 
CEU San Pablo and Laboratorio Cajal de Circuitos Corticales (CTB), Universidad 
Politécnica de Madrid, performed the characterization of some of the compounds in 
several models of AD tissues. 
(a) Characterization of 6b labelling in the somatosensory cortex of APP/PS1 transgenic 
mice. 
First, compound 6b was selected for a preliminary labelling study, in which the 
somatosensory cortex of APP/PS1 transgenic mice, an AD animal model that 
accumulates amyloid beta burden in the brain from 6 to 7 months of age, was stained. 
The results showed that the compound specifically binds the β-sheet amyloid, as 
detected when exciting at several wavelengths. (Figure 3.25) The optimal signal to 
visualize amyloid beta plaques was obtained with an excitation wavelength of 458 nm, 
although the staining is also well detected at 488 and 555 nm. (Figure 3.25 A-D) 
However, no staining was observed with excitation wavelengths of 405 or 594 nm. 
(Figure 3.25 E, F)   
(b) Characterization of 6b labelling in the temporal cortex of AD samples. 
In the next step the ability of 6b and 6c to detect aggregates in human Alzheimer´s 
disease patients was also tested. To this end, double immunofluorescence techniques 
and confocal microscopy visualization were employed. Interestingly, it was found that   
in samples of temporal neocortex from one AD patient, the compounds specifically 
labelled the amyloid beta plaques, but not neurofibrillary tangles. (Figure 3.26) As 
shown in Figure 3.26, no colocalization was found between the structures labeled with 
the antibody AT8 (phosphor-tau antibody) and 6c. This is one of the main differences 
compared to Thioflavin S (ThS), which has been shown to detect beta-pleated sheet 
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structures and phosphorylated tau in AD brain samples.113 Moreover, as expected from 
the previous study in mice, the binding with beta amyloid was confirmed by the 
colocalization with the amyloid beta antibody. (Figure 3.26 D-F) It is worth nothing that 
6c binds with higher efficiency to the plaque core as shown in Figure 3.27 D-F.  
 
 
Figure 3.25. 6b labelling in the somatosensory cortex of APP/PS1 transgenic mice. Representative Z 
projection photomicrographs taken from two different confocal stacks (A-C and D-F) showing amyloid 
beta deposits labelled with 6b. Several excitation wavelengths are tested with positive labelling for 
amyloid beta plaques at 458 (A), 555 (B), 647 (C) and 488 (D). No amyloid beta deposits are detected at 
594 nm (E) or 405 nm (F) wavelengths. White arrows indicate some of the amyloid beta deposits. White 
scale bar in F indicates 20 µm. 
 
113 Santa-María, I.; Pérez, M.; Hernández, F.; Avila, J.; Moreno, F.J. J Alzheimers Dis. 2006, 9, 279.  





Figure 3.26 and 3.27. Characterization of 6b and 6c labelling in the temporal cortex of AD samples. 
Labelling by AT8 antibody is shown in B, whereas labelling with amyloid beta antibody is shown in E. Small 
white arrows indicate some of the phosphorylated tau fibrils. Big white arrows indicate the paired helical 
filaments and big yellow arrows indicate the core of the amyloid beta plaque. White scale bar in F indicates 
20 µm 
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As a summary, our styrylquinolines can be considered as attractive multitarget directed 
ligands against oxidative stress and act as tau protein aggregation inhibitors with a safe 
toxicity profile. Moreover, further studies are being carried out and preliminary data 
showed their ability to inhibit beta amyloid aggregation. 
From the imaging point of view, styrylquinolines 6 have proved to have interesting 
fluorescent properties with one if their emission maximum close to the NIR region, being 
able to enhance their fluorescent intensity in non-polar environments, this results was 
correlated with their increase in fluorescence emission upon fibrils binding, with proved 
their ability to detect amyloid aggregates. Finally, their ability to detect amyloid plaques 
in samples of Alzheimer’s disease brain tissue was evaluated, showing promising results 
and being able to selectively detect beta amyloid aggregates. 
With these results, we can confirm that styrylquinolines 6 are an interesting starting 
point for developing new theranostic multitarget agents against Alzheimers diseases, 
being able to detect one of the main hallmarks of the disease, while delivering a 
therapeutic effect.  
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3.8. Experimental section  
General experimental details.  
 
All reagents (Aldrich, Fischer, Alpha Aesar, SDS) and solvents (Scharlau, Fischer, SDS) 
were of commercial quality and were used as received. Reactions under microwave 
irradiation were carried out in a CEM Discover SP microwave reactor. Reactions were 
monitored by thin layer chromatography on aluminium plates coated with silica gel and 
fluorescent indicator (Macherey‐Nagel Xtra SIL G/UV254). Separations by flash 
chromatography were performed on silica gel (Scharlau 40–60 μm, 230–400 mesh 
ASTM) or neutral alumina (Merck S22). Melting points were determined using a Stuart 
Scientific apparatus, SMP3 Model, and are uncorrected. Infrared spectra were recorded 
with an Agilent Cary630 FTIR spectrophotometer with a diamond accessory for solid and 
liquid samples. NMR spectroscopic data were recorded using a Bruker Avance 250 
spectrometer operating at 250 MHz for 1H NMR and 63 MHz for 13C NMR, maintained by 
the NMR facility of Universidad Complutense (CAI de Resonancia Magnética Nuclear); 
chemical shifts are given in ppm and coupling constants in Hertz. High‐resolution mass 
spectra (HRMS) were recorded on a mass spectrometer fitted with an electrospray 
detector (ESI) by the mass spectral facility of Universidad Complutense (CAI de 
Espectrometría de Masas) and elemental analyses were determined by the 
microanalysis facility of Universidad Complutense (CAI de Microanálisis Elemental), 
using a Leco 932 combustion microanalyzer.  
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Synthesis of push-pull (E)-2-styrylquinolines derivatives 6a-h. 
 
3.8.1. Synthesis of (2-methylquinolin-6-yl)methanol (3) 
 
Method A: A suspension of lithium aluminium hydride (10 eq) in dry THF was prepared 
and cooled down to 0 °C with an ice‐water bath. Then ethyl 2‐methylquinoline‐6‐
carboxylate (2 g, 9.29 mmol) was dissolved in dry THF (20 ml) under argon.  This solution 
was slowly added to the suspension previously prepared. The mixture was stirred for 
24h and then quenched by the sequential addition of ethyl acetate (30 mL) and water (2 
mL). The suspension was filtered, and the filtrate was extracted with AcOEt, dried with 
anhydrous Na2SO4 and evaporated in vacuo to afford the title compound 3 as a yellowish 
solid. The compound was used in the next step without further purification. Yield: 3.52 
g, 88 %. 
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Method B:  The 2-methylquinoline-6-carboxylic acid (1.5 g, 8 mmol), chloroacetyl 
chloride and Et3N (1.2 eq) were dissolved in THF (45 mL) at 0 ºC and stirred for 
30 min. After this time, the anhydride is formed, and NaBH4 (1.210 g, 32 mmol) 
and H2O (10 mL) were added and stirred over night at room temperature. Once 
the reaction is finished, the mixture is quenched by stirring with HCl 1 N for 1 h. 
Then the crude is neutralized with NaHCO3, extracted with AcOEt, dried with 
anhydrous Na2SO4 and evaporated in vacuo to afford the title compound. Yield: 
4.67 g, 58 %. 
Mp 118-121 ºC. 
IR (neat) 3172, 1061, 823 cm‐1 
1H NMR (250 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 
1.2 Hz, 1H), 7.67 (dd, J = 8.4 y 1.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 4.90 (s, 2H), 2.76 (s, 
3H) ppm.  
13C NMR (63 MHz, CDCl3) δ 159.3, 147.7, 138.8, 136.7, 129.2, 129.1, 126.74, 125.3, 
122.7, 65.3 (CH2), 25.6 (CH3) ppm.  
Elemental analysis (%): calcd. for C11H11NO: C 76.28, H 6.40, N 8.09; found: C 76.45, H 
6.35, N 7.97.  
 
3.8.2. Synthesis of 2-methylquinoline-6-carbaldehyde (4) 
 
 
The corresponding alcohol (1.6 g, 7.43 mmol) was first dissolved in CH2Cl2 (40 mL) and 
manganese oxide (5 eq.) was added. The mixture was stirred for 24 h; the resulting 
suspension was filtered through a pad of Celite. The filtrate was evaporated to afford the 
corresponding aldehyde. The crude was purified by flash chromatography through a 
silica column using hexane: ethyl acetate (2:1, v/v) as the mobile phase to give 
compound 4 as a yellow solid. Yield: 1.27 g, 80%  
Mp 103‐106 ºC 
IR (neat) 1684 (C=O), 823 cm‐1 
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1H NMR (250 MHz, CDCl3) δ 9.95 (d, J = 0.5 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 8.00‐7.93 (m, 
2H), 7.88 (dd, J = 8.4 y 0.5 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 2.58 (s, 3H) ppm.  
13C NMR (63 MHz, CDCl3): δ 192.0, 162.9, 151.0, 137.8, 134.0, 133.8, 130.3, 127.3, 126.3, 
123.6, 26.1 ppm. 
Elemental analysis (%): calcd. for C11H9NO: C 77.17, H 5.30, N 8.18; found: C 77.42, H 
5.42, N 8.03.  
 
3.8.3. Synthesis of 2-((2 methylquinolin-6-yl)methylene)malononitrile  (5) 
                
The corresponding aldehyde 4 (1.2 g, 4.6 mmol) was placed in a round bottom flask and 
ethanol (6 ml) was added, the mixture was heated until the aldehyde was completely 
dissolved. The solution was cooled to room temperature and malononitrile (0.31, 4.6 
mmol) was added and stirred, with immediate formation of a precipitate. The reaction 
was controlled by TLC; 6h later the reaction was finished, and the solvent was 
evaporated. The crude product was washed with a mixture of hexane and ethyl ether 
(10:1) and finally the product was recrystallized from acetone: methanol (5:1) yielding 
the desired product as a dark red solid. Yield: 0.94 g, 80%. 
Mp 190‐193 °C 
IR (neat) 2222, 1575, 833 cm‐1. 
1H NMR (250 MHz, d6-DMSO) δ 8.72 (s, 1H), 8.49 (d, J = 1.7 Hz, 1H), 8.43 (d, J = 8.5 Hz, 
1H), 8.28 (dd, J = 9.0, 1.7 Hz, 1H), 8.11 (d, J = 9.0 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 2.72 (s, 
3H) ppm.  
13C NMR (63 MHz, d6-DMSO): δ 163.2, 161.1, 149.5, 137.9, 134.3, 130.0, 128.9, 128.3, 
126.1, 124.1, 114.7, 113.7, 82.0 (CH2), 25.56 (CH3) ppm.  
Elemental analysis (%): calcd. for C14H9N3: C 76.70, H 4.14, N 19.17; found: C 76.89, H 
4.19, N 18.86.  
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3.8.4. General method for the synthesis of push-pull styrylquinolines (6a-h) 
 
 
2‐((2‐Methylquinolin‐6‐yl)methylene)malononitrile (0.200 g, 0.9 mmol), the 
corresponding aldehyde  (1.5 eq)  and zinc chloride (0.006 g, 0.045 mmol) were 
suspended in acetic anhydride (1.5 ml) in a pressure tight microwave tube containing a 
stirring bar. The reaction mixture was heated under microwave irradiation for 5 min at 
125 °C, with an irradiation power of 250 W. The solvent was removed under reduced 
pressure to give a dark purple residue which was purified by flash chromatography 
through a silica column using hexane: ethyl acetate (9:1, v/v) as the mobile phase to give 
the desired compounds 6a-h  
(E)-2-((2-(4-(Dimethylamino)styryl)quinolin-6-yl)methylene)malononitrile (6a) 
Prepared from 4-(dimethylamino)benzaldehyde (0.200 
g, 1.35 mmol), as a dark red solid. Yield: 0.267 g, 85 %.  
Mp 188‐191 °C 
IR (neat) 2224, 1568 y 1521, 1164, 818 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.33‐8.03 (m, 4H), 7.87 (s, 1H), 7.73 (m, 2H), 7.58 (d, J = 8.4 
Hz, 2H), 7.18 (d, J = 16.1 Hz, 1H), 6.76 (d, J = 8.6 Hz, 2H), 3.08 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 160.8, 159.3, 151.6, 151.3, 138.3, 137.5, 133.6, 130.8, 129.7 
(2C), 129.4, 128.2, 126.9, 124.3, 123.4, 121.4, 114.5, 113.4, 112.5 (2C), 82.1, 40.6 (2C) 
ppm. 
Elemental analysis (%): calcd. for C23H18N4: C 78.83, H 5.18, N 15.99; found: C 78.69, H 
5.28, N 16.16.  
(E)-2-((2-(4-(diethylamino)styryl)quinolin-6-yl)methylene)malononitrile (6b) 
Prepared from 4-(diethylamino)benzaldehyde 
(0.239 g, 1.35 mmol), as a dark red solid. Yield: 0.176 
g, 55 %. 
Mp 197‐200 °C. 
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IR (neat) 2221, 1564, 1518, 1177, 819 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.33‐8.10 (m, 4H), 7.88 (s, 1H), 7.81‐7.70 (m, 2H), 7.57 (d, J 
= 8.2 Hz, 2H), 7.19 (d, J = 16.4 Hz, 1H), 6.72 (d, J = 8.2 Hz, 2H), 3.46 (d, J = 6.9 Hz, 4H), 
1.25 (t, J = 6.9 Hz, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 160.9, 159.2, 151.3, 149.2, 138.3, 137.3, 133.6, 130.7, 130.0 
(2C), 129.4, 128.1, 126.8, 123.3, 122.8, 121.3, 114.5, 113.4, 111.8 (2C), 81.8, 44.9 (2C), 
13.1 (2C) ppm. 
Elemental analysis (%): calcd. for C25H22N4: C 79.34, H 5.86, N 14.80; found: C 79.81, H 
6.12, N 14.91.  
(E)-2-((2-(4-(Piperidin-1-yl)styryl)quinolin-6-yl)methylene)malononitrile (6C)  
Prepared from 4-(piperidin-1-yl)benzaldehyde   
(0.255 g, 1.35 mmol), as a dark red solid. Yield: 0.126 
g, 40 %. 
Mp 180‐183°C. 
IR (neat) 2223, 1565,1511, 1172, 1120, 822 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.30‐8.10 (m, 4H), 7.88 (s, 1H), 7.80 – 7.70 (m, 2H), 7.57 (d, 
J = 8.7 Hz, 2H), 7.22 (d, J = 16.1 Hz, 1H), 6.96 (d, J = 8.7 Hz, 2H), 3.39 – 3.28 (m, 4H), 1.78‐
1.64 (m, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 160.5, 159.2, 152.9, 151.1, 137.9, 137.5, 133.6, 130.8, 129.5 
(2C), 129.4, 128.3, 126.9, 126.1, 124.2, 121.4, 115.6 (2C), 114.5, 113.4, 82.1, 49.7 (2C), 
25.9 (2C), 24.7 ppm. 
Elemental analysis (%): calcd for C26H22N4: C 79.97, H 5.68, N 14.35; found: C 77.43, H 
5.66, N 14.82.  
(E)-2-((2-(4-Morpholinostyryl)quinolin-6-yl)methylene)malononitrile (6d) 
Prepared from 4-morpholinobenzaldehyde (0.257 g, 
1.35 mmol), as a dark red solid. Yield: 0.129 g, 35 %. 
Mp 179‐182°C. 
IR (neat) 2227, 1572, 924, 813 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.20‐7.98 (m, 4H), 7.79 (s, 1H, H1”), 7.71‐7.59 (m, 2H), 7.51 
(d, J = 8.7 Hz, 2H), 7.15 (d, J = 16.2 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 3.86‐3.75 (m, 4H), 
3.25‐3.14 (m, 4H) ppm. 
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13C NMR (63 MHz, CDCl3): δ 160.4, 159.2, 152.3, 151.1, 137.7, 137.5, 133.5, 131.0, 129.4 
(3C), 128.4, 127.5, 127.0, 125.2, 121.5, 115.4 (2C), 114.4, 113.3, 82.5, 67.1 (2C), 48.7 (2C) 
ppm. 
Elemental analysis (%): calcd. for C25H20N4O: C 76.51, H 5.14, N 14.28; found: C 76.25, H 
5.32, N 14.45.  
(E)-((4-(2-(6-(2,2-Dicyanovinyl)quinolin-2-yl)vinyl)phenyl)azanediyl)bis(ethane-2,1-
diyl) diacetate (6e) 
Prepared from ((4-formylphenyl)azanediyl) 
bis(ethane-2,1-diyl) diacetate (0.395 g, 1.35 
mmol), as a dark red solid. Yield: 0.070 g, 20 %.  
Mp 98-100°C. 
IR (neat) 2224, 1728, 1516, 1220 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.27 (d, J = 1.5 Hz, 1H), 8.20 (dd, J = 8.9, 1.5 Hz, 1H), 8.14 
(d, J = 8.9 Hz, 1H), 8.08 (d, J = 8.9 Hz, 1H), 7.85 (s, 1H), 7.72 (d, J = 16.2 Hz, 1H), 7.67 (d, J 
= 8.9 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 16.2 Hz, 1H), 6.81 (d, J = 8.8 Hz, 2H), 
4.30 (t, J = 6.1 Hz, 4H), 3.72 (t, J = 6.1 Hz, 4H), 2.09 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 171.4 (2C), 160.5, 159.2, 151.1, 148.7, 137.7, 137.6, 133.6, 
130.8, 129.9, 129.4 (2C), 128.3, 126.9, 125.1, 124.0, 121.4, 114.5, 113.4, 112.4 (2C), 82.2, 
61.6, 50.0 (2C), 21.3 (2C) ppm. 
Elemental analysis (%): calcd. for C29H26N4O4: C 70.43, H 5.30, N 11.33; found: C 70.37, 
H 4.99, N 11.31.  
(E)-9-(2-(6-(2,2-dicyanovinyl)quinolin-2-yl)vinyl)-2,3,6,7-tetrahydro-1H,5H-
pyrido[3,2,1-ij]quinolin-8-yl acetate (6f) 
Prepared from 8-hydroxy-2,3,6,7-tetrahydro 1H,5H-
pyrido[3,2,1-ij]quinoline-9-carbaldehyde (0.350 g, 1.35 
mmol), as a dark red solid. Yield: 0.156g, 40%.  
Mp 144-146 °C. 
IR (neat) 2922, 2217, 1750, 1563, 1186 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.17 (d, J = 1.9 Hz, 1H), 8.10 (dd, J = 9.0, 1.9 Hz, 1H), 8.00 
(d, J = 8.9 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.77 (s, 1H), 7.61 (d, J = 16.1 Hz, 1H), 7.50 (d, J 
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= 8.9 Hz, 1H), 7.23 (s, 1H), 7.01 (d, J = 16.1 Hz, 1H), 3.18-3.12 (m, 4H), 2.70-2.68 (m, 2H), 
2.56-2.48 (m, 2H), 2.38 (s, 3H), 1.99 – 1.83 (m, 4H) ppm. 
13C NMR (63 MHz, CDCl3): δ 169.6, 160.6, 159.2, 151.3, 146.9, 145.5, 137.3, 133.6, 131.6, 
130.8, 129.3, 128.1, 126.9, 125.3, 124.2, 121.4, 119.9, 115.6, 114.5, 113.4, 113.5, 81.9, 
50.3, 49.7, 30.1, 28.0, 22.0, 21.3, 21.1 ppm. 
Elemental analysis (%): calcd. for C29H24N4O2: C 75.63, H 5.25, N 12.17; found: C 75.22, 
H 5.20, N 11.97.  
 (E)-2-((2-(2-(4-(Dimethylamino)naphthalen-1-yl)vinyl)quinolin-6-
yl)methylene)malononitrile (6g) 
Prepared from 4-(dimethylamino)-1-naphthaldehyde 
(0.269 g, 1.35 mmol), as a dark red solid. Yield: 0.201 g, 
56%.  
Mp 95-97 °C. 
IR (neat) 2930, 2105, 1568 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.63 (d, J = 15.9 Hz, 1H), 8.35-8.30 (m, 2H), 8.28 – 8.12 (m, 
4H), 7.89 (d, J = 8.6 Hz, 1H), 7.83 (s, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.65 – 7.51 (m, 2H), 7.37 
(d, J = 15.9 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 3,07 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 160.1, 159.2, 153.0, 151.1, 137.8, 134.4, 133.6, 133.2, 131.1, 
129.4, 128.9, 128.8, 128.6, 127.8, 127.1, 126.9, 125.7, 125.5, 125.3, 124.3, 121.8, 114.4, 
114.1, 113.3, 82.6, 45.5 (2C) ppm. 
Elemental analysis (%): calcd. for C27H20N4: C 80.98, H 5.03, N 13.99; found: C 81.17, H 
5.32, N 13.50.  
(E)-2-((2-(4-(Pyrrolidin-1-yl)styryl)quinolin-6-yl)methylene)malononitrile (6h) 
Prepared from 4-(pyrrolidin-1-yl)benzaldehyde 
(0.236 g, 1.35 mmol), as a dark red solid. Yield: 0.259 
g, 76%. 
Mp 123-125 °C. 
IR (neat) 2851, 2222, 1694, 1568, 1520 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.27 (d, J = 1.7 Hz, 1H), 8.19 (dd, J = 8.9, 1.7 Hz, 1H), 8.11 
(d, J = 9.1 Hz, 1H), 8.07 (d, J = 9.1 Hz, 1H), 7.85 (s, 1H), 7.76 (d, J = 16.1 Hz, 1H), 7.68 (d, J 
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= 8.7 Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 16.1 Hz, 1H), 6.59 (d, J = 8.8 Hz, 2H), 
3.38 (t, J = 6.5 Hz, 4H), 2.05 (t, J = 6.5 Hz, 4H) ppm.  
13C NMR (63 MHz, CDCl3): δ 160.9, 159.2, 151.4, 149.2, 138.8, 137.4, 133.5, 130.7, 129.9 
(2C), 129.4, 128.1, 126.9, 123.6, 122.7, 121.5, 113.6, 113.4, 112.2 (2C), 81.9, 48.0 (2C), 
25.9 (2C) ppm. 
Elemental analysis (%): calcd. for C25H20N4: C 79.76, H 5.36, N 14.88; found: C 79.78, H 
5.02, N 14.39.  
 
Synthesis of BODIPY-styrilquinoline derivatives (11) 
 
3.8.5. Condensation starting materials (7a-b) 
 
Ethyl 2‐methylquinoline‐6‐carboxylate (1 g, 4.64 mmol), the corresponding aldehyde 
(1.1 eq) and zinc chloride (0.031 g, 0.232 mmol) were suspended in acetic anhydride (2 
ml) in a pressure tight microwave tube containing a stirring bar. The reaction mixture 
was heated under microwave irradiation for 35 min at 150 °C, with an irradiation power 
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of 250 W. The crude product was diluted with ethyl acetate and neutralized using a 
NaHCO3 saturated solution. The organic phase was extracted with NaHCO3 (15 mL x 3), 
dried with anhydrous Na2SO4 and evaporated in vacuo to give a dark purple residue 
which was purified by flash chromatography through a silica column using hexane: ethyl 
acetate (7:1, v/v) as the mobile phase to give the desired compounds 7a-b  
 
Ethyl (E)-2-(4-(dimethylamino)styryl)quinoline-6-carboxylate (7a) 
Prepared from p‐dimethylaminobenzaldehyde (0.762 
g, 5.11 mmol), brown solid. Yield: 0.75 g, 47 %.  
Mp 158‐160 °C. 
IR (neat) 1708, 1584, 1269 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.51 (d, J= 1.8 Hz, 1H), 8.27 (dd, J = 1.8 Hz y J = 8.8 Hz, 1H), 
8.15 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.69 (d, J = 16.2 Hz, 1H), 7.68 (d, J = 8.7 
Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 16.2 Hz, 1H), 6.73 (d, J = 8.7 Hz, 2H), 4.44 (c, 
J = 7.1 Hz, 2H), 3.03 (s, 6H), 1.45 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 166.1, 158.7, 150.7, 150.1, 136.8, 136.1, 130.3, 128.9, 128.7, 
128.6 (2C), 126.8, 125.8, 123.9, 123.5, 119.6, 111.8 (2C), 60.9, 39.9 (2C), 14,2 ppm. 
Elemental analysis (%): calcd. for C22H22N2O2: C 76.28, H 6.40, N 8.09, found: C 76.33, H 
6.75, N 8.08.  
Ethyl (E)-2-(4-(diethylamino)styryl)quinoline-6-carboxylate (7b) 
Prepared from p‐diethylaminobenzaldehyde (0.906 
g, 5.11 mmol), orange solid. Yield: 0.911 g, 52 %.  
Mp 120‐122 °C. 
IR (neat) 1707, 1585, 1182 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.50 (d, J = 1.8 Hz, 1H), 8.26 (dd, J = 1.9 Hz y J = 8.8 Hz, 1H), 
8.14 (d, J = 8.7 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.68 (d, J = 16.1 Hz, 1H), 7.67 (d, J = 8.7 
Hz, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 16.2 Hz, 1H), 6.69 (d, J = 8.9 Hz, 2H), 4.44 (c, 
J = 7.1 Hz, 2H), 3.41 (c, J = 7.1 Hz, 4H), 1.45 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 166.4, 159.1, 150.4, 148.4, 137.0, 136.4, 130.4, 129.2 (2C), 
128.9 (2C), 127.0, 126.0, 123.3, 123.1, 119.9, 111.4 (2C), 61.2, 44.4 (2C), 14.4, 12.6 (2C) 
ppm. 
Chapter 3. Styrylquinoline derivatives as theranostic agents for Alzheimer’s disease 
93 
 
Elemental analysis (%): calcd. for C24H26N2O2: C 76.98, H 7.00, N 7.48, found: C 76.83, H 
6.75, N 7.08.  
 
3.8.6. Reduction of styrilquinoline esters (8a-b) 
 
  
A suspension of lithium aluminium hydride (10 eq) in dry THF (10 ml) was prepared and 
cooled down to 0 °C with an ice‐water bath. Then the suitable ester derivative (1 eq) was 
dissolved in dry THF (10 ml) under argon.  This solution was slowly added to the 
suspension previously prepared. The mixture was stirred for 1h and then quenched by 
the sequential addition of ethyl acetate (30 mL) and water (2 mL). The suspension was 
filtered, and the filtrate was extracted with AcOEt, dried with anhydrous Na2SO4 and 
evaporated in vacuo to afford the title compounds. These compounds were directly used 
in the next step without purification or characterization due to solubility issues.  
 
(E)-(2-(4-(Dimethylamino)styryl)quinolin-6-yl)methanol (8a) 
Prepared from ethyl (E)‐2‐(4‐(dimethylamino) 
styryl)quinoline‐6‐carboxylate (0.022 g; 0,58 mmol) and 
LiAlH4 (0.219 g, 5.8 mmol). Reddish solid. Yield: 0.120 g. 
 
(E)-(2-(4-(Diethylamino)styryl)quinolin-6-yl)methanol (8b) 
Prepared from ethyl (E)‐2‐(4‐(diethylamino) 
styryl)quinoline‐6‐carboxylate (0.583 g; 1.55 mmol) 
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3.8.7. Oxidation of styrilquinone alcohols (9a-b) 
Dess Martin periodinane oxidation 
 
 
Dess Martin periodinane (0.578 g, 1.36 mmol / 0.082 g, 0.19 mmol) was added to a 
solution of compounds 8 (8a 0.277 g, 0.91 mmol / 8b 0.043 g, 0.13 mmol) in CH2Cl2 (20 
mL), the reaction mixture was stirred at 0 °C for 20 min. After this time, the reaction was 
quenched using a Na2S2O3/NaHCO3 solution (20 mL) and the mixture was stirred for 30 
min at room temperature. The crude was extracted with CH2Cl2 (3 x 15 mL), dried with 
anhydrous Na2SO4 and evaporated in vacuo to give dark red crudes which were purified 
by flash chromatography through a silica column using hexane: ethyl acetate (7:1, v/v) 
as the mobile phase to give the desired compounds 9a-b.  
 
PCC oxidation  
Pyridinium chlorochromate on alumina: 
 
On a 250 mL round bottom flask a solution of chromium oxide (VI) 2,5 g in 5 mL of HCl 
(6 M) was prepared stirring and heating up to 40°C. To this solution 2,5g of pyridine were 
added dropwise. The solution was cooled until an orange precipitate was observed and 
heated up again to 40 °C until complete redissolution. At this point 20 g of Al2O3 were 
added to the stirring mixture. The solvents were evaporated under reduced pressure and 
dried at 100 °C under vacuum overnight. This way the load of the reagent obtained is 1 
mmol/g. 
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PCC oxidation protocol 
 
  
To a solution of the corresponding alcohol 8b (0.039 g, 0.12 mmol) in dry CH2Cl2 (15 mL) 
pyridinium chlorochromate on alumina (0.120 g, 1 eq, 0.12 mmol) was added. The 
mixture was stirred for 72 h at room temperature. After this time, the suspension was 
filtered and washed with ethyl ether (5 x 10 mL). The organic solvents were dried under 
reduced pressure and the crude product was purified by flash chromatography through 
a silica column using hexane: ethyl acetate (7:1, v/v) as the mobile phase to give the 
compound 9b (7 mg) as a red solid (18%). 
 
TPAP oxidation  
 
 
Solutions of the corresponding alcohols 8 (8a 0.172 g, 0.56 mmol /8b 0.040 g, 0.12 
mmol) in dry CH2Cl2 (15 mL) with N‐methylmorpholine‐N‐oxide (0.099 g, 0.85 mmol / 
0.021 g, 0.18 mmol) in dry acetonitrile (4 mL) were prepared under an argon 
atmosphere. To these solutions, 4Å molecular sieves and tetrapropylamonium 
perrutenate (TPAP, 0.2 eq.) were added and the suspension was stirred at room 
temperature for 3.5 h. After this time, the crude was filtered through a pad of celite and 
washed with CH2Cl2 (3 x 10 mL). The filtrate was evaporated, and the crude was purified 
by flash chromatography through a silica gel column using hexane: ethyl acetate (7:1, 
v/v) as the mobile phase to give compounds 9a/9b as reddish solids. Yield:  Xa 0.025 g, 
15%; Xb 0.016 g, 40%. Yield: 1.27 g, 80%. Compounds 9 were only characterized by NMR 
due to their instability.  
 




1H NMR (250 MHz, CDCl3): δ  10.15 (s, 1H), 8.25 (s, 1H), 
8.21 – 8.11 (m, 3H), 7.74 (d, J = 16.2 Hz, 1H), 7.69 (d, J = 
8.8 Hz, 1H), 7.57 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 16.2 Hz, 
1H), 6.74 (d, J = 8.8 Hz, 2H), 3.05 (s, 6H) ppm. 
(E)-2-(4-(Diethylamino)styryl)quinoline-6-carbaldehyde (9b) 
1H NMR (250 MHz, CDCl3): δ 10.15 (s, 1H), 8.25 (d, J = 
1.3 Hz, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.13‐8.07 (m, 2H), 
7.69 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 16.2 Hz, 1H), 7.53 (d, 
J = 8.9 Hz, 2H), 7.17 (d, J = 16.1 Hz, 1H), 6.69 (d, J = 8.9 
Hz, 2H), 3.42 (c, J = 7.1 Hz, 4H), 1.21 (t, J = 7.1 Hz, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 191.5, 159.9, 151.4, 148.6, 137.1, 137.0, 133.2, 133.1, 129.9, 
129.3 (2C), 127.1, 126.3, 123.1, 122.8, 120.3, 111.4 (2C), 44.4 (2C), 12.6 (2C) ppm. 
 
3.8.8. Synthesis of BODIPY (10)  
 
 
A solution of benzaldehyde (0.106 g, 1.1 mmol), 2,4‐dimethyl‐1H‐pyrrole (0.215 g, 2.2 
mmol) and a catalytic amount of trifluoroacetic acid (2‐3 drops) in CH2Cl2 (5 mL) were 
stirred at room temperature for 16 h. After this time, a solution of DDQ (1 eq. in 2 ml of 
CH2Cl2) was added dropwise. The mixture was stirred for 15 minutes and after this time 
BF3O.Et (2 mL) and Et3N (2 mL) were added and stirring was maintained for 3 more hours. 
After completion of the reaction, the crude was extracted with water (3 x 15 mL), dried 
with anhydrous Na2SO4 and evaporated in vacuo to give dark residue, which was purified 
by flash chromatography through a silica column using hexane: ethyl acetate (9:1, v/v) 
as the mobile phase to give the desired compound 10 as a greenish solid. Yield: 0.459 g, 
29%. 
Mp 155‐157 °C. 
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IR (neat) 1502 cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.40‐7.37 (m, 3H), 7.19‐7.15 (m, 2H), 5.89 (s, 2H), 2.47 (s, 
6H), 1.28 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 155.3 (2C), 143.1 (2C), 141.7, 134.9 (2C), 131.3, 129.1 (2C), 
128.9, 127.8 (2C), 121.1 (2C), 14.5 (t, J = 2.1 Hz, 2C), 14.2 (2C) ppm.  
19F-RMN (235 MHz, CDCl3, δ): ‐146.67 (dd, 2F, J = 66.0 Hz, J = 32.8 Hz, BF2) ppm. 
Elemental analysis (%): calcd. for C19H19BF2N2: C 70.40, H 5.91, N 8.64, found: C 70.58, 
H 5.96, N 8.24. 
 
3.8.9.  Condensation of aldehyde derivatives with the BODIPY core (11) 
 
A mixture of aldehyde 9a (0.185 g, 0.61 mmol), compound 10 (0.199 g, 0.61 mmol), 
acetic acid (1 drop) and piperidine (1 drop) were dissolved in DMF (1 mL) in a pressure 
tight microwave tube containing a stirring bar. The reaction mixture was heated under 
microwave irradiation for 5 min at 150 °C, with an irradiation power of 250 W. Once the 
reaction is finished, the crude product was diluted with ethyl acetate and washed with 
a LiCl saturated solution (3 x 15 mL). The organic phase was dried with anhydrous Na2SO4 
and evaporated in vacuo to a crude which was purified by flash chromatography through 
a silica column using hexane: ethyl acetate (7:1, v/v) as the mobile phase to give the 
desired compound XX as a pink fluorescent solid. Yield: 0.015 g, 5%. 
  





Mp 105‐107 °C. 
IR (neat) 2920, 1706, 1536, 1497 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.12‐8.03 (m, 3H), 
7.88‐7.80 (m, 2H), 7.71‐7.52 (m, 7H), 7.42‐7.32 
(m, 4H), 6.76 (d, J = 8.4 Hz, 2H), 6.68 (s, 1H), 
6.07 (s, 1H), 3.06 (s, 6H), 2.66 (s, 3H), 1.47 (s, 
3H), 1.43 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 159.7, 156.7, 156.6, 152.3, 152.3, 143.9, 143.9, 142.7, 141.1 
(2C), 137.1 (2C), 135.4, 135.2, 134.6, 129.6 (2C), 129.5 (2C), 129.2 (2C), 128.6, 128.5 (2C), 
127.2, 127.1, 123.0, 122.1 (2C), 120.5 (3C), 120.5, 117.9, 25.6 (2C), 15.3, 15.00, 14.9 
ppm. 
19F-RMN (235 MHz, CDCl3) δ: ‐146.68 (dd, 2F, J = 66 Hz y J = 32.8 Hz, BF2) ppm. 
11B NMR (160 MHz, CDCl3) δ: 0.93 (t, J = 32.3 Hz) ppm.  

















4.1. A deeper view of Type II Diabetes Mellitus etiopathology 
Amylin 
As previously mentioned, Type II Diabetes Mellitus (T2DM) is a multifactorial disease 
involving genetic and environmental factors. From a physiopathologic point of view, 
T2DM is mainly characterized by β-cell dysfunction, insulin resistance and chronic 
inflammation. All these combined failures finally provoke an increase in blood glucose 
levels, which leads to micro and macrovascular complications.46 
There are several factors that contribute to β-cell failure, including ageing, genetic 
abnormalities, lipotoxicity, glucotoxicity, insulin resistance leading to β-cell stress 
hypersecretion, oxidative stress, activation of inflammatory pathways and 
hypersecretion of the islet amyloid polypeptide (IAPP). 46 
Islet amyloid polypeptide (IAPP), or amylin, is a 37-aminoacid peptidic pancreatic 
hormone found in all mammals. IAPP and insulin are co-produced, co-stored in the 
secretory granules and co-secreted through exocytosis with a molar ratio IAPP: insulin 
of 1: 100 in healthy individuals, although this ratio can increase to 1: 20 in T2DM 
patients. Even if the function of hIAPP remains unclear, it is known that it may be 
involved in glucose metabolism regulation, gastric emptying control, glucagon 
suppression and satiety.114,115,116 
Monomeric hIAPP can be in numerous flexible configurations and can be classified as an 
intrinsically disordered protein (IDP). These are proteins that, under physiological 
conditions, lack a stable or fixed tertiary structure, in contrast to the traditional dogma 
of structural biology, in which the three-dimensional, functional structure of a protein is 
univocally determined by its amino acid sequence: one protein, one structure, one 
function. Due to their high conformational entropy, IDPs can interact with different 
targets or ligands, behaving as multitasking proteins. On the other hand, these proteins 
are prone to aggregation due to the ability of their hydrophobic amino acid side chains 
 
114 Caillon, L.; Hoffmann, A. R. F.; Botz, A.; Khemtemourian, L. J. Diabetes Res. 2016, 2016, ID: 5639875. 
115 Lutz, T. A.; Meyer, U. Front. Neurosci. 2015, 9, 218. 
116 Raleigh, D.; Zhang, X.; Hastoy, B.; Clark, A. J. Mol. Endocrinol. 2017, 59, 121. 
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to sustain intermolecular rather than intramolecular interactions, leading to their 
folding.117 
It is worth nothing that only the IAPPs from humans, non-human primates and cats are 
able to aggregate. In contrast, the IAPPs from rodents do not form amyloid fibres and, 
interestingly, these animals do not develop spontaneous diabetes. Differences in the 
sequences of IAPP, mainly affecting the residues 20-29, have been observed. When 
rodent IAPP (rIAPP) and human IAPP (hIAPP) are compared, six amino acids differ in the 
mentioned region, being the most important the three proline residues in rIAPP at 
positions 25, 28 and 29. The restricted rotational freedom of proline and the disruption 
of hydrogen bonding and intramolecular β-sheet formation explain the lower tendency 
of rIAPP to aggregate and hence the lack of islet amyloid in rodent diabetes models. 
(Figure 4.1) 
Figure 4.1 
This absence of these prolines triggers the formation of β-sheet structures, which tend 
to aggregate creating dimers and small oligomers. These oligomers act as template 
structures that facilitate the quick formation of bigger oligomers, in a sigmoidal kinetics. 
(Figure 4.2)  
  
 
117 Fernández, M. S. Cell Calcium, 2014, 56, 416. 





These oligomers are thought to be the most harmful structures, due to their role as 
nuclear structures as well as their own potential damage capability.118 Thus, on  
one hand, it has been demonstrated that hIAPP oligomer accumulation increases 
oxidative stress, causes endoplasmic reticulum (ER) stress, damages mitochondrial 
membranes, decreases ubiquitin-proteasome functionality and impairs the autophagy 
recycling system. More specifically, it has been proved that pancreatic β-cell lines 
overexpressing hIAPP, present higher mitochondrial damage and a defective 
mitochondrial elimination autophagy process, called mitophagy.119 (Figure 4.3) 
On the other hand, larger aggregates could form fibrils that causing plasmatic 
membrane permeabilization and a secondary activation of the inflammatory 
response.120 It is known that membranes promote hIAPP aggregation while also being 
the target of toxicity. It has been proved that amyloid proteins are able to induce the 
formation of cation-selective channels in planar lipid bilayers, causing membrane 
disruption.119  
 
118 Kahn S.E. Diabetologia, 2010, 53, 1046.  
119 García-Hernández, M.; García-Aguilar, A.; Burillo, J.; Gómez-Oca, R.; Manca, M. A.; Novials, A.; Alcarraz-
Vizan, G.; Guillén, C.; Benito, M. Cell Death and Disease, 2018, 9, 1. 
120 Mukherjee, A.;  Morales-Scheihing, D.; Butler, P.C.; Soto, C. Trends in Molecular Medicine, 2015, 1. 
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Due to this amylin overexpression and misfolding, T2DM can be classified as a protein- 
misfolding disease, sharing the histopathological characteristic hallmark of fibrillar 
amyloid deposits, in this case affecting in the pancreatic islets of Langerhans. 
 
 
   Figure 4.3. Reproduced with permission from reference 121. 
 
4.2. hIAPP and A: Partners in crime?   
Both, AD and T2DM are multifactorial age-related disorders, leading to a considerable 
morbidity and mortality in elderly population. During the past years, several 
epidemiological studies demonstrated that T2DM patients present a 2 to 5 times higher 
risk of developing AD than the normal population. Furthermore, people with T2DM 
often experience a significant decline in cognitive function and around 70% of them 
eventually develop AD. Moreover, animal models of T2DM have been shown to develop 
spontaneous AD-like pathologies, exhibiting typical neuropathological characteristics 
 
121 Westermark, P.; Andersson, A.; Westermark, G. T. Physiol. Rev. 2011, 91, 795. 
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such as high APP and -secretase levels, A formation, tau hyper-phosphorylation and 
neuronal death.  
Although both pathologies appear to share several pathophysiological pathways, the 
exact molecular connection between them remains unclear.122 
One of these hypotheses is associated with hIAPP and A aggregates. These two 
proteins have a total of 25% amino acid sequence identity and a high binding affinity to 
each other. Moreover, they share several biophysical and physiological properties and 
exert similar cytotoxic mechanisms once aggregated. 
Also, hIAPP deposits have been found in cerebral samples of AD patients. Cerebral IAPP 
has also been found in rats overexpressing hIAPP. Additionally, IAPP has been found to 
precipitate with A to form diffuse and dense senile plaques. (Figure 4.4) 
It has been proved that IAPP aggregates can exert cytotoxic effects on neurons by 
several mechanisms. On one hand, IAPP and A could interact with each other and 
synergistically exert their toxic effect. One possible reason is that IAPP can aggregate in 
the walls of cerebral blood vessels and induce failure in brain A elimination.122 On the 
other hand, IAPP aggregates can have a direct toxic effect on neurons, by causing 
damage in cellular structures, disturbing ion homeostasis (Ca2+), triggering inflammatory 
responses, inducing oxidative stress or activating apoptotic signalling pathways. 
These facts provide enough evidence to hypothesize that IAPP aggregation during T2DM 
development plays a key role in AD pathogenesis.  
 
Figure 4.4. Brain parenchyma of a T2DM patient with Alzheimer´s disease 
 
122 Zhang, Y.; Song, W. Prog. Neurobiol. 2017, 153, 100. 
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The transcription levels of IAPP in brain are undetectable, and this may indicate that 
cerebral IAPP comes from pancreatic islet -cells and travels through circulation to the 
central nervous system. This hypothesis is further corroborated by the discovery of IAPP 
deposits on blood vessel walls and pericapillary brain spaces. One plausible hypothesis 
is that that hIAPP aggregates are exported form -cells inside exosomes and travel this 
way through blood vessels to reach the central nervous system.122 (Figure 4.5) 
To verify this hypothesis, compounds able to detect hIAPP aggregates are needed. 
Moreover, they could be used as diagnostic tools for advanced prediabetic stages or 




4.4. Preliminary results 
In order to test one of our styrylquinolines as an amylin sensor, preliminary experiments 
were carried out by Jesús Burillo, under the supervision of Drs. Carlos Guillén and 
Manuel Benito at the Departamento de Bioquímica y Biología Molecular, Facultad de 
Farmacia, Universidad Complutense de Madrid. To this end, compound 6b was tested 
in insulinoma cell lines (INS1-E) overexpressing rat amylin (non-amyloidogenic), human 
amylin (amyloidogenic) and wild type (WT). Due to solubility issues, DMSO was selected 
as solvent for preparing the stain stock solutions. First, the optimal staining 
concentration needed to be determined. For this purpose, different concentrations 
ranging from 1 to 10 µM were tested, finding that, even if staining was already observed 
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with the 1 µM concentration, 10 µM gave the best results, being selected for further 
immunofluorescence assays. Next, different staining times and labeling methods were 
tested in order to establish a standardized protocol, finding that, the best conditions for 
6b staining corresponded to 10 µM concentration for 20 min.  6b staining was done on 
cells after fixation and antibody-labeling classic immunofluorescence protocols.  
Preliminary experiments on a fluorescence microscope were initially performed.  To this 
end, INS1-E cells were exposed to two different glucose concentrations (11 mM, “basal” 
concentration and 16.7 mM, secretory concentration) in order to stimulate hIAPP 
production and accumulation. As shown in Figure 4.6, only the INS1-E hIAPP cell line 
presents fluorescent emission, which is increased under basal glucose conditions. On 
the other hand, no fluorescent beyond basal “noise” is observed in INS1-E WT and INS1-




The next experiment was performed using a confocal microscope. This time the cell lines 
were submitted to the same conditions and the HT-22 mouse hippocampal cell line was 
used as a control to confirm the specificity of 6b for amyloid aggregates. The same 
staining protocol was used for 6b and this time DAPI was used to stain the cell nuclei. As 
in the previous case, no fluorescent signal was observed neither in INS1-E WT, rIAPP or 
HT-22. However, INS1-E hIAPP showed a dot-shaped signal, pointing to a specific 
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labeling of hIAPP aggregates. Curiously, it seems that less dots are found in high glucose 
than in basal glucose conditions. (Figure 4.7) A tentative explanation is that hIAPP 
aggregates are exported inside exosomes, as a detoxifying method. 
 
Figure 4.7. 
In order to verify this possible mechanism, several experiments were performed. First, 
the exosomal extract was evaluated (Figure 4.8), proving that the INS1E cells were able 
to secrete exosomes containing amylin.  
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Then cells were submitted to GW4869, an inhibitor of exosomal secretion, showing that 
under these conditions the amount of amylin inside cells considerably increases. 
(Figures 4.9 and 4.10) 
Figure 4.9. Cell protein extract after GW4869 treatment( exosomal secretion inhibitor). 
 
Figure 4.10. 
To further verify this hypothesis, colocalization experiments were carried out. INS1-E 
hIAPP cells were labelled with a protein belonging to the exosome formation pathway, 
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confirm the presence of hIAPP aggregates inside multivesicular bodies (MVB), the 
structures from exosomes are derived, although if positive results were found further 
experiments need to be done.  
 
Figure 4.11. 
Finally, compound 6b and a non-aggregated hIAPP specific antibody were used in 
combination in order to check if 6b acts as a β-amyloid aggregates specific dye within 
pancreatic β-cells. INS1-E cells were submitted to basal and high glucose conditions and 
labelled with the antibody and the 6b following the standard protocol previously 
described. The results showed a clear different fluorescent signal of 6b and hIAPP 
antibody, confirming the ability of 6b to target specifically hIAPP aggregates. (Figure 
4.12)  
  





Future experiments will be performed on a T2DM mice model, which will express human 
amylin within their pancreas. 6b will be tested on sections of different tissues (pancreas, 
liver, kidney, etc.) in order to check the accumulation of hIAPP aggregates, focusing on 












CHAPTER 5. NOVEL MITOCHONDRIAL-
TARGETED LEISHMANICIDAL DERIVATIVES OF 
THE 4-AMINOSTYRYLQUINOLINE SCAFFOLD 
 




5.1. Why are mitochondria-targeted compounds interesting for 
leishmaniasis?  
As mentioned in the Introduction, leishmaniasis is a protozoal tropical disease surpassed 
only by malaria in terms of human health impact factor. Current therapy is based in a 
few drugs with several drawbacks such as the need for parenteral administration with 
hospitalization of the patient, drug resistance and toxicity. Thus, there is still an urgent 
need to discover new antileishmanial drugs.123,124 
Understanding the biology of these parasites is key for developing novel new drug 
targets and leishmanicidal compounds. Protozoa are interesting form a biological point 
of view because they possess unique organelles and cytoplasmic structures. One of the 
main characteristics of trypanosomatids such as Leishmania is that they bear a single 
mitochondrion, which is thus of vital importance. The structure of the trypanosomatid 
mitochondria is peculiar compared to multicellular organisms regarding the density of 
the matrix as well as the shape and number of cristae. Also, depending on the nutritional 
resources available, it can occupy up to 12% of the cell volume. The most unusual 
structure in the organelle is the kinetoplastid DNA (kDNA), which is found in the most 
dilated regions. 125 (Figure 5.1) 
Moreover, about 70% of trypanosomatids energetic metabolism is based on oxidative 
phosphorylation.  In L. donovani promastigotes, only 30% of ATP production is fulfilled 
through glycolysis, 126 and a higher mitochondrial dependence has been reported in L. 
mexicana intracellular amastigotes. 127  In addition, it was demonstrated that in 
tafenoquine-resistant L. major strains the ability of glycolysis to compensate for 
mitochondrial dysfunction is quite limited. 128  All these data evidence that 
 
123 Alvar, J.; Velez, I.D.; Bern, C.; Herrero, M.; Desjeux, P.; Cano, J.; Jannin, J.; den Boer, M. PLoS One 2012, 
7, e35671. 
124 Ponte-Sucre, A.; Gamarro, F.; Dujardin, J.C.; Barrett, M.P.; Lopez-Velez, R.; García-Hernandez, R. A. 
Pountain, W.; Mwenechanya, R.; Papadopoulou, B. PLoS Neglected Trop. Dis. 2017, 11, e0006052. 
125 Fidalgo, L. M.; Gille, L. Pharm. Res. 2011, 28, 2758. 
126 Sen, N.; Das, B.B.; Ganguly, A.; Banerjee, B.; Sen, T.; Majumder, H.K. Exp. Parasitol. 2006, 114, 204. 
127 Saunders, E.C.; Ng, W.W.; Kloehn, J.; Chambers, J.M.; Ng, M.; McConville, M.J. PLoS Pathog. 2014, 10, 
e1003888. 
128  Manzano, J.I.; Carvalho, J.; Perez-Victoria, J.M.; Castanys, S.; Gamarro, F. Antimicrob. Agents 
Chemother. 2011, 55,1045. 
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mitochondrion disfunction is particularly toxic for these protozoa, in contrast to 




Drugs targeting the mitochondrial ATP synthesis process must hamper the bioenergetic 
requirements of Leishmania. In agreement with this idea, several studies about the 
mechanism of action of antiprotozoal drugs suggest that many of the drugs that show 
effectiveness against the parasite act on the Leishmania mitochondrion.126 For example, 
artemisinin, a sesquiterpene lactone, is an antimalarial drug that has also shown 
antileishmanial activity, which is due to loss of the mitochondrial membrane potential. 
Moreover, amphotericin B and pentamidine induce mitochondrial membrane 
permeability with a rapid decrease of the mitochondrial membrane potential 
Additional leishmanicidal drugs acting at mitochondria are atovaquone, a 
hydroxynaphthoquinone that acts as a ubiquinone competitor, inhibiting the 
cytochrome bc1 complex, and tafenoquine, an 8-aminoquinoline, whose antileishmanial 
mechanism of action involves mitochondrial dysfunction by inhibiting cytochrome C 
reductase (respiratory complex III), decreasing oxygen consumption and depolarizing 
the mitochondrial membrane potential. 125  (Figure 5.2)  
 






5.2. Design of antileishmanial 4-aminostyrylquinolines 
Quinolines have shown a high potential to develop effective and affordable oral 
treatments as leishmanicidal agents.129 For instance, the quinoline derivative I (Figure 
5.3) showed a better antileishmanial activity than the reference drug miltefosine with a 
good selectivity index (SI), and it entered in the Drugs for Neglected Diseases initiative 
(DNDi) pipeline for in vivo evaluation.130 Also, the quinaldine derivative II (Figure 5.3), 
designed to inhibit the type-2 NADH dehydrogenase (NDH2) of Leishmania infantum, 
exhibited good activity against both promastigote and amastigote forms.131 Moreover, 
as previously mentioned for the case of tafenoquine132 (Figure 5.3), it has been proved 
that 8-aminoquinoline polyamines inhibit the respiratory chain at the Leishmania 
mitochondrion. Among them, the most relevant example is sitamaquine (Figure 5.3), 
 
129 K.A. Reynolds, W.A. Loughlin, D.J. Young, Quinolines as chemotherapeutic agents for leishmaniasis, 
Mini Rev. Med. Chem. 2013, 13, 730. 
130 Loiseau, P.M.; Gupta, S.; Verma, A.; Srivastava, S.; Puri, S.K.; Sliman, F.; Normand-Bayle, M.; Desmaele, 
D. Antimicrob. Agents Chemother. 2011, 55, 1777. 
131 Stevanovic, S.; Perdih, A.; Sencanski, M.; Glisic, S.; Duarte, M.; Tomas, A.M.; Sena, F.V.; Sousa, F.M.; 
Pereira, M.M.; Solmajer, T. Molecules, 2018, 23, 772. 
132 Carvalho, L.; Luque-Ortega, J.R.; Manzano, J.I.; Castanys, S.; Rivas, L.; Gamarro, F. Antimicrob. Agents 
Chemother. 2010, 54, 5344. 
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which reached phase IIb clinical trials, affording oral treatment for leishmaniasis by 
inhibiting the succinate dehydrogenase (complex II) of the respiratory chain.133,134 
Figure 5.3 
 
Among quinolines, 2-substituted derivatives have often shown higher activities and 
metabolic stabilities with lower toxicity than their non-substituted counterparts.135 Also, 
the presence of conjugated double bonds seems beneficial for activity, as shown by the 
case of compound I.136,137 
Using as a starting point the activities of 8-aminoquinoline-based polyamines, we 
reasoned that an increase in the positive charge of quinoline core would enable the 
molecules to have a preferential mitochondrial accumulation. This is because, among 
intracellular organelles, mitochondria present a higher electrochemical potential (m) 
that would drive the preferential accumulation.  
In this context, we designed a library of 2-substituded styrylquinolines,110 which were 
decorated with polyamine chains in the C-4 position of the quinoline scaffold. The 4-
aminoquinoline fragment would lead to an increased basicity of the heterocyclic 
 
133 Loiseau, P.M.; Cojean, S.; Schrevel, J. Parasite, 2011, 18, 115. 
134  Carvalho, L.; Luque-Ortega, J.R.; Lopez-Martín, C.; Castanys, S.; Rivas, L.; Gamarro, F. Antimicrob. 
Agents Chemother. 2011, 55, 4204. 
135 Desrivot, J.; Herrenknecht, C.; Ponchel, G.; Garbi, N.; Prina, E.; Fournet, A.; Bories, C.; Figadere, B. 
Hocquemiller, R.; Loiseau, P.M. Biomed. Pharmacother. 2007, 61, 441. 
136 X. Franck, A. Fournet, E. Prina, R. Mahieux, R. Hocquemiller, B. Figadere Bioorg. Med. Chem. Lett. 2004, 
14, 3635. 
137 Nakayama, H.; Desrivot, J.; Bories, C.; Franck, X.; Figadere, B.; Hocquemiller, R.; Fournet, A.; Loiseau, 
P.M. Biomed. Pharmacother. 2007, 61, 186. 




nitrogen, and more importantly, to a delocalized positive charge by resonance across 
the N1=C2-C3=C4-NH fragment. This approach was expected to enhance the behaviour 
of the molecule as a lipophilic cation, essential for its transport across the inner 
mitochondrial membrane and mitochondrial accumulation.138 Finally, the substituents 
at the end of the polyamine chain (represented by Z, Figure 5.4)139 were chosen in order 
to modulate the basicity of the nitrogen atoms at C-4 and evaluate its influence. This 
may be of relevance because the presence of a second amino group in the polyamine 
chain would increase compound retention at the acidic pH present on the 
phagolysosomes, where the amastigote forms multiply.140 Finally, the presence of the 
2-styryl fragment, besides potentially increasing activity, was expected to confer 




5.3. Synthesis of 4-aminostyrylquinoline derivatives  
To be able tests the importance of each part of the molecules and perform some SAR 
studies, we synthesized and tested a library of compounds that included Boc-protected 
polyamine chains and deprotected ones. We also evaluated two different polyamine 
 
138 Murphy, M.P. Biochim. Biophys. Acta 2008, 1777, 1028. 
139 Staderini, M.; Piquero, M.; Abengozar, M.A.; Nacher-Vazquez, M.; Romanelli, G.; Lopez-Alvarado, P.; 
Rivas, L.; Bolognesi, M. L.; Menendez, J.C. Eur. J. Med. Chem. 2019, 171, 38.  
140 Dias, M.P.; Souza, I.O.; Lima, W.P; Gameiro, J.; da Silva, A.D.; Coimbra, E.S. Chem. Biol. Drug Des. 
2015, 86, 704. 
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chains to evaluate the importance in length of this one, and in the Z residue different 
groups such as alkylamines (19a-h), arylamides (19i-l) or alkoxy (20a-b) were included. 
 
Table 5.1 
derivatives were tested. Furthermore, compound 22 was evaluated to verify the 
importance of the styryl group, while compounds 25 and 26 were tested in order to 
evaluate the influence of the 4-amino substitution of the polyamine chain. (Table 5.1)  






For the preparation of our chemical library, we started with the synthesis of 4-chloro-2-
styrylquinoline 13, followed by its decoration with the selected basic chains at C-4.  The 
commercially available 4-chloroquinaldine 12 was condensed with benzaldehyde in the 
presence of zinc chloride through a microwave-promoted aldol condensation. After 
preparation of the desired Boc-monoprotected polyamine chains (15a and 15b), 
compound 13 and the suitable amine were heated in the presence of phenol, which acts 
as both the solvent and the acidic promoter of the nucleophilic aromatic substitution 
that yielded compounds 16a and 16b. (Scheme 5.2) These intermediates were 
deprotected using a solution of trifluoroacetic acid in methanol, giving 17a and 17b, 
which  were directly transformed into halides 18 by treatment with bromoacetyl 
bromide at -5 °C for 30 minutes Finally, compounds 18 were treated with a variety of 
aliphatic amines under microwave irradiation in the presence of Cs2CO3 to yield the 
desired compounds 19a-h. For the synthesis of the ethoxy intermediate 18 was treated 
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Unfortunately, this method failed for the preparation of the aniline derivatives 19i-l, 
probably due to the low nucleophilicity of the required starting amines. For this reason, 
alternative method was needed and to this end we prepared N-arylglycine derivatives 
by reacting the suitable commercially available anilines with ethyl bromoacetate in the 
presence of sodium hydride, followed by ester hydrolysis. Once compounds 21a-b were 
available, the last step was the coupling with the previously mentioned primary amines 
17a-bin the presence of EDC/HOAt. (Scheme 5.3) 
 
Scheme 5.3 
In order to evaluate the influence of the polyaminoalkyl chain, compound 25 was 
required as a reference. The commercially available 4-amino-2-methylquinoline was 




condensed with benzaldehyde in the presence of zinc chloride and acetic anhydride 
under microwave irradiation, giving a mixture of compounds 23 and 24, with different 
N-acetylation levels. Although both compounds were purified for their biological 
evaluation, for synthetic purposes their mixture was hydrolysed in the presence of an 
hydroalcoholic solution of KOH under microwave irradiation to give the target 




5.4. Activity and mechanistic studies of 4-aminostyrylquinolines  
5.4.1 Computational drug-likeness study 
First, preliminary ADME-tox computational studies of the synthesized compounds were 
carried out using SwissADME. For all the compounds, a high gastrointestinal absorption, 
important for oral bioavailability, was predicted. Moreover, only compound 19l showed 
violations Lipinski's rule of five. The details of this study are shown Table 5.2. 
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Table 5.2: Computational drug-likeness study 
5.4.2 Antileishmial activities 
The biological studies were carried out in the group of Dr. Luis Rivas, at the Centro de 
Investigaciones Biológicas, CSIC, Madrid. First the activity of the compounds was tested 
against Leishmania donovani promastigotes (strain MHOM/SD/00/1S-2D) in a 
phenotypic screening. Promastigotes were chosen due to the fact that at this stage of 
the parasite cycle about 70 % of the ATP synthesis is accomplished through the 
 
141 Topological Polar Surface Area calculated from Etrl, P.; Rohde, B.; Selzer, P. J. Med. Chem. 2000, 43, 
3714. 
142 Consensus Log P o/w average of 5 prediction methods. 
143 Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliv. Rev. 2001, 46, 3. 
144 ESOL topological method implemented from Delaney, J. S. Prediction of aqueous solubility and 
partition coefficient optimized by a genetic algorithm-based descriptor selection method. J. Chem. 
Inf. Model. 2004, 44, 1000. 
145 Saina, A.; Zoete, V. A   Chem. Med. Chem. 2016, 11, 1117. 










16a 9 63.25 4.39 -5.33 High 0 0 
16b 11 63.25 4.89 -5.80 High 0 0 
17a 5 50.94 3.26 -4.07 High 0 0 
17b 7 50.94 3.88 -4.52 High 0 0 
19a 9 57.26 3.24 -4.42 High 0 0 
19b 11 57.26 3.84 -4.90 High 0 0 
19c 9 57.26 3.70 -4.86 High 0 0 
19d 9 57.26 3.91 -5.17 High 0 0 
19e 9 66.49 3.08 -4.41 High 0 0 
19f 9 60.50 3.03 -4.59 High 0 0 
19g 10 60.50 4.17 -6.10 High 0 0 
19h 11 57.26 4.28 -5.33 High 0 0 
20a 10 63.25 3.54 -4.48 High 0 0 
20b 12 63.25 4.18 -4.94 High 0 0 
19i 10 66.05 4.26 -5.77 High 0 0 
19j 12 66.05 4.92 -6.24 High 0 0 
19k 10 66.05 5.35 -6.96 High 0 0 
19l 12 66.05 6.00 -7.43 High 2  0 
22 0 38.91 1.93 -2.80 High 0 0 
23 5 50.27 3.56 -4.33 High 0 0 
24 4 41.99 3.55 -4.21 High 0 0 
25 2 38.91 3.41 -4.26 High 0 0 
26 2 12.89 3.99 -4.66 High 0 0 




mitochondria, and thus the study of promastigotes facilitate the identification of drugs 
targeting mithochondria. 126,128 
All compounds, with the exception of control 26, inhibited the proliferation of the 
parasites, showing IC50 values in between 0.2-35.1 M (Table 6.3).  It is worth 
highlighting that most of our compounds present better inhibition values than the 
positive control miltefosine. The 2-styrylquinoline 26, lacking the amino group at its C-4 
position, was inactive (IC50 > 50 mM) compared to compounds 22 and 25, verifying that 
this structural fragment is critical for the activity. Moreover, the lower activity of 
compound 22 compared to 25 proved the importance of the styryl fragment.  
With these good results on our hands, the activity of our compounds against Leishmania 
pifanoi axenic amastigotes (strain MHOM-ET-67/L82) was tested (Table 5.3). This model 
was chosen because of the extensive documentation that confirms the similarity 
between this axenic line and the amastigotes obtained from lesions in leishmaniasis 
patients.147 Most compounds exhibited a good inhibition of amastigote proliferation, 
and some of them (19b and 19c) showed submicromolar IC50 values, being only slightly 
less potent than miltefosine. The fact that our compounds possess similar or even higher 
activities against amastigotes than against promastigotes is important because both 
stages present remarkable differences in terms of biochemical and mitochondrial 
bioenergetics, and many drugs active against promastigotes tend to fail in 
amastigotes.148 Finally, the mammalian cell toxicity of the compounds was evaluated on 
machophages, the host cells of amastigotes. For that purpose, the tumoral murine 
macrophage cell line J774, a model extensively used to test drug activity on intracellular 
amastigotes, was employed,149 and the IC50 values obtained were used to calculate a 
selectivity index (SI). As shown in Table 5.3, many compounds show macrophage toxicity 
at leishmanicidal concentrations, with selectivity indexes below 10. However, 
compounds 19a, 19c, 19k and 20a present potent antileishmanial activities with 
acceptable or good SI values. 
 
147 An, A.A.; Duboise, S.M.; Eperon, S.; Rivas, L.; Hodgkinson, V.; Traub-Cseko, Y.; McMahon-Pratt, D.; J. 
Eukaryot. Microbiol. 1993, 40, 213. 
148 Peters, W.; Trotter, E.R.; Robinson, B.L.; Ann. Trop. Med. Parasitol. 1980, 74, 321. 
149 Yardley, V.; Koniordou, M. Drug assay methodology in leishmaniasis: from the microplate to image 
analysis, in: L. Rivas, C. Gil (Eds.), Drug Discovery for Leishmaniasis, RSC Drug Discovery Series, 2018, pp. 
57e76 (Chapter 4). 
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Regarding SAR conclusions, it is worth nothing that the two-carbon spacer always led to 
better results than the 4 carbon one. Moreover, while several compounds exhibit 
micromolar activities against amastigotes with good SI, the best one was compound 19k. 
The fact that this compound presents the least basic side chain, but still carries the 4-
amino substituent, suggests that while the protonation of the quinoline moiety is crucial 
for activity, the side chain does not need the presence of a high basic residue. 
Table 5.3: a All results are representative of two experiments performed independently. 
b SI = IC50(J774)/IC50 (L. pifanoi amastigotes). 
Cmpd. 
L. donovani promastigotes, 
IC50 (μM) a 
L. pifanoi amastigotes, 
IC50 (μM) a 
J774, IC50 (μM)a SIb 
16a 0.45 ±0. 32 4.3 ± 1.2 6.6 ± 1.8 4.7 
16b 0.56 ±0.12 4.9 ±0.8 3.7 ± 0.5 0.8 
17a 2.4 ±0.3 >50 4.6 ± 0.2 <0.1 
17b 0.44 ± 0.1 > 25 6.6 ± 0.6 <0.3 
19a 1.6 ± 0.0 1.1 ± 0.1 15.0 ±2.7 13.6 
19b 1.6 ± 0.0 0.9 ± 0.1 0.7 ± 0.1 0.8 
19c 2.1 ± 0.2 0.9 ± 0.1 12.5 ±3.5 13.9 
19d 2.1± 0.2 1.2 ± 0.1 4.7 ± 1.0 3.4 
19e 1.3 ± 0.1 > 25 > 50 2.0 
19f 3.5 ± 0.3 3.5 ± 0.3 34 ± 1.2 9.7 
19g 2.1 ± 0.1 1.5 ± 0.2 4.5 ± 0.2 3.0 
19h 0.2 ± 0.0 5.3 ± 0.8 7.1 ±1.0 1.4 
19i 3.3 ± 0.8 4.3 ± 2.4 7.8 ± 1.2 1.8 
19j 1.6 ±0.4 6.9 ± 1.5 3.3 ± 0.8 0.48 
19k 8.4 ± 2.4 1.2 ± 0.8 >50 > 41.6 
19l 2.1 ± 0.2 12.3 ± 3.2 7.3 ± 1.2 0.6 
20a 3.4 ± 0.2 1.6 ± 0.4 22.2 ± 4.6 13.8 
20b 1.06 ± 0.11 4.5 ± 1.2 7.2 ± 0.9 1.6 
22 10.9 ± 2.2 > 50 > 50 - 
23 35.1 ± 4.6 13.4 ±3.8 >25 >1.86 
24 ND. 9.5 ±2.2 >25 >2.6 
25 0.5 ±0.1 8.9 ±2.0 4.4 ± 0.2 0.5 
26 >50 > 50 > 50 ND 
miltefosine 4.4 ± 0.7 6.2 ± 1.6 > 50 > 8.1 





The next step was to evaluate the leishmanicidal activity of one selected compound 
against macrophage cells infected with L. pifanoi amastigotes. Several compounds had 
exhibited similar activities and were suitable for the studies, but compound 20a was 
selected due to its better synthetic accessibility. To this end, parasites were 
fluorescently labelled with carboxyfluorescein succinimidyl ester (CFSE) before the 
infection to facilitate their visualization inside the macrophages. As expected, treatment 
with compound 20a at 10 M concentration decreased the infection index (number of 
parasites/macrophage) from 5.3 ± 2.5 in untreated macrophages to 1.6 ± 0.8. (Figure 
5.5) 
 
Figure 6.5: Peritoneal infected macrophages with L. pifanoi amastigotes were observed under a confocal 
microscope, after 12h incubation with 20a. Amastigotes were preloaded with CFSE (carboxyfluorescein 
succinimidyl ester) (green) and  cell nuclei were stained with DAPI (blue). 20a reduced the infection index 
(number of parasites/ macrophage) 
 
5.4.3 Mechanistic studies 
 In order to corroborate the mechanism of action of our compounds, some of them were 
selected and further experiments were carried on.  First, to study whether our 
compounds were affecting the mitochondrion ATP synthesis of Leishmania variations in 
intracellular levels were monitored using L. donovani promastigotes from the 3-Luc 
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strain. 150  This strain expresses a cytoplasmic form of firefly luciferase, which upon 
addition of a lipophilic luciferin ester in excess that can cross the parasite’s membrane, 
generates in vivo luminescence. In this reaction the free cytoplasmic ATP is the limiting 
substrate, this way the ATP levels can be indirectly measured. At 50 M concentration, 
all studied compounds showed a fast and concentration-dependent drop in free 
cytoplasmatic ATP levels. (Table 5.4) For instance, the behaviour of compound 20a is 
shown in Figure 5.6, which showed a threshold of 3.12 M and reached the inhibition 
endpoint in less than 5 min after compound addition. 
Styrylquinoline 
Luminescence (% respect  









Table 5.4: Percentage of luminescence relative to untreated 3-Luc L. donovani promastigotes after 10 
min incubation with 50 µM of the respective styrylquinoline. Results were expressed as mean of 
triplicate ± SD. 
 
Figure 5.6. Real time variation of luminescence of living 3-Luc L. donovani promastigotes caused by 
styrylquinoline 20a. 
 
150 Luque-Ortega, J.R.; Rivero-Lezcano, O.M.; Croft, S.L.; Rivas L. Antimicrob. Agents Chemother. 2001, 
45, 1121. 




This dramatic drop in ATP levels can be attributed to permeabilization of the cell 
membrane or to mitochondrial dysfunction. To check which of these two possible 
mechanisms was responsible for this ATP drop, further experiments were done. First the 
ability of the compounds to induce plasma membrane permeabilization was tested. To 
this end, cells were treated with the corresponding styrylquinolines and then the entry 
of the vital dye SYTOX Green, included in the incubation medium, was monitored by 
examining the increase in, fluorescence due to its binding to intracellular nucleic acids.  
As a positive control, fully permeabilized cells were obtained by addition of 0.1% Triton 
X-100.  It was concluded that none of the compounds was able to alter the membrane 
permeability. (Figure 5.7)  
 
Figure 5.7: Plasma membrane permeabilization of L. donovani promastigotes by styrylquinolines 
. 
As membrane permeabilization was discarded, the ability of compounds to produce loss 
of mitochondrial functionality was tested. To this end, after addition of the selected 
compounds, variations in the mitochondrial electrochemical potential (m), essential 
for ATP synthesis, were monitored. Under physiological conditions rhodamine 123 is 
accumulated in mitochondrion driven by m, and can be measured by flow cytometry. 
Compounds 19d, 19h, and 20a showed the highest inhibition and were selected for a 
concentration dependency study. The selected styrylquinolines markedly decreased 
rhodamine 123 levels at a 25 M concentration, corresponding to the decrease induced 
by KCN 20mM, employed as a control for full mitochondrial depolarization. (Figure 5.8)  
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Figure 5.8. Variation of the intracellular accumulation of rhodamine 123 in L. donovani promastigotes 
induced by selected styrylquinolines. 
In the light of these results, we assume that exposure to our compounds induces 
mitochondrial dysfunction. To further corroborate this hypothesis, the localization of 
compound 20a inside Leishmania was determined on axenic amastigotes by confocal 
microscopy. First, at 20 mM, compound 20a appeared as a punctuated fluorescence 
pattern. (Figure 5.9, panel A) Upon addition of 1mM KCN, concentration able to 
depolarize mitochondrion while preserving parasite viability, fluorescence was 
considerably inhibited. This experiment verified the importance of the m in the 
compound accumulation. Furthermore, a double-labelling experiment was performed. 
Compound 20a and MitoTracker Red (MTR), a mitochondrial probe, were incubated 












Figure 5.9. Confocal microscopy of L. pifanoi axenic amastigotes incubated with compound 20a. 
Due to the key role that mitochondria play in apoptosis, 151  the possibility that the 
Leishmania toxicity involved programmed cell death processes was also explored.  Cells 
at the late stage of apoptosis, characterized by a fragmented chromatin, can be 
identified by a lower degree of staining with propidium iodide (subG1 population). The 
experiments summarized in Figure 5.10, which used miltefosine (HePc) as a control, 
discard this possibility.  
 
Figure 5.10. Induction of subG1 population in L. donovani promastigotes by compound 20a. 
 
151Wang, C.; Youle, R. J. Annu. Rev. Genet. 2009, 43, 95. 
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Finally, morphological studies of the treated L. donovani promastigotes were assessed 
by transmission electron microscopy. Parasites treated with compound 20a showed a 
swollen mitochondrion, strong vacuolization of the cytoplasm and the appearance of 
expanded acidocalcisomes. (Figure 5.11) 
 
Figure 5.11. Transmission electron microscopy of L. donovani promastigotes treated with 20a (5 mM). 
Legend: (K) kinetoplast, (M) mitochondrion, (N) nucleus, (FP) flagellar pocket, (*) acidocalcisome. 
 
To summarize, all these results suggested that the 4-aminostyrylquinoline derivatives 
owe their leishmanicidal activity to an alteration of the mitochondrial activity of the 
parasite, which leads to ATP depletion and bioenergetic collapse. 
  




5.5. Experimental section 
General experimental details 
All reagents (Aldrich, Fischer, Alpha Aesar, SDS) and solvents (Scharlau, Fischer, SDS) 
were of commercial quality and were used as received. Reactions under microwave 
irradiation were carried out in a CEM Discover SP microwave reactor. Reactions were 
monitored by thin layer chromatography on aluminium plates coated with silica gel and 
fluorescent indicator (Macherey‐Nagel Xtra SIL G/UV254). Separations by flash 
chromatography were performed on silica gel (Scharlau 40–60 μm, 230–400 mesh 
ASTM) or neutral alumina (Merck S22). Melting points were determined using a Stuart 
Scientific apparatus, SMP3 Model, and are uncorrected. Infrared spectra were recorded 
with an Agilent Cary630 FTIR spectrophotometer with a diamond accessory for solid and 
liquid samples. NMR spectroscopic data were recorded using a Bruker Avance 250 
spectrometer operating at 250 MHz for 1H NMR and 63 MHz for 13C NMR, maintained 
by the NMR facility of Universidad Complutense (CAI de Resonancia Magnética Nuclear); 
chemical shifts are given in ppm and coupling constants in Hertz. High‐resolution mass 
spectra (HRMS) were recorded on a mass spectrometer fitted with an electrospray 
detector (ESI) by the mass spectral facility of Universidad Complutense (CAI de 
Espectrometría de Masas) and elemental analyses were determined by the 
microanalysis facility of Universidad Complutense (CAI de Microanálisis Elemental), 
using a Leco 932 combustion microanalyzer.  
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5.5.2. Synthesis of (E)-4-Chloro-2-styrylquinoline (13) 
 
 
4-Chloroquinaldine (1.500 g, 8.44 mmol), benzaldehyde (1.343 g, 12.66 mmol) and ZnCl2 
(0.057 g, 0.422 mmol) were suspended in THF (3 ml) in a pressure tight microwave tube 
containing a stirring bar. The reaction mixture was heated under microwave irradiation 
for 1 hour at 130 ºC, with an irradiation power of 250 W. The reaction mixture was 
extracted with CH2Cl2, dried with anhydrous Na2SO4 and evaporated in vacuo. The dark 
residue was purified by flash chromatography through a silica gel column eluting with 




hexane: ethyl acetate (98:2, v/v) as the mobile phase to give compound 13 as a yellow 
solid. Yield: 1.188 g, 53%. 
Mp 113- 115 °C. 
IR (neat) 3048, 2100, 1573, 1488, 968, 752, 695 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.21 (dd, J= 8.4, 1.3 Hz, 1H), 8.11 (dd, J= 8.4, 1.3 Hz, 1H), 
7.82 – 7.57 (m, 6H), 7.49 – 7.28 (m, 4H) ppm. 
13C NMR (63 MHz, CDCl3): δ 156.0, 149.1, 142.8, 136.2, 135.4, 130.8, 129.6, 129.1, 128.9 
(2C), 128.0, 127.5 (2C), 127.2, 125.5, 124.1, 119.4 ppm. These spectral data were 
identical to those found in the literature.152 
 
5.5.3. Synthesis of monoprotected diamines (15a-b) 
A solution of di-tert-butyl dicarbonate (14 mmol, 1 eq) in 1,4-dioxane (50 ml) was slowly 
added (4 h), using a syringe pump, to the suitable diamine (56 mmol, 4 eq.) dissolved in 
1,4-dioxane (30 ml). The reaction mixture was stirred at room temperature overnight, 
the solvent was evaporated under vacuum and water (20 ml) was added. The precipitate 
obtained was filtered to eliminate the diprotected amine and the aqueous phase was 
extracted with dichlorometane (3 x 20 ml), dried with anhydrous Na2SO4 and 
evaporated in vacuo, to give the desired products.  
 
tert-Butyl N-(2-aminoethyl)carbamate (15a)  
Prepared from 1,2-diaminoethane (3.365 g, 56 mmol) and di-tert-
butyl dicarbonate (3.055 g, 14 mmol); whitish oil. Yield: 1.288 g, 57%. 
IR (neat) 3354, 2973, 2484, 2114, 1683, 1518, 1247, 1163 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 3.11 (t, J = 6.2 Hz, 2H), 2.69 (t, J = 6.2 Hz, 2H), 1.44 
(s, 9H) ppm. 
13C NMR (63 MHz, d4-methano): δ 158.5, 79.9, 43.7, 42.3, 28.8 (3C) ppm. These data are 




152 Gong, L.; Xing, L.-J.; Xu, T.; Zhu, X.-P.; Zhou, W.; Kang, N.; Wang, B. Org. Biomol. Chem. 2014, 12, 6557. 
153 Holland, J. P.; Fisher, V.; Hickin, J. A.; Peach, J. M. Eur. J. Inorg. Chem. 2010, 48. 
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tert-Butyl N-(4-aminobutyl)carbamate (15b) 
Prepared from 1,4-diaminobutane (4.936 g, 56 mmol) and di-
tert-butyl dicarbonate (3.055 g, 14 mmol); whitish oil, Yield: 
1.950 g, 74 %. 
IR (neat) 3363, 2930, 2864, 2116, 1680, 1520, 1474, 1164 cm-1. 
1H NMR (250 MHz, d4-methano): δ 3.06 (d, J = 6.4 Hz, 2H), 2.69 (m, 2H), 1.57 – 1.46 (m, 
4H), 1.43 (s, 9H) ppm.  
13C NMR (63 MHz, d4-methano): δ 158.5 79.8, 41.8, 41.0, 30.0, 28.8 (3C), 28.2 ppm. 
These data are in good agreement with the literature.154 
 
5.5.4. General procedure for the synthesis of protected polyamino styrylquinolines 
(16a-b) 
 
(E)-4-Chloro-2-styrylquinoline 13 (1 eq), the corresponding monoprotected diamine 15 
(1.5 eq) and phenol (6 eq) were placed in a round bottom flask and stirred at 110 °C for 
6 h. The reaction mixture was basified with an aqueous solution of NaOH (5M) and 
extracted with ethyl acetate (3 × 10 ml). The combined organic phases were dried with 
anhydrous Na2SO4 and evaporated. The resulting crude was purified by flash 
chromatography through a silica gel column eluting with hexane: ethyl acetate (2:1, v/v) 
as the mobile phase to give the desired products. 
tert-Butyl (E)-(2-((2-styrylquinolin-4-yl)amino)ethyl) carbamate (16a).  
Prepared from (E)-4-chloro-2-styrylquinoline 13 (0.654 g, 2.46 
mmol), tert-butyl (2-aminoethyl)carbamate 15a (0.591 g, 3.69 
mmol) and phenol (2.1 g, 22.3 mmol); brown solid. Yield: 0.678 
g, 71%. 
Mp 71-73 °C. 
 
154 Vonlanthen, M.; Finney, N. S. J. Org. Chem. 2013, 78, 3980. 




IR (neat) 3346, 2925, 1682, 1585, 1534, 1161 cm-1. 
1H NMR (250 MHz, d4-methano): δ 8.00 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.77 
– 7.59 (m, 4H), 7.44 – 7.32 (m, 4H), 7.25 (d, J = 16.5 Hz, 1H), 7.03 (s, 1H), 3.53 (t, J = 5.8 
Hz, 2H), 3.42 (t, J = 5.8 Hz, 2H), 1.44 (s, 9H) ppm. 
13C NMR (63 MHz, d4-methano): δ 159.6, 157.6, 153.6, 148.3, 138.3, 136.7, 131.6, 130.3 
(3 C), 129.0, 128.7 (2 C), 128.1, 126.1, 122.6, 119.9, 96.6, 80.7, 45.1, 40.4, 29.2 (3C) ppm. 
Elemental analysis (%): calcd. for C24H27N3O2: C 74.01, H 6.99, N 10.79; found: C 73.85, 
H 6.84, N 10.46. 
tert-Butyl (E)-(4-((2-styrylquinolin-4-yl)amino)butyl) carbamate (16b).  
Prepared from (E)-4-chloro-2-styrylquinoline 13(0.6 g, 2.25 
mmol), tert-butyl (4-aminobutyl) carbamate 15b (0.637 g, 
3.38 mmol) and phenol (1.91 g, 20.3 mmol); orange solid. 
Yield: 0.627 g, 74%. 
Mp 93- 95 °C. 
IR (neat) 3338, 2923, 1681, 1586, 1535, 1162 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.07 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.69 
– 7.57 (m, 4H), 7.45 – 7.24 (m, 5H), 6.84 (s, 1H), 3.48 (t, J = 6.7 Hz, 2H), 3.14 (t, J = 6.7 Hz, 
2H), 1.87 – 1.74 (m, 2H), 1.72 – 1.59 (m, 2H), 1.41 (s, 9H)ppm. 
13C NMR (63 MHz, d4-methanol): δ 159.1, 158.2, 153.1, 149.6, 138.5, 135.5, 131.1, 130.3, 
130.3 (2 C), 130.0, 129.0, 128.6 (2C), 125.7, 122.5, 120.2, 96.9, 80.3, 44.1, 41.5, 29.2 (3C), 
27.2(2C) ppm. 
Elemental analysis (%): calcd. for C26H31N3O2: C 74.79, H 7.48, N 10.06; found: C 74.54, 
H 7.51, N 9.70. 
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5.5.5. General procedure for the synthesis of polyamino styrylquinolines (17a-b) 
The suitable styrylquinoline 16 was dissolved in a mixture of methanol: trifluoroacetic 
acid (2:1, v/v) and stirred at room temperature for 1h. Once the reaction was finished, 
the reaction mixture was basified with aqueous NaOH (5 M) and extracted with a 
mixture of CH2Cl2: MeOH (10:1, v/v), which was dried with anhydrous Na2SO4 and 
evaporated in vacuo to give the pure product. 
 
(E)-N1-(2-Styrylquinolin-4-yl)ethane-1,2-diamine (17a).  
Prepared from compound 16a (0.578 g, 1.49 mmol); yellow solid. 
Yield: 0.374 g, 87%. 
Mp 85- 86 °C. 
IR (neat) 3250, 2921, 1583, 1531, 753 cm-1. 
1H NMR (250 MHz d4-methanol): δ 8.06 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.68 
– 7.55 (m, 4H), 7.43 – 7.22 (m, 5H), 6.87 (s, 1H), 3.51 (t, J = 6.3 Hz, 2H), 3.01 (t, J = 6.3 Hz, 
2H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 158.2, 153.1, 149.5, 138.5, 135.6, 131.2, 130.3 (3 C), 
130.1, 129.1, 128.6 (2 C), 125.9, 122.5, 120.3, 96.9, 46.7, 41.5 ppm. 
Elemental analysis (%): calcd. for C19H19N3: C 78.86, H 6.62, N 14.52; found: C 78.56, H 
6.72, N 14.32. 
(E)-N1-(2-Styrylquinolin-4-yl)butane-1,4-diamine (17b).  
Prepared from compound 16b (0.150 g, 0.359 mmol); yellow 
solid. Yield: 0.100 g, 88%. 
Mp 68-69 °C. 
IR (neat) 3261, 2918, 2850, 1580, 1531, 752 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.05 (d, J = 8.3 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.68 
– 7.53 (m, 4H), 7.44 – 7.22 (m, 5H), 6.78 (s, 1H), 3.41 (t, J = 6.7 Hz, 2H), 2.70 (t, J = 6.7 Hz, 
2H), 1.78 (dd, J = 13.8, 6.9 Hz, 2H), 1.64 (dd, J = 13.8, 6.9 Hz, 2H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 158.2, 153.1, 149.6, 138.5, 135.5, 131.1, 130.4, 130.3 
(2 C), 130.0, 129.1, 128.6 (2C), 125.8, 122.5, 120.2, 96.9, 44.2, 42.6, 31.5, 27.4ppm. 
Elemental analysis (%): calcd. for C21H23N3: C 79.46, H 7.30, N 13.24; found: C, 79.12; H, 
6.93; N, 13.13. 









A solution of 2-bromoacetyl bromide (1 eq, 0.53 mmol) in CH2Cl2 (20 ml) was slowly 
added (30 min) using a syringe pump to a solution of compound 17a or 17b (1 eq) in 
dichlorometane (20 ml). Once the addition was finished, the reaction mixture was 
stirred at -5 °C for an additional 30 min period. Then, the resulting crude was basified 
with an aqueous solution of NaOH (1M) and extracted with a mixture of CH2Cl2: MeOH 
(10:1, v/v), dried with anhydrous Na2SO4 and evaporated in vacuo, to give the desired 
product, which was used in the next step without further purification. 
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5.5.8. Aliphatic amine derivatives (19a-h)  
Compound 18 (80 mg, 0.195 mmol), the suitable amine (1 eq) and Cs2CO3 (0.127 g, 0.39 
mmol, 2 eq) were suspended in EtOH (1 ml) in a pressure-tight microwave tube 
containing a stirring bar. The mixture was heated under microwave irradiation for 30 
minutes at 120 °C, with an irradiation power of 200 W, using a focused microwave 
reactor. Thereafter, the cooled reaction mixture was dissolved in CH2Cl2 and washed 
with water, which was re-extracted with CH2Cl2. The combined organic layers were dried 
with anhydrous Na2SO4 and evaporated in vacuo. The resulting crude products were 
subsequently crystallized from MeOH-hexane mixtures or purified via a neutral alumina 
column. 
(E)-2-(Dimethylamino)-N-[2-(2-styrylquinolin-4-ylamino)ethyl]acetamide (19a)110  
Prepared from 18a (80 mg, 0.195 mmol) and dimethylamine 
(0.02 ml, 0.195 mmol); the compound was crystallized from a 
MeOH-hexane mixture to give 19a as an orange powder. Yield: 
0.052 g, 72%  
IR (neat) 3346, 2923, 2850, 2780, 1660, 1588, 1365, 1044 cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.99 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.76 (t, J = 
6.7 Hz, 1H), 7.71 – 7.60 (m, 4H), 7.47-7.32 (m, 5H), 6.62 (s, 1H), 6.55 (br s, 1H), 3.86-3.75 
(m, 2H), 3.60 – 3.47 (m, 2H), 3.03 (s, 2H), 2.30 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 174.0, 156.7, 150.7, 137.3, 133.7, 133.5, 130.5, 129.8 (2C), 
129.1 (2C), 128.7, 127.6 (2C), 125.0, 120.6, 118.7, 96.3, 63.3, 46.5 (2C), 46.2, 38.9 ppm. 
Elemental analysis (%): calcd. for C23H26N4O: C 73.77, H 7.00, N 14.96; found: C 73.61, H 
7.16, N 14.40. 
(E)-2-(Diethylamino)-N-[2-(2-styrylquinolin-4-ylamino)ethyl]acetamide (19b)110  
Prepared from 18a (80 mg, 0.195 mmol) and diethylamine (14 
mg, 0.195 mmol); the compound was crystallized from a 
MeOH-hexane mixture to give 19b as an orange powder. Yield: 
0.056 g, 71 %.  
Mp 54- 57 °C. 
IR (neat) 3341, 2959, 2905, 2850, 1658, 1588, 1430, 1367, 756 cm-1. 




1H NMR (250 MHz, CDCl3): δ 7.99 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.71-7.59 
(m, 4H), 7.49 – 7.30 (m, 5H), 6.62 (s, 1H), 3.85 – 3.75 (m, 2H), 3.60 – 3.46 (m, 2H), 3.12 
(s, 2H), 2.56 (q, J = 7.1 Hz, 4H), 1.04 – 0.93 (t, J = 7.1 Hz, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 175.6, 156.6, 150.8, 137.2, 133.6, 130.3, 130.3, 129.8, 129.6, 
129.1 (2C), 128.7, 127.6 (2C), 125.1, 120.6, 118.7, 96.2, 57.8, 49.2 (2C), 46.2, 38.9, 12.7 
(2C) ppm. 
Elemental analysis (%): calcd. for C25H30N4O: C 74.59, H 7.51, N 13.92; found: C 74.52, H 
7.10, N 13.50. 
(E)-2-(Pyrrolidin-1-yl)-N-(2-(2-styrylquinolin-4-ylamino)ethyl)acetamide (19c)  
Prepared from 18a (80 mg, 0.195 mmol) and pyrrolidine (14 
mg, 0.195 mmol); the compound was crystallized from a 
MeOH-hexane mixture to give 19c as a red solid. Yield: 0.054 g, 
69 %. 
Mp 68- 71 °C. 
IR (neat) 3346, 2918, 2848, 2809, 1655, 1588, 1539, 1365 cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.98 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.70 – 7.60 
(m, 4H), 7.48-7.32 (m, 5H), 6.62 (s, 1H), 6.59 (br s, 1H), 3.85-3-78 (m, 2H), 3.60 – 3.46 
(m, 2H), 3.26 (s, 2H), 2.67-2.53 (m, 4H), 1.85-1.75 (m, 4H) ppm. 
13C NMR (63 MHz, CDCl3): δ 174.4, 156.7, 150.7, 148.9, 137.3, 133.5, 130.5, 129.8 (2C), 
129.1 (2C), 128.7, 127.6 (2C), 125.0, 120.6, 118.7, 96.3, 59.4, 55.1 (2C), 46.2, 38.9, 24.4 
(2C) ppm. 
Elemental analysis (%): calcd. for C25H28N4O: C 74.97, H 7.05, N 13.99; found: C 74.04, H 
6.98, N 13.83.  
(E)-2-(Piperidin-1-yl)-N-(2-(2-styrylquinolin-4-ylamino)ethyl)acetamide (19d)110  
Prepared from 18a (80 mg, 0.195 mmol) and piperidine (17 mg, 
0.195 mmol); the compound was crystallized from a MeOH-
hexane mixture to give 19d as a yellow solid. Yield: 0.057 g, 
70%. 
Mp 71- 74°C. 
IR (neat) 3348, 2936, 2851, 1659, 1563, 1538, 1366, 1129 cm-1. 
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1H NMR (250 MHz, CDCl3): δ 8.10 (d, J = 8.2 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.8-7.72 (m, 
4H), 7.6-7.4 (m, 5H), 6.74 (s, 1H), 3.99 – 3.84 (m, 2H), 3.72-3.58 (m, 2H), 3.14 (s, 2H), 
2.62-2.48 (m, 4H), 1.70 – 1.67 (m, 4H), 1.57 – 1.55 (m, 2H) ppm. 
13C NMR (63 MHz, CDCl3): δ 174.2, 156.6, 150.8, 137.2, 133.6, 130.3 (2C), 129.8, 129.7, 
129.1 (2C), 128.7, 127.6 (2C), 125.1, 120.6, 118.7, 96.2, 62.6, 55.4 (2C), 46.2, 38.9, 26.6 
(2C), 24.0 ppm. 
Elemental analysis (%): calcd. for C26H30N4O: C 75.33, H 7.29, N 13.52; found: C 75.66, H 
7.05, N 13.70.  
(E)-2-Morpholino-N-[2-(2-styrylquinolin-4-ylamino)ethyl]acetamide (19e)110 
Prepared from 18a (80 mg, 0.195 mmol) and morpholine (17 
mg, 0.195 mmol); the compound was crystallized from a 
MeOH-hexane mixture to give 19e as an orange powder. Yield: 
0.048 g, 59%. 
Mp 67- 70 °C. 
IR (neat) 3297, 2918, 2850, 1656, 1599, 1560, 1538, 1464 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.03 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.79 (br s, 
1H), 7.72 -7.57 (m, 4H), 7.48 – 7.31 (m, 5H), 6.59 (s, 1H), 3.88  3.77 (m, 2H), 3.77 – 3.65 
(m, 4H), 3.62 – 3.45 (m, 2H), 3.10 (s, 2H), 2.60 – 2.49 (m, 4H)ppm. 
13C NMR (63 MHz, CDCl3): δ 173.2, 153.1, 151.5, 147.6, 136.8, 131.4, 130.4, 129.6, 129.2 
(2C), 129.1, 128,4, 127.8 (2C), 125.4, 120.9, 118.3, 95.8, 67.3 (2C), 62.2, 54.3 (2C), 45.9, 
38.8ppm. 
Elemental analysis (%): calcd. for C25H28N4O2: C 72.09, H 6.78, N 13.45; found: C 71.73, 
H 6.81, N 13.24. 
(E)-2-(4-Methylpiperazin-1-yl)-N-[2-(2-styrylquinolin-4-ylamino)ethyl] acetamide 
(19f)110  
Prepared from 18a (80 mg, 0.195 mmol) and 1-
methylpiperazine (20 mg, 0.195 mmol); the compound was 
crystallized from a MeOH-hexane mixture to give 19f as an 
orange powder. Yield: 0.049 g, 59 %. 
Mp 64- 67 °C. 
IR (neat) 3348, 2923, 2850, 1666, 1588, 1537, 1373, 756 cm-1. 




1H NMR (250 MHz, CDCl3): δ 7.99 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.61 – 7.50 
(m, 4H), 7.38 – 7.20 (m, 5H), 6.52 (s, 1H), 6.05 (br s, 1H), 3.75 – 3.64 (m, 2H), 3.48 – 3.38 
(m, 2H), 3.11 (s, 2H), 2.52 –.2.41 (m, 4H), 2.37 – 2.25 (m, 4H), 2.28 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 173.5, 156.7, 150.7, 148.9, 137.2, 133.5, 130.4, 129.8 (2C), 
129.3 (2C), 128.7, 127.6 (2C), 125.1, 120.5, 118.7, 96.3, 61.6, 55.5 (2C), 53.9 (2C), 46.4, 
46.0, 38.9 ppm. 
Elemental analysis (%): calcd. for C26H31N5O: C 72.70, H 7.27, N 16.30; found: C 71.87, H 
7.86, N 15.39. 
(E)-2-(4-Phenylpiperazin-1-yl)-N-[2-(2-styrylquinolin-4-ylamino)ethyl]acetamide 
(19g)110  
Prepared from 18a (80 mg, 0.195 mmol) and 1-
phenylpiperazine (32 mg, 0.195 mmol); the compound 
was purified by chromatography through a neutral 
alumina column using CH2Cl2-MeOH (95:5, v/v) as mobile phase to give 19g as an orange 
solid. Yield: 0.043 g, 45 %. 
Mp 92- 95 °C. 
IR (neat) 3352, 2940, 2825, 1661, 1588, 1538, 1435, 969, 757 cm-1. 
1H NMR (250 MHz, d4-methanol) δ 8.04 (dd, J = 8.4, 0.8 Hz, 1H), 7.88 (dd, J = 8.4, 0.8 Hz, 
1H), 7.76 – 7.61 (m, 4H), 7.47 – 7.31 (m, 5H), 7.23 – 7.15 (m, 2H), 7.03 (s, 1H), 6.86 – 6.78 
(m, 3H), 3.68 (s, 2H), 3.35 – 3.31 (m, 4H), 3.03 – 2.97 (m, 4H), 2.59 – 2.52 (m, 4H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 174.2, 158.3, 153.2, 153.0, 149.6, 138.5, 135.9, 131.3, 
130.4 (2C), 130.3 (2C), 130.2, 130.1, 129.2, 128.7 (2C), 126.0, 122.4, 121.5, 120.1, 117.9 
(2C), 96.8, 62.7, 54.8 (2C), 50.9 (2C), 43.9, 39 ppm. 
Elemental analysis (%): calcd. for C31H33N5O: C 75.73, H 6.77, N 14.25; found: C 75.01, H 
6.44, N 13.92. 
(E)-2-(Pyrrolidin-1-yl)-N-[4-((2-styrylquinolin-4-yl)amino)butyl]acetamide (19h) 
Prepared from 18b (80 mg, 0.18 mmol) and pyrrolidine; the 
crude product was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate 
(3:7, v/v) as the mobile phase to give 19h as a red solid. Yield: 0.04 g, 52%. 
Mp 72-73 °C. 
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IR (neat) 3313, 2922, 2853, 1654, 1582, 1530, 965,754 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.07 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.71 
– 7.57 (m, 4H), 7.46 – 7.24 (m, 5H), 6.82 (s, 1H), 3.48 (t, J = 6.6 Hz, 2H), 3.39 – 3.29 (m, 
2H), 3.12 (s, 2H), 2.54 (m, 4H), 1.90 – 1.64 (m, 8H) ppm. 
13C NMR (63 MHz, d4-methanol) δ 173.2, 157.5, 152.7, 148.8, 138.0, 135.3, 130.8, 129.9 
(2 C), 129.7, 128.4, 128.2 (2 C), 125.4, 122.1, 119.8, 96.5, 59.9, 55.2 (2C), 43.5, 39.7, 28.3, 
26.7, 24.6 (2C) ppm. 
Elemental analysis (%): calcd. for C27H32N4O: C 75.67, H 7.53, N 13.07; found: C 74.91, H 
7.79, N 12.77.  
 
5.5.9. Ethoxy derivatives (20a-b) 
The suitable halide 18 (1 eq) and Cs2CO3 (2 eq) were suspended in EtOH (1 ml) in a 
pressure-tight microwave tube containing a stirring bar. The mixture was heated under 
microwave irradiation for 30 minutes at 120 °C, with an irradiation power of 200 W, 
using a focused microwave reactor. Thereafter, the reaction mixture was dissolved in 
CH2Cl2 and washed with water. The combined organic layers were dried with anhydrous 
Na2SO4 and evaporated in vacuo. The crude product was directly purified by flash 
chromatography through a silica gel column using hexane: ethyl acetate (1:1, v/v) as the 
mobile phase to give the desired product. 
 
(E)-2-Ethoxy-N-(2-((2-styrylquinolin-4-yl)amino)ethyl)acetamide (20a)  
Prepared from 18a (0.124 g, 0.3 mmol), and Cs2CO3 (0.195 g, 0.6 
mmol, 2 eq); yellow solid. Yield: 0.051 g, 45 %  
Mp 59- 61 °C. 
IR (neat) 3329, 2865, 2108, 1654, 1583, 1528, 1111,753 cm-1. 
1H NMR (250 MHz, d4-methanol) δ 7.86 (dd, J = 8.4, 0.8 Hz, 1H), 7.73 (dd, J = 8.4, 0.8 Hz, 
1H), 7.61 – 7.47 (m, 4H), 7.34 – 7.12 (m, 5H), 6.86 (s, 1H), 3.83 (s, 2H), 3.45 (m, 6H), 1.06 
(t, J = 7.0 Hz, 3H) ppm. 
13C NMR (63 MHz, d4-methanol) δ 173.9, 157.8, 152.6, 149.0, 138.0, 135.5, 130.8, 129.8 
(2C), 129.7, 129.6, 129.6, 128.2 (2C), 125.5, 121.9, 119.7, 96.3, 70.7, 68.1, 43.28, 38.9, 
15.3 ppm. 




Elemental analysis (%): calcd for C23H25N3O2: C 73.57, H 6.71, N 11.19; found: C 73.16, 
H 6.84, N 10.95. 
(E)-2-Ethoxy-N-(4-((2-styrylquinolin-4-yl)amino)butyl)acetamide (20b)  
Prepared from 18b (0.089 g, 0.2 mmol), and Cs2CO3 (0.132 g, 
0.40 mmol, 2 eq); yellow solid. Yield: 0.044 g, 51%. 
Mp 52- 54 °C. 
IR (neat) 3313, 2925, 2358, 1662, 1585, 1535 cm-1. 
1H NMR (250 MHz, d4-methanol) δ 8.09 (dd, J = 8.4, 0.9 Hz, 1H), 7.86 (dd, J = 8.4, 0.9 Hz, 
1H), 7.71 – 7.58 (m, 4H), 7.46 – 7.27 (m, 5H), 6.85 (s, 1H), 3.91 (s, 2H), 3.60 – 3.45 (m, 
4H), 3.39 – 3.35 (m, 2H), 1.92 – 1.62 (m, 4H), 1.20 (t, J = 7.0 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ CDCl3) δ 170.6, 156.8, 150.4, 148.9, 137.2, 133.7, 130.3, 
130.1, 129.7, 129.1 (2C), 128.7, 127.6 (2C), 124.8, 119.8, 118.7, 97.3, 70.3, 67.5, 43.5, 
38.7, 28.2, 26.3, 15.5 ppm. 
Elemental analysis (%): calcd for C25H29N3O2: C 74.41, H 7.24, N 10.41; found: C 73.98, 
H 7.05, N 10.06. 
 
5.5.10. General procedure for the synthesis of glycine derivatives (21a-b) 
 
 
The suitable aniline (1 eq, 20 mmol) and ethyl 2-bromoacetate (1 eq) were dissolved in 
dry DMF (100 ml) under argon atmosphere. To this mixture was added NaH (1 eq) 
portionwise and the reaction was stirred at room temperature for 18 h. Upon 
completion of the reaction, the solvent was removed under reduced pressure and the 
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residue was suspended in a LiCl aqueous saturated solution (100 ml) and extracted with 
ethyl acetate (3 x 100 ml) to eliminate the DMF. The combined organic layers were dried 
with anhydrous Na2SO4 and evaporated in vacuo. The crude ester thus obtained was 
hydrolysed using a 5 M aqueous solution of NaOH (2.5 eq) in EtOH (5 ml) at reflux for 1 
h. The cooled reaction mixture was extracted with ethyl acetate. The aqueous phase 
was acidified and extracted again with ethyl acetate, the organic phase was dried with 
anhydrous Na2SO4 and evaporated in vacuo to obtain the desired product, which was 
finally purified by flash chromatography through a silica column using hexane: ethyl 
acetate as the mobile phase. 
 
N-Phenylglycine (21a) 
Prepared from aniline (1.862 g, 20 mmol), and ethyl 2-bromoacetate 
(3.36 ml, 20 mmol); pale brown solid. Yield: 1.529 g; 51 %. 
Mp 118-120°C. 
IR (neat) 3019, 2944, 1556, 1489, 1378, 1314, 692 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 7.18 – 7.08 (m, 2H), 6.73 – 6.59 (m, 3H), 3.88 (s, 2H) 
ppm. 
13C NMR (63 MHz, d4-methanol): δ 174.1, 148.3, 129.1 (2C), 117.7, 113.1 (2C), 45.4 ppm. 
These data are in good agreement with the literature.155 
N-(2,4-Dichlorophenyl)glycine (21b) 
Prepared from 2,4-dichloroaniline (3.220 g, 20 mmol), and ethyl 2-
bromoacetate (3.36 ml, 20 mmol); brown solid. Yield: 0.704 g;16 %. 
Mp 147- 150 °C (Lit,156 148-151 °C). 
IR (neat) 3405, 2875, 2082, 1717, 1593, 1494, 1236, 861, 796 cm-1. 
1H NMR (250 MHz, d4-methanol): δ 7.28 (d, J = 2.4 Hz, 1H), 7.13 (dd, J = 8.7, 2.4 Hz, 1H), 
6.57 (d, J = 8.7 Hz, 1H), 3.97 (s, 2H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 174.4, 144.4, 130.0, 129.2, 122.8, 120.9, 113.6, 46.1 
ppm. 
 
155 Zhikuan, L.; Twieg, R. J. Tetrahedron Lett. 2005, 46, 2997.  
156 Arct, J.; Przemysl Chemiczny 1964, 43, 332. 




Elemental analysis (%): calcd. for C8H7Cl2NO2: C 43.67, H 3.21, N 6.37; found: C 43.58, H 
3.43, N 6.26. 
5.5.11. General procedure for the synthesis of arylamino derivatives (21i-l) 
To a solution of the suitable glycine derivative, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl, 1 eq), and the suitable 2-
styrylquinoline derivative 17 (1 eq) in dry THF, Et3N (2 eq) was added, followed by the 
addition of 1-hydroxy-7-azabenzotriazole (HOAt, 0.6M solution in DMF, 1 eq). The 
reaction mixture was refluxed for 12 hours. Then, the solvent was removed under 
reduced pressure and the residue was suspended in a LiCl saturated aqueous solution 
(5 ml) and extracted with ethyl acetate (3 × 5 ml). The combined organic layers were 
dried with anhydrous Na2SO4 and evaporated in vacuo. The product was purified by flash 
chromatography through a silica column using hexane: ethyl acetate (1:1, v/v) as the 
mobile phase to give the desired products. 
 
(E)-2-(Phenylamino)-N-(2-((2-styrylquinolin-4-yl)amino)ethyl)acetamide (19i) 
Prepared from phenylglycine 21a (0.037 g, 0.127 mmol), 
and 17a (0.024 g, 0.127 mmol); yellow solid. Yield: 0.018 g; 
34 %. 
Mp 174- 176 °C. 
IR (neat) 3362, 2922, 2430, 1657, 1586, 1306, 963, 749, 689 cm-1. 
1H NMR (250 MHz, d4-methanol) δ 7.95 – 7.82 (m, 2H), 7.75 – 7.62 (m, 4H), 7.47 – 7.26 
(m, 5H), 7.06 – 6.94 (m, 3H), 6.64 – 6.50 (m, 3H), 3.78 (s, 2H), 3.61 (m, 4H) ppm. 
13C NMR (63 MHz, d4-methanol) δ 175.9, 158.1, 153.2, 149.8, 149.1, 138.5, 136.1, 131.3, 
130.5 (2 C), 130.3 (2C), 130.1, 129.8, 128.7, 128.7 (2C), 126.1, 122.4, 120.0, 119.4, 114.2 
(2C), 96.7, 49.7, 44.3, 39.5 ppm. 
HRMS found m/z 422.2155 [M+], calculated for C27H26N4O 422.2107. 
(E)-2-(Phenylamino)-N-(4-((2-styrylquinolin-4-yl)amino)butyl)acetamide (19j) 
Prepared from phenylglycine 21a (0.042 g, 0.22 mmol), 
and 17b (0.070, 0.22 mmol); yellow solid. Yield: 0.026 g; 
26 %. 
Mp 82- 85 °C. 
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IR (neat) 3315, 2929, 1654, 1582, 964, 749, 691 cm-1. 
1H NMR (250 MHz, d4-methanol) δ 8.07 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.72 
– 7.62 (m, 4H), 7.46 – 7.27 (m, 5H), 7.14 – 7.02 (m, 2H), 6.84 (s, 1H), 6.66 – 6.52 (m, 3H), 
3.74 (s, 2H), 3.47 (t, J = 6.7 Hz, 2H), 3.37 (m, 2H), 1.82 – 1.61 (m, 4H) ppm. 
13C NMR (63 MHz, d4-methanol) δ 174.7, 158.2, 153.1, 149.7, 149.5, 138.5, 135.6, 131.1, 
130.5 (2C), 130.3 (3C), 130.1, 129.0, 128.6 (2C), 125.8, 122.5, 120.2, 119.5, 114.3 (2C), 
96.9, 49.5, 43.9, 40.2, 28.6, 27.1 ppm. 
HRMS found m/z 451.2497 [M+1], calculated for C29H31N4O 451.2498. 
(E)-2-((2,4-Dichlorophenyl)amino)-N-(2-((2-styrylquinolin-4-yl)amino)ethyl)acetamide 
(19k) 
Prepared from (2,4-dichlorophenyl)glycine 21b (0.101 g, 
0.46 mmol), and  17a (0.134 g, 0.46 mmol); yellow solid. 
Yield: 0.111 g, 50 %. 
Mp 99- 102 °C. 
IR (neat) 3332, 2922, 1657, 1585, 1500, 754 cm-1. 
1H NMR (250 MHz, , d4-methanol): δ 7.90 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.73 
– 7.60 (m, 4H), 7.45 – 7.19 (m, 6H), 6.96 (s, 1H), 6.80 (dd, J = 8.8, 2.4 Hz, 1H), 6.36 (d, J = 
8.8 Hz, 1H), 3.85 (s, 2H), 3.66 – 3.50 (m, 4H)  ppm. 
13C NMR (63 MHz, d4-methanol): δ 173.9, 157.4, 152.9, 148.2, 143.9, 137.9, 136.0, 131.1, 
129.9 (2C), 129.8, 129.7, 128.9, 128.7, 128.3 (2C), 128.0, 125.7, 122.9, 122.0, 120.7, 
119.5, 113.0, 96.2, 48.2, 43.8, 39.2 ppm. 
HRMS found m/z 491.1410 [M+1], calculated for C27H25Cl2N4O 491.1405. 
(E)-2-((2,4-Dichlorophenyl)amino)-N-(4-((2-styrylquinolin-4-
yl)amino)butyl)acetamide (19l) 
Prepared from (2,4-dichlorophenyl)glycine 21b 
(0.138 g, 0.63 mmol), and 17b (0.200 g, 0.63 mmol); 
yellow solid. Yield: 0.220 g, 67 %.  
Mp 74- 76 °C. 
IR (neat) 2929, 2493, 1654, 1581, 1491, 1438, 755 cm-1. 




1H NMR (250 MHz, d4-methanol): δ 8.04 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.66 
– 7.57 (m, 4H), 7.43 – 7.21 (m, 6H), 7.00 (dd, J = 8.7, 2.4 Hz, 1H), 6.80 (s, 1H), 6.44 (d, J = 
8.7 Hz, 1H), 3.80 (s, 2H), 3.45-3.40 (m, 2H), 3.33-3.29 (m, 2H), 1.75 – 1.67 (m, 4H) ppm.  
13C NMR (63 MHz, d4-methanol): δ 173.2, 158.2, 153.1, 149.6, 144.5, 138.5, 135.6, 131.1, 
130.3, 130.3 (2C), 130.1, 130.0, 129.2, 129.0, 128.6 (2C), 125.8, 123.3, 122.5, 121.2, 
120.2, 113.5, 96.9, 48.6, 43.90, 40.4, 28.6, 27.2 ppm.  
HRMS found m/z 519.1713 [M+1], calculated for C29H29Cl2N4O 519.1718. 
 
5.5.12. Synthesis of compound 25. 
 
Compound 22 (0.500 g, 3.1 mmol) and ZnCl2 (0.021 g, 0.15 mmol) were suspended in 
acetic anhydride (3 ml) in a pressure-tight microwave tube containing a stirring bar. The 
reaction mixture was heated under microwave irradiation for 5 min at 130 °C, with an 
irradiation power of 250 W, using a CEM Discover SP microwave reactor. Then, 
benzaldehyde (0.498 g, 4.7 mmol) was added and the mixture was again heated under 
microwave irradiation for 25 min at 130 °C. The reaction mixture was basified with an 
aqueous solution of NaOH (5M) and extracted with CH2Cl2, dried with anhydrous Na2SO4 
and evaporated in vacuo.  The dark purple residue was purified by flash chromatography 
through a silica column using hexane: ethyl acetate (4:1, v/v) as the mobile phase to give 
0.335 g (33%) of compound 18 as a yellow solid and 0.265 g (30%) of compound 19 as a 
white solid.  
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Mp 130-133 °C. 
IR (neat) 2652, 2321, 2112, 1718, 1699, 1362, 1217, 754 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.20 (d, J = 8.4 Hz, 1H), 7.86 – 7.55 (m, 
7H), 7.49 – 7.36 (m, 4H), 2.39 (s, 6H) ppm. 
13C NMR (63 MHz, CDCl3): δ 172.8 (2C), 157.3, 150.2, 145.2, 136.5, 136.0, 131.1, 130.5, 
129.5, 129.3 (2C), 128.4, 128.3, 127.8 (2C), 125.0, 121.8, 120.1, 27.05 (2C) ppm. 
Elemental analysis (%): calcd. for C21H18N2O2: C 76.34, H 5.49, N 8.48; found: C 75.83, H 
5.47, N 8.25. 
(E)-N-(2-Styrylquinolin-4-yl)acetamide (24)  
Mp 198- 200 °C. 
IR (neat) 3258, 2322, 1737, 1657, 1523, 1371, 954, 755 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.31 (s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.56 
(d, J = 8.4 Hz, 1H), 7.51 – 7.37 (m, 4H), 7.30 – 7.05 (m, 5H), 2.14 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 169.3, 156.9, 148.9, 140.5, 136.5, 134.9, 130.3, 129.8, 129.0, 
128.9 (2C), 128.8, 127.4 (2C), 126.1, 119.3, 119.1, 109.5, 25.2 ppm. 
Elemental analysis (%): calcd. for C19H16N2O: C 79.14, H 5.59, N 9.72; found: C 78.74, H 
5.47, N 9.37.  
(E)-2-Styrylquinolin-4-amine (25)  
Compound 23 (0.150 g, 0.454 mmol) and KOH (5M) (10 eq) were 
dissolved in MeOH (3 ml) in a pressure tight microwave tube 
containing a stirring bar. The reaction mixture was heated under microwave irradiation 
for 1 hour at 135 °C, with an irradiation power of 200 W, using a CEM Discover SP 
microwave reactor. Thereafter, the reaction mixture was extracted with ethyl acetate, 
dried with anhydrous Na2SO4 and evaporated in vacuo, to give compound 25 (0.100 g, 
89% yield) as a yellow solid.  
Mp 103-106 °C. 
IR (neat) 3446, 3296, 3047, 2920, 1640, 1578, 1511, 967, 752 cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.03 (dd, J = 8.5, 0.6 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.72 – 
7.58 (m, 4H), 7.47 – 7.26 (m, 5H), 6.91 (s, 1H), 4.79 (s, 2H) ppm. 




13C NMR (63 MHz, CDCl3): δ 156.3, 149.9, 149.0, 136.8, 133.7, 129.9, 129.7, 129.4, 128.9 
(2C), 128.5, 127.3 (2C), 124.7, 120.2, 118.4, 101.7ppm. 
Elemental analysis (%): calcd for C17H14N2: C 82.90, H 5.73, N 11.37; found: C 81.92, H 
5.92, N 11.08. 
When applied to 24 (0.200 g, 0.69 mmol), the same procedure furnished 0.150 g of 
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6.1. Bis-indolyl quinones: interesting natural scaffolds 
6.1.1. Origin of bis-indolyl quinones or Asterriquinones 
In the 80s, some bis-indolyl quinones were isolated from Aspergillus terreus by 
Yamamoto et al., receiving the name of asterriquinones. They are secondary 
metabolites produced by several fungal species, like Chaetomium sp. Aspergillus terreus 
or Pseudomassaria sp.157  Asterriquinones are based on two indolyl groups, bearing 
different substituents, attached through position 3 to a central benzoquinone core, 




6.1.2. Pharmacological properties of bis-indolyl quinones 
The main interest on indolylquinones lies on their potential as pharmacophores due to 
their wide range of biological activities among different pathologies. Some of them have 
shown activity against different enzymes involved in human immunodeficiency virus 
(HIV). For instance, semicochlinodiol A inhibits the HIV protease by forming hydrogen 
 
157  a) Arai, K.; Yamamoto, Y. Chem. Pharm. Bull. 1990, 38, 2929. b) Kaji, A.; Saito, R.; Nomura, M.; 
Miyamoto, K.; Kiriyama, N. Biol. Pharm. Bull. 1998, 21, 945. c) Brewer, D.; Jerram, W.; Taylor, A. Can. J. 
Microbiol. 1968, 14, 861. d) Sekita, S. Chem. Pharm. Bull. 1983, 31, 2998. e) Kaji, A.; Saito, R.; Hata, Y.; 
Kiriyama, N. Chem. Pharm. Bull. 1999, 47,77. 




bonds with the aspartic acid and isoleucine residues present in the active site of the 
enzyme.158 On the other hand, demethylasterriquinone A is able to inhibit the viral 
reverse transcriptase.159 
Some analogues of natural asterriquinones have shown antitumoral properties due to 
direct DNA interaction,160 while some others show the same response by inhibiting the 
union of Grb-2 grown factor to the tyrosine kinase receptor EGF-R. In human cancers, 
Grb2 is viewed as an attractive therapeutic target because it mediates the activation of 
receptor tyrosine kinase and adapters to the p21ras signal transduction pathway.161 
Moreover, a potent oral antidiabetic activity was found for demethylasterriquinone B1 
(DMAQ-B1), which attracted a great deal of interest due to being the first small organic 
molecule being able to act as an insulin mimetic while showing a very good oral 
bioability. This compound was discovered by a virtual screening process designed to find 
new compounds able to activate the tyrosine kinase activity of the insulin human 
receptor. DMAQ-B1 showed selectivity against insulin receptor among other tyrosine 
kinase receptors, and it was orally active in two diabetes mice models, reducing 
glycaemia levels considerably. These findings promoted the development of simpler, 
non-natural analogues such as Cpd2, a compound developed by Merck.162 (Figure 6.1) 
The nerve growth factor (NGF) belongs to a family of neurotrophin proteins that support 
the growth and survival of many populations of neurons. NGF binds TrkA, a neurotrophin 
receptor able to protect neuronal cells from apoptosis and stimulate neuronal 
regeneration in model systems. Some preclinical and clinical findings suggest that 
neurotrophins could be a promising therapy for neurodegenerative diseases. However, 
the main disadvantage of using neurotrophins as drug candidates is their poor 
pharmacokinetic properties, including the inability to cross the blood-brain barrier. For 
these reasons, a great effort has been done to find non-peptidic small molecules able to 
 
158 Fredenhagen, A.; Petersen, F.¸Tintelnot-Blomley, M.; Rosel, J.; Mett, H.; Hug, P. J. Antibiot. 1996, 395. 
159 Ono, K.; Nakane, H.; Shimizu, S.; Koshimura, S. Biochem. Biophys. Res. Commun. 1991, 174, 56. 
160 a) Shimizu, S.; Yamamoto, Y.; Koshimura, S. Chem. Pharm. Bull. 1982, 30, 1896. b) Kaji, A.; Saito, R.; 
Nomura, M.; Miyamoto, K.I.; Kiriyama, N. Biol. Pharm. Bull. 1998,21, 945.  
c) Kaji, A.; Iwata, T.; Kiriyama, N.; Nomura, M.; Miyamoto, K.I. J. Antibiot. 1998, 51, 235. 
161 Alvi, K.A.; Pu, H.; Luche, M.; Rice, A.; App, H.; McMahon, G.; Dare, H.; Margolis, B.  J. Antibiot. 1999, 52, 
215. 
162 a) Wood, H. B.; Black, R.; Salituro, G.; Szalkowski, D.; Li, Z., Zhang, Y.; Moller, D.E.; Zhang, B.; Jones, A. 
B.; Bioorg. Med. Chem. Lett. 2000, 10, 1189. (b) Liu, K.; Xu, L.; Szalkowski, D.; Li, Z.; Ding, V.; Kwei, G.; 
Huskey, S.; Moller, D. E.; Heck, J. V.; Zhang, B. B.; Jones, A. B. J. Med. Chem. 2000, 43, 3487. (c) Tsai, H. J.; 
Chou, S. Y. J. Biomed. Sci. 2009, 16, 68.   




activate TrkA receptors. In this context, it has been proved that certain asterriquinones 
are with good oral bioavailability are able to activate Trk receptors and cross the BBB. 
Thus, Lin and co-workers screened a chemical library of mono- and bis-indolylquinones, 
in order to detect hit compounds able to activate TrkA receptor while not exhibiting 
cytotoxic activity due to the activation of other Trk receptors. In this study, compounds 
1H5 and 5E5 were the ones exhibiting the best profile. (Figure 6.2) In this context, it is 
interesting to note that some functionalized quinones, such as a tryptophan-
naphthoquinone hybrid163 and memoquin,164 have shown very interesting multi-target 
profiles of relevance in the treatment of Alzheimer’s disease. 
 
Figure 6.2. 
6.1.3. Bis-indolyl quinones as potential MSOT theranostic agents 
As mentioned in the introduction, MSOT is appealing as an alternative imaging 
technique, but its main problem relies on the difficulty of developing adequate MSOT 
probes. These probes should possess low toxicity, biocompatibility, suitable lipophilicity 
to cross membranes and good clearance values, while exhibiting absorbance maxima 
(λabs) in the NIR range with a low fluorescence quantum yield. To achieve this goal, 
conjugated structures bearing aromatic systems with push-pull architectures and 
fluorescence quenchers are the best alternative. 
 
163 Scherzer-Attali, R; Pellarin, R.; Convertino, M.; Frydman-Marom, A.; Egoz-Matia, N.; Peled, S.; Levy-
Sakin, M.; Shalev, D. E.; Caflisch, A.; Gazir, E., Segal, D. PLoS One 2010, 5: e11101. 
164 Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Neurotherapeutics 2009, 6, 152. 




In this context, we envisioned that bis-indolylquinones could be a good starting point 
for developing MSOT theranostic agents. On one hand, they have exhibited interesting 
therapeutic effects that can be modulated depending on the chosen substituents. 
Moreover, many of them present good oral bioavailability and capacity to cross the 
blood-brain barrier. 
To this end, we designed a chemical library of compounds based on a bis-indolylquinone 
core. First, the highly conjugated non-planar nature of this kind of structures would 
endow them with high absorbance maxima in or close to the NIR region and low 
fluorescence quantum yields. Moreover, the introduction of halogen groups such as 
bromine and chlorine would quench their fluorescence due to a heavy-atom effect.165 
In order to displace absorption into the NIR region, we considered introducing different 
electron donor groups into the indole core, as well as acceptor groups different from 
carbonyl, like cyanimines or dicyanomethylene, onto the quinone core, thus building a 




6.2. Precedent for the synthesis of bis-indolylquinones 
Even though several methodologies for the synthesis of indolylquinones have been 
described, many of them are based on cross-coupling reactions. In order to do a review 
 
165 Berberán-Santos, M. N. Phys. Chem. Comm. 2000, 3, 18.  




on previously described synthesis procedures, we will focus only on the ones using direct 
Michael additions due to their similarity to our planned route.  
Pirrung and co-workers described the synthesis of di-chlorinated indolylquinones by a 
direct Michael addition of indole derivatives into dichloro benzoquinones. In this 
methodology, different Brønsted acids (hydrochloric acid, sulphuric acid or acetic acid) 
were used as catalysts and DDQ was added in order to oxidize the formed hydroquinone. 
Long reactions times (8-24 h) were usually needed.166  (Scheme 6.1) Yadav and co-
workers demonstrated afterwards that these Michael additions, followed by oxidations, 




Harris and co-workers reported a faster methodology to obtain this kind of compounds, 
using tetrabromobenzoquinone as the starting material. This reaction has the advantage 





166 a) Pirrung, M. C.; Park, K.; Li, Z. Org. Lett., 2001, 3, 365. b) Pirrung, M. C.; Deng, L.; Li, Z.; Park, K. J. 
Org. Chem. 2002, 67, 8374. 
167 Yadav, J. S.; Reddy, B. V. S.; Swamy, T. Tetrahedron Lett. 2003, 44, 9121. 
168 Yadav, J. S.; Reddy, B. V. S.; Swamy, T. Synthesis 2004, 1, 106. 
169 Harris, G. D.; Nguyen, A.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Org. Lett. 1999, 1, 431. 




Some examples of single Michael additions of indoles to quinones, followed by oxidation 
of the obtained hydroquinone, have been reported, three of which will be discussed 
below. The first example is based on the use of molecular iodine as a catalyst under 
ultrasound irradiation at room temperature.170 (Scheme 6.3) 
 
 Scheme 6.3. 
In the second example, Kamble and co-workers developed a heterogeneously catalysed 
domino synthesis of 3-indolylquinones, starting from either quinones or hidroquinones 
as starting materials. The addition reaction was catalysed by ferrite 
(Fe3O4)/povidone−phosphotungstic acid (PVP−PWA), while the oxidation step took 
place thanks to the presence of Ag2O and H2O2. The main advantages of this 
methodology are the shorter times needed (2-5 h) and the possibility of recover and 
reuse the catalytic system. 171 (Scheme 6.4) 
 
Scheme 6.4. 
Finally, the third example comes from Escobedo-González et al., who compared the 
synthesis of four natural indolylquinone derivatives (Scheme 6.5) under different 
conditions in order to compare typical synthetic procedures with uncommon activating 
modes such as microwave irradiation, IR irradiation and mechanochemical procedures. 
 
170 Liu, B.; Ji, S.J.; Su, X.M.; Wang S. Y. Synth. Commun., 2008, 38, 1279. 
171 Kamble, S. B.; Vyas, P. P.; Jayaram, R. V.; Rode, C. V. ACS Omega, 2017, 2, 2238. 




To this end, different quinones and naphthoquinones were reacted with indole under 





MH MW IR HSBM 
I 24 79 62 24 
II 12 35 31 18 
III 46 42 51 30 
IV 25 41 64 35 
Table 6.1.  MH: mantle heating, 95 °C, 60 min; MW: microwave, 250 W, 100 °C, 10 min; IR, 121 °C, 10 min; 
HSBM: High speed ball milling, 500 rpm, 60 min. 
 
The introduction of a second indole ring is much more difficult, usually needing the 
isolation of the mono addition intermediates. Thus, Pirrung and co-workers reported a 
second indole addition to the mono-indolyl-2,5-dichlorobenzoquinones previously 
mentioned by using different Brønsted or Lewis acids. 173 (Scheme 6.6) The reported 
methodology requires an inert atmosphere, long reaction times (12 to 48 h), reflux and 
1 to 4 equivalents of the acid promoter. Moreover, an additional long (14h) oxidation 




172 Escobedo-González, R. G.; Pérez-Martínez, H.; Nicolás-Vázquez, M.; Martínez, J. Gómez, G.; Serrano, J. 
N.; Carranza-Téllez, V. Vargas-Requena, C. L.; Miranda-Ruvalcaba, R. J. Chem. 2016, ID 3870529. 
173 Pirrung, M. C.; Liu, Y.; Deng, L.; Halstead, D. K.; Li, Z.; May, J. F.; Wedel, M.; Austin, D. A.; Webster N. J. 
G. J. Am. Chem. Soc. 2005, 127, 4609. 




Finally, a last methodology for the synthesis of indolylquinones is based on a solvent-
free photochemical reaction between 1,4-naphtoquinone and indole, giving the desired 
compound A and a second product B, which comes from the Diels-Alder reaction 
between A and a second molecule of the starting quinone, followed by a final oxidation 
step. (Scheme 6.7)174 
 
Scheme 6.7. 
6.3. Multiple bond-forming synthetic methodologies under 
mechanochemical conditions. 
Typical synthetic methodologies generate large amounts of residues, mainly coming 
from organic solvents. They are typically considered essential, as most reactions take 
place in solution to facilitate thorough mixing and thermal energy transfer. 
Nevertheless, with the beginning of the green chemistry era the interest in developing 
solvent-free synthetic methodologies has considerably increased. In this context, 
mechanochemical activation techniques such as manual grinding or ball-milling appear 
as attractive approaches to solvent-free synthesis.175 
Wilhelm Ostwald, a Russian-German chemist who received the Nobel Prize in Chemistry 
in 1909, defined for the first time ̈ mechanochemistry¨ in 1919 as ̈ a branch of chemistry 
which is concerned with chemical and physicochemical changes of substances of all 
states of aggregation due to the influence of mechanical energy¨.176 Similarly, in its 
Compendium of chemical terminology, also known as the “Gold book”, IUPAC defines 
 
174 Wang, Y. M., Wen, Z., Chen, X. M., Du, D. M., J. Heterocycl. Chem. 1998, 36, 313. 
175 Achar, T. K.; Bose, A.; Mal, P. Beilstein J. Org. Chem. 2017, 13, 1907. 
176 Stauch, T.; Dreuw, A. Chem. Rev. 2016, 116, 14137.  




mechanochemical reactions as those that are induced by the absorption of mechanical 
energy,177 which comes from grinding or milling processes. 
During the grinding of two solids, complex transformations are generated. Mechanical 
energy can break the order of crystalline structures and produce novel surfaces, where 
at the collision points, solids can be deformed and even melt, generating the so called 
¨hot spots¨ where molecules can achieve high vibrational energies that lead to bond 
breaking. Moreover, under solvent-free conditions, solvation phenomenon are not 
relevant, potentially leading to accelerated reactions. This factor, associated with the 
fact that reactions are performed at very high concentrations, can lead to alterations in 
product selectivity and therefore to new chemistry.178 
The first mechanochemical reactions took place by grinding reactants with a mortar and 
a pestle. This technique does no need any specialized equipment and is easy to perform, 
but relies on the strength of the operator and is not feasible for long reaction times. 
(Figure 6.4) Therefore, specifically designed milling equipment is preferred. 179 
nowadays. With these instruments energy input can be controlled by adjusting the 
milling frequency, making the work more reproducible. Also, as the reactions take place 
in closed vessels, the operator is not exposed to the reactants, enabling safer reaction 
conditions. Two main types of such equipment are available (Figure 6.4): 
1. Mixer (shaker) mills: Reagents are loaded into a jar with one or more balls. The 
jars are then fit horizontally and shaken at the desired frequency. In this case the 
main mechanical energy is impact force. This kind of milling is usually described 
as high-speed vibration milling (HSVM) or high-speed ball milling (HSBM). 
2. Planetary mills: Reagents are loaded in the same way, but the movement is 
different. In this case the jars are mounted on to a spinning disc called the ¨sun 
wheel¨, and the jars orbit around it while spinning in the opposite direction.  
 
177 https://goldbook.iupac.org/terms/view/MT07141. 
178 Hernández, J. C.; C. Bolm, J. Org. Chem., 2017, 82, 4007. 
179 Howard, J. L.; Cao, Q.; Browne, D. L. Chem. Sci. 2018, 9, 3080. 





Figure 6.4: Types of grinding. 
 
In both cases, the reaction time, milling frequency, material or jar size and balls can be 
varied. Sometimes inert milling auxiliaries, such as NaCl, Al2O3 or SiO2, can be used in 
order to increase the friction, especially when liquid reagents are employed.180 
On the other hand, the interest on reactions able to generate several bonds in one single 
step (multiple bond-forming transformations, MBFTs) is considerably increasing.181 This 
is mainly due to their high synthetic efficiency, which is a goal in itself and also allows 
the reduction of isolation and purification steps and consequently the use of lower 
amounts of organic solvents. 
Among MBFTs, reactions can be classified into domino, consecutive or multicomponent. 
Tietze and Beifuss182 defined a domino reaction as “a transformation of two or more 
bond-forming reactions under identical reaction conditions, in which the latter 
transformations take place at the functionalities obtained in the former bond forming 
reactions”. These domino reactions can be inter-, intramolecular, or combine both 
modalities. 183  Consecutive (or sequential) reactions, unlike domino, require some 
change in reaction conditions to complete the bond forming sequence. Examples of such 
changes are an increase in temperature or a successive addition of reagents.  
Multicomponent reactions (MCR) are defined as convergent process in which three or 
more starting materials are combined, by mixing all of them simultaneously or by 
sequential addition in a single reaction vessel, to form a product that contains significant 
fragments of all the reactants. MCRs are characterized by the creation of a high 
molecular complexity and diversity by using simple and accessible building blocks. 
 
180 Leonardi, M.; Villacampa, M.; Menéndez, J. C. Chem. Sci. 2018, 9, 2042. 
181 Bonne, D.; Constantieux, T.; Coquerel, Y.; Rodriguez, J. Chem. Eur. J. 2013, 19, 2218. 
182 Tietze, L. F.; Beifuss, U.; Angew. Chem. 1993, 32, 131. 
183 Green, N. J.; Sherburn, M. S. Aust. J. Chem. 2013, 66, 267. 




Moreover, the experimental simplicity and the possibility of automatization make MCRs 
a promising green chemistry methodology.184,185  
Compared to conventional methods in which the diversity is introduced step by step 
MBFTs, due to their highly convergent character, allow obtaining of high number of 
diverse compounds with a minimal number of steps. (Figure 6.5) 
 
Figure 6.5: MBFTs vs. conventional steps reactions 
 
As previously mentioned, with MBFT reactions the number of isolation and purification 
steps is reduced, decreasing the amount of solvents employed, and the residues 
generated. For these reasons, the combination of mechanochemical methodologies 
with MBFTs appears as an interesting approach to the synthesis of new bioactive 
compounds using green chemistry methodologies. 
 
 
184 Dömling, A.; Ugi, I. Angew. Chem. Int. Ed. Engl. 2000, 39, 3168.  
185 Zhu, J.; Bienayme, H. (eds.), Multicomponent Reactions. Wiley-VCH, 2005.  




6.4. Synthesis of indolylquinones 
Most of the previously reported methodologies for the synthesis of indolylquinones 
present several disadvantages associated to the poor solubility and difficult purification 
of quinone derivatives. As one of the interests in our group is the development of novel 
mechanochemical synthetic methodologies, we reasoned that mechanochemistry was 
a perfect choice to overcome these problems. In this context, we set as our goal the 
development of a general mechanochemical method to obtain mono- indolylquinones 
or symmetric or non-symmetric bis-indolylquinones, using indoles and dihalogenated 
quinones as starting materials.  
To obtain these derivatives, two Michael additions followed by oxidation steps are 
needed. Position 3 of the indole core may attack to one of the available positions of the 
quinone, forming intermediate I, which will tautomerize into the corresponding 
hydroquinone II. After oxidation, this intermediate will give the desired mono-
substituted indolylquinone III, which can suffer a second nucleophilic attack from 
another molecule of indole, that after keto-enol tautomerization will give hydroquinone 
V. A final oxidation step will provide the desired compound VI.  (Scheme 6.8) 
According to literature precedent, 166,173 the Michael addition of the indole takes place 
selectively on the position adjacent to the halogen group. This can be explained by the 
Spartan-calculated Mulliken charges, which show that this position is more electrophilic 
than the one directly attached to the bromine group. (Figure 6.6) 
 
Figure 6.6. 







6.4.1 Synthesis of mono-indolylquinones 
In order to start with the synthesis of our library of indolyl-quinone derivatives, we first 
needed to optimize the preparation of mono-indolyl derivatives. To this end, in a first 
attempt 1 equivalent of indole and 1 equivalent of 2,5-dibromoquinone were placed in 
a 20 mL ball mill vessel, along with a zirconium oxide ball. The vessel was fitted to one 
of the horizontal vibratory arms of the ball mill, while the other arm was occupied with 
an empty vessel, and the mill was set to vibrate at a frequency of 20 s-1 for 60 min at 
room temperature. Under these conditions, the desired product was obtained in a 20% 
yield, along with starting materials, hydroquinone and the desired compound in its 
hydroquinone form.  Many of the previously reported methodologies for the synthesis 
of this kind of derivatives used an excess of the starting quinone in order to act as the 
oxidizing agent, but the main problem of such a protocol lies on the difficult separation 
of the mixture obtained. To avoid these problems, we decided to add an external 




oxidizing agent. As we were performing mechanochemical reactions, solid reagents 
were preferable; moreover, in order to avoid a purification step, we wanted to be able 
to remove the oxidant by simple filtration in the workup. This way, different reagents 
were studied. (Scheme 6.9 and Table 6.2) Many of the tested oxidizers, such as cerium 
amonium nitrate (CAN), molecular iodine (I2), ferric chloride (FeCl3) and percarbamide 
(urea-hydrogen peroxide adduct) resulted in indole degradation. On the other hand, 
with manganesum oxide (MnO2) or magnesium monoperoxyphthalate (MMPP) no 
reaction was observed. The best results were obtained with the use of Fetizon´s reagent 
(Ag2CO3 on celite), which has been used in some cases for the oxidation of 
hydroquinones. 166,173 
  
Scheme 6.9. and Table 6.2. *Crude 1H-RMN calculated conversions. Q: 2,5-dibromoquinone; HQ: 2,5-
dibromohydroquinone; I: indole 
Once Fetizons´s reagent was selected as the best alternative, different conditions were 
tried for the reaction. When just one equivalent of the oxidizing agent was employed, 
complex mixtures of the starting materials, hydroquinone, the desired compound and 
its reduced form were found.  Only with 2 equivalents of the Fetizon´s reagent the 
Oxidizing agent Auxiliar Eq. Time (min) Conversion* Other products 
- - - 60  20% Q + I+ HQ + reduced 26 
CAN - 2 60  - Indole decomposition 
I2 - 2 60  - Indole decomposition 
FeCl3 - 2 60  - Indole decomposition 
Percarbamide - 2 60  - Q + I + HQ 
Percarbamide ethanol 2 60  - Indole decomposition 
Percarbamide - 4 60  - Indole decomposition 
Percarbamide celite 2 60  - Indole decomposition 
MnO2 - 2 60  - Q + I 
MMPP  2 60  - Q + I 
Ag2CO3 celite - 1 30  65% Q + I+ reduced 26 
Ag2CO3 celite - 1 60  88% Q + I + reduced 26 
Ag2CO3 celite - 2 60 97% Q 
Ag2CO3 celite - 2 30  88% Q + I 
Ag2CO3 celite - 3 60  100% - 




reduced species disappeared. It is worth highlighting that other authors using different 
oxidizing agents as DDQ also reported the need for at least 2 equivalents of 
oxidizer.166,173 
This way, we decided to establish our standard protocol with 1 equivalent of the suitable 
indole derivative and quinone, 2 equivalents of Fetizon´s reagent, for 1 hour under high-
speed vibration milling at a frequency of 20 s-1. 
Once we started exploring the scope of the method, we observed that, not 
unexpectedly, the reactivity changed depending on the nature of the substituents found 
in the indole nucleophile, and when electron acceptor groups were introduced, the 
reactivity decreased considerably. Another problem came from compound purification, 
which was accompanied by considerable loss of material when performed by 
chromatography. Thus, when using conventional silica gel column chromatography, 
most of the compound decomposes. The same behaviour was observed when using 
alumina, both in its activated commercial form or de-activated by addition of controlled 
amounts of water. When silica gel was previously deactivated with oxalic acid, better 
results were observed, but still a high amount of compound was lost. Finally, it was 
observed that most of the compounds precipitate in hexane/dichloromethane mixtures, 
giving the best purification method. However, precipitation was only possible when the 
crude compounds were almost pure. 
For these reasons, we considered that the efficiency of the method needed to be 
improved. For this purpose, one equivalent of para-toluensulphonic acid (p-TsOH) was 
added, which was hoped to enhance the quinone reactivity by acting as a Brønsted acid. 
After some preliminary assays, this was regarded as the optimal method and was used 
to establish the scope of our reaction (Scheme 6.10). As can be observed in Table 6.3, a 
broad scope of indole derivatives were employed, generally giving good to excellent 
isolated yields. Regarding the quinone component, no significant changes were 
observed between 2,5-dibromoquinone and 2,5-diclhoroquinone.  





Cpd. R X Yield (%) 
26a H Br 80 
26b H Cl 96 
26c H Quinone I Complex mixture 
26d H Quinone II 45 
26e H Quinone III Complex mixture 
26f 5-NO2 Br 69 
26g 5-NO2 Cl 15 
26h N-Methyl Br 42 
26i 2- Methyl Br 53 
26j 7- Methyl Br 72 
26k 5-Br Br  81 
26l 4-Br Br 79 
26m 4-Br Cl 67 
26n 5-Methoxy Br 75 
26o 5-Methoxy Cl 95 
26p 5-Methoxy-2-methyl Br  98 
26q 5-Methylcarboxylate Br 64 
26r 5-NH2 Br Unstable 
26s 5-NH2 Cl Unstable 
26t 5-Methoxy-N-methyl Br  75 
 
 
Scheme 6.10 and Table 6.3. 
Although not related to asterriquinones, some more complex quinones were also briefly 
examined in order to establish the scope of the method. In the case of 2-
bromonaphtoquinone (I), the reaction took place, but product purification was not 
possible because of compound instability. When other quinones, with both positions 
free, as 1,4-naftoquinone (II) or 4-methylquinoline-2,5,8(1H)-trione (III) were used, 
complex insoluble mixtures were obtained. It is possible that in such cases the desired 
reaction is not the only one taking place, after the indolylquinone formation, and that 




second Diels Alder reaction between the formed product and a molecule of the starting 
quinone takes place.174,186 
6.4.2. Synthesis of symetric bis-indolylquinones 
Once the methodology to obtained mono-indolylquinones was optimized, we decided 
to extend the method to the preparation of bis-indolylquinones. In a first attempt, after 
following the standard protocol for the obtention of mono-indolylquinones, a second 
equivalent of indole and 2 equivalents of Fetizon´s reagent were added to the same 
milling vessel, which was then submitted to one additional hour at the same vibration 
frequency. Under these conditions, no reaction was observed. However, in a second 
attempt, when the same conditions were tried in the presence of a second equivalent 
of the Brønsted acid catalyst, the desired double substitution product was isolated in an 
60% yield. (Scheme 6.11) 
 
Scheme 6.11. 
As in the case of the monoindolylquinones, the methodology needed to be improved to 
avoid the presence of intermediate species of the domino mechanism so that 
chromatographic purification could be avoided. For this purpose, the combination of p-
TsOH with CAN as a Lewis acid catalyst was assayed at different reaction times and 
substrate/Brønsted acid ratios. (Scheme 6.12) 
 
186 a) López-Alvarado P.; Alonso M. A.; Avendaño C.; Menéndez J. C. Tetrahedron Lett. 2001, 42, 7971. b) 
Alonso M.A.; López-Alvarado P.; Avendaño C.; Menéndez J.C. Tetrahedron 2003, 59, 2821. 






 At this point we decided to start synthesizing derivatives; but when different 
substituents were introduced, the obtained yields were not as good as expected. This 
was mainly due to the difficult purification of the compounds, as soon as a mixture of 
mono- and bis-indolylquinone was obtained, column chromatography was needed, 
decomposing a considerable amount of product. Thus, we decided that the 
methodology needed to be improved in order to avoid purification. For this purpose, 
different times and equivalents of p-TsOH were tried in the presence of a 10 % of CAN 
as a Lewis catalyst. (Table 6.4)  
Entry Indole eq p-TsOH eq CAN (%) Time (min) Mono- (%) Indole (%) Bis- (%) 
1 2 2 -- 120 30 10 60 
2 2 1 10  60 65 35 -- 
3 2 1 10  120 40 30 30 
4 2 2 10  60 16 18 66 
5 2 2 10  120 8 22 70 
Table 6.4. *Crude 1H-RMN calculated conversions. 
Since the improvements were not sufficient, we decided to try a different milling 
technique. Thus, the same reaction was performed in a planetary ball mill. To first 
evaluate the adequate milling settings, the previous conditions of 1 equivalent of the 
corresponding quinone, 4 equivalents of Fetizon´s reagent, 2 equivalents of p-TsOH and 








After trying different settings and indole equivalents, the best conditions found were 
2.1 equiv. of indole, at a rotation speed of 650 rpm, changing the direction every 2 min 
for a reaction time of 90 min and without a pause between these changes in rotation 
direction. 
Entry Indole eq Milling Time (min) Mono- (%)* Indole (%)* Bis- (%)* 
4 2 
500 rpm, 
2 min, 10 s pause 
60 56 39 5 
5 2 
500 rpm, 
2 min, 10 s pause 
75 45 36 19 
6 2 
500 rpm, 
2 min , 10 s pause 
90 24 40 36 
7 2 
600 rpm, 
2 min , 5 s pause 
120 50 -- 50 
8 2 650 rpm, 2 min  90 44 -- 56 
9 2,1 650 rpm, 2 min  120 30 -- 70 
10 2,2 650 rpm, 2 min  90 -- 44 56 
11 2,2 650 rpm, 2 min  120 16 27 57 
12 2,1 650 rpm, 2 min  90 27 -- 72 
Table 6.5. *Crude 1H-RMN calculated conversions. 
Once the milling conditions were selected the influence of different Lewis acids was 
studied. As it is shown in Table 6.6 Ferric chloride (FeCl3) gave the best results. To further 
evaluate the best conditions in the presence of FeCl3, shorter reaction times were 
tested, but lower yields were obtained (63 %). 
Lewis acid (10%) Mono- (%) Bis- (%) 
CAN 27 72 
InCl3 49 49 
BF3·Et2O 51 50 
ScTfO3 37 63 
FeCl3 5 95 
ZnCl2 33 67 
Table 6.6. *Crude 1H-RMN calculated conversions. 
Afterwards, the same reaction times but with lower amounts of the catalyst were 
evaluated. It was found that the use of 1 % catalyst decreased considerably the yield to 




a 64 %, while 5 % was enough to maintain a 92 % yield, being chosen as our optimal 
conditions. 
Once this protocol was established, indoles bearing different substitution patterns were 
used (Scheme 6.14 and Table 6.7). As expected, the heterocycles bearing electron-
acceptor substituents afford considerably lower yields, with the reaction involving 5-
nitroindole affording only the mono-substituted product in a 92 % yield.  
 
 
Cpd. R Yield (%) 
27a H 92 
27b 5-Methoxy 77 
27c 5-Br 21 
27d 4-Br 26 
27e N-Methyl 50 
27f 2-Methyl 80 
27g 5-Methoxy-2-methyl 94 
Scheme 6.14. and Table 6.7. 
 As it can be shown in Table 6.6, indoles bearing different substitution patterns were 
used. On one side, as it can be expected the heterocycles bearing electron acceptor 
substituents afford considerably lower yields. Moreover, the addition of a second 5-
nitroindole did not took place, affording just the mono-substituted in a 92% yield. 
 
6.4.3. Synthesis of non-symmetric bis-indolylquinones 
Finally, in order to obtained non-symmetric bis-indolylquinones, we assayed a two-
steps, one-pot protocol introducing two different indoles, which allowed us to obtain 
compounds 28a-g (Scheme 6.15 and Table 6.8) 






Cpd. R1 R2 Yield (%) 
28a 5-NO2 2-Methyl 70 
28b H 5-Br 40 
28c H 2-Methyl 83 
28d H 5-Methoxy 80 
28e 5-Methoxy 5-Methoxy-2-methyl 55 
28f 5-Methoxy 2-Methyl 71 
28g 5-Methoxy 5-Br 65 
Table 6.8. 
Some preliminary studies regarding the UV absorption maxima of representative 
indolylbenzoquinones (26a, 26h, 26n and 27b) showed that compounds present a 
maximum of absorption between 500 and 650 nm. As expected, indoles bearing electron 
donor groups present a red-shift in their maximum of absorption. Moreover, compound 
26h showed a clear solvatochromic effect in polar environments, displacing its 
maximum towards red region. (Table 6.9) 
Compound 
26a 26n 26h 
27b 
MeOH 532 573 570 529 
H2O 550 575 607 543 
Table 6.9. 
In order to advance towards our goal of developing MSOT probes, a further 
displacement of these absorption maxima towards the IR region was considered 
relevant. With this goal, some preliminary experiments to substitute the carbonyls with 
more electron-withdrawing groups were performed (Scheme 6.15). Unfortunately, 
none of them afford positive results, and further studies will be needed.  











6.5. Experimental section 
General experimental details. 
All reagents (Aldrich, Fischer, Alpha Aesar, SDS) and solvents (Scharlau, Fischer, SDS) 
were of commercial quality and were used as received. Mechanochemical reactions 
were carried out in a vibratory mixer mill (Retsch MM 200) at a frequency of 20 Hz using 
a 25 mL zirconium oxide grinding jar and a single zirconium oxide ball 20 mm in diameter 
or in a planetary ball mill (Retsch PM 100) at 650 rpm using a 12 mL stainless steel 
grinding jar and 30 steel balls 5 mm in diameter.  Reactions were monitored by thin layer 
chromatography on aluminium plates coated with silica gel and fluorescent indicator 
(Macherey-Nagel Xtra SIL G/UV254). Compounds were purified by precipitation in 
different solvent mixtures or by separation by flash chromatography with oxalic acid 
precoated silica gel (Scharlau 40–60 μm, 230–400 mesh ASTM), Melting points were 
determined using a Stuart Scientific apparatus, SMP3 Model, and are uncorrected. 
Infrared spectra were recorded with an Agilent Cary630 FTIR spectrophotometer 
working by attenuated total reflection (ATR), with a diamond accessory for solid and 
liquid samples. NMR spectroscopic data were recorded using a Bruker Avance 250 
spectrometer operating at 250 MHz for 1H NMR and 63 MHz for 13C NMR maintained by 
the NMR facility of Universidad Complutense (CAI de Resonancia Magnética Nuclear); 
chemical shifts are given in ppm and coupling constants in Hertz. High-resolution mass 
spectra (HRMS) were recorded on a mass spectrometer fitted with an electrospray 
detector (ESI) by the mass spectral facility of Universidad Complutense (CAI de 
Espectrometría de Masas) and elemental analyses were determined by the 
microanalysis facility of Universidad Complutense (CAI de Microanálisis Elemental), 
using a Leco 932 combustion microanalyzer. 
  




6.5.1 Preparation of non-commercial reactives 
Synthesis of Fetizon’s reagent  
17 g of AgNO3 were dissolved in 100 ml of distilled water, the resulting solution was 
stirred and 15 g of Celite were added. A solution of 5.299 g of Na2CO3 in 150 ml of 
distilled water was added to the previous suspension. The resulting mixture was stirred 
for 1h and after this time the yellowish-green precipitate was filtered and washed with 
water until its neutralization. The resulting precipitate was dried in an oven overnight.187 
Oxalic acid-precoated silica gel  
Silica gel was added over a 0.1N solution of oxalic acid and the mixture was stirred over 
night at room temperature. After this time, the excess of oxalic acid was eliminated with 
water (3 x 250 mL), the resulting precoated silica was dried overnight under 110C in an 
oven.188 
2,5-Dibromobenzoquinone 189 
To a solution of 1,4-dimethoxybenzene (10 g, 72.5 mmol) in acetic acid (20 
mL) was dropwise added Br2 (23.15 g, 145 mmol) in acetic acid (7 mL), at 
room temperature. After stirring for 2 h, the solution was cooled and the 
white precipitate (16.2 g) of 2,5-dibromo-1,4-dimethoxybenzene was filtered. The 
filtrate was diluted with water (15 mL) and extracted with CHCl3, which was washed with 
10% aqueous NaHCO3, dried over anhydrous sodium sulphate and evaporated, yielding 
an additional amount (3.1 g) of 2,5-dibromo-1,4-dimethoxybenzene. A part of the 2,5-
dibromo-1,4-dimethoxybenzene obtained (15 g, 50.7 mmol) was dissolved in CH3CN 
(150 mL) in an oil bath at 100 ºC. A solution of cerium ammonium nitrate (75.0 g, 136.8 
mmol) in water (300 mL) was added to the boiling CH3CN solution. After completion of 
the addition, the reacting mixture was left to cool to room temperature while stirred 
over 30 min. The precipitate that formed was filtered and washed with water (50 mL), 
yielding 11.5 g (87% overall) of 2,5-dibromobenzoquinone, as a yellow solid.190 
1H NMR (250 MHz, d6-DMSO) δ:  7.77 (s, 2H) ppm. 
13C NMR (63 MHz, d6-DMSO) δ: 178.37 (2C), 138.09 (2C), 137.48 (2C) ppm. 
 
 
187 Fieser, M.; Fieser, L. Reagents for Organic Synthesis, Vol. 2, p. 363. 
188 Yamamoto, Y.; Nishimura, K.; Kiriyama, N.; Chem. Pharm. Bull. 1976, 24, 1853-1859. 
189 López-Alvarado P., Avendaño C., Menéndez J. C. Synth. Commun. 2002, 20, 3233-3239. 
190 These spectral data were identical to those found in literature 189 





Neat SO2Cl2 (15.17 mL,188.17 mmol, 2.6 eq.) was slowly added at room 
temperature to 1,4-dimethoxybenzene (10 g, 72.37 mmol). The mixture 
was warmed at 40 ºC and stirred for 3.5 h. Excess SO2Cl2 was removed by 
attaching the flask to a water pump for 1 h. The residue was triturated with Et2O (10 
mL), filtered and washed with Et2O (10 mL), yielding 10.27 g of 2,5-dichloro-1,4-
dimethoxybenzene as a white solid. A further amount of 2,5-dichloro-1,4-
dimethoxybenzene (4.44 g) precipitated from the ether solution. An aliquot of 0.5 g (2.4 
mmol) of the 2,5-dichloro-1,4-dimethoxybenzene obtained was dissolved in CH3CN (7 
mL) at 50 ºC. A solution of cerium ammonium nitrate (7.28 g, 12.0 mmol) in water (7 
mL) was added, and the reacting mixture was stirred at room temperature for 1 h. The 
yellow precipitate was filtered and washed with water (1 mL), yielding 0.417 g (97% 
overall) of 2,5-dichlorobenzoquinone as a yellow solid.191 
1H NMR (250 MHz, d6-acetone): δ 7.35 (s) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.4 (2C), 144.6 (2C), 134.2 (2C) ppm. 
 
5-Methoxy-1-methyl-1H-indole  
To a stirring solution at 0 ºC of 5-methoxyindole (2 g, 13.60 mml) in dry 
DMF (60 mL) NaH 60% dispersion in mineral oil (0.54 g, 20.40 mmol) was 
added. After stirring for 15 min at this temperature methyl iodide (2,54 
mL, 40.80 mmol) was added. The mixture was stirred for 1 h at room temperature, after 
this time, water (200 mL) was added to quench the reaction and the white solid obtained 
is filtered, washed with water and dried, yielding the desired product. Yield: 1.753 mg, 
80%.192 
Mp 97-99 °C. 
1H NMR (250 MHz, d4-methanol): 7.23 (d, J = 8.8 Hz, 1H), 7.08 (d, J = 3.0 Hz, 1H), 7.04 (d, 
J = 2.4 Hz, 1H), 6.80 (dd, J = 8.8, 2.4 Hz, 1H), 6.32 (dd, J = 3.0, 0.7 Hz, 1H), 3.80 (s, 3H), 
3.75 (s, 3H) ppm. 
 
191 These spectral data were identical to those found in the literature 189 
192 These spectral data were identical to those found in literature: Qinqin X.; Xiaodong B.; Chuchu S.; Di 
W.; Xiaona R.; Zhiguo L.; Yugui G.; Jianmin Z.; Guang L. Eur. J. Med. Chem. 2018, 160,120-132. 




13C NMR (63 MHz, d4-methanol): δ 155.3, 133.7, 130.4, 130.4, 112.5, 110.8, 103.4, 101.2, 
56.6, 56.2, 32.9 ppm. 
 
6.5.1. Synthesis of mono indolylquinones (26a-s) 
 
The suitable quinone (1 eq), the corresponding indole (1 eq), p-toluensulphonic acid 
(PTSA, 1 eq) and silver carbonate on Celite 50 wt. % (2 eq) were added to a 12 mL ball 
mill vessel, along with a zirconium oxide ball. The vessel was fitted to one of the 
horizontal vibratory arms of the mall mill, while the other arm was occupied with an 
empty vessel. The ball mill was set to vibrate at a frequency of 20 s-1 for 60 min at room 
temperature. Then, the reaction vessel was cleansed with ethyl acetate and the 
suspension obtained was filtered to remove the silver carbonate. The organic layer was 
washed with water (6 mL), dried over anhydrous sodium sulphate and the solvent was 
removed under reduced pressure. The compounds were purified by column 
chromatography, using oxalic acid precoated silica gel silica gel as stationary phase and 




Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), indole (110 mg, 0.94 
mmol); the compound was purified by precipitation in a 
CH2Cl2/hexane mixture to give the desired product as a purple solid. 
Yield: 0.284 g, 80%  
Mp 83– 85°C. 
IR (neat) 3346 (NH), 1666 (C=O), 741 (C-Br) cm-1. 
1H NMR (250 MHz, d4-methanol): δ 7.66 (s, 1H), 7.61 (s, 1H), 7.47 (dd, J = 7.2, 0.8 Hz, 
1H), 7.38 (dd, J = 7.2, 0.8 Hz, 1H), 7.24 – 7.17 (m, 1H), 7.15 – 7.08 (m, 1H) ppm. 




13C NMR (63 MHz, d4-methanol): δ 179.7, 178.6, 145.1, 139.0, 138.8, 138.3, 132.2, 131.5, 
126.4, 123.5, 122.9, 121.5, 113.3, 110.1 ppm. 
Elemental analysis (%): calcd. for C14H7Br2NO2: C 44.13 H 1.85, N 3.68; found: C 44.45, 
H 1.54, N 3.33. 
2,5-Dichloro-3-(1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26b) 
Prepared from 2,5-dichlorobenzoquinone (0.250 g, 1.42 mmol) 1H-
indole, (0.230 g, 1.42 mmol); the compound was purified by 
precipitation in a mixture of hexane: ethyl eter to give the desired 
product as a purple solid. Yield: 0.395 g, 96 %. 
Mp 153-155 °C. 
IR (neat) 3293 (NH), 1646 (C=O) cm-1. 
1H NMR (250 MHz, d4-methanol) δ: 7.60 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8 Hz, 
1H), 7.28 (d, J = 1.0 Hz, 1H), 7.21 – 7.14 (m, 1H), 7.12-7.06 (m, 1H) ppm. 
13C NMR (63 MHz, d4-methanol) δ: 179.7, 179.3, 145.4, 140.7, 138.10 137.7, 134.8, 
132.0, 127.3, 123.6, 122.9, 121.6, 113.3, 107.9 ppm. 
Elemental analysis (%): calcd. for C14H7Cl2NO2: C 57.56, H 2.42, N 4.80; found: C 57.91, 
H 2.70, N 4.70.  
2-Bromo-3-(1H-indol-3-y)naphthalene-1,4-dione (26d) 
Prepared from 2-bromo-1,4-naftoquinone (0.250 g, 1.06 mmol), 1H-
indole (0.171 g, 1.06 mmol); the compound was purified by flash 
chromatography using oxalic acid precoated silica gel188 as stationary 
phase and hexane: ethyl acetate (3:1, v/v) as the mobile phase. The 
compound was unstable, so no further characterization could be done. Brown solid, 
yield: 0.167 g, 45 %. 
1H NMR (250 MHz, d6-acetone) δ: 8.21 – 8.17 (m, 1H), 8.16 – 8.12 (m, 1H), 7.91 (d, J = 
3.2 Hz, 1H), 7.89 (d, J = 3.3 Hz, 1H), 7.78 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.48 
(d, J = 7.8 Hz, 1H), 7.27 (dd, J = 6.1, 3.2 Hz, 1H), 7.22 – 7.15 (m, 1H), 7.15 – 7.06 (m, 1H) 
ppm. 





Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), 5-
nitro-1H-indole (0.152 g, 0,94 mmol); the compound was purified 
by precipitation in hexane to give the desired product as a purple 
solid. Yield: 0.275 g, 69%. 
Mp 129 – 131°C. 
IR (neat) 3346 (NH), 1669 (C=O), 1570 (NO2) 735 (C-Br) cm-1. 
1H NMR (250 MHz, d6-DMSO) δ: 8.49 (d, J = 2.2 Hz, 1H), 8.07 (dd, J = 9.0, 2.2 Hz, 1H), 
7.87 (s, 1H), 7.86 (s, 1H), 7.67 (d, J = 9.0 Hz, 1H) ppm 
13C NMR (63 MHz, d6-DMSO) δ: 178.4, 176.6, 141.5, 141.4, 139.4, 137.4, 137.3, 134.3, 
133.0, 125.1, 118.5, 117.3, 113.1, 110.8 ppm. 
Elemental analysis (%): calcd. for C14H6Br2N2O4: C 39.47, H 1.42, N 6.58; found: C 39.04, 
H 1.76, N 6.51. 
2,5-Dibromo-3-(N-methyl-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26h) 
Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), N-
methylindole (0.123 g, 0,94 mmol); the compound was purified by 
precipitation in hexane to give the desired product as a purple solid. 
Yield: 0.156 g, 42% 
Mp 98 – 100°C. 
IR (neat) 3458 (NH), 1666 (C=O), 738 (C-Br) cm-1. 
1H NMR (250 MHz, CDCl3) δ: 7.57 (s, 1H), 7.49 (s, 1H), 7.45 (t, J = 1.3 Hz, 1H), 7.42 (t, J = 
1.3 Hz, 1H), 7.32 (m, 1H), 7.24 (m, 1H), 3.92 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3) δ: 178.3, 177.6, 142.0, 137.9, 137.4, 137.2, 134.4, 131.6, 125.9, 
123.0, 122.6, 121.2, 110.6, 107.8, 34.0 ppm. 
Elemental analysis (%): calcd. for C15H9Br2NO2: C 45.61, H 2.30, N 3.55; found: C 45.75, 
H 2.37, N 3.71. 
2,5-Dibromo-3-(2-methyl-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26i) 
Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol) 2-
methyl-1H-indole (0.124 g, 0,94 mmol); the compound was purified 
by precipitation in hexane to give the desired product as a purple 
solid. Yield: 0.197 g, 53%. 




Mp 82-84 °C. 
IR (neat) 3375 (NH), 1667 (C=O) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 10.59 (s, 1H), 7.70 (s, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.25 
(d, J = 7.9 Hz, 1H), 7.13 – 7.05 (m, 1H), 7.05 – 6.97 (m, 1H), 2.36 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 178.8, 177.0, 144.0, 138.2, 137.9, 137.4, 136.6, 136.3, 
127.9, 122.0, 120.5, 120.4, 111.7, 108.1, 13.5 ppm. 
Elemental analysis (%): calcd. for C15H9Br2NO2: C 45.61, H 2.30, N 3.55; found: C 45.29, 
H 2.06, N 3.68. 
2,5-Dibromo-3-(7-methyl-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26j) 
Prepared from 2,5-dibromobenzoquinone (100 mg, 0.376 mmol), 7-
methyl-1H-indole (0.049 g, 0,376 mmol); the compound was 
purified by precipitation in hexane to give the desired product as a 
purple solid. Yield: 0.105mg, 72%. 
Mp 132 – 134°C. 
IR (neat) 3398 (NH), 1646 (C=O), 745 (C-Br) cm-1. 
1H NMR (250 MHz, CDCl3) δ: 8.66 (s, 1H), 7.39 (s, 1H), 7.35 (d, J = 2.1 Hz, 1H), 7.10 (d, J = 
7.8 Hz, 1H), 6.96 (t, J = 7.8 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 2.35 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3) δ: 178.3, 177.4, 142.4, 137.8, 137.6, 137.4, 135.6, 132.9, 129.4, 
124.8, 123.9, 121.5, 119.9, 109.8, 17.0 ppm. 
Elemental analysis (%): calcd. for C15H9Br2NO2: C 45.61, H 2.30, N 3.55; found: C 45.32, 
H 2.21, N 3.29. 
2,5-Dibromo-3-(5-bromo-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26k) 
Prepared from 2,5-dibromobenzoquinone (0.100g, 0,376 mmol), 5-
bromo-1H-indol (0.073 g, 0.376 mmol); the compound was purified 
by precipitation in hexane to give the desired product as a purple 
solid. Yield: 0.139 g, 81 %.  
Mp 106 – 108 °C. 
IR (neat) 3347 (NH), 1646 (C=O), 796 (Br), 736 (C-Br) cm-1. 
1H NMR (250 MHz, d4-methanol) δ: 7.66 (s, 1H), 7.63 (s, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.40 
(d, J = 8.6 Hz, 1H), 7.30 (dd, J = 8.6, 1.8 Hz, 1H) ppm. 




13C NMR (63 MHz, d6-acetone) δ: 179.1, 177.9, 143.2, 138.6, 138.2, 136.2, 134.4, 132.1, 
128.7, 126.0, 125.0, 115.2, 114.2, 109.7 ppm. 
Elemental analysis (%): calcd. for C14H6Br3NO2: C 36.56, H 1.32, N 3.05; found: C 36.29, 
H 1.13, N 3.13. 
2,5-Dibromo-3-(4-bromo-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26l) 
Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), 4-
bromo-1H-indole (0.184 g, 0,94 mmol); the compound was purified 
by precipitation in a mixture of hexane: ethyl acetate to give the 
desired product as a purple solid. Yield: 0.337 g, 79 %. 
Mp 103 - 107 °C. 
IR (neat) 3330 (NH), 1648 (C=O), 771 (C-Br), 736 (C-Br) cm-1. 
1H NMR (250 MHz, d4-methanol) δ: 7.77 (s, 1H), 7.65 (d, J = 2.8 Hz, 1H), 7.60 – 7.56 (dd, 
J = 2.8, 0.8 Hz, 1H), 7.29 (dd, J = 7.6, 0.8 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 179.1, 178.0, 145.5, 138.8, 138.7, 138.3, 136.9, 129.1, 
126.9, 125.3, 124.6, 114.2, 113.0, 111.1 ppm. 
Elemental analysis (%): calcd. for C14H6Br3NO2: C 36.56, H 1.32, N 3.05; found: C 36.34, 
H 1.70, N 3.03  
2,5-Dichloro-3-(4-bromo-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26m) 
Prepared from 2,5-dichlorobenzoquinone (0.250 g, 1.42 mmol) 4-
bromo-1H-indole, (0.279 g, 1.42 mmol); the compound was purified 
by precipitation in a hexane: ethyl acetate mixture to give the desired 
product as a purple solid. Yield: 0.353 g, 67%. 
Mp 228-230 °C. 
IR (neat) 3336 (NH), 1652 (C=O) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 11.11 (s, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.57 (d, J = 8 Hz, 
1H), 7.45 (s, 1H), 7.28 (d, J = 7.5 Hz, 1H), 7.14 (d, J = 8 Hz, 1H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 178.6, 178.3, 144.8, 141.7, 141.2, 138.4, 134.3, 128.9, 
126.6, 124.9, 124.2, 113.8, 112.6, 107.9 ppm. 
Elemental analysis (%): calcd. for C14H6BrCl2NO2: C 45.32, H 1.63, N 3.78; found: C 45.53, 
H 2.02, N 3.90.  
 





Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), 5-
methoxy-1H-indole (0.138 g, 0,94 mmol); the compound was 
purified by precipitation in a mixture of hexane: CH2Cl2 to give the 
desired product as a purple solid. Yield: 0.290 g, 75%  
Mp 112 – 115 °C. 
IR (neat) 3325 (NH), 1650 (C=O), 1211 (OCH3), 792 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 10.91 (s, 1H), 7.71 (s, 1H), 7.67 (s, 1H), 7.43 (d, J = 8.8 
Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 3.79 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 179.1, 178.2, 155.8, 138.6, 138.2, 138.0, 132.7, 132.5, 
131.7, 127.4, 113.9, 113.5, 109.9, 104.9, 56.2 ppm. 
Elemental analysis (%): calcd. for C15H9Br2NO3: C 43.83, H 2.21, N 3.41; found: C 43.98, 
H 2.45, N 3.81 
2,5-Dichloro-3-(5-methoxy-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (26o) 
Prepared from 2,5-dichlorobenzoquinone (0.250 g, 1.42 mmol) 5-
methoxy-1H-indole, (0.209 g, 1.42 mmol); the compound was 
purified by precipitation in a mixture of hexane: methanol to give 
the desired product as a purple solid. Yield: 0.435 g, 95%. 
Mp 174-176 °C. 
IR (neat) 3306 (NH), 1672 (C=O) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 10.93 (s, 1H), 7.68 (d, J = 3.0 Hz, 1H), 7.42 (d, J = 8.8 
Hz, 1H), 7.36 (s, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.85 (dd, J = 8.8, 2.3 Hz, 1H), 3.77 (s, 3H) 
ppm. 
13C NMR (63 MHz, d6-acetone) δ: 178.7, 178.4, 155.5, 144.4, 139.8, 136.8, 134.1, 132.1, 
131.7, 127.2, 113.5, 113.1, 107.3, 104.4, 55.8 ppm. 
Elemental analysis (%): calcd. for C15H9Cl2NO3: C 55.93, H 2.82, N 4.35; found: C 56.16, 










Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol) 5-
methoxy-2-methyl-1H-indole (0.151 g, 0,94 mmol); the compound 
was purified by precipitation in a mixture of hexane: CH2Cl2 to give 
the desired product as a purple solid. Yield: 0.391 g, 98%. 
Mp 108 - 111°C. 
IR (neat) 3362 (NH), 1658 (C=O), 686 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 10.50 (s, 1H), 7.72 (s, 1H), 7.27 (d, J = 8.7 Hz, 1H), 6.82 
(d, J = 2.5 Hz, 1H), 6.75 (dd, J = 8.7, 2.5 Hz, 1H), 3.73 (s, 3H), 2.35 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 179.3, 177.5, 155.7, 144.5, 138.6, 138.5, 138.4, 136.4, 
132.0, 128.9, 112.7, 112.2, 108.5, 103.5, 56.3, 14.0 ppm. 
Elemental analysis (%): calcd. for C16H11Br2NO3: C 45.21, H 2.61, N 3.30; found: C 45.15, 
H 2.44, N 3.36. 
Methyl 3-(2,5-dibromo-3,6-dioxocyclohexa-1,4-dien-1-yl)-1H-indole-5-carboxylate 
(26q) 
Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol), 
methyl 1H-indole-5-carboxylate (0.164 g, 0,94 mmol); the 
compound was purified by precipitation in a mixture of hexane: 
ethyl acetate mixture to give the desired product as a purple solid. 
Yield: 0.264 g, 64%. 
Mp 132 - 135°C. 
IR (neat) 3319 (NH), 1696 (C=O), 771 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 11.27 (s, 1H), 8.21 (s, 1H), 7.89 (dd, J = 8.4, 1.7 Hz, 1H), 
7.81 (d, J = 1.7 Hz, 1H), 7.75 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 3.88 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 179.1, 177.9, 168.4, 143.3, 140.1, 138.7, 138.2, 134.8, 
132.2, 126.5, 125.2, 124.4, 123.5, 113.2, 111.2, 52.4 ppm. 
Elemental analysis (%): calcd. for C16H9Br2NO4: C 43.77, H 2.07, N 3.19; found: C 43.66, 
H 2.36, N 3.16. 
 






Prepared from 2,5-dibromobenzoquinone (0.250 g, 0,94 mmol) 5-
methoxy-1-methyl-1H-indole (0.124 g, 0,94 mmol); the compound 
was purified by precipitation in hexane to give the desired product 
as a purple solid. Yield: 0.299 g, 75%. 
Mp 92-94 °C. 
IR (neat) 3040 (NH), 1667 (C=O),1643 (C=O) cm-1. 
1H NMR (250 MHz, d6-acetone) δ: 7.67 (s, 1H), 7.57 (s, 1H), 7.44 – 7.35 (m, 1H), 6.91 – 
6.86 (m, 2H), 3.93 (s, 3H), 3.77 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone) δ: 178.6, 177.8, 155.6, 142.9, 138.2, 137.5, 135.1, 132.9, 
131.6, 127.3, 112.9, 111.8, 108.1, 104.9, 55.8, 33.6 ppm. 
Elemental analysis (%): calcd. for C16H11Br2NO3: C 45.21, H 2.61, N 3.30; found: C 45.48, 
H 3.02, N 3.29.  
 
6.5.2. Synthesis of symmetric bis-indolylquinones (27a-i) 
 
The suitable quinone (1 eq), the corresponding indole (2.1 eq), p-toluensulphonic acid 
(p-TsOH, 2 eq), silver carbonate on Celite 50 wt. % (4 eq) and FeCl3 on Celite 50 wt. % 
(0.05 eq)193 were added to a 12 mL stainless steel grinding jar with 30 steel balls of 5 mm 
in diameter. In the case of methoxy derivatives the use of FeCl3 produces decomposition 
of the corresponding indole, so cerium ammonium nitrate (0.05 eq.) was used. The 
vessel was fitted into the planetary mill and it was set at a frequency of 650 rpm  for 90 
min at room temperature. Then, the reaction vessel was cleansed with ethyl acetate and 








was washed with water (6 mL), dried over anhydrous sodium sulphate and the solvent 
was removed under reduced pressure. The compounds were purified by column 
chromatography, using oxalic acid precoated silica gel silica gel as stationary phase and 
eluting with a mixture of hexane-ethyl acetate or by precipitation in different solvent 
mixtures. 
2,5-Dibromo-3,6-di(1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27a) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 mmol) 
1H-indole (0.046 g, 0.399 mmol), the compound was purified 
by precipitation in hexane to give the desired product as a 
purple solid. Yield: 0.102 g, 92 %. 
Mp 104 – 107 °C. 
IR (neat) 3364 (NH), 1651 (C=O), 742 (C-Br) cm-1. 
1H NMR (250 MHz, d6-DMSO): δ 11.87 (s, 2H), 7.73 (d, J = 2.7 Hz, 2H), 7.50 (d, J = 7.8 Hz, 
2H), 7.44 (d, J = 7.8 Hz, 2H), 7.19 (t, J = 6.9 Hz, 2H), 7.11 (t, J = 6.9 Hz, 2H) ppm. 
13C NMR (63 MHz, d6-DMSO): δ 177.6 (2C), 142.2(2C), 136.2 (2C), 132.2 (2C), 130.5 (2C), 
125.7 (2C), 122.0 (2C), 121.7 (2C), 120.0 (2C), 112.5 (2C), 108.6 (2C) ppm. 
Elemental analysis (%): calcd. for C22H12Br2N2O2: C 53.26, H 2.44, N 5.65; found: C 53.40, 
H 2.60, N 5.72. 
2,5-Dibromo-3,6-bis(5-methoxy-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27b) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 
mmol) 5-methoxy-1H-indole (0.058 g, 0.399 mmol) and 
cerium ammonium nitrate (0.05 eq) instead of FeCl3 on 
Celite 50 wt. %. The compound was purified by precipitation 
in hexane to give the desired product as a purple solid. Yield: 0.081 g, 77 %.  
Mp 138 - 139°C. 
IR (neat) 3352 (NH), 1653 (C=O), 743 (C-Br) cm-1. 
1H NMR (300 MHz, d6-DMSO): δ 11.71 (s, 2H), 7.65 (d, J = 2.8 Hz, 2H), 7.39 (d, J = 8.8 Hz, 
2H), 6.91 (d, J = 2.3 Hz, 2H), 6.83 (dd, J = 8.8, 2.3 Hz, 2H), 3.75 (s, 6H) ppm. 
13C NMR (75 MHz, d6-DMSO): δ 177.9 (2C), 154.3 (2C), 142.3 (2C), 132.1 (2C), 131.3 (2C), 
131.1 (2C), 126.1 (2C), 112.8 (2C), 111.8 (2C), 108.6 (2C), 104.4 (2C), 55.2 (2C) ppm. 




Elemental analysis (%): calcd. for C24H16Br2N2O4: C 51.83, H 2.90, N 5.04; found: C 51.70, 
H 3.03, N 4.71. 
2,5-Dibromo-3,6-bis(5-bromo-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27c) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 mmol) 
5-bromo-1H-indole (0.078 g, 0.399 mmol), the compound was 
purified by flash chromatography to give the desired product 
as a purple solid. Yield: 0.026 g, 21%. 
Mp 98 – 100°C. 
IR (neat) 3373 (NH), 1652 (C=O), 748 (C-Br) cm-1. 
1H NMR (300 MHz, d6-acetone): δ 11.02 (s, 2H), 7.70 (d, J = 1.8 Hz, 2H), 7.59 (d, J = 1.8 
Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 7.22 (dd, ,J = 8.6, 1.8 Hz,  2H) ppm. 
13C NMR (75 MHz, d6-acetone): δ 177.2 (2C), 141.8 (2C), 135.0 (2C), 133.3 (2C), 130.7 
(2C), 127.6 (2C), 124.7 (2C), 123.8 (2C), 113.8 (2C), 112.9 (2C), 108.7 (2C) ppm. 
Elemental analysis (%): calcd. for C22H10Br4N2O2: C 40.41, H 1.54, N 4.28; found: C 40.65, 
H 1.27, N 4.26. 
2,5-Dibromo-3,6-bis(4-bromo-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27d) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 mmol) 
4-bromo-1H-indole (0.078 g, 0.399 mmol), the compound was 
purified by flash chromatography to give the desired product as 
a purple solid. Yield: 0.032, 26 %. 
The NMR spectra show a mixture of rotamers A and B in a 1:3 relation. 
Mp 95 – 99 °C. 
IR (neat) 3317 (NH), 1660 (C=O), 734 (C-Br), 678 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ  11.12 (s, 2H), 7.75 (d, J = 2.7 Hz, 0.5H, B), 7.71 (d, J = 
2.7 Hz, 1.5H, A), 7.61 (dd, J = 8.0, 0.8 Hz, 2H), 7.31 (dd, J = 8.0, 0.8 Hz, 2H), 7.15 (t, J = 8.0 
Hz, 2H) ppm.  
1H NMR (300 MHz, d6-DMSO): δ 11.98 (s, 2H), 7.77 (d, J = 2.6 Hz, 0.5H, B), 7.66 (d, J = 2.6 
Hz, 1.5H, A), 7.54 (d, J = 7.8 Hz, 1.5H, A), 7.53 (d, J = 7.8 Hz, 0.5H, B),  7.25 (d, J = 7.8 Hz, 
2H), 7.11 (t, J = 7.8 Hz, 2H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.8 (2C), 145.4 (2C), 138.7 (2C), 136.7 (2C), 128.9 
(2C), 127.1 (2C), 125.3 (2C), 124.6 (2C), 114.2 (2C), 113.0 (2C), 111.3 (2C) ppm. 




Elemental analysis (%): calcd. for C22H10Br4N2O2: C 40.41, H 1.54, N 4.28; found: C 40.19, 
H 1.92, N 4.33. 
2,5-Dibromo-3,6-bis(1-methyl-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27e) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 mmol) 
1-methyl-1H-indole (0.052g, 0.399 mmol), the compound was 
purified by precipitation in hexane to give the desired product 
as a purple solid. Yield: 0.049 g, 50%. 
Mp 98 – 101 °C. 
IR (neat) 3456 (NH), 1643 (C=O), 739 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 7.65 (s, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 8.1 Hz, 
2H), 7.27 (t, J = 7.3 Hz, 2H), 7.16 (t, J = 7.3 Hz, 2H), 3.99 (s, 6H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 179.1 (2C), 138.7 (2C), 138.2 (2C), 137.9 (2C), 135.0 
(2C), 132.8 (2C), 127.3 (2C), 123.3 (2C), 123.1 (2C), 121.3 (2C), 111.5 (2C), 33.9 (2C) ppm. 
Elemental analysis (%): calcd. for C24H16Br2N2O2: C 54.99, H 3.08, N 5.34; found: C 53.97, 
H 3.00, N 5.22. 
2,5-Dibromo-3,6-bis(2-methyl-1H-indol-3-yl)cyclohexa-2,5-diene-1,4-dione (27f) 
Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 mmol) 
2-methyl-1H-indole (0.052g, 0.399 mmol), the compound was 
purified by precipitation in hexane to give the desired product 
as a purple solid. Yield: 0.079 g, 80%. 
Mp 147 – 149 °C. 
IR (neat) 3369 (NH), 1658 (C=O), 731 (C-Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 10.65 (s, 2H), 7.41 (d, J = 6.8 Hz, 2H), 7.38 – 7.28 (m, 
2H), 7.16 – 7.09 (m, 2H), 7.09 – 7.00 (m, 2H), 2.44 (d, J = 4.9 Hz, 6H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 177.4 (2C), 143.5 (2C), 136.8 (2C), 136.3 (2C), 127.7 
(2C), 121.5 (2C), 120.3 (2C), 120.2 (2C), 119.9 (2C), 111.3 (2C), 108.0 (2C), 13.2 (2C) ppm. 
Elemental analysis (%): calcd. for C24H16Br2N2O2: C 54.99, H 3.08, N 5.34; found: C 54.59, 
H 3.02, N 5.24. 






Prepared from 2,5-dibromobenzoquinone (0.05 g, 0.19 
mmol) 5-methoxy-2-methyl-1H-indole (0.064g, 0.399 
mmol), the compound was purified by precipitation in 
hexane to give the desired product as a purple solid. Yield: 0.105 g, 94 % 
Mp 131 - 135 °C. 
IR (neat) 3356 (NH), 1658 (C=O), 730 (Br) cm-1. 
1H NMR (250 MHz, d6-DMSO): δ  11.36 (s, 2H), 7.24 (d, J = 8.7 Hz, 2H), 6.84 (dd, J = 8.3, 
2.3 Hz, 2H), 6.73 (dd, J = 8.7, 1.4 Hz, 2H), 3.73 (d, J = 0.9 Hz, 6H), 2.32 (d, J = 4.8 Hz, 6H) 
ppm. 
13C NMR (63 MHz, d6-DMSO): δ 177.4 (2C), 154.0 (2C), 142.9 (2C), 137.9 (2C), 135.6 (2C), 
130.9 (2C), 127.7 (2C), 111.8 (2C), 110.7 (2C), 107.3 (2C), 103.4 (2C), 56.0 (2C), 14.0 (2C) 
ppm. 
Elemental analysis (%): calcd. for C26H20Br2N2O4: C 53.45, H 3.45, N 4.79; found: C 52.68, 
H 4.11, N 4.73. 
 
6.5.3. Synthesis of asymmetric bis-indolylquinones (28a-g) 
 
The suitable quinone (1 eq.), the corresponding indole (1 eq.), p-toluensulphonic acid 
(PTSA, 1 eq.) and silver carbonate on Celite 50 wt. % (2 eq.) were added to a 12 mL 
stainless steel grinding jar with 30 steel balls of 5 mm in diameter. The vessel was fitted 
into the planetary mill and it was set at a frequency of 650 rpm  for 1 h at room 
temperature. Once this time was finished and the first addition was completed, the 
second indole (1 eq.), p-toluensulphonic acid (PTSA, 1 eq.), silver carbonate on Celite 50 
wt. % (2 eq.) and FeCl3 on Celite 50 wt. % (0.05 eq.) [In the case of methoxy derivatives 




the use of FeCl3 produces decomposition of the corresponding indole, so Cerium 
ammonium nitrate (0.05 eq.) was used.] were added to the same grinding jar. Once 
again, the vessel was fitted into the planetary mill and it was set at a frequency of 650 
rpm for 1 more hour. Then, the reaction vessel was cleansed with ethyl acetate and the 
suspension obtained was filtered to remove the silver carbonate. The organic layer was 
washed with water (6 mL), dried over anhydrous sodium sulphate and the solvent was 
removed under reduced pressure. The compounds were purified by column 
chromatography, using oxalic acid precoated silica gel silica gel as stationary phase and 




Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23), 5-
nitro-1H-indole (0.037 g, 0.23 mmol) and 2-methyl-1H-indole 
(0.030 g, 0.23 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: 
ethyl acetate as the mobile phase to give the desired product as a purple solid. Yield: 
0.089 g,70 %  
Mp 136-138 °C. 
IR (neat) 3374 (NH), 1664 (C=O), 741 (Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ  11.53 (s, 1H), 10.62 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 
8.13 (dd, J = 9.0, 2.2 Hz, 1H), 7.98 (d, J = 1.7 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.39 (d, J = 
7.3 Hz, 1H), 7.32 (d, J = 7.3Hz, 1H), 7.10 (td, J = 7.5, 1.5 Hz, 1H), 7.03 (td, J = 7.5, 1.5 Hz, 
1H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.5, 178.1, 144.5, 143.3, 142.4, 140.6, 137.8, 137.2, 
136.9, 133.7, 128.5, 126.6, 122.4, 121.05, 120.8, 119.5, 118.5, 113.8, 112.6, 112.1, 108.9, 
14.1 ppm. 
Elemental analysis (%): calcd. for C23H13Br2N3O4: C 49.76, H 2.36, N 7.57; found: C 49.46, 
H 3.18, N 6.92 






Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),1H-indole (0.027 g, 0.23 mmol) and 5-bromo-1H-indole 
(0.045 g, 0.23 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: ethyl acetate as the mobile 
phase to give the desired product as a purple solid. Yield: 0.053 g, 40 %  
Mp >250 °C. 
IR (neat) 3384 (NH), 1661 (C=O), 746 (Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 11.21 (s, 1H), 11.06 (s, 1H), 7.80 (d, J = 2.8 Hz, 1H), 
7.77 (d, J = 2.8 Hz, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.56 – 7.45 (m, 3H), 7.32 (dd, J = 8.6, 1.9 
Hz, 1H), 7.24 – 7.17 (m, 1H), 7.16 – 7.09 (m, 1H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.2, 178.1, 143.2, 142.6, 137.2, 135.8, 134.1, 133.1, 
131.7, 130.6, 128.4, 126.6, 125.5, 124.7, 122.8, 122.5, 120.7, 114.7, 113.7, 112.8, 109.8, 
109.5 ppm. 
Elemental analysis (%): calcd. for C22H11Br3N2O2: C 45.95, H 1.93, N 4.87; found: C 45.25, 
H 1.42, N 4.54.   
2,5-Dibromo-3-(1H-indol-3-yl)-6-(2-methyl-1H-indol-3-yl) cyclohexa-2,5-diene-1,4-
dione (28c) 
Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),1H-indole (0.027 g, 0.23 mmol) and 2-methyl-1H-indole 
(0.030 g, 0.23 mmol); the compound was purified by 
precipitation in hexane to give the desired product as a purple solid. Yield: 0.097 g, 83 %  
Mp 117-119 °C. 
IR (neat) 3366 (NH), 1658 (C=O), 731 (Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 11.02 (s, 1H), 10.64 (s, 1H), 7.76 (s, 1H), 7.52 (app. t, J 
= 8.0 Hz, 2H), 7.42 – 7.32 (m, 2H), 7.17 (m, 2H), 7.10 – 6.99 (m, 2H), 2.41 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.3, 177.7, 143.8, 143.1, 137.3, 137.1, 136.6, 136.3, 
133.4, 130.6, 128.1, 126.5, 122.7, 122.4, 121.9, 120.7, 120.6, 120.3, 112.8, 111.7, 109.7, 
108.4, 13.7 ppm. 




Elemental analysis (%): calcd. for C23H14Br2N2O2: C 54.15, H 2.77, N 5.49; found: C 54.10, 
H 2.62, N 5.41. 
2,5-Dibromo-3-(1H-indol-3-yl)-6-(5-methoxy-1H-indol-3-yl) cyclohexa-2,5-diene-1,4-
dione (28d) 
Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),1H-indole (0.027 g, 0.23 mmol), 5-methoxy-1H-indole 
(0.034 g, 0.23 mmol) and cerium ammonium nitrate (0.05 eq) 
instead of FeCl3 on Celite 50 wt. %.; the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the mobile phase to give the 
desired product as a purple solid. Yield: 0.097 g, 80 %  
Mp 225-227 °C. 
IR (neat) 3317 (NH), 1652 (C=O), 741 (Br) cm-1. 
1H NMR (250 MHz, d6-DMSO): δ 11.85 (s, 1H), 11.73 (s, 1H), 7.71 (d, J = 2.7 Hz, 1H), 7.65 
(d, J = 2.7 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 
7.17 (t, J = 7.0 Hz, 1H), 7.09 (t, J = 7.0 Hz, 1H), 6.91 (d, J = 2.2 Hz, 1H), 6.82 (dd, J = 8.8, 
2.4 Hz, 1H), 3.74 (s, 3H) ppm. 
13C NMR (63 MHz, d6-DMSO): δ 177.4, 177.3, 153.7, 141.8, 135.9, 131.9, 131.3, 130.8, 
130.7, 130.13, 125.8, 125.3, 121.7, 121.4, 119.7, 112.7, 112.1, 111.7, 108.3, 108.1, 103.6, 
79.2, 55.4, 30.7 ppm. 
Elemental analysis (%): calcd. for C23H14Br2N2O3: C 52.50, H 2.68, N 5.32; found: C 52.40, 
H 2.39, N 4.82 
2,5-Dibromo-3-(5-methoxy-1H-indol-3-yl)-6-(5-methoxy-2-methyl-1H-indol-3-
yl)cyclohexa-2,5-diene-1,4-dione (28e) 
Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),    5-methoxy-1H-indole (0.034 g, 0.23 mmol),2-methyl-
5-methoxy-1H-indole (0.037 g, 0.23 mmol) and cerium 
ammonium nitrate (0.05 eq) instead of FeCl3 on Celite 50 wt. %.; the compound was 
purified by flash chromatography through a silica gel column using hexane: ethyl acetate 
as the mobile phase to give the desired product as a purple solid. Yield: 0.072 g, 55 %  
Mp 250 °C. 
IR (neat) 3360 (NH), 1659 (C=O), 745 (Br) cm-1. 




1H NMR (250 MHz, d6-acetone): δ 10.92 (s, 1H), 10.50 (s, 1H), 7.71 (d, J = 2.9 Hz, 1 H), 
7.43 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.8 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.85 (m, 2H), 6.75 
(dd, J = 8.8, 2.4 Hz, 2H), 3.78 (s, 3H), 3.73 (s, 3H), 2.38 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 206.3, 178.5, 155.4, 155.2, 143.9, 143.1, 137.9, 136.0, 
132.8, 132.1, 131.6, 131.3, 128.6, 127.0, 113.4, 112.9, 112.3, 111.6, 109.6, 108.4, 104.7, 
103.3, 55.9, 55.9, 13.7 ppm. 
Elemental analysis (%): calcd. for C25H18Br2N2O4: C 52.66, H 3.18, N 4.91; found: C 53.85, 
H 3.95, N 5.05  
2,5-Dibromo-3-(5-methoxy-1H-indol-3-yl)-6-(2-methyl-1H-indol-3-yl) cyclohexa-2,5-
diene-1,4-dione (28f) 
Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),    2-methyl-1H-indole (0.030 g, 0.23 mmol), 5-
methoxy-1H-indole (0.034 g, 0.23 mmol) and cerium 
ammonium nitrate (0.05 eq.) instead of FeCl3 on Celite 50 wt. %.; the compound was 
purified by precipitation in hexane to give the desired product as a purple solid. Yield: 
0.088 g, 71 %  
Mp 168-170 °C. 
IR (neat) 3362 (NH), 1656 (C=O), 730 (Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 10.90 (s, 1H), 10.62 (s, 1H), 7.71 (d, J = 2.9 Hz, 1H), 
7.43 (d, J = 8.8 Hz, 1H), 7.38 (dd, J = 7.2, 12 Hz, 2H), 7.31 (d, J = 7.1 Hz, 1H), 7.12 – 7.07 
(m, 1H), 7.04 (dd, J = 7.6, 1.2 Hz, 2H), 6.99 (d, J = 2.4 Hz, 2H), 6.86 (dd, J = 8.8, 2.4 Hz, 
1H), 3.78 (s, 3H), 2.41 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.5, 177.7, 15546, 143.9, 143.1, 137.3, 136.7, 136.4, 
132.83, 132.1, 131.2, 128.1, 127.1, 121.9, 120.6, 120.4, 113.4, 112.9, 111.7, 109.6, 108.5, 
104.68, 55.8, 13.7 ppm. 
Elemental analysis (%): calcd for C24H16Br2N2O3: C 53.36, H 2.99, N 5.19; found: C 52.46, 
H 3.55, N 5.36 
2,5-Dibromo-3-(5-bromo-1H-indol-3-yl)-6-(5-methoxy-1H-indol-3-yl) cyclohexa-2,5-
diene-1,4-dione (28g) 
Prepared from 2,5-dibromobenzoquinone (0.060 g, 0.23 
mmol),    5-bromo-1H-indole (0.045 g, 0.23 mmol), 5-




methoxy-1H-indole (0.034 g, 0.23 mmol) and cerium ammonium nitrate (0.05 eq) 
instead of FeCl3 on Celite 50 wt. %.; the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the mobile phase to give the 
desired product as a purple solid. Yield: 0.090 g, 65%  
Mp >250 °C. 
IR (neat) 3338 (NH), 1649 (C=O), 745 (Br) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 11.17 (s, 1H), 10.91 (s, 1H), 7.80 (d, J = 2.8 Hz, 1H), 
7.72 (d, J = 2.8 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H), 7.52 (d, J = 8.7 Hz, 1H), 7.43 (d, J = 8.7 Hz, 
1H), 7.31 (dd, J = 8.7, 1.9 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 8.7, 2.4 Hz, 1H), 
3.78 (s, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 178.4, 178.0, 155.4, 143.2, 142.5, 135.8, 134.1, 132.4, 
132.1, 131.7, 131.2, 128.4, 127.1, 125.5, 124.7, 114.7, 113.7, 113.5, 113., 109.63, 109.5, 
104.6, 55.8 ppm. 
Elemental analysis (%): calcd for C23H13Br3N2O3: C 45.66, H 2.17, N 4.63; found: C 46.57, 
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7.1. Drug combinations vs. Multitarget Directed Ligands in Tuberculosis 
As previously mentioned, the current pharmacological treatments of tuberculosis are 
based on combinations of the available drugs. Tuberculosis treatment started in 1944 
with the discovery of streptomycin (SM) and para-aminosalicylic acid (PAS). It was in 
1950 when the first clinical trial comparing their efficacy as monotherapy or 
combination demonstrated that combined therapies were more effective and resulted 
in the first multidrug antitubercular treatment. Isoniazid (INH) appeared in 1952, and it 
was soon added to this previous combination, shortening the duration of treatments, 
but still 18 to 24 months of administration were needed. In the ‘60s, ethambutol (EMB) 
replaced PAS, shortening the treatment to 18 months, while in the ‘70s the addition of 
rifampicin (RIF) allowed the physicians to shorten the treatment to just 9 months. 
Finally, in 1980, the introduction of pyrazinamide (PZA) reduced the treatments to six 
months. (Figure 7.1) There are three main reasons that explain why combination 
therapies are more effective than monotherapies in TB. The first one is that treatment 
of TB with just one drug results in the selection of drug-resistant bacilli and fails to 
eliminate the disease. The second one is that different populations of bacilli, with 
different drug susceptibilities may coexist in the same patient, and the third one is that 
by inhibiting different biochemical pathways of the bacteria a synergic effect can be 
elicited. Although during the last decades of the twentieth century important 
improvements in the treatment of TB were achieved, it is worth nothing that for the last 
40 years no antitubercular drug with a novel mechanism of action has been approved. 
Moreover, soon after soon after the introduction of the first antimycobacterial drugs, 
drug resistant strains started to emerge. During the first decades the launch of 
combination therapies and more effective drugs seemed to control the disease, and 
indeed it was thought that TB could be eradicated by the end of the 20th century. 
However, in the ’80s tuberculosis re-emerged and the rate of appearance of MDR-TB 
and XDR-TB increased, showing that the currently available treatments are not enough 
to control the disease.194  
 
194 Almeida de Silva, P.; Ainsa, J. A. Tuberculosis 2007. From basic science to patient care, first edition, 
2007. 




Figure 7.1: Mechanism of action of the currently available antitubercular treatments. 
As mentioned in the Introduction, the current therapies present several drawbacks 
including the long treatments, which compromise the adherence to the therapy of the 
patients, the toxicities associated to this long term drug exposition, the frequently found 
drug-drug interactions and the increasing appearance of MDR and XDR strains. 53  
To fight against these drawbacks, an ideal new antitubercular agent should possess:195 
- Adequate ADME properties and good pharmacokinetics so it can be orally 
administered. 
-  Long half-life, so the frequency can be reduced to a single dose per day 
preferentially. 
- Novel mechanism of action, to ensure effectiveness against resistant strains. 
- Availability at relatively low cost in order to be accessible to patients in low-
income countries. 
- Admit co-administration with other therapies such as anti-HIV. 
- Lower toxicities. 
 
195 Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. Nature 2011,469, 483. 
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- Ability to shorten treatment, with strong bactericidal activity to kill the active TB 
and good activity on latent populations 
In this context, it seems that a good approach to achieve all these goals is the design of 
multitarget-directed ligands (MTDLs) as antitubercular agents.64 With MTDLs several 
targets can be inhibited at the same time, obtaining a synergic effect. Moreover, as 
tubercular drug resistance is chromosomally encoded, agents directed against several 
targets are likely to be effective against drug-resistant strains. Thus, if two different 
pharmacophores are combined in a single molecule, one of them based on a well-known 
antitubercular drug while the other inhibits a new target, the new drug would be 
potentially active against sensible and resistant strains, hence solving the problem of 
having different strains in one patient.  
Although several formulations which contain some of the drug combinations needed in 
one single dose are commercially available, facilitating patient’s adherence to treatment 
and supervision of therapy. Nevertheless, the possibility of having one single chemical 
entity able to perform several activities would avoid drug-drug interactions, simplify the 
formulation processes, the pharmacokinetic profiles, the clinical trials and of course the 
patient’s adherence. 
During the past years several authors have disclosed some examples of hybrid structures 
as antitubercular agents, showing promising results. 196 , 197 , 198 , 199 , 200  , 201 , 202 , 203  Even 
though most of these examples showed encouraging results, few of them were 
conceived through a rational design, and moreover most of their mechanism of actions 
remain still unknow. 
 
 
196  Bijev, A. Arzneimittelforschung 2009, 59, 34. 
197 Shaveta, S. M.; Singh. S. Eur. J. Med. Chem. 2016, 124, 500. 
198 Yan, M.; Xu, L.; Wang, Y.; Wan, J.; Liu, T.; Liu, W.; Wan, Y.; Zhang, B.; Wang, R.; Li, Q. Drug Dev. Res. 
2020, doi: 10.1002/ddr.21638. 
199 Hu, Y. Q.; Zhang, S.; Zhao, F.; Gao, C.; Feng, L.; Lv, Z.; Xu, Z.; Wu, X.Eur. J. Med. Chem. 2017, 133, 255. 
200 Stewart, G. R., Robertson, B. D.; Young, D. B. Nat. Rev. Microbiol. 2003, 1, 97. 
201 Sirim, M. M.; Krishna, V. S.; Sriram, D.; Unsal Tan, O. Eur. J. Med. Chem. 2020, 188, 112010. 
202 Gao, F.; Ye, L.; Wang, Y.; Kong, F.; Zhao, S.; Xiao, J.; Huang, G. Eur. J. Med. Chem. 2019, 183, 111678. 
203 Shah, S. R.; Katariya, K. D. J. Heterocycl. Chem. 2020, doi:10.1002/jhet.3893. 
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7.2. MmpL3 (Mycobacterium membrane protein Large 3) as an anti-TB 
target 
During the past years several efforts have been done in order to identify new targets for 
TB. To achieve this goal, libraries of compounds have been phenotypically screened in 
whole cells. Once the initial hits were obtained, efforts were made to find their targets 
by mutant generation coupled to whole genome sequencing. As the whole genome of 
Mycobacterium tuberculosis is known, it is assumed that by comparing the genomes of 
hit-resistant strains to the wild type the mutations found would correspond to their 
main target. This way, several targets as AtpE, DprE1 or MmpL3, have been identified.204 
MmpL3 is a membrane protein belonging to the MDR RND family (resistance nodulation 
division). This superfamily is a group of transmembrane proteins that mediate the 
transport of several compounds, which include positively charged, negatively charged 
and neutral compounds, including drugs, fatty acids or salts. This activity is driven by the 
proton motive force (PMF).205 
Mycobacteria contain 13 RND proteins known as Mycobacterial membrane protein large 
(MmpL), which usually possess 12 transmembrane domains and two extra cytoplasmic 
loops. MmpL3, 4, 5, 7, 8, 10, and 11 have been reported to participate in the biosynthesis 
of the complex cell envelope of mycobacteria, while MmpL5 and MmpL7 can actively 
efflux anti-tubercular drugs. MmpL3 is the only protein of this family essential for Mtb 
viability and replication. Indeed, downregulation of MmpL3 expression prevents cell 
division and leads to rapid cell death.206,207 
Two essential activities have been so far attributed to MmpL3. On one hand, it has been 
proved that MmpL3 is involved in the Mycobacterium cell wall formation. Mycolic acids 
are key components of the mycobacterial outer membrane. Mycolic acids are 
synthetized inside cells from fatty acids, and then they are conjugated with a trehalose 
molecule in order to form trehalose monomycolate (TMM). In this form, they are 
 
204 Goldman, R. C. Tuberculosis, 2013, 93, 569. 
205 Székely, R.; Cole, T. Molecular Microbiology, 2016, 99, 831. 
206 Domenech, P.; Reed, M.B.; Barry, C.E. Infect. Immun. 2005, 73, 3492. 
207 Degiacomi, G.; Benjak, A.; Madacki, J.; Boldrin, F.; Provvedi, R.; Palu, G.; Kor- dulakova, J.; Cole, S.T.; 
Manganelli, R. Sci. Rep. 2017, 7, 43495. 
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transported through the inner membrane thanks to MmpL3. Once in the periplasmic 
space, micolyltransferases transfer the TMM chain onto a molecule of arabinogalactan, 
yielding wall-bound mycolates, or to another TMM molecule forming a trehalose 
dimycolate (TDM). These molecules give the bacterial envelope its characteristic thick, 
waxy, and difficult-to-permeate consistence. 208 (Figure 7.2)  
 
Figure 7.2: MmpL3 functions. 
On the other hand, Mycobacteria, like most organisms, require iron for many vital 
functions. During infection, iron acquisition is challenging for pathogenic bacteria, 
because usually iron cations are bound to host iron-binding proteins in charge of its 
storage or transport; thus, in vertebrates two thirds of iron is incorporated into the 
heme group. For this reason, bacteria need to develop heme acquisition systems. Mtb 
secretes some hemophore proteins such as Rv0203, which is able to acquire heme from 
haemoglobin, allowing its transport through the inner membrane mediated by MmpL11 
 
208 Zhang, B.; Li, J.; Yang, X.; Guddat, L. W.; Yang, H.; Rao, Z. Cell 2019, 176, 636. 
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or MmpL3. Once inside the bacteria, heme can be degraded to release iron or be used 
whole for the synthesis of heme-containing proteins.209 (Figure 7.2) 
During the last years several compounds with apparently very different structures, 
haven been identified as MmpL3 inhibitors. These inhibitors include 1,2-
ethylenediamine, 210 the 1,5-diarylpyrrole derivative BM212 211  and its analogues, 
including the repurposed inverse agonist for the cannabinoid receptor CB1 rimonabant, 
derivatives of the tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide framework 
(THPPs), 212 , 213  indole-2-carboxamides (e.g. NITD-304 and NITD-349) 214 , 215  and 
adamantyl ureas (AUs), such as SQ109 and AU1235.216 (Figure 7.3) 
Understanding the mechanism of action of MmpL3 inhibitors is critical for their 
optimization process. Due to the diversity of the chemical scaffolds and differences in 
their activities, several authors wondered how all these widely heterogeneous 
compounds were all able to inhibit MmpL3. In answer to this question, several theories 
have been proposed.  
 
209 Fang, Z.; Leigh Sampson, S.; Warren. R. M. Tuberculosis 2015, 95, 123. 
210 Protopopova, M.; Hanrahan, C.; Nikonenko, B.; Samala, R.; Chen, P.; Gearhart, J.; Einck, L.; Nacy, C.A. 
J. Antimicrob. Chemother. 2005, 56, 968. 
211 La Rosa, V.; Poce, G.; Canseco, J. O.; Buroni, S.; Pasca, MR.; Biava, M.; Raju, RM.; Porretta, GC.; Alfonso, 
S.; Battilocchio, C.; Javid, B.; Sorrentino, F.; Ioerger, T.R.; Sacchettini, J.C.; Manetti, F.; Botta, M.; De Logu, 
A.; Rubin, E.J.; De Rossi, E. Antimicrob. Agents Chemother. 2012, 56, 324. 
212 Remuiñán, M. J.; Pérez-Herrán, E.; Rullás, J.; Alemparte, C.; Martínez-Hoyos, M.; Dow, D.J.; Afari, J.; 
Mehta, N.; Esquivias, J.; Jiménez, E.; Ortega-Muro, F.; Fraile-Gabaldón, MT.; Spivey, V. L.; Loman, N. J.; 
Pallen, M. J.; Constantinidou, C.; Minick, D. J.; Cacho, M.; Rebollo-López, M. J.; González, C.; Sousa, V.; 
Angulo-Barturen, I.; Mendoza-Losana, A.; Barros, D.; Besra, G. S.; Ballell, L.; Cammack, N. PLoS One, 2013, 
8, e60933.  
213 Ioerger, T.R.; O’Malley, T.; Liao, R.; Guinn, K.M.; Hickey, M.J.; Mohaideen, N.; Murphy, K C.; Boshoff. 
H.I.; Mizrahi, V.; Rubin, E.J.; Sassetti, C.M.; Barry, C.E.; Sherman, D.R.; Parish, T.; Sacchettini, C. PLoS One. 
2013, 8, e75245.  
214  Onajole, O.K.; Pieroni, M.; Tipparaju, SK.; Lun, S.; Stec, J.; Chen, G.; Gunose-Woyo, H.; Guo, H.; 
Ammerman, N.C.; Bishai, W.R.; Kozikowski, A.P. J. Med. Chem. 2013, 56, 4093. 
215 Rao SP.; Lakshminarayana SB.; Kondreddi RR.; Herve M.; Camacho LR.; Bifani P.; Kalapala SK.; Jiricek J.; 
Ma, N.L.; Tan, B.H.; Ng, S.H.; Nanjundappa, M.; Ravindran, S.; Seah, P.G.; Thayalan, P.; Lim, S.H.; Lee, B.H.; 
Goh, A.; Barnes, W.S.; Chen, Z.; Gagaring, K.; Chatterjee, A.K.; Pethe, K.; Kuhen, K.; Walker, J.; Feng, G.; 
Babu, S.; Zhang, L.; Blasco, F.; Beer, D.; Weaver, M.; Dartois, V.; Glynne, R.; Dick, T.; Smith, P.W.; Diagana, 
T,T.; Manjunatha, U.H. Sci. Transl. Med. 2013, 5, 214. 
216 Grzegorzewicz, A.E.; Pham, H.; Gundi, V.A.; Scherman, M.S.; North, E.J.; Hess T.; Jones, V.; Gruppo, V.; 
Born, S.E.; Korduláková, J.; Chavadi, S.S.; Morisseau, C.; Lenaerts, A.J.;Lee, R.E.; McNeil, M.R.; Jackson, M.; 
Nat. Chem. Biol. 2012, 8, 334. 





Some studies revealed that SQ109 inhibits enzymes involved in menaquinone synthesis, 
respiration, and, consequently ATP synthesis; moreover, this compound acts as an 
uncoupler of the proton gradient that is established during the normal activity of 
electron carriers in the electron transport chain, collapsing the proton motive force 
(PMF), arising from the Δψ and ΔpH contributions, where Δψ is the membrane potential 
and ΔpH is the pH gradient. 217  Later, Wei Li and coworkers proved that BM212, 
indolecarboxamides, AUs, and THPPs, also abolish PMF-driven translocation processes 
through the dissipation of the transmembrane electrochemical proton gradient (pH) 
or membrane potential (ψ) or both components of the PMF.218 While these authors 
propose an indirect inhibition mechanism, some others have proved MmpL3 direct 
inhibition. 
 
217 Li, K.; Schurig-Briccio, L.A.; Feng, X.; Upadhyay, A.; Pujari, V.; Lechartier, B.; Fontes, F.; Yang ,H.; Rao, 
G.; Zhu, W.; Gulati, A.; No, J.H.; Cintra, G.; Bogue, S.; Liu, Y.L.; Molohon, K.; Orlean, P.; Mitchell, D.A.; 
Freitas-Junior, L.; Ren, F.; Sun, H.; Jiang T.; Li, Y.; Guo, R.T.; Cole, S T.; Gennis, R.B.; Crick, D.C.; Oldfield, E. 
J. Med. Chem. 2014, 57, 3126. 
218 Li, W.; Upadhyay, A.; Fontes, F. L.; North, E. J.; Wang, Y.; Crans, D. C.; Grzegorzewicz, A. E; Jones, V.; 
Franzblau, S. G; Lee, R. E; Crick, D. C Antimicrob. Agents Chemother. 2014, 58, 6413. 
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In 2017, Zhujun Xu and co-workers proved that [14C]-labelled BM212 bound directly to 
the purified MmpL3 protein from Mycobacterium smegmatis.219 After this finding, Wei 
Li and co-workers reported in 2019 an in vitro whole cell method for the identification 
of direct MmpL3 inhibitors, moreover, they were able to prove that most of the 
described compounds inhibit MmpL3 by targeting the protein in a direct manner, even 
if its also true that some of them also exert an indirect inhibition by altering the PMF. 
Furthermore, they found that the expression of Mtb MmpL3 conditional knock-down, 
leads to a dramatic increase in , suggesting that the alteration in  can be either a 
cause or a consequence of MmpL3 inhibition.220 Finally, also in 2019, Bing Zhang and 
colleagues determined the crystal structure of Mycobacterium smegmatis MmpL3, in 
the presence and absences of four different inhibitors, validating the direct binding 
mode of different families of inhibitors in the same site within the proton translocation 
channel of the transporter and providing a structural vision of MmpL3 inhibition.221 
Moreover, their crystal structure provides some basis about the TMM export molecular 
mechanism. MmpL3 is a transmembrane protein, whose periplasmic domain is 
composed of two subdomains, PN and PC. (Figure 7.4.A) These domains interact 
creating a central cavity, with three openings, GT (top), GF (front) and GB (back). (Figure 
7.4.A) The transmembrane region of MmpL3 contains 12 transmembrane  helices 
(TMHs) and two extra  helices attached to the cytoplasmic membrane. The central core 
of the transmembrane domain is formed by TMH IV and TMH X, where two pairs of 
hydrophilic residues (Asp256-Tyr646 and Asp645-Tyr257) are located. These residues 
link the two helices by hydrogen bonds formed between their side chains. (Figure 7.4.B) 
These Asp-Tyr pairs are highly conserved residues among the MmpL family of 
transporters. Furthermore, their location is quite similar to the one found in other 
families of transporter, in which they are known to be involved in a proton-relay 
pathway. In addition, it has been proved that mutations in MmpL3 Asp-Tyr pairs 
compromise the growth of mycobacterial cultures, in agreement with them playing an 
important role in proton translocation.221,221 
 
219 Xu, Z.; Meshcheryakov, V. A.; Poce, G.; Chang, S. S. Proc. Natl. Acad. Sci. 2017, 114, 7993. 
220 Li, W.; Stevens, Casey, M.; Pandya, A. N.; Darzynkiewicz, Z.; Bhattarai, P.; Tong, W.; Gonzalez-Juarrero, 
M.; Weiwei, T.; North, E. J.; Zgurskaya, H. I.; Jackson, M. ACS Infect. Dis. 2019, 5, 1001. 
221 Zhang, B.; Li, Jun;Yang, X.; Guddat, L. W.; Yang, H.; Rao, Z. Cell 2019, 176, 636. 




Figure 7.4. Reproduced with permission of reference221. 
 
Regarding the MmpL3 mechanism, the authors proposed two plausible pathways for 
substrate entry into the transporter. (Figure 7.5) They suggest that substrates located in 
the inner side of the membrane could be transported across the membrane through the 
transmembrane channel at the periphery of transmembrane domain. Alternatively, 
TMM located in the outer side of the membrane could be transport through the GF that 
opens into the periplasm. GT is proposed as the TMM exit, since it does not appear to 
form strong interactions with the trehalose, making it convenient for substrate release. 
It is unknown whether this flipping and release mechanism is coupled or not and it 
seems clear that these events are driven by the PMF, in which the Asp-Tyr pairs play a 
key role. 




Figure 7.5. Reproduced with permission of reference221. 
 
In this context, MmpL3 has emerged as an attractive therapeutic target to develop new 
antitubercular agents, owing to its essentiality to Mtb. In the past few years the scientific 
community has done a big effort in order to elucidate its biological implication in 
mycobacterial physiology. Finally, the inhibition mechanism of the most importer 
inhibitors reported has been elucidated. In addition, many of the reported inhibitors 
have demonstrated efficacy in animal models, and the most advanced one, SQ109, has 
shown promising results in Phase 2b-3 clinical studies222  as an anti-TB agent, with 
excellent activity against all forms of Mtb, including drug-resistant clinical strains.   
 
7.3. Isoniazid (INH) 
Since its approval as an antitubercular agent, isoniazid has been used as first-line 
treatment for both active and latent tuberculosis. After it was launched, an extensive 
research on its mode of action started, but it took about 50 years to establish a general 
consensus. Still nowadays there are several hypotheses, even though the main 
mechanism is clear. 
 
222 World Health Organization. Global Tuberculosis Report 2018 (WHO) 
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This principal mode of action proposes that IHN acts as a prodrug that needs to be 
activated. This activation process involves an enzymatic oxidation by katG, a catalase-
peroxidase expressed in Mtb. The isonicotinoyl radical formed by the action of this 
enzyme reacts with nicotinamide adenine dinucleotide, forming the so-called INH-NAD 
adduct. (Figure 7.6) 223,224 Due to its structural analogy with the NADH cofactor, this 
adduct acts as a potent inhibitor of enoyl acyl-carrier-protein reductase (InhA), an 
enzyme essential for mycobacteria due to its key role in the reduction of fatty acids, a 
step of the biosynthesis of essential components of Mtb cell wall, the mycolic acids. 
(Figure 7.7) 
Some authors also propose that the isonicotinoyl radical can similarly react with NADP 
forming an INH-NADP adduct that inhibits dfrA-encoded dihydrofolate reductase225 and 
MabA (3-oxoacyl-ACP reductase).226 
 
Figure 7.6: Bioactivation of isoniazid. 
 
Figure 7.7: Interaction between InhA and the INH-NAD adduct, generated from 1ZID. 
 
223 Unissa, A. N.; Subbian, S.; Hanna, L. E.; Selvakumar, N. Infect. Genet. Evol. 2016, 45, 474. 
224 Jena, L.; Nayak, T.; Deshmukh, S.; Wankhade, G.; Waghmare, P.; Harinath, B. C. J. Infect. Dis. Ther. 2016, 
4, 1000297. 
225 Argyrou, A.; Jin, L.; Siconilfi-Baez, L.; Angeletti, R.H.; Blanchard, J.S.; Biochemistry, 2006, 45, 13947. 
226 Timmins, G. S.; Deretic, V. Mol. Microbiol. 2006, 62, 1220. 
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Even if these are the most accepted mechanisms of action of isoniazid, during the past 
years some concerns have been expressed. The main one is the observation that 
isoniazid is active on latent Tb, a stage where Mtb does not possess a cell wall. These 
observations make it clear that INH must possess one or more additional mechanisms 
of action that remain to be identified. The main hypotheses proposed in this regard 
are:227 
1. As mentioned above, INH requires a one-electron enzymatic oxidation step to be 
activated. Inside Mtb, katG promotes this activation, however, there are several 
human enzymes able to perform this kind of reactions. One of them is 
myeloperoxidase (MPO), which is mainly present in neutrophils, monocytes and 
macrophages and has been shown to activate INH. This may explain how INH is 
able to kill Mtb without penetrating the granuloma, since neutrophils may be 
able to activate and deliver the active form of INH directly in latent TB.  
2. The second mechanism proposes a protective role of INH against oxidative 
stress-induced necrosis. During Mtb infection, the host phagocytes induce the 
formation of reactive species to kill bacteria; however, Mtb has efficient 
strategies to defend itself against these species, particularly reactive oxygen 
species (ROS). This way the generated ROS, not able to kill the bacteria, promote 
phagocytic necrosis, the main cause of granuloma degradation. This way, the INH 
cytoprotective effect, may strengthen the host immune defence.  
3. On a third study the authors reveal the capacity of INH to induce monocytic 
differentiation. It is known that monocytes play a key role in killing active and 
latent TB. The capacity of INH to induce differentiation is quite weak, taking 
several weeks to increase the circulating monocytes population, and this could 
be a possible explanation of the long treatment times needed for INH. 
4. Finally, some authors have proposed that INH acts as a nitric oxygen (NO) 
generator through the peroxidation cycle of katG. However, even if this 
mechanism may contribute to isoniazid activity, it is probably not enough to 
explain the activity on the latent form. 
 
227 Khan, S. R.; Manialawy, Y.; Siraki, A. G. Br. J. Pharmacol. 2019, 176, 4599. 
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7.4. Design of pyrrole-isoniazid derivatives 
Several years ago, our group reported a one pot multicomponent reaction related to the 
Hantzsch pyrrole synthesis, which takes place under solvent-free mechanochemical 
conditions, using the High-Speed Vibration Milling (HSVM) technique. 228 , 229  This 
technique allowed the efficient synthesis of pyrroles with different substitution 
patterns. With this capacity in our hands, and bearing in mind the analogy of the 
compounds accessible by this method the above-mentioned MmpL3 inhibitor BM-
212,211 we decided to explore the antitubercular activities of our pyrrole derivatives. 
On the other hand, since its approval isoniazid remains as one of the first-line treatments 
against tuberculosis.  One of the main problems associated with INH is its ability to 
generate resistance. Serum concentrations of INH are influenced by several factors, one 
of the most important of which is enzymatic acetylation by human N-acetyltransferase 
(NAT). During long-term treatments with INH, acetylation leads to a lower bioavailability 
and consequent generates INH resistance. Furthermore, polymorphisms in NAT are a 
source of large variability in the individual response to isoniazid, with a clear ethnic 
component. One strategy that can be followed is blocking acetylation by chemical 
modifications of the hydrazine. Moreover, increasing the lipophilicity of INH can 
increase its permeation into bacterial cells. Consequently, INH derivatives with greater 
lipophilicity and higher metabolic stability can lead into more potent anti-TB 
compounds. 
In the last years, the concept of combining two pharmacophores to give one single 
molecule with several activities has been one of the hottest topics in medicinal 
chemistry. When it comes to TB, it seems that the development of MTDL is a perfect 
approach to overcome the increasing resistance problem. Sudoterb (LL-3858), an INH-
pyrrole hybrid that reached phase II clinical trials, is a good example of the efficacy of 
this strategy. (Figure 7.8)230,231 
 
228 V. Estévez, M. Villacampa, J. C. Menéndez, Chem. Commun. 2013, 49, 591. 
229 V. Estévez, V. Sridharan, S. Sabaté, M. Villacampa, J.C. Menéndez, Asian J. Org. Chem. 2016, 5,652. 
230 Beena, D.K.; Khare, G.; Kidwai, S.; Tyagi, A.K.; Singh, R.; Rawat, D.S.; Eur. J. Med. Chem. 2014, 81, 301. 
231 Martins, F.; Santos, S.; Ventura, C.; Elvas-Leitao, R.; Santos, L.; Vitorino, S.; Reis, M.; Miranda, V.; 
Correia, H.F.; Aires-de-Sousa, J.; Kovalishyn, V.; Latino, D.A.R.S.; Ramos, J.; Viveiros, M.; Eur. J. Med. Chem. 
2014, 81, 119.  





With these ideas in mind, we undertook the design, synthesis and pharmacological and 
SAR studies of a family of hybrid compounds bearing pyrrole and isoniazid frameworks. 
These compounds may act as MTDLs against tuberculosis, by inhibiting Iron acquisition 
pathways and cell wall formation through two different mechanism, involving InhA and 
MmpL3 inhibition. At the same time, as they are more lipophilic than isoniazid and their 
acetylation is not possible, they may be more metabolically stable INH derivatives, 
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7.5. Synthesis of pyrrole-isoniazid derivatives 
To achieve our goal, we synthesized a chemical library of pyrrole derivatives bearing a 
wide variety of substituents in all positions to evaluate their activities and try to 
elucidate some Structure Activity Relationships (SAR). (Figure 7.10) 
• In position 1 on the pyrrole core, hydrogen, alkyl, aminoalkyl or phenyl groups 
were introduced. 
• In position 2, due to synthetic accessibility issues, only methyl or propyl groups 
were tested. 
• In position 3, carboxylic acids, ethyl esters, amides or isoniazid hybrids were 
synthesized. 
• Position 4 was most commonly free, but methyl, phenyl or fused structures 
were also evaluated. 




As mentioned above, some years ago our group published a one pot multicomponent 
reaction related to the Hanztsch pyrrole synthesis. This reaction takes place under 
solvent-free mechanochemical conditions, starting from primary amines, -iodoketones 
and -dicarbonyl compounds in the presence of cerium ammonium nitrate (CAN) as a 
catalyst.228,229 
Thus, to obtain the desired pyrroles, the suitable -iodoketones need to be prepared 
first. To this end, two different methodologies were employed depending on the 
stability of the starting materials. The ones containing electron-rich heterocycles were 
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too reactive under HSVM conditions and were prepared through Method A, using 
molecular Iodide and Copper (II) oxide in refluxing methanol. (Scheme 7.1) 
 
Scheme 7.1: Method A. 
For the rest of the derivatives, we were able to perform the iodation step directly using 
the high-speed vibration milling technique, Method B, so that the pyrrole formation 
could be performed as a single sequential process. In this case, the iodation of the 
starting ketones was performed under HSVM conditions by using N-iodosuccinimide 
(NIS) and p-toluensulphonic acid (PTSA), which acts as Brønsted acid, favouring the 
enolic form of the ketone necessary for the iodation process. (Scheme 7.2) 
 
Scheme 7.2: Method B. 
Once the iodo derivatives were obtained, a mixture of the suitable -dicarbonyl 
compound, amine and CAN, previously stirred together at room temperature for 30 min 
to yield the corresponding enaminone, together with silver nitrate, were added to the 
reaction vessel. For R1 = H, the enaminone was commercially available. (Scheme 7.4) 
 
Scheme 7.4: Pyrrole formation. 
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The hydrogen iodide generated in the first step of the reaction can promote a reductive 
dehalogenation of the starting -iodoketone. For this reason, the silver nitrate, able to 
precipitate the generated free iodine was added to the reaction, avoiding this way the 
dehalogenation process. (Scheme 7.5) 
 
Scheme 7.5: Silver nitrate mechanism. 
Once the starting pyrroles were synthetized, in order to obtain the desired isoniazid 
hybrids, the ester group was hydrolysed with ethanolic NaOH, yielding the 
corresponding carboxylic acids. (Scheme 7.6) Finally, the carboxylic acids were coupled 
to the isoniazid moiety through peptide synthesis methodologies, using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) and 1-hydroxy-7-
azabenzotriazole (HOAt) as activating agents. (Scheme 7.6) 
 
Scheme 7.6: Hydrolysis of the ester derivatives and coupling with isoniazid. 
 
The structures of all compounds studied for antitubercular activity can be found in 




232 Verónica Estévez. PhD thesis, Universidad Complutense, 2013. 




Figure 7.11: Ethyl ester pyrrole derivatives. 




Figure 7.12: Carboxylic acids and amide pyrrole derivatives.  
 
Figure 7.13: Fused pyrrole derivatives. 
 






Figure 7.14: Pyrrole-isoniazid hybrids. 
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7.6. Activity and mechanistic studies of pyrrole-isoniazid derivatives 
7.6.1 Computational drug-likeness study 
First, to evaluate the drug-like properties of the compounds ADME-tox computational 
studies of the synthesized derivatives were carried out using SwissADME and are 












29a 4 42.09 3.51 -3.94 High 0 0 
29b 5 51.32 2.98 -3.41 High 0 0 
29c 5 31.23 5.26 -6.03 High 1 1 
29d 5 42.09 4.83 -5.45 High 0 0 
29e 7 47.02 4.10 -4.50 High 0 0 
29f 7 31.23 4.65 -5.31 High 0 0 
29g 4 55.23 2.27 -2.71 High 0 0 
29h 4 42.09 3.64 -4.52 High 0 0 
29i 4 42.09 3.51 -3.94 High 0 0 
29j 4 42.09 4.03 -4.53 High 0 0 
29k 4 42.09 3.60 -4.26 High 0 0 
29l 4 42.09 3.29 -3.51 High 0 0 
29m 7 31.23 5.45 -5.77 High 1 0 
29n 5 34.47 3.03 -3.81 High 0 0 
29o 9 31.23 5.75 -6.02 High 1 0 
29p 7 36.16 4.14 -4.54 High 0 0 
29q 8 34.47 4.45 -4.87 High 0 0 
29r 6 31.23 4.70 -5.09 High 0 0 
29s 7 31.23 5.02 -5.36 High 1 0 
29t 6 40.46 4.73 -5.50 High 0 1 
29u 7 31.23 4.54 -4.73 High 0 0 
Table 7.1:  Properties of ethyl ester pyrrole derivatives. 
 














30a 4 53.09 2.92 -4.10 High 0 0 
30b 5 53.09 2.79 -3.52 High 0 0 
30c 5 53.09 3.31 -4.10 High 0 1 
30d 5 53.09 2.88 -3.84 High 0 0 
30e 7 53.09 2.56 -3.09 High 0 0 
30f 7 42.23 4.97 -5.56 High 1 0 
30g 4 47.16 3.27 -4.10 High 0 0 
30h 4 45.47 3.20 -2.98 High 0 0 
30i 4 42.23 4.32 -4.87 High 0 0 
30j 2 42.23 4.94 -5.38 High 1 0 
30k 2 53.09 2.79 -3.52 High 0 0 
30l 2 42.23 3.80 -4.28 High 0 0 
30m 2 42.23 4.51 -5.59 High 1 0 
30n 2 51.46 3.98 -5.06 High 0 0 
30o 7 76.26 2.86 -3.12 High 0 0 
30p 5 48.02 3.60 -3.97 High 0 0 
30q 6 48.02 3.20 -3.58 High 0 0 
30r 5 48.02 3.40 -3.68 High 0 0 
30s 7 48.02 4.94 -5.48 High 0 0 
30t 7 48.02 4.87 -5.57 High 0 0 
31a 6 48.02 3.92 -4.26 High 0 0 
31b 8 31.23 5.65 -4.34 High 0 0 
31c 6 31.23 4.93 -5.82 High 1 0 
31d 6 31.23 4.93 -5.12 High 0 0 












32a 9 76.02 3.78 -4.69 High 0 0 
32b 7 76.02 4.48 -5.95 High 0 1 
32c 8 85.25 3.86 -5.43 High 0 1 
32d 6 86.88 2.68 -3.90 High 0 0 
32e 6 86.88 2.82 -4.48 High 0 0 
32f 6 86.88 2.73 -3.90 High 0 0 














32g 6 86.88 3.17 -4.48 High 0 0 
32h 6 86.88 2.74 -4.21 High 0 0 
32i 6 86.88 2.43 -3.46 High 0 0 
32j 7 96.11 2.23 -3.37 High 0 0 
32k 11 76.02 4.94 -5.98 High 0 0 
32l 9 80.95 3.39 -4.49 High 0 0 
32m 9 76.02 4.18 -5.29 High 0 0 
32n 11 76.02 4.82 -5.80 High 0 0 
32o 9 91.81 3.25 -4.45 High 0 0 
32p 10 79.26 3.63 -4.83 High 0 0 
Isoniazi
d 
2 68.01 -0.35 -0.56 High 0 0 
Table 7.3:  Properties of pyrrole-isoniazid hybrids. 
For all compounds, the TPSA value was under 140, important for been able to permeate 
cells. Moreover, a high gastrointestinal absorption, important for oral bioavailability, 
was predicted. Furthermore, only compounds 6 compounds showed a PAINS alert. And 
finally, the few violations of Lipinski's rule of five were always due to a high lipophilicity, 
which is usually considered a positive feature in antitubercular agents, which need to 
penetrate the granuloma and cross the very lipophilic cover of mycobacteria.  It is also 
worth noting that all isoniazid derivatives exhibit high LogP values. 
7.6.2 Antitubercular activity 
The synthetitized compounds were then analysed in vitro against Mycobacterium 
tuberculosis H37Rv (Mtb H37Rv) in a high-throughput screen by Professor Ashraf Ali 
Mohamed in the University Sains Malaysia, Penang. Selected compounds were also 
tested against clinically isolated MDR-TB strains, obtained from the Tuberculosis 
Research Centre (Chennai, India). These strains were resistant to isoniazid, rifampicin 
and ethambutol. The toxicity of the compounds was evaluated in mammalian Vero cell 
line at concentrations of 6.25 mg/L. After 72 h of exposure, viability was assessed, and 
none the tested compounds showed toxicity.  
The results obtained can be found in Tables 7.4, 7.5 and 7.6.  
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Table 7.4:  Antitubercular activity of ethyl ester pyrrole derivatives. 
 
 
Cmpd. H37Rv  IC50 (μM) H37Rv MIC (μM) MDR-TB MIC (μM) Cytotoxicity μg/ml 
29a 7.87 25 --- >6.25 
29b 22.87 50 --- >6.25 
29c 44.95 100 --- >6.25 
29d 37 100 --- >6.25 
29e 2.87 6.25 10.17 >6.25 
29f 25.87 100 --- >6.25 
29g 44.95 100 --- >6.25 
29h --- 1.170 1.970 >6.25 
29i 18.57 50 --- >6.25 
29j 08.28 50 --- >6.25 
29k 12.87 50 --- >6.25 
29l 25.87 100 --- >6.25 
29m --- Inactive --- >6.25 
29n --- Inactive --- >6.25 
29o --- 1.000 1.200 >6.25 
29p --- 2.270 2.527 >6.25 
29q --- 0.100 0.170 >6.25 
29r --- 8.0000 8.200 >6.25 
29s --- 22.27 22.527 >6.25 
Rifamycin --- 0.200 4.120 >6.25 
Ethambutol 32.79 5.790 92.500 >6.25 
Isoniazid 0.29 0.390 11.740 >6.25 
Cmpd. IC50 (μM) H37Rv MIC (μM) MDR-TB MIC (μM) Cytotoxicity μg/ml 
30a 7.87 50.00 --- >6.25 
30b 25.87 50.00 --- >6.25 
30c 44.95 25.00 --- >6.25 
30d 37 50.00 --- >6.25 
30e 2.87 50.00 --- >6.25 
30f 25.87 50.00 --- >6.25 
30g 44.95 1.470 1.970 >6.25 
30h --- 1.420 3.200 >6.25 
30i 18.57 0.600 0.750 >6.25 
30j 08.28 6.470 6.970 >6.25 
30k 12.87 11.420 13.20 >6.25 
30p 25.87 10.600 10.75 >6.25 
30q --- Inactive --- >6.25 
30r --- Inactive --- >6.25 
30s --- Inactive --- >6.25 
30t --- Inactive --- >6.25 
30u --- Inactive --- >6.25 
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Table 7.5:  Antitubercular activity of carboxylic acid pyrrole derivatives and fused pyrroles. 
Table 7.6:  Antitubercular activity of pyrrole-isoniazid hybrids. 
Aanalysing these data, we were able to obtain some structure activity relationship (SAR) 
conclusions. (Figure 7.15) 
- In position 1 of the pyrrole ring the best results were obtained with H, hexyl, butyl 
or dimethylaminopropyl groups. The latter residue seems to be the most promising 
one, and the corresponding isoniazid hybrid is now under study. 
- In position 2, a methyl group gave considerably better results than a propyl group. 
- As expected, the hybrid derivatives exhibited considerably better activities than the 
corresponding esters or carboxylic acids. On the other hand, all the amide 
derivatives were inactive. 
Cmpd. IC50 (μM) H37Rv MIC (μM) MDR-TB MIC (μM) Cytotoxicity μg/ml 
31a --- Inactive --- >6.25 
31b --- Inactive --- >6.25 
31c --- Inactive --- >6.25 
31d --- Inactive --- >6.25 
Rifamycin --- 0.200 4.120 >6.25 
Ethambutol 32.79 5.790 92.500 >6.25 
Isoniazid 0.29 0.390 11.740 >6.25 
Cmpd. IC50 (μM) H37Rv MIC (μM) MDR-TB MIC (μM) Cytotoxicity μg/ml 
32a 3.28 15 --- >6.25 
32b 6.38 25 --- >6.25 
32c 2.81 15 --- >6.25 
32d 4.28 15 --- >6.25 
32e 47.20 1.320 2.320 >6.25 
32f 1.87 25.00 --- >6.25 
32g 0.90 6.25 --- >6.25 
32h 5.81 25.00 --- >6.25 
32i 2.20 25.00 --- >6.25 
32j 47.20 100.00 --- >6.25 
32k --- 0.100 0.320 >6.25 
32l --- 0.230 0.250 >6.25 
32m --- 9.320 9.320 >6.25 
32n --- 15.230 20.25 >6.25 
32o --- 12.000 13.200 >6.25 
Rifamycin  0.200 4.120 >6.25 
Ethambutol 32.79 5.790 92.500 >6.25 
Isoniazid 0.29 0.390 11.740 >6.25 
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- In position 4 of the pyrrole, it seems that aryl substituents are not favourable for the 
activity, although the number of examples available is not high. The option of smaller 
substituents remains unexplored. 
- More complex and rigid systems containing an additional ring fused at the 4 and 5 
positions were inactive.  
- In position 5, clearly indole rings, 3-4-dichlorophenyl or p-iodophenyl groups 
exhibited the best activities. 
 
Figure 7.15.  Preliminary SAR study of pyrrole-isoniazid hybrids. 
Remarkably, many of the active compounds with the higher activities were also active 
against multidrug-resistant strains, which can be viewed as a proof of concept of the 
alternative mechanisms of the hybrids and confirms that using MTDL against TB is a 
promising approach. None of these hit compounds exhibited any PAINS alerts. 
 
7.6.3 Mechanistic studies 
Once the activities of our compounds were tested, we wanted to prove if our 
compounds were acted on the desired targets. For that purpose, mechanistic studies 
were carried out by Dr. Katherine Abrahams in the group of Professor Gurdyal S. Besra 
from the School of Biosciences, University of Birmingham. 
7.6.3.1. KatG activation and InhA inhibition 
First, to evaluate if our compounds could be activated by katG, INH resistant mutants 
were generated to sequence katG and InhA. A mutant which had a frameshift in katG, 
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making the gene non-functional, was selected. Also, it was verified that InhA had no 
mutations so that the resistance to INH was due to the inability of the cells to make katG. 
Three of the hybrid compounds (32g, 32i and 32j) and INH as control, were tested 
against these strains, and it was observed that the katG mutant was resistant to them, 
meaning that the compounds are katG substrates. (Figure 7.16)  
 
 
Figure 7.16:  Resistance of the katG mutant strain on compounds INH, 32g, 32i and 32j.  The katG (INH 
resistant) mutant survived at all concentrations of compound tested.   
To further evaluate if our compounds were able to inhibit InhA, strains overexpressing 
InhA were cultured, and again compounds 32g, 32i and 32j and INH as control, were 
tested against these strains. Once again, the hybrid compounds exhibit the same 
behaviour as INH, causing the death of the wild type strains while the InhA over-
expressing strains survived, proving that our compounds target InhA. (Figure 7.17) 




Figure 7.17: Impact of InhA over-expression on resistance to INH, 32g, 32i and 32j.  Unshaded and 
shaded bars represent pMV261 empty vector and InhA over-expressor strains respectively.  Bars are the 
mean of duplicate data with error bars showing the SEM. 
In the aggregate, these results verified that the hybrid compound are able acts as 
isoniazid prodrugs that are activated by katG and further inhibit InhA.  
On the other hand, due to their design and as the antitubercular activities showed we 
were intrigued by the observation that no antibacterial activity could be detected on the 
katG mutants or InhA over-expressors. Moreover, some of the pyrrole derivatives not 
bearing the isoniazid moiety showed excellent antimycobacterial activities, 
demonstrating that they should inhibit and alternative target. To clarify these doubts, 
the compounds 30p and 30e, not presenting the isoniazid fragment, were tested against 
the katG mutants and InhA over-expressor.  
This time, as expected, the compound exhibited the same behaviour against the wild 
type cells and the mutants, while again INH presented no effect against any of the 
mutants. (Figure 7.18) This experiment verified the existence of an additional 
mechanism due to the pyrrole core. 
 




Figure 7.18. Impact of InhA over-expression and katG mutant on INH, 30p and 30e. 
7.6.3.2. MmpL3 target 
Spontaneous resistant mutants against 32g, 32i and 32j in M. bovis BCG were generated, 
8 of them were cultured, and their genomic DNA was extracted. The mmpL3 gene was 
amplified via PCR and sequenced. It was observed that every mutant contained two 
mutations responsible of the loss of activity, phenylalanine 384 changed into isoleucine 
and aspartic acid 466 into a glutamic acid. This result can be interpreted as indirect proof 
of an interaction of our compounds with MmpL3.  When we mapped our mutations into 
the MmpL3, structure we found they are located in opposite sides of the protein 
structure. Nevertheless, it has to be borne in mind that 80% of mutations found lie inside 
or within 10 Å of the known binding pocket, altering in a direct way the mechanism of 
action of inhibitors. The remaining 20% are located in different domains, probably 
altering in an indirect way the binding of inhibitors.221 (Figure 7.19) 
 
Figure 7.19. Homology model obtained from the Mmpl3 sequence (P9WJV5) using Phyre2. 
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7.6.3.3. MmpL3 docking studies 
 
As mentioned above, in 2019 Zhang and colleagues reported the crystal structure of 
Mycobacterium smegmatis MmpL3, in the presence and absence of several inhibitors. 
Moreover, docking studies of other reported inhibitors were performed.  
Analysing the structures of the four crystalized ligands, the authors verified that all of 
them bind to the proton-translocation channel, even if their ways of interacting differ 
slightly. The binding pocket was divided into four subsites (S1-S5). While S1, S2, S3, and 
S5 are hydrophobic pockets, the key components of S4 are two hydrophilic Asp-Tyr pairs 
S1 and S2 are smaller compared to S3 and S5, which can accommodate bulky 
hydrophobic groups to enhance binding. As the superposition image of the four 
structures shows (Figure 7.20), the four drug candidates so far crystallized with the 
protein occupy 3-5 subsites in the proton-translocation channel. While rimonabant 
(yellow sticks) occupies S1, S2 and S4, SQ109 (magenta sticks), AU1235 (green sticks) 
and ICA38 (orange sticks) are located at the S3, S4 and S5 subsites. All of them disrupt 
the two Asp-Tyr pairs, consequently blocking the proton motive force, essential for 
substrate translocation.221  
 




Figure 7.20. Reproduced with permission from reference 221. 
Whit this information in hand, preliminary docking studies of some of our inhibitors 
were performed by Dr. Ángel Cores from our group.  To this end, the crystal structure of 
Mycobacterium smegmatis MmpL3 in the presence of rimonabant (PDB 6AJI) was 
chosen due to the structural analogy between rimonabant and our compounds. 
First, the docking was performed with the rimonabant structure and compare to the 
reported crystal structure, in order to validate the docking method. The arm of 
rimonabant bearing the 2, 4-dichlorophenyl ring occupies S2 (green), a hydrophobic 
pocket surrounded by five aliphatic amino acid. The 4-chlorophenyl ring goes into the 
nearby hydrophobic S1 pocket (yellow), while the pyrazole ring core is inserted into the 
centre of the TMH package, perpendicular to the membrane at the S4 pocket (purple). 
Finally, the polar piperidinyl-1-carbamoyl residue is the one inserted into the Asp-Tyr 
pairs at the S4 pocket (red), breaking the hydrogen bonds by forming polar interactions 
with them. S3 (blue) and S5 (red) remain empty. (Figure 7.21) 
 






We chose our derivatives 32k and 29o as representative examples for docking studies. 
As it is shown in Figure 7.22, comparing the poses of 32k (grey) and rimonabant (yellow), 
both compounds share a similar pose. While the central pyrrole core shares the same 
position as the pyrazole ring in the middle of the TMH package, the 2, 4-dichlorophenyl 
ring occupies S1. In contrast with rimonabant, the hexyl chain appears located inside S2, 
while S3 remains empty. Moreover, the two amide functions of our compounds are able 
to interact with S4, were the Asp-Tyr pairs are located. The pyridine ring is able to occupy 
S5 in a very efficient way by establishing − interactions with adjacent tyrosine and 
phenylalanine residues.  
 
Figure 7.22. 
Chapter 7. Multitarget anti-tuberculosis agents bearing pyrrole-isoniazid fragments 
231 
 
When we examined the docking of 29o, the compound could be located in the same 
pocket, even if it seems that its size is too small to interact with it in an efficient way. 





From these results, it seems that the introduction of a phenyl ring at C-4 position, 
directly or with a flexible linker between both rings, would considerably improve 
binding, as shown by the docking of the non-synthesized derivative 32z (Figure 7.24). 
The antitubercular activity results seemed to show that bulky substituents in position 4 
of the pyrrole core were not beneficial for activity, but it has to be borne in mind that 
all of them bear an amide function, which always has led to inactive compounds, 
probably due to their physicochemical characteristics rather than structural factors. 
 







7.6.4 Proposed mechanism of action for the pyrrole-isoniazid hybrids 
We can conclude that the pyrrole-isoniazid hybrids are able to exert their antibacterial 
activity through two different mechanisms. On one hand, there are able to inhibit 
Mmpl3 by direct interaction with the protein, probably by occupy the S3 to S5 subsites 
in the proton-translocating channel of MmpL3, and consequently disrupting the proton 
motive force necessary for substrate translocation.221 On the other hand, it was proved 
that our compounds act as prodrugs, which need to be activated by katG and furnish a 
metabolite that finally inhibits InhA. This mechanism involves the synergistic effects of 
a compound and its active metabolite, which is an emerging type of multitarget strategy 
described as metabolism-activated multitargeting (MAMUT).62 Thus, it can proposed 
that, when the hybrids get in contact with MmpL3 they directly interact with the protein 
and by inhibiting the PMF, they inhibit mycolic acid translocation and heme 
internalization. On the other hand, considering the possible metabolism of the hybrid 
compounds according to literature data for isoniazid233, once katG activates the hybrid 
compounds, isonicotinoyl radical exert its action by inhibiting InhA, and the resulting 
acyldiazenepyrrole derivative is formed.  (Figure 7.25)  
 
233 Laborde, J.; Deraeve, C.; Lecoq, L.; Sournia-Saquet, A.; Stigliani, J. L.; Orena, B. S.; Mori, G.; Pratviel, G.; 
Bernardes-Génisson, V. ChemistrySelect 2016, 1, 172. 




Figure 7.25: Proposed mechanism of pyrrole-isoniazid hybrids 
Even though the participation of both mechanisms seems unequivocal, some details 
remain still unclear. When it comes to the hybrid activity against InhA over-expressors 
and katG mutants, it is not clear why no bactericidal activity was observed. This could 
be due to the fact that antitubercular activities were assessed in M. tuberculosis strains 
while the mechanistic studies were performed in M. bovis. Furthermore, high doses 
required to observe antibacterial activity of the pyrrole derivatives against mutant 
strains. As consequence, it is possible that in the case of the hybrids higher 
concentrations needed to be achieve in order to see the bactericidal effect 
corresponding to the pyrrole fragment.  
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7.7. Experimental section  
General experimental details.  
All reagents (Aldrich, Fischer, Alpha Aesar, SDS) and solvents (Scharlau, Fischer, SDS) 
were of commercial quality and were used as received. Mechanochemical reactions 
were carried out in a vibratory mixer mill at a frequency of 20 Hz using a 25 mL zirconium 
oxide grinding jar and a single zirconium oxide ball 20 mm in diameter. Reactions were 
monitored by thin layer chromatography on aluminium plates coated with silica gel and 
fluorescent indicator (Macherey-Nagel Xtra SIL G/UV254). Separations by flash 
chromatography were performed on silica gel (Scharlau 40–60 μm, 230–400 mesh 
ASTM) or neutral alumina (Merck S22). Melting points were determined using a Stuart 
Scientific apparatus, SMP3 Model, and are uncorrected. Infrared spectra were recorded 
with an Agilent Cary630 FTIR spectrophotometer working by attenuated total reflection 
(ATR), with a diamond accessory for solid and liquid samples. NMR spectroscopic data 
were recorded using a Bruker Avance 250 spectrometer operating at 250 MHz for 1H 
NMR and 63 MHz for 13C NMR maintained by the NMR facility of Universidad 
Complutense (CAI de Resonancia Magnética Nuclear); chemical shifts are given in ppm 
and coupling constants in Hertz. High-resolution mass spectra (HRMS) were recorded on 
a mass spectrometer fitted with an electrospray detector (ESI) by the mass spectral 
facility of Universidad Complutense (CAI de Espectrometría de Masas) and elemental 
analyses were determined by the microanalysis facility of Universidad Complutense (CAI 
de Microanálisis Elemental), using a Leco 932 combustion microanalyzer. 
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7.7.1. Preparation of -iodocarbonyl derivatives 
Method A: 
 
To a solution of the suitable ketone (1 eq) in anhydrous methanol, iodine (1 eq) and 
copper (II) oxide (1 eq) were added. The mixture was stirred at room temperature for 5 
min and, then, refluxed until no starting material was detected by TLC. The reaction was 
cooled, filtered and the solvent was removed. The residue was dissolved in ethyl acetate 
(10 mL) and washed with a 10% solution of Na2S2O3 (20 mL). The aqueous phase was 
extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were dried 
over anhydrous sodium sulphate and the solvent was evaporated. The -iodoketones 
thus obtained were used in the next reaction without further purification. 
Method B: 
 
The corresponding ketone (1 mmol), N-iodosuccinimide (NIS, 225 mg, 1 mmol) and p-
toluenesulphonic acid (18 mg, 10% mmol) were added to a ball mill vessel, along with a 
zirconium oxide ball. The vessel was fitted to one of the horizontal vibratory arms of the 
ball mill, while the other arm was occupied with an empty vessel. The ball mill was set 
to vibrate at a frequency of 20 s-1 for 15-60 min at room temperature. Then, the reaction 
vessel was cleansed with ethyl acetate. The organic layer was washed with water (2 mL), 
dried over anhydrous sodium sulphate and the solvent was evaporated under reduced 
pressure. 
1-(3-Indolyl)-2-iodoethanone 
Method A. Prepared from 1-(3-indolyl)ethanone (0.395 g, 2.5 mmol); 
reaction time: 3 h. Yellowish solid. Yield: 0.620 g, 87% 
Mp 87-89 °C. 
IR (neat) 3222.7 (N-H), 1635.7 (C=O) cm-1. 
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1H NMR (250 MHz, d4-methanol): δ 8.30 (s, 1H); 8.24-8.19 (m, 1H); 7.51-7.45 (m, 1H); 
7.28-7.25 (m, 2H); 4.94 (s, 2H) ppm.  
13C NMR (63 MHz, d4-methanol): δ 191.8, 138.9, 136.2, 127.5, 124.9, 123.8, 123.2, 115.0, 
113.3, 3.5 ppm.  
Elemantal analysis (%): calcd. for C10H8NOI: C 42.13, H 2.83, N 4.91; found: C 41.42, H 
2.85, N 5.10.  
2-Iodo-1-(2-furyl)ethenone232 
Method B. Prepared from 1-(2-furyl) ethanone (0.550 g, 5 mmol). Reddish 
oil. Yield: 1.1 g, 93% 
IR (neat) 1665.7 (C=O), 766.8 (C-I) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.65 (dd, J = 1.7, 0.7 Hz, 1H); 7.34 (dd, J = 3.6, 0.7 Hz, 1H); 
6.61 (dd, J = 3.6, 1.7 Hz, 1H); 4.27 (s, 2H) ppm. 
13C NMR (63 MHz, CDCl3): δ 182.1, 149.8, 147.0, 118.9, 112.9, 0.51 ppm. 
1-(9H-Fluoren-2-yl)-2-iodoethanone232  
Method A. Prepared from 1-(9H-fluoren-2-yl)ethanone (0.624 g, 3 
mmol); reaction time: 2 h. 
White solid. Yield: 0.972 g, 97% 
Mp: 162-164 °C. 
IR (neat) 1658.8 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.21 (d, J = 0.8 Hz, 1H ); 8.07 (d, J = 8.1 Hz,1H); 7.89 (d, J = 
7.5 Hz, 2H); 7.65-7.62 (m, 1H); 7.49-7.39 (m, 2H); 4.45 (s, 2H), 4.02 (s, 2H) ppm. 
13C NMR (63 MHz, CDCl3): δ 192.7, 147.2, 144.6, 143.5, 140.3, 131.8, 128.5, 128.3, 127.1, 
125.7, 125.3, 121.0, 119.9, 36.9, 2.0 ppm. 
Elemental analysis (%): calcd. for C15H11IO: C 53.92, H 3.32; found: C 53.94, H 3.26. 
1-(1-methyl-1H-indol-3-yl)ethan-1-one  
A mixture of 1-(3-indolyl)ethanone (2.5 g, 15.8 mmol), potassium 
hydroxide (1.7 g, 31.61 mmol) and methyl iodide (1.96 mL, 31.61 mmol) in 
DMF (3 mL) were stirred at room temperature for 4 h. Upon completion of 
the reaction, a saturated solution of amonium chloride (5 mL) was added. This solution 
was extracted with ethyl acetate (3 x 10 mL), dried over anhydrous sodium sulphate and 
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the organic solvents were evaporated under reduced pressure, to give the desired 
product.  
Beige solid. Yield: 2.4 g, 99% 
Mp: 106-107 °C  
IR (neat) 1634.8 (C=O), 1096.3 (N-C) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.30 – 8.14 (m, 1H), 7.55 (s, 1H), 7.20 – 7.10 (m, 3H), 3.69 
(s, 3H), 2.37 (s, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 193.4, 137.8, 136.2, 126.6, 123.7, 122.9, 122.9, 117.2, 110.0, 
33.9, 28.0 ppm. 
Elemental analysis (%): calcd. for C11H11NO: C 76.28 H 6.48 N 8.09; found: C 76.23 H 6.45 
N 7.99. 
2-Iodo-1-(1-methyl-1H-indol-3-yl)ethan-1-one  
Method A. Prepared from 1-(1-methyl-1H-indol-3-yl)ethan-1-one (2.4 g, 
13.54 mmol); reaction time: 5 h. Orange solid. Yield: 0.890 g, 36% 
Mp 106-108 °C. 
IR (neat) 1624.3 (C=O), 1125.2 (N-C) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.41 – 8.34 (m, 1H), 7.83 (s, 1H), 7.39 (t, J = 2.7 Hz, 3H), 4.27 
(s, 2H), 3.89 (s, 3H) ppm.  
13C NMR (63 MHz, CDCl3): δ 188.1, 138.01, 136.7, 126.8, 124.2, 123.3, 123.1, , 113.1, 
110.2, 34.1, 4.1 ppm. 
Elemantal analysis (%): calcd. for C11H10INO: C 44.17, H 3.37, N 4.68; found: C 44.14, H 
3.35, N 4.64. 
2-Iodo-1-(2-thienyl)ethanone232  
Method A. Prepared from 1-(2-thienyl)ethanone (0.315 g, 2.5 mmol); 
reaction time: 1 h. Yellow solid. Yield: 0.559 g, 89% 
Mp: 130-134 °C. 
IR (neat) 1705.6 (C=O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.81 (dd, J = 3.9 Hz, 1.1 Hz, 1H); 7.71 (dd, J = 7.3, 2.4 Hz, 1H, 
); 7.17 (dd, J = 7.3, 2.4 Hz, 1H ); 4.32 (s, 2H) ppm. 
13C NMR (63 MHz, CDCl3): δ 186.0, 140.2, 135.1, 133.4, 128.3, 1.4 ppm. 
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7.7.2. Pyrrole synthesis 
 
The suitable ketone (1 mmol), N-iodosuccinimide (NIS, 1 mmol) and p-toluensulphonic 
acid (PTSA, 10% mmol) were added to a ball mill vessel, along with a zirconium oxide 
ball. The vessel was fitted to one of the horizontal vibratory arms of the mall mill, while 
the other arm was occupied with an empty vessel. The ball mill was set to vibrate at a 
frequency of 20 s-1 for 60 min at room temperature. Then, a mixture of the 
corresponding amine (1.95 mmol), the suitable -dicarbonyl compound (1.5 mmol) and 
cerium (IV) ammonium nitrate (CAN, 5% mmol), previously stirred at room temperature 
during 30 min, and silver nitrate (1 mmol) were added to the vessel. The reaction was 
subjected to the vibratory movement at the same frequency for 60 min. Then, the 
reaction vessel was cleansed with ethyl acetate and the suspension was filtered to 
remove the silver iodide precipitate. The organic layer was washed with water (2 mL), 
dried over anhydrous sodium sulphate and the solvent was removed under reduced 
pressure. Purification by column chromatography on silica gel eluting with a hexane-
ethyl acetate mixture afforded the desired compounds 29a-u. 
Ethyl 5-(4-chlorophenyl) -2-methyl-1H-pyrrole-3-carboxylate) (29a) 
Prepared from 2-(p-chlorophenyl)ethanone (0.464 g, 3 mmol) 
and comercially available ethyl 3-amino-2-butenoate (0.580 mg, 
4.5 mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the 
mobile phase to give the desired product as a white solid. Yield: 0.475 g, 60%. 
Mp 155-157 °C 
IR (neat) 3321.8 (N-H), 1672.1 (C=O), 1235.2 (C-O) cm-1 
1H RMN (250 MHz, CDCl3): δ 8.69 (s, 1H); 7.43-7.33 (m, 4H); 6.85 (d, J = 2.9 Hz, 1H ); 4.32 
(q, J = 7.1Hz, 2H); 2.61 (s, 3H); 1.39 (t, J = 7.1 Hz, 3H ) ppm.  
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13C RMN (63 MHz, CDCl3): δ 165.5, 136.6, 132.1, 130.3, 129.1 (2C), 128.9, 124.8 (2C), 
113.5, 107.8, 59.7, 14.5, 13.4 ppm.  
Elemental analysis (%): calcd. for C14H14ClNO2: C 63.76, H 5.35, N 5.31; found: C 63.69, 
H 5.30, N 5.30.  
Ethyl 5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylate (29b) 
 Prepared from 2-(p-methoxyphenyl)ethanone (0.450 g, 3 mmol) 
and comercially available ethyl 3-amino-2-butenoate (0.580 mg, 
4.5 mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the mobile phase to give the 
desired product as a grey solid. Yield: 0.210 g, 27%. 
Mp 141-145 °C 
IR (neat) 3308.5 (N-H), 1669.9 (C=O), 1250.6 y 1234.9 (C-O) cm-1. 
1H RMN (250 MHz, CDCl3): δ 8.58 (s, 1H); 7.41 (d, J = 8.7 Hz, 2H); 6.92 (d, J = 8.7 Hz, 2H); 
6.74 (d, J = 2.7Hz, 1H); 4.32 (q, J = 7.1Hz, 2H); 3.84 (s, 3H) 2.59 (s, 3H); 1.38 (t, J = 7.1Hz, 
3H) ppm.  
13C RMN (63 MHz, CDCl3): δ 165.7, 158.4, 135.6, 130.0, 125.1 (2C), 124.8, 114.3 (2C), 
113.1, 106.1, 59.4, 55.3, 14.5, 13.3 ppm. 
Elemental analysis (%): calcd. for C15H17NO3: C 69.48, H 6.61, N 5.40; found: C 69.45, H 
6.60, N 5.36. 
Ethyl 1,5-bis(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29c)232  
Prepared from 2-(p-chlorophenyl)ethanone (0.154 g, 1 mmol), p-
chloroaniline (0.191 g, 1.5 mmol) and ethyl acetoacetate (0.195 
g, 1.5 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: ethyl 
acetate as the mobile phase to give the desired product as a yellow solid. Yield: 0.296 g, 
79%. 
Mp 123-127 °C. 
IR (neat) 1701.7 (C=O), 1229.5 (C-O), 1088.7 and 1073.7 (C-Cl) cm-1. 
1H RMN (250 MHz, CDCl3): δ 7.41 (d, J = 8.6 Hz, 2H); 7.16 (d, J = 8.6 Hz, 2H); 7.09 (d, J = 
8.6 Hz, 2H); 6.99 (d, J = 8.6 Hz, 2H); 6.81 (s, 1H); 4.35 (q, J = 7.1 Hz, 2H); 2.42 (s, 3H); 1.40 
(t, J = 7.1 Hz, 3H) ppm. 
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13C RMN (63 MHz, CDCl3): δ 165.3, 138.2, 136.3, 134.4, 132.6, 132.6, 130.5, 129.6 
(2C).129.6 (2C), 129.2 (2C), 128.4 (2C), 113.3, 110.6, 59.7, 14.5, 12.5 ppm.  
Elemental analysis (%): calcd. for C20H17Cl2NO2: C 64.18, H 4.58, N 3.74; found: C 64.00, 
H 4.50, N 3.68. 
Ethyl 5-(p-chlorophenyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylate (29d)232 
Prepared from 1-(p-chlorophenyl)-2-iodo-2-phenylethanone 
(0.355 g, 1 mmol), ethyl 3-amino-2-butenoate (0.194 g, 1.5 
mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the 
mobile phase to give the desired product as a yellowish solid. Yield: 0.173 g, 51 %.  
Mp 232-234 °C. 
IR (neat) 3292.9 (N-H), 1672.4 (C=O), 1093.9 (C-Cl) cm-1. 
1H RMN (250 MHz, CDCl3): δ 8.39 (br s, 1H), 7.33-7.22 (m, 5H), 7.18 (d, J=8.7 Hz, 2H), 
7.04 (d, J=8.7 Hz, 2H), 4.10 (q, J=7.1 Hz, 2H), 2.63 (s, 3H), 1.06 (t, J=7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.5, 135.7, 135.0, 132.1, 131.4, 131.2 (2C), 130.6 (2C), 
128.0 (2C), 127.4 (2C), 126.7, 126.5, 123.8, 112.7, 59.3, 13.9, 13.8 ppm. 
Elemental analysis (%): calcd. for C20H18ClNO2: C 70.69, H 5.34, N 4.12; found: C 70.59, 
H 5.30, N 4,00. 
Ethyl 1-butyl-5-(3-indolyl)-2-methyl-1H-pyrrole-3-carboxylate (29e) 
Prepared from 1-(3-indolyl)-2-iodoethanone (0.285 g, 1 mmol), 
butylamine (0.142 g, 1.95 mmol) and ethyl acetoacetate (0.195 g, 
1.5 mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the 
mobile phase to give the desired product as a yellowish solid. Yield: 
0.243 g, 75%. 
Mp 87-91°C. 
IR (neat) 3318.6 (N-H), 1672.9 (C=O), 1244.9 (C-O) cm-1. 
1H RMN (250 MHz, CDCl3): δ 8.33 (br s, 1H); 7.59 (d, J = 7.8 Hz, 1H); 7.46 (d, J = 8.0 Hz, 
1H); 7.27 (t, J = 7.1 Hz, 1H); 7.24 (d, J = 2.6 Hz, 1H); 7.18 (t, J = 7.1 Hz, 1H); 6.65 (s, 1H); 
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4.32 (q, J = 7.1 Hz, 2H); 3.91-3.85 (m, 2H); 2.67 (s, 3H); 1.58-1.46 (m, 2H); 1.38 (t, J =7.1 
Hz, 3H); 1.15 (sext, J = 7.3 Hz, 2H); 0.76 (t, J = 7.3, 3H) ppm. 
13C RMN (63 MHz, CDCl3): δ 165.8, 135.9, 135.7, 127.7, 125.6, 123.7, 122.5, 120.3, 119.8, 
111.7, 111.2, 110.4, 108.9, 59.2, 44.0, 32.9, 19.7, 14.6, 13.5, 11.7 ppm. 
Elemental analysis (%): calcd. for C20H24N2O2: C 74.04, H 7.46, N 8.63; found: C 73.99, H 
7.39, N 8.59. 
Ethyl 1-butyl-5-(p-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29f)232 
Prepared from 1-(p-iodophenyl)ethanone (0,492 g, 2 mmol), 
butylamine (0,284 g, 3.9 mmol), ethyl acetoacetate (0,390 g, 3 
mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the 
mobile phase to give the desired product as a white solid. Yield: 0,632 g, 77%. 
Mp 65-68 °C. 
IR (neat) 1685.2 (C=O), 1235.6 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.75 (d, J = 8.3 Hz, 2H); 7.11 (d, J = 8.3 Hz, 2H); 6.56 (s, 1H); 
4.30 (q, J = 7.1 Hz, 2H); 3.90-3.84 (m, 2H); 2.63 (s, 3H); 1.58-1.46 (m); 1.26-1.11 (m, 2H); 
1.37 (t, J = 7.1 Hz, 3H); 0.83 (t, J = 7.2 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.5, 136.8, 132.6, 132.2, 137.5 (2C), 130.9 (2C), 112.1, 
110.1, 93.0, 59.3, 43.9, 32.7, 19.7, 14.5, 13.5, 11.6 ppm. 
Elemental analysis (%): calcd. for C18H22INO2: C 52.57, H 5.39, N 3.41; found: C 52.49, H 
5.30, N 3.37. 
Ethyl 5-(2-furyl) -2-methyl-1H-pyrrole-3-carboxylate (29g)232 
Prepared from 2-iodo-1-(2-furyl)ethanone (0.236 m, 1 mmol), ethyl 
aminocrotonate (0.194 g, 1.5 mmol); the compound was purified by 
flash chromatography through a silica gel column using hexane: 
ethyl acetate as the mobile phase to give the desired product as a white solid. Yield: 
0,164 g, 75%. 
Mp 133-135 °C. 
IR (neat) 3298.1 (N-H), 1674.5 (C=O), 1242.3 (C-O) cm-1. 
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1H RMN (250 MHz, CDCl3): δ 8.62 (br s, 1H, NH); 7.36 (dd, J =1.8, 0.7 Hz, 1H); 6.76 (d, J = 
2.9 Hz, 1H); 6.45 (dd, J = 3.4, 1.8 Hz, 1H); 6.38 (dd, J = 3.4, 0.7 Hz, 1H); 4.31 (q, J = 7.1 Hz, 
2H); 2.59 (s, 3H); 1.38 (t, J = 7.1 Hz, 3H) ppm. 
13C RMN (63 MHz, CDCl3): δ 165.4, 147.2, 140.5, 135.5, 121.8, 113.0, 111.5, 106.5, 102.8, 
59.2, 14.5, 13.2 ppm. 
Elemental analysis (%): calcd for C12H13NO3: C 65.74, H 5.98, N 6.39; found: C 65.63, H 
5.91, N 6.32. 
Ethyl 5-(4-iodophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29h) 
Prepared from 1-(p-iodophenyl)ethanone (0.738 g, 3 mmol), ethyl 
3-amino-2-butenoate (0.580 g, 4.5 mmol); the compound was 
purified by flash chromatography through a silica gel column using 
hexane: ethyl acetate as the mobile phase to give the desired product as a grey solid. 
Yield: 0,362 g, 34%. 
Mp 153-155 °C. 
IR (neat) 3330.3 (N-H), 1657.5 (C=O), 1239.94 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.29 (s, 1H), 7.62 – 7.54 (m, 2H), 7.14 – 7.06 (m, 2H), 6.75 
(d, J = 3.0 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 2.50 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.7, 138.4 (2C), 136.9, 131.7, 129.2, 125.7 (2C), 114.1, 
108.4, 91.6, 60.0, 14.9, 13.8 ppm. 
Elemental analysis (%): calcd. for C14H14INO2: C 47.34, H 3.97, N 3.94; found: C 47.15, H 
3.90, N 3.92. 
Ethyl 5-(3-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29i) 
Prepared from 2-(m-chlorophenyl)ethanone (0.464 g, 3 mmol), 
ethyl 3-amino-2-butenoate (0.580 g, 4.5 mmol); the compound 
was purified by flash chromatography through a silica gel column 
using hexane: ethyl acetate as the mobile phase to give the desired product as a grey 
solid. Yield: 0.403 g, 51%. 
Mp 139-141 °C. 
IR (neat) 3279.4 (N-H), 1662.2 (C=O), 760.0 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.35 (s, 1H), 7.30 – 6.93 (m, 4H), 6.67 (d, J = 3.0 Hz, 1H), 
4.11 (q, J = 7.1 Hz, 2H), 2.40 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H) ppm. 
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13C NMR (63 MHz, CDCl3): 165.8, 137.1, 135.3, 133.9, 130.6, 128.9, 126.8, 124.0, 122.1, 
114.1, 108.8, 60.1, 14.9, 13.8 ppm. 
Elemental analysis (%): calcd. for C14H14ClNO2: C 63.76, H 5.35, N 5.31; C 62.84, H 5.39, 
N 5.22. 
Ethyl 5-(3,4-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29j)  
Prepared from 2-(3,4-dichlorophenyl)ethanone (0.576 g, 3 
mmol), ethyl 3-amino-2-butenoate (0.580 g, 4.5 mmol); the 
compound was purified by flash chromatography through a 
silica gel column using hexane: ethyl acetate as the mobile phase to give the desired 
product as a yellowish solid. Yield: 0.420 g, 47 %.  
Mp 178-180 °C. 
IR (neat) 3287.2 (N-H), 1661.72 (C=O), 768.3 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.44 (s, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 
7.32 – 7.26 (m, 1H), 6.87 (d, J = 3.0 Hz, 1H), 4.31 (q, J = 7.1 Hz, 2H), 2.61 (s, 3H), 1.38 (t, 
J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 163.1, 134.8, 131.0, 129.7, 128.7, 127.9, 125.4, 123.1, 120.7, 
111.7, 106.6, 57.6, 12.4, 11.3 ppm. 
Elemental analysis (%): calcd. for C14H13Cl2NO2: C 56.39, H 4.39, N 4.70; found: C 56.06, 
H 4.35, N 4.64. 
Ethyl 5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29k) 
Prepared from 2-(p-bromophenyl)ethanone (597 mg, 3 mmol), 
ethyl 3-amino-2-butenoate (0.580 g, 4.5 mmol); the compound 
was purified by flash chromatography through a silica gel column 
using hexane: ethyl acetate as the mobile phase to give the desired product as a beige 
solid. Yield: 0.517 g, 56 %.  
Mp 169-171°C. 
IR (neat) 3332.4 (N-H), 1658.9 (C=O), 775.3 (C-Br) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.48 (s, 1H), 7.43 – 7.37 (m, 2H), 7.28 – 7.21 (m, 2H), 6.76 
(d, J = 3.0 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 2.51 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.8, 136.9, 132.4 (2C), 131.1, 129.2, 125.5 (2C), 120.5, 
114.0, 108.3, 60.1, 14.9, 13.8 ppm. 
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Elemental analysis (%): calcd. for C14H14BrNO2: C 54.56, H 4.58, N 4.55; found: C 54.58, 
H 4.69, N 4.50. 
Ethyl 5-(4-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29l) 
Prepared from 2-(p-fluorophenyl)ethanone (0.414 g, 3 mmol), 
ethyl 3-amino-2-butenoate (0.580 mg, 4.5 mmol); the compound 
was purified by flash chromatography through a silica gel column 
using hexane: ethyl acetate as the mobile phase to give the desired product as a violet 
solid. Yield:  0.526 g, 71%.  
Mp 137-139°C. 
IR (neat) 3282.9 (N-H), 1656.0 (C-OH),1226.7 (C-F) cm-1. 
1H NMR (250 MHz, CDCl3): δ 8.49 (s, 1H), 7.41 – 7.25 (m, 2H), 6.97 (ddd, J = 10.6, 6.0, 2.6 
Hz, 2H), 6.67 (d, J = 2.8 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 166.0, 162.1 (d, J = 246.2 Hz), 136.6, 129.6, 128.6 (d, J = 2.9 
Hz, 2C), 125.8 (d, J = 8.0 Hz, 2C), 116.3 (d, J = 21.8 Hz), 113.8, 107.6, 60.02, 14.9, 13.7 
ppm. 
Elemental analysis (%): calcd. for C14H14FNO2:C 68.00, H 5.71, N 5.66; found: C 67.80, H 
5.35, N 5.55.  
Ethyl 1-butyl-5-(9H-fluoren-2-yl)-2-methyl-1H-pyrrole-3-carboxylate (29m)232 
Prepared from 1-(9H-fluoren-2-yl)ethanone (0.208 g, 1 
mmol), butylamine (0.142 g, 1.95 mmol) and ethyl 
acetoacetate (0.195 g, 1.5 mmol); the compound was 
purified by flash chromatography through a silica gel column 
using hexane: ethyl acetate as the mobile phase to give the desired product as a white 
solid. Yield: 0.362 g, 97%.  
Mp 68-70 °C. 
IR (neat) 1697.7 (C=O), 1229.3 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.84 (d, J = 7.8 Hz, 2H); 7.60 (d, J = 7.3 Hz, 1H); 7.55 (s, 1H); 
7.46-7.32 (m, 3H); 6.62 (s, 1H); 4.32 (q, J = 7.1 Hz, 2H); 3.97 (s, 2H); 3.97-3.91 (m, 2H); 
2.66 (s, 3H); 1.56 (q, J = 7.3 Hz, 2H); 1.38 (t, J = 7.1 Hz, 3H); 1.20 (sext, J = 7.3 Hz, 2H); 
0.82 (t, J = 7.3 Hz, 3H) ppm. 
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13C NMR (63 MHz, CDCl3): δ 165.7, 143.4, 143.3, 141.2, 141.0, 136.4, 133.8, 131.6, 128.0, 
126.8 (2C), 126.0, 125.1, 119.9, 119.7, 111.9, 109.7, 59.3, 43.9 , 36.9, 32.7, 19.7, 14.5, 
13.5, 11.6 ppm. 
Elemental analysis (%) calcd. for C25H27NO2: C 80.40, H 7.29, N 3.75; found: C 80.26, H 
7.25, N 3.76. 
Ethyl 1-dimethylamino-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate (29n)232 
Prepared from acetophenone (0.120g, 1mmol), N,N-
dimethylhydrazine (0.90 g, 1.5 mmol) and ethyl acetoacetate (0.195 
g, 1.5 mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the mobile 
phase to give the desired product as a reddish oil Yield: 0.163 g, 60%.  
IR (neat) 1695.8 (C=O), 1241.8 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.52 (dd, J = 8.3, 1.8 Hz, 2H); 7.43-7.32 (m, 3H); 6.53 (s, 1H); 
4.30 (q, J = 7.1 Hz, 2H); 2.95 (s, 6H); 2.71 (s, 3H); 1.37 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.3, 137.3, 132.7, 132.7, 129.0, 127.8, 127.0, 110.3, 107.4, 
59.3, 45.2, 14.5, 12.1 ppm. 
Elemental analysis (%) calcd. for C16H20N2O2: C 70.56, H 7.40, N 10.29; found: C 70.48, H 
7.35, N 10.19. 
Ethyl 5-(3,4-dichlorophenyl)-1-hexyl-2-methyl-1H-pyrrole-3-carboxylate (29o) 
Prepared from 2-(3,4-dichlorophenyl)ethanone (2.84 g, 15 
mmol), hexylamine (2.964 g, 29.3 mmol) and ethyl acetoacetate 
(2.928 g, 22.5 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: ethyl 
acetate as the mobile phase to give the desired product as a 
yellow oil. Yield: 1.70 g, 30%. 
IR (neat) 1185.1 (N-C), 1695.7 (C=O), 1185.1 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.35 – 7.29 (m, 2H), 7.04 (dd, J = 8.2, 2.1 Hz, 1H), 6.42 (s, 
1H), 4.13 (q, J = 7.1 Hz, 2H), 3.66 (t, J = 7.6 Hz, 2H), 2.46 (s, 3H), 1.33 (m, 2H), 1.16 (t, J = 
7.1 Hz, 3H), 0.97 (m, 6H), 0.67 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 166.1, 137.9, 133.9, 133.2, 132.2, 131.5 (2C), 131.1, 128.9, 
112.9, 111.4, 60.1, 44.9, 31.8, 31.3, 26.8, 23.1, 15.2, 14.6, 12.3 ppm. 
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Elemental analysis (%): calcd. for C20H25Cl2NO2: C 62.83, H 6.59, N 3.66; found: C 62.74, 
H 6.60, N 3.61. 
Ethyl 1-butyl-2-methyl-5-(1-methyl-1H-indol-3-yl)-1H-pyrrole-3-carboxylate (29p) 
Prepared from 2-iodo-1-(1-methyl-1H-indol-3-yl)ethan-1-one (0.7 
g, 2.67 mmol), butylamine (0.380 g, 5.206 mmol) and ethyl 
acetoacetate  (0.521 g; 4 mmol); the compound was purified by 
flash chromatography through a silica gel column using hexane: 
ethyl acetate as the mobile phase to give the desired product as an orange solid. Yield:  
0.398 g, 35 %.  
Mp 122-123 °C. 
IR (neat) 1189.7 (N-C), 1690.7 (C=O), 1227.5 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.40 – 7.34 (m, 1H), 7.21 – 7.15 (m, 1H), 7.13 – 7.06 (m, 
1H), 6.96 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 6.86 (s, 1H), 6.41 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 
3.65 (d, J = 4.5 Hz, 5H), 2.46 (s, 3H), 1.35 – 1.25 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H), 0.95 (dd, 
J = 15.0, 7.4 Hz, 2H), 0.56 (t, J = 7.3 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 166.3, 137.8, 136.3, 128.6 (2C), 122.5, 120.4, 120.2, 112.1, 
110.7, 109.7, 107.6, 59.6, 44.4, 33.3, 33.2, 20.1, 15.0, 14.0, 12.1ppm. 
Elemental analysis %): calcd. for C21H26N2O2: C 74.53, H 7.74, N 8.28; found: C 74.50, H 
7.69, N 8.20. 
Ethyl 5-(3,4-dichlorophenyl)-1-(3-(dimethylamino)propyl)-2-methyl-1H-pyrrole-3-
carboxylate (29q) 
Prepared from 2-(3,4-dichlorophenyl)ethanone (3.15 g 10 
mmol), N1,N1-dimethylpropane-1,3-diamine (1.999 g, 19.57 
mmol) and ethyl and acetoacetate (1.957 g; 15.05 mmol); the 
compound was purified by flash chromatography through a silica 
gel column using hexane: ethyl acetate as the mobile phase to 
give the desired product as an orange oil   Yield: 0.905  g, 24 %.  
IR (neat) 1197.7 (N-C), 1690.5 (C=O), 1064.8 (C-O) cm-1) 
1H NMR (250 MHz, CDCl3): δ 7.40 (dd, J = 8.0, 5.1 Hz, 2H), 7.15 – 7.09 (m, 1H), 6.50 (s, 
1H), 4.20 (q, J = 7.1 Hz, 2H), 3.95 – 3.85 (m, 2H), 2.53 (s, 3H), 2.24 (d, J = 8.3 Hz, 8H), 1.75 
– 1.63 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H)  ppm. 
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13C NMR (63 MHz, CDCl3): δ 165.7, 137.67, 133.2, 133.1, 132.1, 131.1, 131.0, 131.02, 
128.6, 112.9, 111.6, 59.9, 56.1, 44.7 (2C), 42.3, 27.9, 14.9, 11.9 ppm. 
Elemental analysis (%): calcd. for C19H24Cl2N2O2: C 59.54, H 6.31, N 7.31; found: C 59.46, 
H 6.29, N 7.25. 
Ethyl 1-butyl-5-(3,4-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29r) 
Prepared from 2-(3,4-dichlorophenyl)ethanone (0.567 g, 3 
mmol), butylamine (0.402 g, 5.5 mmol) and ethyl and 
acetoacetate (0.523 g, 4.25 mmol); the compound was purified 
by flash chromatography through a silica gel column using 
hexane: ethyl acetate as the mobile phase to give the desired product as a yellow oil. 
Yield:  0.438 g, 41 %.  
IR (neat) 1695 (C=O), 773 (C-Cl) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 7.65 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 7.41 
(dd, J = 8.3, 2.1 Hz, 1H), 6.56 (s, 1H), 4.23 (q, J = 7.1 Hz, 2H), 4.06 – 3.97 (m, 2H), 2.62 (s, 
3H), 1.63 – 1.48 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H), 1.21 (dd, J = 14.9, 7.4 Hz, 2H), 0.82 (t, J 
= 7.3 Hz, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 165.8; 138.5; 135.1; 133.2; 132.0 (2C); 131.9; 130.1 
(2C); 113.5; 112.1; 60.0; 45.0; 33.8; 20.7; 15.3; 14.2; 12.0 ppm. 
Elemental analysis (%): calcd. for C18H21Cl2NO2: C 61.03, H 5.98, N 3.95; found: C 60.79, 
H 5.82, N 4.24. 
Ethyl 1-butyl-5-(3,4-dichlorophenyl)-2-propyl-1H-pyrrole-3-carboxylate (29s) 
 Prepared from 2-(3,4-dichlorophenyl)ethanone (0.567 g, 3 
mmol), butylamine (0.657 g, 9 mmol) and ethyl 3-oxohexanoate 
(0.950 g, 6 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: ethyl 
acetate as the mobile phase to give the desired product as a yellow oil. Yield: 0.411 g, 
36 %.  
IR (neat) 1697 (C=O), 775 (C-Cl) cm-1. 
1H NMR (250 MHz, d6-acetone): δ 7.44 (d, J = 5.6 Hz, 1H), 7.41 (s, 1H), 7.21 (dd, J = 8.4, 
2.0 Hz, 1H), 6.34 (s, 1H), 4.00 (q, J = 7.1 Hz, 2H), 3.89 – 3.78 (m, 2H), 2.85 – 2.76 (m, 2H), 
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1.43 (dq, J = 14.9, 7.4 Hz, 2H), 1.28 (dt, J = 21.4, 7.5 Hz, 2H), 1.09 (t, J = 7.1 Hz, 3H), 0.97 
(dd, J = 14.9, 7.4 Hz, 2H), 0.79 (t, J = 7.4 Hz, 3H), 0.57 (t, J = 7.3 Hz, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 165.5; 143.1; 135.3; 133.3; 132.0 (2 C); 131.9; 131.8; 
130.1; 113.3; 112.5; 60.0; 45.0; 34.4; 28.4; 24.6; 20.7; 15.3; 14.8; 14.2 ppm. 
Elemental analysis (%) calcd. for C20H25Cl2NO2: C 62.83, H 6.59, N 3.66; found: C 62.70, 
H 6.53, N 3.90. 
Ethyl 5-(p-chlorophenyl)-1-(p-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylate 
(29t)232 
Prepared from p-anisidine (0.185 g, 1.5 mmol), 2-(p-
chlorophenyl)ethanone (0.154 g, 1 mmol) and ethyl acetoacetate 
(0.195 g, 1.5 mmol); the compound was purified by flash 
chromatography through a silica gel column using hexane: ethyl 
acetate as the mobile phase to give the desired product as a white 
solid. Yield: 0.229 g, 62 %.  
Mp 108-111°C 
IR (neat) 1699.3 (C=O), 1227.4 (C-O), 1076.3 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.15 (d, J = 8.7 Hz, 2H); 7.07 (d, J = 9.0 Hz, 2H); 7.00 (d, J = 
8.7 Hz, 2H); 6.93 (d, J = 9.0 Hz, 2H); 6.80 (s, 1H); 4.35 (q, J = 7.1 Hz, 2H); 3.87 (s, 3H); 2.41 
(s, 3H); 1.40 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.4, 159.3, 138.7, 132.7, 132.3, 130.9, 130.5, 129.4 (2C), 
129.2 (2C), 128.3 (2C), 114.4 (2C), 112.7 (C), 110.0 (C4), 59.5, 55.4, 14.5, 12.4 ppm. 
Elemental analysis (%): calcd. for C21H20ClNO3: C 68.20, H 5.45, N 3.79; found: C 68.00, 
H 5.36, N 3.70. 
Ethyl 1-butyl-5-(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate (29u)   
Prepared from p-chloroacetophenone (0.154 g, 1 mmol), 
butylamine (0.142 g, 1.95 mmol) and ethyl acetoacetate (0.195 g, 
1.5 mmol); the compound was purified by flash chromatography 
through a silica gel column using hexane: ethyl acetate as the 
mobile phase to give the desired product as a yellowish viscous liquid. Yield: 0.252 g, 79 
%.  
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IR (neat) 1698.2 (C=O), 1246.2 (C-O) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.43-7.28 (m, 4H); 6.56 (s, 1H); 4.31 (q, J = 7,1 Hz, 2H); 3.91-
3.84 (m, 2H); 2.64 (s, 3H); 1.55-1.48 (m, 2H); 1.37 (t, J = 7.1 Hz, 3H); 1.19 (sext, J = 7.3 Hz, 
2H); 0.83 (t, J = 7.3 Hz, 3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 165.4, 136.6, 133.4, 132.0, 131.6, 130.5 (2C), 128,6 (2C), 
112.0, 110.1, 59.3, 43.9, 32.7, 19.7, 14.5, 13.5, 11.5 ppm. 
Elemental analysis (%): calcd. for C18H22ClNO2: C 67.60, H 6.93, N 4.38; found: C 67.56, 
H 6.84, N 4.22. 
 




The suitable pyrrole derivative (1 mmol) was dissolved in ethanol (3 mL) and a solution 
of 5M NaOH was added (10 eq). Then, the mixture was refluxed for 5h. After completion 
of the reaction, the resulting suspension was neutralized with 2N HCl and extracted with 
ethyl acetate (5 mL) and. The organic layer was washed with water (3 mL) and dried over 
anhydrous sodium sulphate. Removal of the solvent gave the desired pyrrole-3-
carboxylic acid derivatives.  
5-(4-Iodophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30a) 
Prepared from pyrrole 29h (0.300 g, 0.85 mmol). Beige solid. Yield: 
0.255 g, 92%.  
Mp 200-202 °C. 
IR (neat) 3410.6 (N-H), 1648.2 (C=O) cm-1. 
1H RMN (250 MHz, d4-methanol): δ 7.57 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 6.71 
(s, 1H), 2.42 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 169.9, 139.4, 139.3 (2C), 133.7, 130.9, 127.1 (2C), 
114.5, 109.5, 91.1, 13.7 ppm. 
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Elemental analysis (%): calcd. for C12H10INO2: C 44.06, H 3.08, N 4.28; found: C 44.03, H 
3.01, N 3.96. 
5-(3-Chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30b) 
Prepared from pyrrole 29i (0.304 g, 1.15 mmol). Brown solid. Yield: 
0.203 g, 75%.  
Mp 177-179 °C. 
IR (neat) 3426.1 (N‐H), 1599.21 (C=O), 763.44 (C‐Cl) cm-1.  
1H RMN (250 MHz, d4-methanol): δ 7.44 (t, J = 1.8 Hz, 1H), 7.38 – 7.31 (m, 1H), 7.17 (t, J 
= 7.9 Hz, 1H), 7.05 – 6.99 (m, 1H), 6.69 (s, 1H), 2.39 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 169.7, 139.4, 136.2, 136.1, 131.7, 130.5, 127.2, 124.8, 
123.3, 114.3, 109.7, 13.5 ppm. 
Elemental analysis (%): calcd. for C12H10ClNO2: C 61.16, H 4.28, N 5.94; found: C 60.90, 
H 4.28, N 5.94. 
5-(3,4-Dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30c) 
Prepared from pyrrole 29j (0.298 g, 2.41 mmol). Brown solid. Yield: 
0.546   g, 84 %.  
Mp 194-196 °C. 
IR (neat) 3349.0 (N-H), 1624.9 (C=O), 767.52 (C-Cl) cm-1. 
1H NMR (250 MHz, d4-methanol): δ 7.62 (d, J = 1.1 Hz, 1H), 7.37 (d, J = 1.7 Hz, 2H), 6.75 
(s, 1H), 2.43 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 169.6, 139.7, 134.5, 134.1, 132.2, 130.6, 129.5, 126.5, 
124.7, 114.6, 110.2, 13.5 ppm. 
Elemental analysis (%): calcd. for C12H9Cl2NO2: C 53.36, H 3.36, N 5.19; found: C 52.98, 
H 3.29, N 5.02. 
5-(4-Bromophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30d) 
Prepared from pyrrole 29k (0.300 mg, 0.97 mmol). Reddish solid. 
Yield: 0.236 g, 87 %.  
Mp 152-154 °C. 
IR (neat) 3224.5 (N-H), 1627.3 (C=O), 781.7 (C‐Br) cm-1. 
1H RMN (250 MHz, d6-acetone): δ 10.68 (br s, 1H), 7.43 (q, J = 8.6 Hz, 4H), 6.75 (d, J = 2.6 
Hz, 1H), 2.41 (s, 3H) ppm. 
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13C RMN (63 MHz, d4-methanol): δ 199.8, 169.8, 139.2, 133.2 (2C), 130.8, 126.7(2C), 
120.8, 114.3, 109.2, 13.4 ppm. 
Elemental analysis (%): calcd. for C12H10BrNO2: C 51.45, H 3.60, N 5.00; found: C 51.20, 
H 3.60, N 4.63. 
5-(4-Fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30e) 
Prepared from pyrrole 29l (0.381 g, 1.54 mmol). Reddish solid. 
Yield: 0.330 g, 98%.  
Mp 148-150 °C. 
IR (neat) 3282.9 (N-H), 1656.0 (C=O), 1226.7 (C-F) cm-1. 
1H RMN (250 MHz, d4-methanol): δ 11.12 (br s, 1H), 7.58 (dd, J = 8.3, 5.6 Hz, 2H), 7.10 
(t, J = 8.8 Hz, 2H), 6.74 (s, 1H), 2.55 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 169.9, 163.2 (d, J = 243.8 Hz), 138.7, 131.18, 130.72 
(d, J = 3.3 Hz), 126.9 (d, J = 7.8 Hz, 2C), 116.9 (d, J = 21.9 Hz, 2C), 114.0, 108.5, 13.4 ppm. 
Elemental analysis (%): calcd. for C12H10FNO2: C 65.75, H 4.60, N 6.39; found: C 65.61, H 
4.63, N 6.41. 
5-(4-Methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30f) 
Prepared from pyrrole 29b (0.105 g, 0.4 mmol). Red solid. Yield: 
0.067 g, 73%.  
Mp 179-181°C. 
IR (neat) 3414.8 (N-H), 1654.5 (C=O), 1250.4 y 1231.7 (C-O) cm-1. 
1H RMN (250 MHz, d6-acetone): δ 10.47 (br s, 1H), 7.42 (d, J = 8.9 Hz, 2H), 6.81 (d, J = 8.9 
Hz, 2H), 6. 56 (s, 1H), 3.67 (s, 3H), 2.39 (s, 3H) ppm. 
13C RMN (63 MHz, d6-acetone): δ 167.3, 159.9, 137.2, 130.9, 126.6, 126.2 (2C), 116.1 
(2C), 114.1, 107.2, 55.8, 13.8 ppm.  
Elemental analysis (%): calcd. for C13H13NO3: C 67.52, H 5.67, N 6.06; found: C 67.84, H 
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5-(3,4-Dichlorophenyl)-1-hexyl-2-methyl-1H-pyrrole-3-carboxylic acid (30g) 
Prepared from pyrrole 29o (1 g, 2.65 mmol). White solid. Yield: 
0.580 g, 62%.  
Mp 103-105 °C 
IR (neat) 1640.4 (C=O), 1268.7 (C-O) cm-1 
1H RMN (250 MHz, d6-acetone): δ 7.51 (dd, J = 8.9, 5.2 Hz, 2H), 7.29 
(dd, J = 8.3, 2.1 Hz, 1H), 6.43 (s, 1H), 3.87 (d, J = 7.7 Hz, 2H), 2.48 (s, 3H), 1.47 – 1.35 (m, 
2H), 1.06 (d, J = 9.1 Hz, 6H), 0.68 (t, J = 6.6 Hz, 3H) ppm 
13C RMN (63 MHz, d6-acetone): δ 206.6, 166.8, 138.7, 135.2, 133.2, 131.9, 131.8, 130.2, 
113.3, 112.4, 45.1, 32.2, 31.5, 31.0, 27.1, 23.5, 14.6, 11.9 ppm  
Elemental analysis (%): calcd. for C18H21Cl2NO2: C 61.03, H 5.98, N 3.95; found: C 61.01, 
H 5.92, N 3.92. 
1-Butyl-2-methyl-5-(1-methyl-1H-indol-3-yl)-1H-pyrrole-3-carboxylic acid (30h) 
Prepared from pyrrole 29p (0.300 g, 0.886 mmol). Grey solid. Yield:  
0.195 g, 71%.  
Mp 160-161 °C 
IR (neat) 1654.7 (C=O), 1254.8 (C-O) cm-1 
1H NMR (500 MHz, d4-methanol): δ 7.43 (t, J = 8.2 Hz, 2H), 7.26 – 7.20 (m, 2H), 7.10 (t, J 
= 7.5 Hz, 1H), 6.50 (s, 1H), 3.94 – 3.89 (m, 2H), 3.86 (s, 3H), 2.62 (s, 3H), 1.48 – 1.43 (m, 
2H), 1.11 (dt, J = 14.7, 7.4 Hz, 2H), 0.71 (t, J = 7.4 Hz, 3H) ppm. 
13C NMR (63 MHz, d6-acetone): δ 169.7, 138.3, 137.3, 129.7, 129.6, 127.6, 123.0, 120.7, 
120.4, 112.5, 111.8, 110.5, 108.1, 44.9, 33.9, 32.9, 20.6, 13.8, 11.9 ppm 
Elemental analysis (%): calcd. for C19H22N2O2: C 73.52, H 7.14, N 9.03; found: 
C 73.51, H 7.07, N 9.39.  
5-(3,4-dichlorophenyl)-1-(3-(dimethylamino)propyl)-2-methyl-1H-pyrrole-3-
carboxylic acid (30i) 
Prepared from pyrrole 29q (0.150 g, 0.392 mmol). Orange solid. 
Yield: 0.098 g, 65%.  
Mp 112-114 °C 
IR (neat) 1672.6 (C=O), 1237.8 (C-O) cm-1. 
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1H NMR (500 MHz, d4-methanol): δ 7.60 (t, J = 5.4 Hz, 2H), 7.36 (dd, J = 8.3, 1.9 Hz, 1H), 
6.56 (s, 1H), 4.10 (s, 2H), 2.78 (d, J = 7.8 Hz, 2H), 2.74 (s, 3H), 2.65 (1, 6H), 1.93 – 1.84 (m, 
2H) ppm. 
13C NMR (126 MHz, d4-methanol): δ 169.0, 137.4, 133.7, 132.6, 131.6, 130.9, 130.8, 
128.9, 114.1, 111.9, 55.9, 48.5 (2C), 42.3, 27.3, 11.8 ppm.  
Elemental analysis (%): calcd. for C17H20Cl2N2O2: C 57.48, H 5.67, N 7.89; found: C 57.43, 
H 5.68, N 7.86. 
1-Butyl-5-(3,4-dichlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30j) 
Prepared from pyrrole 29r (0.320 g, 0.91 mmol). Yellow solid. 
Yield: 0.238 g, 81 %.  
Mp 150-152 °C. 
IR (neat) 3427.3 (O-H), 1651.7 (C=O), 819.5 (C-Cl) cm-1. 
1H-RMN (250 MHz, d6-acetone): δ  7.53 – 7.50 (m, 1H), 7.48 (d, J = 2.0 Hz, 1H), 7.28 (dd, 
J = 8.3, 2.1 Hz, 1H), 6.43 (s, 1H), 4.03 – 3.69 (m, 2H), 2.48 (s, 3H), 1.41 (ddd, J = 12.5, 8.4, 
6.7 Hz, 2H), 1.18 – 0.88 (m, 2H), 0.67 (t, J = 7.3 Hz, 3H) ppm. 
13C-RMN (250 MHz, d6-acetone): δ 167.0, 138.9, 135.2, 133.2, 132.0 (2C), 131.9 (2C), 
130.2, 113.3, 112.5, 45.0, 33.7, 20.7, 14.2, 12.0 ppm. 
Elemental analysis (%): calcd. for C16H17Cl2NO2: C 58.91, H 5.25, N 4.29; found: C 58.58, 
H 5.68, N 3.95. 
1-Butyl-5-(3,4-dichlorophenyl)-2-propyl-1H-pyrrole-3-carboxylic acid (30k) 
Prepared from pyrrole 29s (0.300 g, 0.79 mmol). Yellow solid. 
Yield: 0.189 g, 68 %.  
Mp 110-112 °C 
IR (neat) 3462.4 (O-H), 1637.7 (C=O), 769.5 (C-Cl) cm-1. 
1H-RMN (250 MHz, d6-acetone): δ 7.52 (d, J = 4.4 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 6.44 
(s, 1H), 3.89 (dd, J = 22.1, 14.3 Hz, 2H), 2.95 – 2.84 (m, 2H), 1.52 (dq, J = 14.9, 7.4 Hz, 2H), 
1.43 – 1.29 (m, 2H), 1.11 - 1.02 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H), 0.65 (t, J = 7.3 Hz, 3H) 
ppm. 
13C-RMN (250 MHz, d6-acetone): δ 166.8, 143.4, 135.3, 133.2, 132.0 (2C), 131.9, 131.7, 
130.1, 113.1, 112.9, 45.0, 34.4, 28.3, 24.6, 20.7, 14.7, 14.2 ppm. 
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Elemental analysis (%): calcd for C18H21Cl2NO2: C 61.03, H 5.98, N 3.95; found:  C 60.83, 
H 5.59, N 3.66. 
5-(4-Chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30l) 
Prepared from pyrrole 29a (0. 380 g, 1.44 mmol). Brown solid. 
Yield: 0.237 g, 70%.  
1H RMN (250 MHz, d6-DMSO): δ 7.91 (d, J = 8.4 Hz, 2H), 7.80 (d, J 
= 8.5 Hz, 2H), 7.01 (s, 1H), 1.91 (s, 3H) ppm. 
13C RMN (63 MHz, d6-DMSO): δ 173.70, 168.63, 138.51, 132.56, 131.49, 129.65 (2C), 
129.50, 129.13 (2C), 128.86, 21.25 ppm. 
Elemental analysis (%): calcd for C12H10ClNO2: C 61.16, H 4.28, N 5.94; found: C 61.11, H 
4.81, N 5.31. 
1-Butyl-5-(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30m)  
Prepared from pyrrole 29u (0.315 g, 1 mmol). White solid. Yield: 
0.270 g, 93%.  
Mp 179-181°C. 
IR (neat) 1660.6 (C=O), 1091.7 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.42 (d, J = 8.6 Hz, 2H), 7.31 (d, 2H, J = 8.6), 6.62 (s, 1H), 
3.92-3.85 (m, 2H), 2.65 (s, 3H), 1.57-1.46 (m, 2H), 1.28-1.12 (m, 2H), 0.84 (t, J = 7.2 Hz, 
3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 170.7, 138.0, 133.6, 132.4, 131.4, 130.6, 128.7, 111.1 110.7, 
44.0, 32.7, 19.7, 13.5, 11.7 ppm. 
Elemental analysis (%): calcd. for C16H18ClNO2: C 65.86, H 6.22, N 4.80; found: C 65.80, 
H 6.15, N 4.77. 
1,5-Bis(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (30n)232 
Prepared from pyrrole 29c (0.374 g, 1 mmol). Yellow oil. Yield: 
0.280 g, 81%.  
IR (neat) 1662.8 (C=O), 1081.9 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.42 (d, J = 8.6 Hz, 2H), 7.20 (d, J = 8.5 
Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 6.87 (s, 1H), 
2.45 (s, 3H) ppm. 
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13C NMR (63 MHz, CDCl3): δ 167.6, 136.2, 136.0, 134.6, 133.1, 132.9, 130.3, 129.7 (2C), 
129.6 (2C), 129.3 (2C), 128.5 (2C), 111.1, 108.8, 12.7 ppm.  
Elemental analysis (%): calcd. for C18H13Cl2NO2: C 62.45, H 3.79, N 4.05; found: C 62.37, 
H 3.75, N 4.04. 
5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxylic acid 
(30o)232 
Prepared from pyrrole 29t (0.369 g, 1 mmol). White solid. Yield: 
0.283 g, 83%. 
Mp 186-188 °C. 
IR (neat) 1667.4 (C=O), 1248.8 (C-O), 1090.3 (C-Cl) cm-1. 
1H NMR (250 MHz, CDCl3): δ 7.16 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 9.0 
Hz, 2H), 7.01 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 6.86 (s, 1H), 3.87 (s, 3H), 2.43 (s, 
3H) ppm. 
13C NMR (63 MHz, CDCl3): δ 170.5, 159.4, 140.1, 133.2, 132.5, 130.7 (2C), 130.4 (2C) 
,129.4 (2C), 129.2 (2C), 114.5 (2C), 111.8, 110.6, 55.5, 12.6 ppm. 
Elemental analysis (%): calcd. for C19H16ClNO3: C 66.77, H 4.72, N 4.10; found: C 66.71, 
H 4.66, N 4.02. 
1-Butyl-5-(1H-indol-3-yl)-2-methyl-1H-pyrrole-3-carboxylic acid (30p) 
Prepared from pyrrole 29e (0.200 g, 0.62 mmol). Brown solid. Yield: 
0.189 g, 87 %.  
Mp 112-114 °C 
IR (neat) 3386.5 (O-H), 3053.9 (N-H), 1649.2 (C=O) cm-1. 
1H-RMN (250 MHz, d6-acetone): δ 7.41 (d, J = 8.1 Hz, 2H), 7.25 (s, 1H), 7.15 (m, 1H), 7.04 
(m, 1H), 6.51 (s, 1H), 3.98 – 3.89 (m, 2H), 2.63 (s, 3H), 1.54 – 1.45 (m, 2H), 1.14 (m, 2H), 
0.72 (t, J = 7.3 Hz, 3H) ppm. 
13C-RMN (250 MHz, d4-methanol): δ 166.9, 141.2, 137.8, 137.3, 128.1, 125.6, 122.9, 
120.7, 120.1, 112.5, 112.4, 111.7, 108.8, 44.9, 34.0, 20.7, 13.9, 12.0 ppm. 
Elemental analysis (%): calcd. for a C18H20N2O2: C 72.95, H 6.80, N 9.45; found: C 73.23, 
H 6.66, N 9.53. 
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7.7.4. Preparation of the pyrrole-isoniazid derivatives 32a-p. 
  
 
To a solution of the suitable pyrrole derivative (0.5 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI·HCl, 1 eq), and isoniazid (1 eq) 
in dry THF (3 mL), was added Et3N (0.02 mL, 2 eq), followed by the addition of 1-hydroxy-
7-azabenzotriazole (HOAt, in 0.6M DMF, 0.16 mL, 1 eq). The reaction mixture was 
refluxed for 12 hours. Then, the solvent was removed under reduced pressure and 
chloroform (3 mL) was added. The obtained precipitate was recrystalized in ethanol, 
providing the expected hydrazides (32a-p).  
If after the addition no precipitate was observed, the solvent was eliminated under 
reduced pressure and the residue was purified by flash chromatography through a silica 
gel column using ethyl acetate: methanol (5:1) as the mobile phase. Finally, the desired 
compounds were recrystalized in ethanol. 
N'-[1-Butyl-5-(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carbonyl]-isonicotinohydrazide 
(32a)232 
Prepared from pyrrole 30m (0.158 g, 0.5 mmol). Yellow solid. 
Yield: 0.150 g, 73%.  
Mp 154-157 °C. 
IR (neat) 3226.3 (N-H),1636.0 (C=O) cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.73 (dd, J = 4.7, 1.4 Hz, 
2H), 7.87 (dd, 2H, J = 4.7, 1.4 Hz), 7.48-7.37 (m, 4H), 6.57 (s, 
1H), 4.00- 3.94 (m, 2H), 2.61 (s, 3H), 1.55-1.43 (m, 2H), 1.24- 1.09 (m, 2H), 0.80 (t, J = 7.3 
Hz, 3H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 167.6 (2C), 151.3 (2C), 142.6, 137.7, 134.9, 134.0, 
133.6, 132.2 (2C), 130.1 (2C), 123.5 (2C), 113.7, 109.0, 45.0, 34.1, 20.9, 14.1, 12.0 ppm. 
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Elemental analysis (%): calcd. for C22H23ClN4O2: C 64.31, H 5.64, N 13.64; found: C 64.20, 
H 5.62, N 13.61. 
N'-[1,5-Bis(p-chlorophenyl)-2-methyl-1H-pyrrole-3-carbonyl] isonicotinohydrazide 
(32b)232 
Prepared from pyrrole 30n (0.172 g, 0.5 mmol). White solid. 
Yield: 0.141 g, 61%.  
Mp 182-184 °C. 
IR (neat) 3200.7 (N-H), 1633.2 (C=O), 1266.9 (C-N) cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.78 (dd, J = 4.7, 1.5 Hz, 
2H), 7.93 (dd, J = 4.7, 1.5 Hz, 2H), 7.52 (d, J = 8.6 Hz,2H), 7.25 
(d, J = 8.7 Hz, 4H), 7.11 (d, J = 8.5 Hz, 2H), 6.89 (s, 1H), 2.43 (s, 3H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 167.7, 167.6, 151.4 (2C), 142.5, 139.0, 138.1, 136.0, 
134.6, 134.2, 132.6, 131.7 (2C), 131.1 (2C), 131.0 (2C), 129.7 (2C), 123.5 (2C), 114.9, 
109.5, 12.9 ppm. 
Elemental analysis (%): calcd. for C24H18Cl2N4O2: C 61.95, H 3.90, N 12.04; found: C 
61.88, H 3.87, N 11.98. 
N'-[5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-2-methyl-1H-pyrrole-3-carbonyl] 
isonicotinohydrazide (32c)232 
Prepared from pyrrole 30o (0.171 g, 0.5 mmol). White solid. 
Yield: 0.179 g, 78%.  
Mp 172-173 °C. 
IR (neat) 3216.4 (N-H), 1630.4 (C=O), 1247.4 (C-N), 1090.3 (C-
Cl) cm-1. 
1H NMR (250 MHz, d4-methanol): δ 8.78 (dd, J = 4.5, 1.6 Hz, 
2H), 7.93 (dd, J = 4.5, 1.6 Hz, 2H); 7.22 (d, J = 8.7 Hz, 2H); 7.18-7.10 (m, 4H); 7.04 (d, J = 
9.0 Hz, 2H), 6.87 (s, 1H); 3.87 (s, 3H); 2.41 (s, 3H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 167.6, 167.4, 161.2, 151.1 (2C), 142.3, 139.1, 134.4, 
133.6, 132.6, 131.7, 130.8 (2C), 130.6 (2C), 129.2 (2C), 123.2 (2C), 115.6 (2C), 114.0, 
108.6, 56.0, 12.6 ppm. 
Elemental analysis (%): calcd for C25H21ClN4O2: C 65.15, H 4.59, N 12.16; found: C 65.35, 
H 4.65, N 11.97. 
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N'-(5-(4-Chlorophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32d) 
Prepared from pyrrole 30l (0.250 g, 1.06 mmol). Yellow solid. 
Yield: 0.131 g, 35 %.  
Mp 152-154 °C. 
IR (neat) 3281.3 (N-H), 1624.8 (C=O), 1275.8 (C-N), 751.16 
(C-Cl) cm-1. 
1H RMN (250 MHz, d6-acetone): δ 10.69 (s, 1H), 9.72 (s, 1H), 8.99 (s, 1H), 8.63 (d, J = 5.8 
Hz, 2H), 7.70 (d, J = 6.0 Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 6.94 (d, J 
= 2.6 Hz, 1H), 2.42 (s, 3H) ppm. 
 13C RMN (63 MHz, d4-methanol): δ 168.1, 167.7, 151.4 (2C), 142.7, 138.2, 133.1, 132.9, 
131.1, 130.3 (2C), 126.5 (2C), 123.6 (2C), 114.4, 106.3, 13.3 ppm. 
Elemental analysis (%) calcd for C18H15ClN4O2: C 60.94, H 4.26, N 15.79; found: C 60.73, 
H 4.50, N 15.44. 
N'-(5-(4-Iodophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32e) 
Prepared from pyrrole 30a (0.196 g, 0.60 mmol). Yellow solid. 
Yield: 0.104 g, 39 %.  
Mp >250 °C 
IR (neat) 3331.2 (N-H), 1637.4 (C=O), 1271.1 (C-N) cm-1.  
1H RMN (250 MHz, d4-methanol): δ 8.62 (s, 2H), 7.76 (d, J = 6.0 
Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 6.79 (s, 1H), 2.43 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 168.1, 167.7, 151.8 (2C), 142.9 (2C), 139.7, 138.1, 
133.7, 131.4, 127.0 (2C), 123.8 (2C), 114.5, 106.3, 91.7, 13.4 ppm. 
Elemental analysis (%): calcd. for C18H15IN4O2: C 48.45, H 3.39, N 12.56; found: C 48.37, 
H 3.70, N 12.85. 
N'-(5-(3-Chlorophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32f) 
Prepared from pyrrole 30b (0.308 g, 1.31 mmol). Yellow solid. 
Yield: 0.178 g, 42%.  
Mp >250 °C 
IR (neat) 3197.1 (N-H), 1594.4 (C=O), 1408.2 (C-N), 791.81 (C-
Cl) cm-1. 
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1H RMN (250 MHz, d4-methanol): δ 8.62 (d, J = 4.7 Hz, 2H), 7.77 (dd, J = 4.6, 1.5 Hz, 2H), 
7.50 (t, J = 1.7 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.09 – 7.03 (m, 1H), 
6.82 (s, 1H), 2.45 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 168.0, 167.7, 151.4 (2C), 142.6, 138.51, 136.2, 136.1, 
131.8, 130.7, 127.3, 124.9, 123.6 (2C), 123.4, 114.5, 106.7, 13.3 ppm. 
Elemental analysis (%): calcd. for C18H15ClN4O2: C 60.94, H 4.26, N 15.79; found: C 61.07, 
H 4.47, N 15.72. 
N'-(5-(3,4-Dichlorophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide 
(32g) 
Prepared from pyrrole 30c (0.452 g, 1.67 mmol). White solid. 
Yield: 0.266 g, 41%.  
Mp >250 °C 
IR (neat) 3218.3 (N-H), 1637.2 (C=O), 1257.0 (C-N), 807.5 (C-
Cl) cm-1. 
1H RMN (250 MHz, d6-DMSO): δ 10.64 (s, 1H), 9.83 (s, 1H), 8.80 (d, J = 5.8 Hz, 2H), 7.88 
– 7.79 (m, 3H), 7.67 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.5, 2.0 Hz, 1H), 7.15 (d, J = 2.2 Hz, 
1H), 2.58 – 2.44 (m, 3H) ppm. 
 13C RMN (63 MHz, d6-DMSO): δ 164.8, 164.3, 150.8 (2C), 140.1, 136.6, 133.1, 132.0, 
131.5, 128.0, 127.0, 124.8, 123.6 (2C), 121.7, 113.9, 106.7, 13.0 ppm. 
Elemental analysis (%) calcd. for C18H14Cl2N4O2: C 55.54, H 3.63, N 14.39; found: C 55.12, 
H 3.80, N 14.05. 
N'-(5-(4-Bromophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32h) 
Prepared from pyrrole 30d (0.140 g, 0.49 mmol). Yellow solid. 
Yield: 0.059 g, 30 %.  
Mp 210-212 °C 
IR (neat) 3272.9 (N-H), 1640.7 (C=O), 1418.6 (C-N), 754.2 (C-
Br) cm-1. 
1H RMN (250 MHz, d4-methanol): δ 8.77 (s, 2H), 7.91 (d, J = 6.0 Hz, 2H), 7.53 (s, 4H), 6.93 
(s, 1H), 2.58 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 194.2, 167.7, 151.4 (2C), 142.7, 138.3, 133.3 (2C), 
131.0, 126.8 (2C), 123.6 (2C), 120.8, 114.4, 106.3, 88.0, 13.3 ppm. 
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Elemental analysis (%): calcd. for C18H15BrN4O2: C 54.15, H 3.79, N 14.03; found: C 52.45, 
H 4.30, N 13.25. 
N'-(5-(4-Fluorophenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32i) 
Prepared from pyrrole 30e (0.149 g, 0.68 mmol). Yellow solid. 
Yield: 0.085 g, 37 %.  
Mp 148-150 °C 
IR (neat) 3262.7 (N-H), 1659.1 (C=O), 1259.5 (C-N), 1232.1 (C-
F) cm-1. 
1H RMN (250 MHz, d4-methanol): δ 8.51 (br s, 2H), 7.67 (dd, J = 7.0, 2.4 Hz, 2H), 7.43 – 
7.30 (m, 2H), 6.88 (t, J = 8.8 Hz, 2H), 6.61 (s, 1H), 2.34 (s, 3H) ppm. 
13C RMN (63 MHz, d4-methanol): δ 168.2, 167.7, 166.7 (d, J = 188.8 Hz), 151.4 (2C), 142.7, 
137.8, 131.8 , 130.7 (d, J = 3.2 Hz), 127.0 (d, J = 7.8 Hz, 2C), 123.6 (2C), 116.9 (d, J = 21.9 
Hz, 2C), 114.2 , 105.5 , 13.3 ppm. 
Elemental analysis (%): calcd. for C18H15FN4O2: C 63.90, H 4.47, N 16.56; found: C 64.27, 
H 4.34, N 16.51. 
N'-(5-(4-Methoxyphenyl)-2-methyl-1H-pyrrole-3-carbonyl) isonicotinohydrazide (32j) 
Prepared from pyrrole 30f (0.047 g, 0.47 mmol). Yellow 
solid. Yield: 0.047 g, 29 %.  
Mp 200-204 °C 
IR (neat) 3319.9 (N-H), 1651.0 (C=O), 1250.2 (C-O) cm1.  
1H RMN (250 MHz, d4-methanol): δ 8.61 (dd, J = 4.5, 1.6 Hz, 
2H), 7.76 (dd, J = 4.5, 1.6 Hz, 2H), 7.39 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 6.62 (s, 
1H), 3.68 (s, 3H), 2.42 (s, 3H) ppm 
13C RMN (63 MHz, d4-methanol): δ 168.4, 167.7, 160.2, 151.4 (2C), 142.8, 137.2, 132.3, 
127.1, 126.5 (2C), 123.6 (2C), 115.6 (2C), 113.9, 104.3, 56.1, 13.3 ppm 
Elemental analysis (%): calcd. for C19H18N4O3: C 65.13, H 5.18, N 15.99; found: C 65.21, 
H 5.41, N 16.30.  





Prepared from pyrrole 30g (0.350 g, 0.99 mmol). White 
solid. Yield: 0.078 g, 15 %.  
Mp 203-205 °C 
IR (neat) 3218.8 (NH), 1632.4 (C=O) cm-1 
1H NMR (250 MHz, d4-methanol): δ 8.57 (d, J = 4.5 Hz, 2H), 
7.72 (d, J = 5.4 Hz, 2H), 7.44 (t, J = 4.8 Hz, 2H), 7.19 (dd, J = 8.3, 2.0 Hz, 1H), 6.46 (s, 1H), 
3.81 (d, J = 7.6 Hz, 2H), 2.45 (s, 3H), 1.35 (s, 2H), 0.99 (s, 6H), 0.67 (s, 3H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 167.9, 167.7, 151.4 (2C), 142.6, 138.3, 135.4, 133.9, 
132.9, 132.8, 132.3, 132.1, 130.4, 123.6 (2C), 114.0, 109.7, 45.2, 32.6, 31.8, 27.4, 23.9, 
14.7, 12.14 ppm.  
Elemental analysis (%): calcd. for C24H26Cl2N4O2: C 60.89, H 5.54, N 11.84; found: C 
60.99, H 5.80, N 11.53. 
N'-(1-Butyl-2-methyl-5-(1-methyl-1H-indol-3-yl)-1H-pyrrole-3-carbonyl) 
isonicotinohydrazide (32l) 
Prepared from pyrrole 30h (0.100 g, 0.322 mmol). White 
solid.  Yield: 0.022 g, 17 %.  
Mp 250 °C 
IR (neat) 3265.23 (NH), 1631.45 (C=O) cm-1 
1H NMR (300 MHz, d4-methanol) δ: 8.75 (br s, 2H), 7.89 (d, J 
= 6.0 Hz, 2H), 7.50 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.28 – 7.19 (m, 2H), 7.11 (s, 
1H), 6.59 (s, 1H), 4.01 – 3.91 (m, 2H), 3.88 (s, 3H), 2.64 (s, 3H), 1.51-1.46 (m, 2H), 1.17-
1.09 (m, 2H), 0.72 (t, J = 7.3 Hz, 3H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 169.9, 169.9, 150.0 (2C), 137.5, 135.4, 128.7, 128.6,  
126.7, 122.2 (2C), 122.2, 122.0, 121.8, 119.7, 119.5, 111.9, 109.5, 107.8, 107.1, 32.9, 
31.9, 19.6, 12.8, 10.8 ppm.  
Elemental analysis (%): calcd. for C25H27N5O2: C 69.91, H 6.34, N 16.31; found: C 69.64, 
H 6.39, N 16.29. 
 





Prepared from pyrrole 30k (0.200 g, 0.57mmol). White solid. 
Yield: 0.103 g, 38 %.  
Mp 180-182 °C 
IR (neat) 3194 (N-H), 3046 (N-H), 1674 (C=O), 1632 (C=O), 
750 (C-Cl) cm-1. 
1H-RMN (250 MHz, d4-methanol ): δ 8.73 (d, J = 5 Hz, 1H), 
7.88 (d, J = 5 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H) , 7.35 (dd, J = 8.3, 
2.1 Hz, 1H), 6.62 (s, 1H), 4.08 – 3.93 (m, 2H), 2.61 (s, 3H), 1.58 – 1.41 (m, 2H), 1.22-1.14 
(m, 2H), 0.81 (t, J = 7.3 Hz, 2H) ppm.  
13C-RMN (250 MHz, d4-methanol): δ 168.0, 167.7, 151.6 (2C), 142.7, 138.4, 135.4, 133.9 
(2C), 132.8, 132.3, 132.2, 130.4, 123.6 (2C), 114.0, 109.8, 45.2, 34.2, 21.1,14.3, 12.1 ppm.  
Elemental analysis (%): calcd for C22H22Cl2N4O2: C 59.33, H 4.98, N 12.58. found: C 59.65, 
H 4.84, N 12.71. 
N'-(1-Butyl-5-(3,4-dichlorophenyl)-2-propyl-1H-pyrrole-3-carbonyl) 
isonicotinohydrazide (32n)  
Prepared from pyrrole 30k (0.200 g, 0.62 mmol). White solid. 
Yield: 0.139 mg, 51 %.  
Mp >250 °C 
IR (neat) 3223 (N-H), 3050 (N-H), 1693 (C=O), 1621 (C=O), 
750 (C-Cl) cm-1 
1H-RMN (250 MHz, d4-methanol) δ 8.73 (d, J = 5.8 Hz, 1H), 
7.88 (d, J = 5.8 Hz, 1H), 7.60 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 2 Hz, 1H), 7.37 (dd, J = 8.2, 2.0 
Hz, 1H), 6.63 (s, 1H), 4.06 – 3.95 (m, 2H), 3.06 – 2.98 (m, 2H), 1.71-1.62 (m, 2H), 1.53 – 
1.39 (m, 2H), 1.22-1.13 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H), 0.80 (t, J = 7.3 Hz, 3H) ppm. 
13C-RMN (250 MHz, d6-acetone): δ 166.4, 151.8, 142.4 (2C), 141.4, 135.3, 133.3 (2C), 
132.0, 131.9, 131.8, 131.7, 130.0, 122.5, 113.9, 109.9, 44.9, 34.5, 28.2, 24.7, 20.8, 14.8, 
14.3, 14.2 ppm. 
Elemental analysis (%): calcd. for C24H26Cl2N4O2: C 60.89, H 5.54, N 11.84. found: C 
60.60, H 5.51, N 11.95. 





Prepared from pyrrole 30p (0.100 g, 0.34 mmol). White solid. 
Yield: 0.078 g, 55 %.  
Mp 188-190 °C 
IR (neat) 3464 (N-H), 3327 (N-H), 3202 (N-H), 1666 (C=O), 
1625 (C=O) cm-1 
1H-RMN (250 MHz, d4-methanol): δ 8.73 (dd, J = 4.5, 1.6 Hz, 
2H), 7.89 (dd, J = 4.5, 1.6 Hz, 2H), 7.48 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.29 (s, 
1H), 7.19- 7.13 (m, 1H), 7.09-7.03 (m, 1H), 6.59 (s, 1H), 3.94 (q, J = 7.3 Hz, 2H), 1.56 – 
1.39 (m, 2H), 1.13 (m, 2H), 0.71 (t, J = 7.3 Hz, 3H) ppm. 
13C-RMN (250 MHz, d4-methanol): δ 167.8, 151.4, 142.9, 138.1, 136.6, 129.5, 128.6, 
125.9 (2C), 123.7 (2C), 123.3, 121.1, 113.2, 112.9, 109.2 (2C), 109.0 (2C), 45.2, 34.4, 21.1, 
14.2, 12.3 ppm. 
Elemental analysis (%): calcd. for C24H25N5O2: C 69.38, H 6.07, N 16.86. found:  C 68.71, 
H 5.93, N 16.57. 
N'-(5-(3,4-Dichlorophenyl)-1-(3-(dimethylamino)propyl)-2-methyl-1H-pyrrole-3-
carbonyl) isonicotinohydrazide (32p) 
Prepared from pyrrole 30i (0.130 g, 0.36 mmol). White 
solid. Yield: 0.050 g, 30 %.  
Mp 155-157 °C 
IR(neat) ) 3197 (N-H), 2946 (N-H), 1631 (C=O)cm-1 
1H NMR (250 MHz, d4-methanol): δ 8.73 (d, J = 6.0 Hz, 2H), 
7.88 (d, J = 6.0 Hz, 2H), 7.63 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 
8.3 Hz, 1H), 7.37 (dd, J = 8.3, 1.8 Hz, 1H), 6.64 (s, 1H), 4.15 – 3.88 (m, 2H), 2.63 (s, 3H), 
2.35 – 2.09 (m, 8H), 1.75 – 1.53 (m, 2H) ppm. 
13C NMR (63 MHz, d4-methanol): δ 167.8, 167.7, 151.5 (2C), 142.8, 138.4, 135.2, 134.0, 
133.1, 132.7, 132.4, 132.3, 130.4, 123.6 (2C), 114.2, 110.1, 57.5, 45.5 (2C), 43.4, 29.5, 
12.1 ppm. 
Elemental analysis (%): calcd for C23H25Cl2N5O2: C 58.23, H 5.31, N 14.76 found: C 58.15, 















1. A family of theranostic styrylquinoles bearing a push pull architecture has been 
designed and synthesized via a good-yielding four-step procedure. Their 
pharmacological profiles were studied, showing their ability to inhibit tau 
aggregation and neuroprotective effects in okadaic acid models. Their full 
spectroscopic characterization has been carried out, showing thet the 
compounds have native fluorescence in the NIR region.  
2. The ability of the styrylquinolines to act as amyloid sensors has been verified 
with different amyloidogenic proteins. First, they were used for ex-vivo imaging, 
showing the capacity to selectively detect -amyloid plaques in the 
somatosensory cortex of APP/PS1 transgenic mice and in the temporal cortex of 
human Alzheimer’s disease samples. Due to the ability to interact with 
amyloidogenic proteins, styrylquinolines were also used to detect amylin, a 
pancreatic protein overexpressed in type II Diabetes mellitus that may be 
involved in the development of Alzheimer’s disease. 
3. As quinolines have shown potential to develop effective and affordable oral 
treatments for leishmaniasis, a family of 2-substituded styrylquinolines, with 
polyamine chains in the C-4 position of the quinoline scaffold has been 
synthesized. Their leishmanicidal activities were tested, showing good activities 
and selectivity indexes for the best compounds. Further mechanistical studies 
were carried out pointing out their ability cause mitochondrial disruption. 
4. In order to achieve our goal of developing novel push-pull multi-spectral 
optoacoustic tomography (MSOT) probes, a new one-pot mechanochemical 
methodology to obtain dihalo-bis-indolylquinones as starting scaffolds has been 
developed.  
5. Finally, a novel family of pyrrole-isoniazid hybrid compounds have been 
synthesised. Their antitubercular activities have been studied, showing 
interesting activities against Mycobacterium tuberculosis, including multidrug-
resistant tuberculosis. Further, their ability to inhibit MmpL3 and InhA was 
verified, proving that they could act through a metabolism-activated 
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